<SEC-DOCUMENT>0001641172-25-022911.txt : 20250811
<SEC-HEADER>0001641172-25-022911.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811083746
ACCESSION NUMBER:		0001641172-25-022911
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALT5 Sigma Corp
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289176
		FILM NUMBER:		251200347

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	JanOne Inc.
		DATE OF NAME CHANGE:	20190912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.5pt; width: 50%; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt; color: rgb(228,0,43)"><B>PROSPECTUS
                                            SUPPLEMENT</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt; color: rgb(228,0,43)"><B>(To
    Prospectus dated August 8, 2025) </B></FONT></P></TD>
    <TD STYLE="border-top: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.5pt; width: 50%; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt; color: rgb(228,0,43)"><B>Filed
                                            Pursuant to Rule 424(b)(5)</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt; color: rgb(228,0,43)"><B>Registration
    No. 333-289176</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">&thinsp;<B>ALT5
SIGMA CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Up
to $1,000,000,000 of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">This
prospectus supplement relates to the issuance and sale of our common stock, par value $0.001 per share (the &ldquo;common stock&rdquo;),
having an aggregate offering price of up to $1,000,000,000, from time to time through or to our sales agent, A.G.P./Alliance Global Partners
(&ldquo;A.G.P.&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">We
have entered into an At the Market Sales Agreement (the &ldquo;Sales Agreement&rdquo;), with A.G.P., dated August 11, 2025, relating
to shares of our common stock offered pursuant to this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Sales
of our common stock, if any, under this prospectus supplement may be made by any method permitted that is deemed an &ldquo;at the market
offering&rdquo; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. A.G.P. is not required to
sell any specific amount but will act as our sales agent and use commercially reasonable efforts to sell on our behalf the shares of
common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between A.G.P.
and us. There is no arrangement for funds to be received in escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">A.G.P.
will be entitled to compensation at a commission rate of 2.5% of the gross sales price per share on the first $500 million of common
stock sold and 2.0% of the gross sales price per share on all sales of shares of common stock thereafter sold under the Sales Agreement.
In connection with the sale of shares of our common stock on our behalf, A.G.P. will be deemed to be an &ldquo;underwriter&rdquo; within
the meaning of the Securities Act and the compensation of A.G.P. will be deemed to be underwriting commissions or discounts. We have
agreed to provide indemnification and contribution to A.G.P. against certain civil liabilities, including liabilities under the Securities
Act. See &ldquo;Plan of Distribution&rdquo; beginning on page S-16 regarding the compensation to be paid to A.G.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;ALTS.&rdquo; On August 8, 2025, the last reported sales price
of our common stock on The Nasdaq Capital Market was $8.97 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Investing
in our securities involves a high degree of risk. See the section entitled &ldquo;Risk Factors&rdquo; commencing on page S-4 of this
prospectus supplement and the accompanying base prospectus for a discussion of information that should be considered in connection with
an investment in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is August 11, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="toc_001"></A>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">ABOUT THIS PROSPECTUS SUPPLEMENT</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">S-1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">PROSPECTUS SUPPLEMENT SUMMARY</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">S-4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">S-14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">S-15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">DILUTION</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">S-15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">S-16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVAILABLE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>
                                                                            <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_001">DESCRIPTION OF SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_002">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">44</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_003">DESCRIPTION OF PREFERRED STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_004">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_005">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_006">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_007">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">64</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_008">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_009">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">65</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_010">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_011">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying base prospectus are part of a registration statement that we filed with the Securities and
Exchange Commission (the &ldquo;SEC&rdquo;) utilizing a &ldquo;shelf&rdquo; registration process. Each time we conduct an offering to
sell securities under the accompanying base prospectus we will provide a prospectus supplement that will contain specific information
about the terms of that offering, including the price, the amount of securities being offered and the plan of distribution. This prospectus
supplement describes the specific details regarding this offering and may add, update or change information contained in the accompanying
base prospectus. The base prospectus, dated August 8, 2025, including the documents incorporated by reference therein, provides general
information about us and our securities, some of which, such as the section entitled &ldquo;Plan of Distribution,&rdquo; may not apply
to this offering. This prospectus supplement and the accompanying base prospectus are an offer to sell only the securities offered hereby,
but only under circumstances and in jurisdictions where it is lawful to do so. We are not, and A.G.P. is not, making offers to sell or
solicitations to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in which the person
making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
information in this prospectus supplement is inconsistent with the accompanying base prospectus or the information incorporated by reference
with an earlier date, you should rely on this prospectus supplement. This prospectus supplement, together with the base prospectus, the
documents incorporated by reference into this prospectus supplement and the accompanying base prospectus and any free writing prospectus
we have provided for use in connection with this offering, include all material information relating to this offering. We have not, and
A.G.P. has not, authorized anyone to provide you with different or additional information and you must not rely on any unauthorized information
or representations. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus,
the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus and any free writing prospectus
we have provided for use in connection with this offering is accurate only as of the respective dates of those documents. Our business,
financial condition, results of operations and prospects may have changed since those dates. <B>You should carefully read this prospectus
supplement, the accompanying base prospectus and the information and documents incorporated herein by reference herein and therein, as
well as any free writing prospectus we have provided for use in connection with this offering, before making an investment decision.
See &ldquo;Incorporation of Certain Documents by Reference&rdquo; and &ldquo;Where You Can Find More Information&rdquo; in this prospectus
supplement and in the accompanying base prospectus</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying base prospectus contain summaries of certain provisions contained in some of the documents
described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their
entirety by the full text of the actual documents, some of which have been filed or will be filed and incorporated by reference herein.
See &ldquo;Where You Can Find More Information&rdquo; in this prospectus supplement. We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus
supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some
cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty
or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying base prospectus contain and incorporate by reference certain market data and industry statistics
and forecasts that are based on Company-sponsored studies, independent industry publications and other publicly available information.
Although we believe these sources are reliable, estimates as they relate to projections involve numerous assumptions, are subject to
risks and uncertainties, and are subject to change based on various factors, including those discussed under &ldquo;Risk Factors&rdquo;
in this prospectus supplement and the accompanying base prospectus and under similar headings in the documents incorporated by reference
herein and therein. Accordingly, investors should not place undue reliance on this information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise indicates, references in this prospectus supplement to &ldquo;ALT5 Sigma Corporation,&rdquo; &ldquo;ALT5 Sigma,&rdquo;
&ldquo;ALT5,&rdquo; &ldquo;ALTS,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer to
ALT5 Sigma Corporation, a Nevada corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus summary highlights information contained elsewhere in this prospectus supplement, the accompanying base prospectus and the
documents incorporated by reference herein and therein. This summary does not contain all of the information that you should consider
before deciding to invest in our securities. You should read this entire prospectus supplement and the accompanying base prospectus carefully,
including the section entitled &ldquo;Risk Factors&rdquo; beginning on page S-4 and our consolidated financial statements and the related
notes and the other information incorporated by reference into this prospectus supplement and the accompanying base prospectus, before
making an investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma Corporation (Nasdaq; ALTS) is a fintech company providing blockchain-powered technologies for tokenization, trading, clearing settlement,
payment and safe keeping of digital assets. Through our Fintech segment, the Company provides next generation blockchain-powered technologies
to enable a migration to a new global financial paradigm, and, through our Biotechnology segment, we are focused on finding treatments
for conditions that cause chronic pain and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>World
Liberty Financial Treasury Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Registered
Direct Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2025, ALT5 Sigma Corporation (the &ldquo;Company&rdquo;) entered into securities purchase agreements (the &ldquo;Registered
Offering Purchase Agreements&rdquo;) with certain institutional investors pursuant to which the Company agreed to issue to the Purchasers
(as defined therein), in a registered direct offering (the &ldquo;Registered Offering&rdquo;), an aggregate of 100,000,000 shares of
the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;common stock&rdquo;), at a purchase price of $7.50 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use up to $10,000,000 of the net proceeds from the Registered Offering to settle existing litigation, pay
existing debt, and fund the Company&rsquo;s existing business operations, and the balance of the net proceeds will be used to fund
the acquisition of $WLFI tokens from World Liberty Financial, Inc. (the &ldquo;Lead Investor&rdquo;) pursuant to a Token Purchase
Agreement and the establishment of the Company&rsquo;s cryptocurrency treasury operations. The shares of common stock to be
issued in the Registered Offering will be issued pursuant to a prospectus supplement, which was filed with the Securities and
Exchange Commission on August 11, 2025, in connection with a takedown from the Company&rsquo;s shelf registration statement on Form
S-3, as amended, (File No. 333-289176), which was declared effective by the Securities and Exchange Commission on August 8,
2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Private
Placement Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2025, the Company entered into a securities purchase agreement (the &ldquo;Private Placement Purchase Agreement&rdquo;
and together with the Registered Offering Purchase Agreements, the &ldquo;Purchase Agreements&rdquo;), with the Lead Investor, pursuant
to which the Company received $750 million of $WLFI tokens and agreed to issue to the Lead Investor, in a concurrent private placement
(the &ldquo;Private Placement&rdquo; and together with the Registered Offering, the &ldquo;Offerings&rdquo;), 1,000,000 shares of
common stock at a purchase price of $7.50 per share (the &ldquo;PIPE Shares&rdquo;), and pre-funded warrants (the &ldquo;PIPE Pre-Funded
Warrants&rdquo;) to purchase up to 99,000,000 shares of common stock at a purchase price of $7.499 per PIPE Pre-Funded
Warrants (the &ldquo;PIPE Pre-Funded Warrant Shares&rdquo; and together with the PIPE Shares and the PIPE Pre-Funded Warrants, the
&ldquo;PIPE Securities&rdquo;). Each of the PIPE Pre-Funded Warrants is exercisable for one share of common stock at an exercise
price of $0.001 per share. The PIPE Pre-Funded Warrants are not exercisable until the Company has filed an amendment to its Articles
of Incorporation to increase the number of authorized shares of capital stock (the &ldquo;Amendment&rdquo;). Following the effectiveness
of the Amendment, the PIPE Pre-Funded Warrants may be exercised at any time until all of the PIPE Pre-Funded Warrants are exercised in
full, subject to certain beneficial ownership limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to hold an annual or special meeting of stockholders on or prior to September 30, 2025 and to file a Preliminary Proxy
Statement with the Commission with the date that is twenty (20) days following the closing date for the purpose of obtaining the stockholder
approval to the amendment (the &ldquo;Stockholder Approval&rdquo;), with the recommendation of the Company&rsquo;s Board of Directors
that the proposal to approve the Amendment. If the Company does not obtain Stockholder Approval at the first meeting, the Company is
obligated to call a meeting every ninety (90) days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder
Approval is obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance and sale of the PIPE Securities will not be, and are not, registered under the Securities Act of 1933 as amended (the
&ldquo;Securities Act&rdquo;), or any state securities laws. The PIPE Securities will be issued in reliance on the exemption from
registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder for transactions not
involving a public offering. Pursuant to the terms of a registration rights agreement entered into on August 11, 2025, by and
between the Company and the Lead Investor, the Company is required to file a registration statement providing for the resale of the
PIPE Securities Shares within 15 days of the closing of the Private Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Offering is expected to result in gross proceeds of $750 million and the Private Placement is expected to result in the receipt
of $750 million of $WLFI, in each case before deducting placement agent commissions and other offering expenses. The closing of the Offerings
is expected to occur on or about August 12, 2025, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreements, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed
issuance of any shares of common stock or common stock equivalents, or file any registration statement or any amendment or supplement
thereto, for a period of thirty (30) days after the initial registration statement has been declared effective, subject to certain customary
exceptions, including the use of the Sales Agreement (as defined herein), without the consent of the Purchasers, the Lead Investor and
the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;ALTS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 325 E. Warm Springs Road, Suite 102, Las Vegas, NV 89119, and our phone number is (703) 997-5968.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website is www.alt5sigma.com. Information contained in, or accessible through, our website does not constitute part of this prospectus
supplement and inclusions of our website address in this prospectus supplement are inactive textual references only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief summary of some of the terms of the offering and is qualified in its entirety by reference to the more detailed
information appearing elsewhere in this prospectus supplement and the accompanying base prospectus. For a more complete description of
the terms of our common stock, see description of our common stock in the accompanying base prospectus in the section, &ldquo;The Securities
We May Offer.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 66%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of our common stock, par value $0.001 per share, having an aggregate offering price of up to $1,000,000,000.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding prior to this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,609,376
    shares of common stock outstanding as of August 11, 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 154,942,710 shares of common stock, assuming sales of 133,333,334 shares of our common stock in this offering at an offering price
    of $7.50 per share, which was the priced sold in the Offering on August 11, 2025. The actual number of shares issued by us
    in this offering will vary depending on how many shares we choose to sell and the sales price under this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner
    of offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with the terms of the Sales Agreement, under this prospectus supplement we may offer and sell common stock having an aggregate
    offering price of up to $1,000,000,000 from time to time through A.G.P., acting as our sales agent. Sales of common stock, if any,
    under this prospectus supplement may be made by any method permitted that is deemed an &ldquo;at the market offering&rdquo; as defined
    in Rule 415 under the Securities Act. See the section entitled &ldquo;Plan of Distribution&rdquo; on page S-16
    of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to use the net proceeds from this offering for working capital and general corporate purposes and to fund the acquisition
    of World Liberty Financial tokens and the establishment of the Company&rsquo;s cryptocurrency treasury options. See &ldquo;Use of
    Proceeds&rdquo; on page S-15.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-4 and the
    other information included or incorporated by reference in this prospectus supplement and the accompanying base prospectus for a
    discussion of factors you should carefully consider before deciding to invest in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Capital Market symbol</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ALTS&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
21,609,376 shares of our common stock outstanding as of August 11, 2025 excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000,000
    shares of common stock issued by the Company to the RD Purchasers in the offering of August 11, 2025; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000
    shares of common stock and 99,000,000 shares of common stock underlying pre-funded warrants issued by the Company to the Lead
    Investor in the private placement offering of August 11, 2025, which are exercisable at price of $0.001 per share; </FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,432,460
    shares of our common stock reserved for issuance pursuant to the conversion of 749,460 shares of preferred stock; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,591,935
    shares of our common stock reserved for issuance upon exercise of outstanding warrants having a weighted average exercise price of
    $2.91.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. Before purchasing our common stock, you should read and consider carefully the following
risk factors and the risk factors included in our most recent Annual Report on Form 10-K filed with the SEC, any subsequent Quarterly
Reports on Form 10-Q as well as all other information contained and incorporated by reference in this prospectus supplement and the accompanying
base prospectus, including our consolidated financial statements and the related notes. Each of these risk factors, either alone or taken
together, could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an
investment in our common stock. There may be additional risks that we do not presently know of or that we currently believe are immaterial,
which could also impair our business and financial position. If any of the events described below were to occur, our financial condition,
our ability to access capital resources, our results of operations and/or our future growth prospects could be materially and adversely
affected and the market price of our common stock could decline. As a result, you could lose some or all of any investment you may make
in our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price
of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict the effect, if any, that future issuances or sales of our securities including sales of shares of our common stock pursuant
to the Sales Agreement or the availability of our securities for future issuance or sale, will have on the market price of our common
stock. Issuances or sales of substantial amounts of our securities, including sales of our common stock pursuant to the Sales Agreement,
or the perception that such issuances or sales might occur, could negatively impact the market price of our common stock and the terms
upon which we may obtain additional equity financing in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Resales
of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue shares of common stock from time to time in connection with this offering. The issuance from time to time of these new shares
of common stock, or our ability to issue new shares of common stock in this offering, could result in resales of our shares of
common stock by our current stockholders concerned about the potential dilution of their holdings. In turn, these resales could have
the effect of depressing the market price for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is not possible to predict the actual number of shares of our common stock we will sell under the Sales Agreement, or the gross proceeds
resulting from those sales.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice
to the sales agent at any time throughout the term of the Sales Agreement. The number of shares of our common stock that are sold through
the sales agent after delivering a placement notice will fluctuate based on a number of factors, including the market price of our common
stock during the sales period, the limits we set with the sales agent in any applicable placement notice, and the demand for our common
stock during the sales period. Because the price per share of each share sold will fluctuate during the sales period, it is not currently
possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
common stock offered hereby will be sold in &ldquo;at the market offerings,&rdquo; and investors who buy shares at different times will
likely pay different prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
who purchase common stock in this offering at different times will likely pay different prices, and so may experience different levels
of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing,
prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in
this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made
at prices lower than the prices they paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management will have broad discretion over the use of the net proceeds from this offering, and you may not agree with how we use the
proceeds and the proceeds may not be invested successfully.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes other than
those contemplated at the time of this offering. We will retain broad discretion over the use of the net proceeds from the sale of the
securities offered hereby. We currently expect to use the net proceeds from this offering for working capital and general corporate purposes,
including to progress the development programs of our drug candidates. See the section entitled &ldquo;Use of Proceeds&rdquo; below for
a more detailed discussion. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds,
and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds will be used appropriately.
It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for the Company and cause
the price of our common stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of our common stock has and may continue to fluctuate significantly, and this may make it difficult for you to resell shares
of common stock owned by you at times or at prices you find attractive.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock has fluctuated widely and may continue to fluctuate widely as a result of a number of factors,
many of which are outside our control. Since August 8, 2024, our common stock has traded at prices as low as $1.69 per share and
as high as $10.255 per share. This volatility may affect the price at which you could sell the shares of our common stock, and
the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our stock price
is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors.
See &ldquo;Risk Factors&rdquo; beginning on page S-4 of this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, you may not be able to sell your shares of common stock at or above the price at which you purchase them. In addition,
the stock market in general, and the stock of treasury strategy companies in particular, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors
may negatively affect the market price of our common stock, regardless of our actual operating performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Resales
of our common stock in the public market during this offering by our stockholders may cause the market price of our shares of
common stock to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of a substantial number of shares of common
stock could occur at any time. The issuance of new shares of common stock could result in resales of our shares of common
stock by our current stockholders concerned about the potential ownership dilution of their holdings. In turn, these resales could
have the effect of depressing the market price for our shares of common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
may experience future dilution as a result of future equity offerings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to raise additional capital, we may in the
future offer additional shares of common stock or other securities convertible into or exchangeable for our shares of common
stock that could result in further dilution to the investors purchasing our shares of common stock in this offering or result
in downward pressure on the price of our common stock. We may sell our shares of common stock or other securities in any
other offering at prices that are higher or lower than the prices paid by the investors in this offering, and the investors purchasing
shares or other securities in the future could have rights superior to existing stockholders. Moreover, to the extent that we issue options
or warrants to purchase, or securities convertible into or exchangeable for, our shares of common stock in the future and those
options, warrants or other securities are exercised, converted or exchanged, stockholders may experience further dilution.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Company
Risk Factors Related to $WLFI</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
historical financial results may not be indicative of future performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical financial statements do not reflect the potential variability in earnings that we may experience in the future relating to
our digital asset strategy and $WLFI holdings. As a result, historic trends in revenue, asset valuation, or volatility should not be
relied upon as indications of future results. If investors view the value of our securities as dependent upon or linked to the value
or change in the value of our $WLFI holdings, the perceived value or price of such digital assets may significantly influence the market
price of our securities and we could see additional volatility in our stock price. If we are required to incur an impairment charge for
changes in the value of our $WLFI holdings, or experience a decrease in reported earnings or increased volatility of such earnings, it
could materially adversely affect our financial results and the market price of our securities. In addition, the application of generally
accepted accounting principles in the United States with respect to digital assets remains uncertain in some respects, and any future
changes in the manner in which we account for our $WLFI holdings could have a material adverse effect on our financial results and the
market price of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
expected concentration of our $WLFI holdings may enhance the risks inherent in utilizing our digital asset treasury strategy.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected concentration of our $WLFI holdings limits the risk mitigation that we could take advantage of by purchasing a more diversified
portfolio of treasury assets, and the absence of diversification enhances the risks inherent in our digital asset acquisition strategy.
Any significant future decline in the value of $WLFI would have a more pronounced impact on our financial condition than if we used our
cash to purchase a more diverse portfolio of assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$WLFI
are non-transferable, and as a result, our $WLFI holdings may not be able to serve as a source of liquidity to the same extent as cash
and cash equivalents or other instruments.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$WLFI
are non-transferable and accordingly may not be transferred or resold. $WLFI holders approved a proposal in July 2025 to make the $WLFI
token transferable, and WLFI is expected to unlock tradability for a portion of $WLFI tokens sold to early purchasers subject to an unlock
schedule. The remainder of the $WLFI tokens sold to early supporters is intended to be subject to a second vote by the community to determine
the unlock and release schedule. Unlock schedules for initial founders, advisors, and others are expected to remain non-transferable,
and in any case, subject to a longer unlock schedule. WLFI retains discretion to determine the timing of and any eligibility requirements
for unlocking $WLFI. In addition, the $WLFI that we have acquired or plan to acquire from the Lead Investor will be subject to lock-up
restrictions of at least 12 months. If $WLFI are not unlocked or are restricted, we may be unable to sell our $WLFI, enter into additional
capital raising transactions using $WLFI as collateral, or otherwise generate funds using our $WLFI holdings, and our business and financial
condition could be negatively impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
liquid secondary market for $WLFI may not develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$WLFI
are not currently transferable. Some platforms purport to offer trading in $WLFI, on a when-issued basis or otherwise, but such trading
is not authorized by WLFI and any pricing or volumes reflected in such markets may not necessarily be indicative of future pricing or
trading activity. A secondary market may or may not arise or be sustained for $WLFI, which could adversely impact our ability to purchase
or sell $WLFI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to execute our digital asset treasury depends on continued access to opportunities to acquire $WLFI.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
$WLFI are current non-transferable, we can currently only acquire $WLFI directly from WLF. Even if transferability is enabled, the initial
supply of tokens may be limited until a sufficient supply of tokens are unlocked. If we cannot acquire $WLFI from WLF, in secondary transactions,
secondary markets, or otherwise on favorable terms or at all, our ability to execute our digital asset treasury strategy may be impaired,
or we may be required to reallocate the treasury to include other assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$WLFI
do not provide any rights to dividends, airdrops or other forms of distributions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$WLFI
is a governance token. Holding the token does not provide any right to any dividend, reward, airdrop or other distribution or form of
income. Unlike bonds and dividend-paying stocks and similar instruments, we cannot expect any passive income from holding $WLFI as part
of our digital asset treasury strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
financial results and the market price of our securities could be adversely affected, and our business and financial condition would
be negatively impacted, if the value or price of $WLFI decreased.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we plan to acquire a significant amount of $WLFI, any change to the value or price of $WLFI could negatively affect us. Such impact could
arise from a variety of reasons, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decrease in the price of other digital assets, to the extent the decrease in the price of such other digital assets may cause a decrease
    in the price of $WLFI or adversely affect confidence in digital assets generally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from other governance tokens or other digital assets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of interest in participating in $WLFI governance for any reason, including without limitation a loss of interest, usage or adoption
    of the World Liberty Financial Protocol (the &ldquo;<B>WLF Protocol</B>&rdquo;) and related applications and services of WLF-branded
    digital assets such as USD1;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to make upgrades to the WLFI interface to adapt to security, technological, legal or other challenges or changes that introduce software
    bugs, security risks or other elements that adversely affect $WLFI;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in consumer preferences and the perceived value or utility of $WLFI or the WLF Protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">activities
    of retail and institutional users, speculators and holders or actual or expected significant dispositions of $WLFI by large holders
    or associated with tokens held by WLFI- affiliated persons;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    publicity, media or social media coverage, or sentiment due to events in or relating to, or perception of, $WLFI, WLFI or its co-founders
    or affiliates, USD1 or the broader digital assets industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    World Liberty Financial Governance Platform (&ldquo;<B>WLF Governance Platform</B>&rdquo;) malfunctioning in an unfavorable way,
    including such that results in the inability to propose and vote on governance proposals or the loss of $WLFI;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory,
    legislative, enforcement and judicial actions that adversely affect use or access to, functionality of, ownership transferability,
    public perception of $WLFI or the WLF Protocol or associated products, including USD1 or that adversely affect the operations of
    or otherwise prevent digital asset custodians, trading venues, lending platforms or other digital assets industry participants from
    accessing $WLFI, USD1, other associated products or the WLF Protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions,
    failures, unavailability, or interruptions in services for venues for acquiring $WLFI;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    filing for bankruptcy protection by, liquidation of, or market concerns about the financial viability of digital asset custodians,
    trading venues, lending platforms, investment funds, or other digital asset industry participants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">macroeconomic
    changes, such as changes in the level of interest rates and inflation, fiscal and monetary policies of governments, trade restrictions
    and fiat currency devaluations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    in mathematics or technology, including in digital computing, algebraic geometry and quantum computing, that could result in the
    cryptography used by WLFI or underlying blockchains becoming obsolete, insecure or ineffective; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in national and international economic and political conditions, including, without limitation, federal government policies, trade
    tariffs and trade disputes, and the adverse impacts attributable to global conflicts, including but not limited to those between
    Russia and Ukraine and in the Middle East.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$WLFI
and other digital assets are novel assets and are subject to significant legal and regulatory uncertainty.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$WLFI
and other digital assets are relatively novel and are subject to significant legal and regulatory uncertainty, which could adversely
impact their use, value and price. The application of state and federal securities laws and other laws and regulations to digital assets
is evolving and unclear in certain respects, and it is possible that regulators in the United States or foreign countries may interpret
or apply existing laws and regulations in a manner that adversely affects the functionality of $WLFI, the WLF Protocol, the price of
$WLFI or the ability of individuals or institutions such as us to use, own or transfer $WLFI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal government, states, regulatory agencies, and foreign countries may also enact new laws and regulations, or pursue regulatory,
legislative, enforcement or judicial actions, that could materially impact the price of $WLFI or the ability of individuals or institutions
such as us to use, own or transfer $WLFI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased
enforcement activity and changes in the regulatory environment, including evolving or changing interpretations and the implementation
of new or varying regulatory requirements by the government or any new legislation affecting $WLFI, as well as enforcement actions involving
or impacting any trading venues, counterparties and custodians, may impose significant costs or significantly limit our ability to use,
hold and transact in $WLFI. Although a number of previously initiated U.S. federal actions have been settled or dismissed, the SEC, CFTC
or other state, federal or foreign regulatory agencies may initiate similar actions in the future, which could materially impact the
operations or functionality of $WLFI, or the WLF Protocol, and our ability to use, own or transfer $WLFI. For example, in April 2025,
the State of Oregon brought a civil enforcement action against Coinbase for allegedly selling unregistered securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to predict whether or when new laws will be enacted that change the legal framework governing digital assets or provide
additional authorities to the SEC, CFTC or other regulators, or whether or when any other federal, state or foreign legislative bodies
will take any similar actions. It is also not possible to predict the nature of any such additional laws or authorities, how additional
legislation or regulatory oversight might impact the ability of digital asset markets to function, the willingness of financial and other
institutions to continue to provide services to the digital assets industry, or how any new laws or regulations, or changes to existing
laws or regulations, might impact the use of $WLFI. It is possible that regulators may interpret laws in a manner that adversely affects
the liquidity, value, or ability to use our $WLFI holdings. Further, the acquisition of large amounts of $WLFI may become difficult or
more costly, which would make it more difficult for us to implement our strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
$WLFI were deemed to be a security, the value of $WLFI could be harmed and could create additional regulatory burdens and impact our
business operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application
of securities laws to the specific facts and circumstances of digital assets is complex, evolving and subject to change. As with other
digital assets, there is a risk that $WLFI could be deemed a security. Neither the SEC nor any other U.S. federal or state regulator
has publicly stated whether they believe that $WLFI is or is not a &ldquo;security,&rdquo; nor has any court addressed the status of
$WLFI under the U.S. federal securities laws or similar laws. We believe that $WLFI is not a &ldquo;security&rdquo; within the meaning
of the U.S. federal securities laws, but a regulator or federal court or other party may allege or determine otherwise. If $WLFI were
determined to be a security, our ability and the ability of others to acquire, trade, hold, use or otherwise enter into transactions
involving $WLFI would be more limited, and we could potentially be required to register as an investment company under the Investment
Company Act or reduce our holdings of $WLFI to fit within an exemption from such registration. If $WLFI were determined to be a security,
it could also have significant regulatory consequences for WLFI or other parties, including enforcement actions, fines, penalties, and
a requirement to register the token under U.S. federal securities laws. Any such developments could negatively impact the utility and
value of $WLFI, reducing liquidity on secondary markets if any, impose additional compliance and disclosure obligations on us, and adversely
affect the development and adoption of the WLF Protocol. Moreover, we could be required to register as a broker-dealer, alternative trading
system, or securities exchange, or to limit or cease certain activities altogether, which could materially and adversely impact our business,
financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of larger token positions may have the ability to exert more influence over governance decisions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
$WLFI tokens have equal voting power within the WLF Protocol, but no person may vote in excess of 5% of the outstanding votable $WLFI
token supply regardless of the number of $WLFI held by such person. WLFI has indicated that it intends to limit voting from any wallet
to 5% of the total token supply and, if known to WLFI, any wallets in which WLFI understands to be affiliated will be limited to 5% in
the aggregate of the total votable token supply. Nevertheless, WLFI may not be able to determine if wallets are affiliated. Some token
holders may seek to coordinate their votes to effectively increase their voting rights above the 5% threshold. The WLF Protocol restrictions
on any such efforts to thwart this voting threshold might not necessarily be successful in stopping such coordinated voting efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not participate in voting, we will not be able to influence decisions related to the WLF Protocol.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to participate in discussions around proposals, we must register with the WLF Forum. In order to vote, we must connect our token
wallet to Snapshot. We also may elect to use other third parties in the future for governance functionality. If one or more of these
parties becomes unavailable for any other reason, we may need to seek other solutions and our ability to make proposals or vote could
be limited for a period of time or indefinitely. $WLFI are being offered and sold for participation in governance of the WLF Protocol.
If we do not participate in governance, we will not be able to influence governance of the WLF Protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risk
of insufficient interest or participation in governance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Token
holder governance requires a minimum quorum of 5% of the total votable $WLFI token supply in order for a proposal to be effective. If
there are insufficient participants, proposals may not be effective even if a majority of participants vote affirmatively. The sole purpose
of purchasing $WLFI is to participate in governance of the WLF Protocol. As with purchases of other goods and services, the interest
or value token holders find in participating in such governance through $WLFI could change or decline over time for a variety of reasons.
For example, interest in participation in governance could change if there is limited participation by others in governance, token holders
decide to engage with alternative platforms or spend their time and energy otherwise, token holders disagree with governance decisions
on the WLF Governance Platform or otherwise, the WLF Protocol does not meet $WLFI token holders&rsquo; expectations, the popularity of
the brand or the brand of our co-founders and affiliates declines, or service agreements providing rights to be associated with that
brand are terminated. The WLF Protocol itself may not meet any person&rsquo;s expectations and is subject to a number of risks and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Proceeds
received by WLFI are not required to be used for development of the WLF Protocol.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
WLF Governance Platform has already been substantially developed, and WLFI has indicated that the WLF Governance Platform and $WLFI token
should be considered and purchased &ldquo;as is&rdquo; without further development. Certain parties have the rights to the proceeds from
the sale of $WLFI, and together with WLF and its affiliates, have full discretion as to how to apply proceeds from $WLFI or operation
of the WLFI platform. As a result, you should assume that WLFI will not use the proceeds from sales of $WLFI or other sources revenues
to develop or enhance the functionality of the $WLFI token or WLF Governance Platform, the WLFI Protocol or otherwise administer $WLFI
voting or use proceeds for any other particular purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
lack of legal recourse and insurance for digital assets increases the risk of total loss in the event of theft or destruction.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to hold $WLFI and other digital assets through our custodians and trade execution partners. Digital assets held in wallets or
with third-party custodians may not be insured or protected under federal deposit insurance programs such as Federal Deposit Insurance
Corporation insurance or the Securities Investor Protection Corporation or any other governmental or non-governmental insurer. Accordingly,
any loss you experience may not be offset by insurance payments or at all. If assets are lost due to theft, cybersecurity breaches, technical
failures, or insolvency of a custodian, there may be no legal recourse or available insurance to cover the loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$WLFI
are not subject to deposit insurance protection, including, but not limited to those from the FDIC or SIPC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face risks relating to the custody of $WLFI, including the loss or destruction of private keys required to access $WLFI and cyberattacks
or other data loss relating to $WLFI, including smart contract related losses and vulnerabilities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
We face risks relating to the custody of $WLFI, including the potential loss, theft, or destruction of private keys required to access
our tokens. If these keys are lost or compromised, we may be permanently unable to access our $WLFI holdings. In addition, cyberattacks,
smart contract vulnerabilities, or other technical failures, whether in our systems or those of third-party custodians, could result
in the loss or misappropriation of $WLFI and materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we or our third-party service providers experience a security breach or cyber-attack and unauthorized parties obtain access to its $WLFI
assets, we may lose some or all of our $WLFI assets and our financial condition and results of operations could be materially adversely
affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of the $WLFI we will hold is expected to be held in custody accounts at U.S.-based institutional-grade digital asset custodians.
Security breaches and cyberattacks are of particular concern with respect to our $WLFI. $WLFI and other blockchain-based cryptocurrencies
and the entities that provide services to participants in the $WLFI ecosystem have been, and may in the future be, subject to security
breaches, cyberattacks, or other malicious activities. For example, in October 2021, it was reported that hackers exploited a flaw in
the account recovery process and stole from the accounts of at least 6,000 customers of the Coinbase exchange, although the flaw was
subsequently fixed and Coinbase reimbursed affected customers. Similarly, in November 2022, hackers exploited weaknesses in the security
architecture of the FTX Trading digital asset exchange and reportedly stole over $400 million in digital assets from customers. A successful
security breach or cyberattack could result in a partial or total loss of our $WLFI in a manner that may not be covered by insurance
or the liability provisions of the custody agreements with the custodians who hold our $WLFI, harm to our reputation and brand, improper
disclosure of data and violations of applicable data privacy and other laws, or significant regulatory scrutiny, investigations, fines,
penalties, and other legal, regulatory, contractual and financial exposure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
any actual or perceived data security breach or cybersecurity attack directed at other companies with digital assets or companies that
operate digital asset networks, regardless of whether we are directly impacted, could lead to a general loss of confidence in the broader
$WLFI blockchain ecosystem or in the use of the $WLFI network to conduct financial transactions, which could negatively impact us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attacks
upon systems across a variety of industries, including industries related to $WLFI, are increasing in frequency, persistence, and sophistication,
and, in many cases, are being conducted by sophisticated, well-funded and organized groups and individuals, including state actors. The
techniques used to obtain unauthorized, improper or illegal access to systems and information (including personal data and digital assets),
disable or degrade services, or sabotage systems are constantly evolving, may be difficult to detect quickly, and often are not recognized
or detected until after they have been launched against a target. These attacks may occur on our systems or those of our third-party
service providers or partners. We may experience breaches of our security measures due to human error, malfeasance, insider threats,
system errors or vulnerabilities or other irregularities. In particular, we expect that unauthorized parties will attempt to gain access
to our systems and facilities, as well as those of our partners and third-party service providers, through various means, such as hacking,
social engineering, phishing and fraud. Threats can come from a variety of sources, including criminal hackers, hacktivists, state-sponsored
intrusions, industrial espionage, and insiders. In addition, certain types of attacks could harm us even if our systems are left undisturbed.
For example, certain threats are designed to remain dormant or undetectable, sometimes for extended periods of time, or until launched
against a target and we may not be able to implement adequate preventative measures. Further, there has been an increase in such activities
due to the increase in work-from-home arrangements. The risk of cyberattacks could also be increased by cyberwarfare in connection with
the ongoing Russia-Ukraine and Israel-Hamas conflicts, or other future conflicts, including potential proliferation of malware into systems
unrelated to such conflicts. Any future breach of our operations or those of others in the cryptocurrency industry, including third-party
services on which we rely, could materially and adversely affect our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we were deemed to be an investment company under the Investment Company Act, applicable restrictions likely would make it impractical
for us to continue our business as currently conducted and our $WLFI treasury functions as currently contemplated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Sections 3(a)(1)(A) and (C) of the Investment Company Act, a company generally will be deemed to be an &ldquo;investment company&rdquo;
if (i) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting,
or trading in securities or (ii) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding, or trading
in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets
(exclusive of U.S. government securities, shares of registered money market funds under Rule 2a-7 of the Investment Company Act, and
cash items) on an unconsolidated basis. Rule 3a-1 under the Investment Company Act generally provides that notwithstanding the Section
3(a)(1)(C) test described in clause (ii) above, an entity will not be deemed to be an &ldquo;investment company&rdquo; for purposes of
the Investment Company Act if no more than 45% of the value of its assets (exclusive of U.S. government securities, shares of registered
money market funds under Rule 2a-7 of the Investment Company Act, and cash items) consists of, and no more than 45% of its net income
after taxes (for the past four fiscal quarters combined) is derived from, securities other than U.S. government securities, shares of
registered money market funds under Rule 2a-7 of the Investment Company Act, securities issued by employees&rsquo; securities companies,
securities issued by qualifying majority owned subsidiaries of such entity, and securities issued by qualifying companies that are controlled
primarily by such entity. We do not believe that we are an &ldquo;investment company&rdquo; as such term is defined in either Section
3(a)(1)(A) or Section 3(a)(1)(C) of the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Section 3(a)(1)(A), following the proposed offering, substantially all of the proceeds of the proposed offering will be used
to acquire $WLFI, which is an amount in excess of 40% of our total assets. Since we believe $WLFI is not an investment security, we do
not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting, or trading
in securities within the meaning of Section 3(a)(1)(A) of the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Section 3(a)(1)(C), we believe we satisfy the elements of Rule 3a-1 and therefore are deemed not to be an investment company
under, and we intend to conduct our operations such that we will not be deemed an investment company under, Section 3(a)(1)(C). We believe
that we are not an investment company pursuant to Rule 3a-1 under the 1940 Act because, on a consolidated basis with respect to wholly-owned
subsidiaries but otherwise on an unconsolidated basis, no more than 45% of the value of the Company&rsquo;s total assets (exclusive of
U.S. government securities, shares of registered money market funds under Rule 2a-7 of the 1940 Act, and cash items) consists of, and
no more than 45% of the Company&rsquo;s net income after taxes (for the last four fiscal quarters combined) is derived from, securities
other than U.S. government securities, shares of registered money market funds under Rule 2a-7 of the 1940 Act, securities issued by
employees&rsquo; securities companies, securities issued by qualifying majority owned subsidiaries of the Company, and securities issued
by qualifying companies that are controlled primarily by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$WLFI
and other digital assets, as well as new business models and transactions enabled by blockchain technologies, present novel interpretive
questions under the Investment Company Act. There is a risk that assets or arrangements that we have concluded are not securities could
be deemed to be securities by the SEC or another authority for purposes of the Investment Company Act, which would increase the percentage
of securities held by us for Investment Company Act purposes. The SEC has requested information from a number of participants in the
digital asset ecosystem regarding the potential application of the Investment Company Act to their businesses. For example, in February
2022, the SEC issued a cease-and-desist order under the Investment Company Act to BlockFi Lending LLC, in which the SEC alleged that
BlockFi was operating as an unregistered investment company because it issued securities and also held more than 40% of its total assets,
excluding cash, in investment securities, including the loans of digital assets made by BlockFi to institutional borrowers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were deemed to be an investment company, Rule 3a-2 under the Investment Company Act is a safe harbor that provides a one-year grace
period for transient investment companies that have a bona fide intent to be engaged primarily, as soon as is reasonably possible (in
any event by the termination of such one-year period), in a business other than that of investing, reinvesting, owning, holding, or trading
in securities, with such intent evidenced by the company&rsquo;s business activities and an appropriate resolution of its board of directors.
The grace period is available not more than once every three years and runs from the earlier of (i) the date on which the issuer owns
securities and/or cash having a value exceeding 50% of the issuer&rsquo;s total assets on either a consolidated or unconsolidated basis
or (ii) the date on which the issuer owns or proposes to acquire investment securities having a value exceeding 40% of the value of such
issuer&rsquo;s total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. Accordingly, the grace
period may not be available at the time that we seek to rely on Rule 3a-2; however, Rule 3a-2 is a safe harbor and we may rely on any
exemption or exclusion from investment company status available to us under the Investment Company Act at any given time. Furthermore,
reliance on Rule 3a-2, Section 3(a)(1)(C), or Rule 3a-1 could require us to take actions to dispose of securities, limit our ability
to make certain investments or enter into joint ventures, or otherwise limit or change our service offerings and operations. If we were
to be deemed an investment company in the future, restrictions imposed by the Investment Company Act, including limitations on our ability
to issue different classes of stock and equity compensation to directors, officers, and employees and restrictions on management, operations,
and transactions with affiliated persons, likely would make it impractical for us to continue our business as contemplated, and could
have a material adverse effect on our business, results of operations, financial condition, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sales
by significant $WLFI holders could depress the price of the $WLFI token.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of the $WLFI token may decline significantly if large holders, including early supporters, team members, advisors, or others
associated with WLFI, sell their tokens or are perceived as likely to sell. These sales may occur on the open market or through private
transactions and could create significant downward pressure on the price of $WLFI, particularly if trading volumes are low or if the
sales are concentrated over a short period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the perception that such holders may sell in the near future, including upon the expiration of any contractual or voluntary lock-up periods,
could also negatively affect the market price. While certain $WLFI holders may be subject to lock-up agreements or vesting schedules
that restrict their ability to sell tokens for a specified period of time, these restrictions are limited in duration. Once such lock-up
or vesting periods expire, these parties could engage in substantial sales of $WLFI tokens, which could further impact the market price,
liquidity, and stability of the token.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
of our directors, officers and shareholders may have conflicts of interest which could diverge from the interests of other shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
closing of the offering, WLFI will own common stock and common stock equivalents and Eric Trump and Zach Witkoff are expected to be nominated
to serve as our directors. Eric Trump and Zach Witkoff, and their respective family members and affiliated entities or persons, have
direct or indirect economic interests in the proceeds received by WLFI from $WLFI token sales protocol fees from WLFI and income earned
from USD1 through equity ownership of affiliated entities and contractual rights. These directors have an interest in purchases by us
of $WLFI or other strategic initiatives involving WLFI. We have also agreed that WLFI may nominate our Chief Investment Officer subject
to our approval. As a result, the interests of our directors or WLFI may diverge from the interests of other shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
emergence of competing digital assets could reduce demand for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
emergence or growth of other digital assets, including those with significant private or public sector backing, including by governments,
consortiums or financial institutions, could have a negative impact on the price of $WLFI and adversely affect our listed securities.
We may face competition from new or existing blockchain networks, tokens, or decentralized applications that offer features or incentives
that attract users and capital away from our ecosystem. If users or developers shift their support to other digital assets perceived
as more secure, efficient, or valuable, demand for $WLFI could decline, adversely affecting its price and the success of the WLF Protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will be subject to significant competition in the growing digital asset industry and our business, operating results, and financial condition
may be adversely affected if we are unable to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the deployment of our proposed $WLFI treasury strategy, we will operate in a competitive environment and will compete against other companies
and other entities with similar strategies, including companies with significant holdings in Bitcoin, Ether and other digital assets,
and our business, operating results, and financial condition may be adversely affected if we are unable to compete effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
availability of spot exchange-traded products for $WLFI and other digital assets may adversely affect the market price of $WLFI and,
consequently, the trading price of listed securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
spot exchange-traded products (ETPs), such as ETFs or other publicly traded investment vehicles, become available for $WLFI or other
digital assets, they may provide investors with more convenient, regulated, or institutionally accepted avenues for digital asset exposure.
As a result, demand for $WLFI through decentralized protocols or non-traditional platforms may decline, which could negatively affect
market liquidity and reduce the price of $WLFI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our business, operations, or financial results are directly or indirectly tied to the value or usage of $WLFI, a decline in $WLFI&rsquo;s
price may adversely impact our performance and prospects. In addition, to the extent our valuation is correlated with the broader digital
asset market, the availability of spot ETPs may shift capital away from companies like ours and reduce investor interest in our listed
securities, adversely affecting its trading price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Digital
asset lending arrangements may expose us to risks of borrower default, operational failures and cybersecurity threats.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
If we engage in digital asset lending activities, we may be exposed to the risk that borrowers will fail to return the lent digital assets
or repay their obligations when due. Such defaults could result from credit risk, liquidity stress, market volatility, or insolvency
of the borrower, and may lead to a partial or total loss of the lent assets. In addition, digital asset lending arrangements often rely
on smart contracts, custodial partners, or third-party platforms that may be subject to operational errors, system outages, or cybersecurity
breaches. Exploits or vulnerabilities in smart contracts or custody infrastructure could result in the loss, theft, or misappropriation
of digital assets without recourse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also use portion of our $WLFI or other digital asset holdings as collateral to indebtedness, and we may incur additional indebtedness
or enter into other financial instruments in the future that may be collateralized by our $WLFI or other digital asset holdings. We may
also consider pursuing strategies to create income streams or otherwise generate funds using our $WLFI holdings. These types of $WLFI-related
transactions are the subject of enhanced regulatory oversight. These and any other $WLFI-related transactions we may enter into, beyond
simply acquiring and holding $WLFI, may subject us to additional regulatory compliance requirements and scrutiny, including under federal
and state money services regulations, money transmitter licensing requirements and various commodity and securities laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
irreversibility of digital asset transactions exposes us to risks of theft, loss and human error, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
asset transactions are irreversible and permanent. If custody or wallet keys are lost, compromised, or mis-transacted, the assets may
be permanently irretrievable. Such irreversibility errors may occur through human error, technical failures, or malicious compromise,
and could result in irrevocable loss of value and damage to our financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Digital
asset trading platform are often unregulated and lack transparency, which could lead to market manipulation or other risks beyond our
control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the unregulated nature and lack of transparency surrounding the operations of many digital asset trading venues, digital asset trading
venues may experience greater fraud, security failures or regulatory or operational problems than trading venues for more established
asset classes, which may result in a loss of confidence in digital asset trading venues and adversely affect the value of digital assets,
and our financial position, operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying base prospectus and the documents we have filed with the SEC that are incorporated by reference
herein and therein contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). In addition, from time to time we or our representatives
have made or will make forward-looking statements in various other filings that we make with the SEC or in other documents, including
press releases or other similar announcements. Forward-looking statements concern our current plans, intentions, beliefs, expectations
and statements of future economic performance. Statements containing terms such as &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;believe,&rdquo;
&ldquo;do not believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate&rdquo;
and other phrases of similar meaning are considered to be forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are based on our assumptions and are subject to known and unknown risks and uncertainties that could cause actual results
to differ materially from those reflected in or implied by these forward-looking statements. Factors that might cause actual results
to differ include, among others, those set forth under &ldquo;Risk Factors&rdquo; in this prospectus supplement and those discussed in
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation&rdquo; in our most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q and in our future periodic reports filed with the SEC, all of which are incorporated
by reference herein. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this prospectus
supplement, the accompanying base prospectus or the documents we have filed with the SEC that are incorporated by reference herein and
therein, which reflect management&rsquo;s views and opinions only as of their respective dates. We assume no obligation to update forward-looking
statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements, except
to the extent required by applicable securities laws. You are advised, however, to consult any additional disclosures we have made or
will make in the filings we make with the SEC, including reports on Forms 10-K, 10-Q and 8-K. All subsequent forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in
this prospectus supplement, the accompanying base prospectus or any related issuer free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue and sell shares of common stock having aggregate sales proceeds of up to $1.0 billion from time to time, before deducting
sales agent commissions and expenses. We are not guaranteed to receive any particular amount of proceeds from this offering. The amount
of proceeds we receive from this offering, if any, will depend upon the number of common shares sold and the market price at which they
are sold. We expect to use the net proceeds from the sale of our common stock offered under this prospectus supplement for working capital
and general corporate purposes and to fund the acquisition of WLFI and the establishment of the Company&rsquo;s cryptocurrency treasury
operations. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will
retain broad discretion over the allocation of net proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_006"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering you will experience dilution to the extent of the difference between the price per share
you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our historical
net tangible book value as of March 29, 2025, was approximately $(23,104,000), or $(1.07) per share of our common stock. Net tangible
book value per share as of March 29, 2025, is equal to our total tangible assets minus total liabilities, all divided by the number of
shares of common stock outstanding as of March 29, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the sale of our common stock in the aggregate amount of $1,000,000,000 at an assumed offering price of $8.97 per share,
the last reported sale price of our common stock on The Nasdaq Capital Market on August 8, 2025, and after deducting estimated offering
commissions and expenses payable by us, our net tangible book value as of March 29, 2025, would have been approximately $999,496,000
or $8.21 per share of common stock. This represents an immediate increase in the net tangible book value of approximately $9.28 per share
of common stock as a result of this offering and immediate dilution of approximately $0.76 per share to new investors. The following
table illustrates this per share dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 240pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Offering price per share</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.97</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net tangible book value per share as of
    March 29, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1.07</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decrease in net tangible
    book value per share attributable to this offering</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.28</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">As adjusted net tangible
    book value per share as of March 29, 2025 after giving effect to this offering</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.21</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dilution per share to
    investors purchasing shares in this offering</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.76</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Assuming a purchase price of&thinsp;$8.97 the closing price of our common stock on August 8, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock shown above is based on 21,609,376 shares outstanding as of March 29, 2025, and excludes, as of
such date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,432,460
    shares of our common stock reserved for issuance pursuant to the conversion of 749,460 shares of preferred stock; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,591,935
    shares of our common stock reserved for issuance upon exercise of outstanding warrants having a weighted average exercise price of
    $2.91.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above illustration of dilution per share to investors participating in this offering assumes no conversion of outstanding shares of preferred
stock and no exercise of outstanding warrants to purchase shares of our common stock. The conversion of outstanding shares of preferred
stock or exercise warrants having a conversion price per share or exercise price per share that is less than the offering price per share
will increase dilution to investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an At the Market Sales Agreement with A.G.P., under which we may offer and sell shares of common stock from time to
time through A.G.P. acting as agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our shares of common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that
is deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly
on the Nasdaq Capital Market, on any other existing trading market for shares of our common stock or to or through a market maker. If
we and A.G.P. agree on any method of distribution other than sales of shares of our common stock on or through the Nasdaq Capital Market
or another existing trading market in the United States at market prices, we will file a further prospectus supplement providing all
information about such offering as required by Rule 424(b) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time we wish to issue and sell shares of common stock under the Sales Agreement, we will provide A.G.P. with a placement notice including
the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to
be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed A.G.P., unless A.G.P. declines
to accept the terms of such notice, A.G.P. has agreed to use its commercially reasonable efforts, consistent with its normal trading
and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market, to sell
such shares up to the amount specified on such terms. The obligations of A.G.P. under the Sales Agreement to sell our shares of common
stock are subject to a number of conditions that we must meet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
for sales of shares of common stock between us and A.G.P., unless the parties agree otherwise, will occur on the second trading day,
or the relevant standard settlement period then in effect, following the date on which any sales are made in return for payment of the
net proceeds to us. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through the facilities
of The Depository Trust Company or by such other means as we and A.G.P. may agree upon. There is no arrangement for funds to be received
in an escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay A.G.P. a commission equal to 2.5% of the gross sales price per share on the first $500 million of common stock sold and 2.0%
of the gross sales price per share on all sales of shares of common stock sold thereafter. Because there are no minimum sale requirements
as a condition to this offering, the actual total public offering price, commissions and net proceeds to us, if any, are not determinable
at this time. The actual dollar amount and number of shares of common stock we sell through this Prospectus Supplement will be dependent,
among other things, on market conditions and our capital raising requirements. Pursuant to the terms of the Sales Agreement, we have
agreed to reimburse the A.G.P. in the amount not to exceed $100,000 for its reasonable and documented out-of-pocket costs and expenses
(including but not limited to the reasonable and documented fees and expenses of its legal counsel) incurred in connection with the Sales
Agreement, and for the reasonable and documented out-of-pocket expenses related to quarterly maintenance of the Sales Agreement (including
but not limited to the reasonable and documented fees and disbursements of its legal counsel) on a quarterly basis in an amount not to
exceed $20,000 per quarter (and no more than $80,000 per fiscal year), and up to an additional $25,000 for each additional program &ldquo;refresh&rdquo;
(filing of a new registration statement, prospectus, or prospectus supplement relating to the shares of common stock sold pursuant to
the Sales Agreement and/or an amendment of the Sales Agreement). We estimate that the total expenses for the offering, excluding any
commissions or expense reimbursement payable to A.G.P. under the terms of the Sales Agreement, will be approximately $350,000. The remaining
sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory
organization in connection with the sales, will equal our net proceeds for the sale of such shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P.
will provide written confirmation to us before the open on the Nasdaq Capital Market on the day following each day on which our shares
of common stock are sold under the Sales Agreement. Each confirmation will include the number of shares of common stock sold on such
day, the volume-weighted average price of the common stock, the compensation payable by us to A.G.P. with respect to such sales, and
the net proceeds payable to us, with an itemization of the deductions made by A.G.P. from the gross proceeds that it receives from such
sales</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of our shares of common stock on our behalf, A.G.P. will be deemed to be an &ldquo;underwriter&rdquo; within
the meaning of the Securities Act, and the compensation of A.G.P. will be deemed to be underwriting commissions or discounts. We have
agreed to provide indemnification and contribution to A.G.P. against certain civil liabilities, including liabilities under the Securities
Act and the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P.
will not engage in any market making activities involving shares of our common stock while the offering is ongoing under this prospectus
supplement if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act. As our
sales agent, A.G.P. will not engage in any transactions that stabilize shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of our shares of common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all shares
of common stock subject to the Sales Agreement, and (ii) the termination of the Sales Agreement as permitted therein. We may terminate
the Sales Agreement in our sole discretion at any time by giving five days&rsquo; prior notice to A.G.P. Further, A.G.P. may terminate
the Sales Agreement under the circumstances specified in the Sales Agreement and in its sole discretion at any time by giving three days&rsquo;
prior notice to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. The
Sales Agreement will be filed with the SEC and will be incorporated by reference into this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P.
and/or its affiliates have in the past engaged, and may in the future engage, in transactions with, and may perform, from time to time,
investment banking and advisory services for us in the ordinary course of their business and for which it would receive customary fees
and expenses. In addition, in the ordinary course of its business activities, A.G.P. and its affiliates may make or hold a broad array
of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including
bank loans) for its own account and for the accounts of its customers. Such investments and securities activities may involve securities
and/or instruments of ours or our affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2025, A.G.P. acted as the sole placement agent in the Registered Direct Offering for total approximate gross proceeds of $750,000,000
and the PIPE Offering for total approximate gross proceeds of $750,000,000. In the Registered Direct Offering, A.G.P. received a cash
fee equal to 3.0% of the aggregate gross proceeds raised and was issued warrants to purchase 3,000,000 shares of common stock,
equal to 3.0% of the securities sold in the Registered Direct Offering. We also reimbursed A.G.P. for out-of-pocket expenses up to $475,000,
including legal fees, in connection with the Registered Direct Offering. In the PIPE Offering, A.G.P. received a cash fee of $6,500,000
for all World Liberty Financial tokens paid in excess of $500,000,000 and 3.0% of the aggregate gross proceeds of the securities sold
in the PIPE Offering. The Company also issued A.G.P warrants to purchase shares of common stock, equal to 3.0% of the pre-funded warrants
sold in the PIPE Offering. We also reimbursed A.G.P. for out-of-pocket expenses up to $475,000, including legal fees, in connection
with the PIPE Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying base prospectus in electronic format may be made available on a website maintained by A.G.P.,
and A.G.P. may distribute the prospectus supplement and the accompanying base prospectus electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the issuance of the shares of our common stock offered by this prospectus supplement will be passed upon for us by
Lucosky Brookman LLP, Woodbridge, New Jersey. Sullivan &amp; Worcester LLP, New York, New York and Herbert Smith Freehills Kramer (US)
LLP are acting as counsel for A.G.P. in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of our Company as of December 28, 2024 and December 30, 2023 and for each of the two years in the period
ended December 28, 2024 incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 28,
2024, have been so incorporated in reliance on the report of Hudgens CPA, PLLC, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting. The report contains an explanatory paragraph regarding our ability
to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC permits us to &ldquo;incorporate by reference&rdquo; the information and reports we file with it. This means that we can disclose
important information to you by referring to another document. The information that we incorporate by reference is considered to be part
of this prospectus supplement, and later information that we file with the SEC automatically updates and supersedes this information.
We incorporate by reference the documents listed below, except to the extent information in those documents is different from the information
contained in this prospectus supplement, and all future documents filed with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the
Exchange Act (other than filings or portions thereof, including exhibits, deemed to be furnished to the SEC pursuant to Item 9 or Item
12 of Form S-3) until we terminate the offering of these securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025015469/alts-20241228.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 28, 2024, filed with the SEC on March
                                            28, 2025;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            description of our securities contained filed as <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-ex4_1.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to our Annual Report on Form
                                            10-K for the fiscal year ended December 28, 2024, including any amendments or reports filed
                                            for the purpose of updating such information;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Quarterly Reports on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025025004/jan-20250329.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the quarters ended March 29, 2025, filed with the SEC
                                            on May 13, 2025; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Current Reports on Form 8-K, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025027114/jan-20250521.htm" STYLE="-sec-extract: exhibit">May
                                            21, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025028621/jan-20250530.htm" STYLE="-sec-extract: exhibit">May
                                            30, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025034268/jan-20250627.htm" STYLE="-sec-extract: exhibit">July
                                            3, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025035754/jan-20250509.htm" STYLE="-sec-extract: exhibit">July
                                            23, 2025</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/862861/000164117225022905/form8-k.htm" STYLE="-sec-extract: exhibit">August 11, 2025</A>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any statement in this prospectus supplement is inconsistent with any statement that is incorporated by reference and
that was made on or before the date of this prospectus supplement, the statement in this prospectus supplement shall supersede such incorporated
statement. The incorporated statement shall not be deemed, except as modified or superseded, to constitute a part of this prospectus
supplement or the registration statement. Statements contained in this prospectus supplement as to the contents of any contract or other
document are not necessarily complete and, in each instance, we refer you to the copy of each contract or document filed as an exhibit
to our various filings made with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide to each person, including any beneficial owner, to whom a prospectus supplement is delivered, without charge upon written
or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement but not delivered
with the prospectus supplement, including exhibits which are specifically incorporated by reference into such documents. You may request
a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325
E. Warm Springs Road, Suite 102</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Las
Vegas, NV 89119</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(702) 997-5968</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Peter Tassiopoulos</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement under the Securities Act that registers the securities offered hereby. The registration
statement, including the exhibits and schedules attached thereto and the information incorporated by reference therein, contains additional
relevant information about the securities and our Company, which we are allowed to omit from this prospectus supplement pursuant to the
rules and regulations of the SEC. In addition, we file annual, quarterly and current reports and proxy statements and other information
with the SEC. Our SEC filings are available on the SEC&rsquo;s website at www.sec.gov. Copies of certain information filed by us with
the SEC are also available on our website at www.meipharma.com. We have not incorporated by reference into this prospectus supplement
the information on our website and it is not a part of this document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,000,000,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell from time to time shares of our common stock, par value $0.001 per share (our &ldquo;Common Stock&rdquo;), shares
of our preferred stock, par value $0.001 per share (our &ldquo;Preferred Stock&rdquo;), debt securities, warrants, rights, and units
that include any of these securities. The Preferred Stock or warrants may be convertible into or exercisable for shares of our Common
Stock or shares of our Preferred Stock or other of our securities registered hereunder. The debt securities may be convertible into or
exchangeable for shares of our Common Stock or shares of our Preferred Stock. Our Common Stock is listed on The Nasdaq Capital Market
and trades under the symbol &ldquo;ALTS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell these securities to or through one or more underwriters, dealers, and agents, or directly to purchasers, on a continuous
or delayed basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of our outstanding Common Stock held by non-affiliates was approximately $117,742,554, based on 20,142,951
shares of outstanding Common Stock as of July 29, 2025, of which approximately 633,000 shares were held by affiliates, and based on the
closing sale price of our Common Stock of $6.035 on July 29, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be offered.
The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in a supplement
to this prospectus. You should read this prospectus and any applicable prospectus supplement carefully before you invest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
the &ldquo;Risk Factors&rdquo; section of this prospectus on page 3, our filings with the SEC, and the applicable prospectus supplement
for certain risks that you should consider before investing in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None
of the Securities and Exchange Commission, any state securities commission, or any other regulatory body has approved or disapproved
of these securities nor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is August 8, 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVAILABLE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>
                                                                            <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#ke_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_001">DESCRIPTION OF SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_002">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">44</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_003">DESCRIPTION OF PREFERRED STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_004">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_005">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_006">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_007">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">64</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_008">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_009">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">65</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_010">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_011">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ke_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is called a prospectus and is part of a Registration Statement on Form S-3 that we have filed with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may, from
time to time, sell any combination of the securities described in this prospectus in one or more offerings in amounts that we will determine
from time to time, up to a total dollar amount of $2,000,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities
described in this prospectus we will provide a prospectus supplement, incorporate information or document by reference into this prospectus
or a related free writing prospectus or use other offering materials, as applicable, containing more specific information about the terms
of the securities that are then being offered. We may also authorize one or more related free writing prospectuses to be provided to
you that may contain material information relating to these offerings and securities. This prospectus, together with applicable prospectus
supplements, any information or document incorporated by reference, and any related free writing prospectus or other offering materials,
as applicable, we file with the SEC, includes all material information relating to these offerings and securities. We may also add, update,
or change in the prospectus supplement any of the information contained in this prospectus or in the documents that we incorporate by
reference into this prospectus, including, without limitation, a discussion of any risk factors or other special considerations that
apply to these offerings or securities or the specific plan of distribution. If there is any inconsistency between the information in
this prospectus and a prospectus supplement or information or document incorporated by reference having a later date, you should rely
on the information in that prospectus supplement or incorporated information having a later date. We urge you to read carefully this
prospectus, any applicable prospectus supplement, and any related free writing prospectus or other offering materials, as applicable,
together with the information incorporated herein by reference as described under the heading &ldquo;Incorporation of Certain Information
by Reference,&rdquo; before buying any of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information we have provided in, or incorporated by reference into, this prospectus, any applicable prospectus
supplement, and any related free writing prospectus or other offering materials, as applicable. We have not authorized anyone to provide
you with different information. No dealer, salesperson, or other person is authorized to give any information or to represent anything
not contained in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials,
as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the delivery of this prospectus nor any sale made under it implies that there has not been any change in our business or affairs or that
the information in this prospectus is correct as of any date after the date of this prospectus. You should assume that the information
in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable,
is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only
as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus
supplement, any related free writing prospectus, or other offering materials, as applicable, or any sale of a security.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registration Statement containing this prospectus, including exhibits to the Registration Statement, provides additional information
about us and the securities offered under this prospectus and any prospectus supplement. We have filed and plan to continue to file other
documents with the SEC that contain information about us and our business. Also, we will file legal documents that control the terms
of the securities offered by this prospectus as exhibits to the reports that we file with the SEC. The Registration Statement and other
reports can be read at the SEC Internet site or at the SEC offices mentioned under the heading &ldquo;Available Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains summaries of certain provisions contained in some of the documents described herein; but, reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the Registration
Statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &ldquo;Available
Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ke_002"></A>AVAILABLE
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a Registration Statement on Form S-3 under the Securities Act with respect to the securities covered by this
prospectus. This prospectus, which is a part of that Registration Statement, does not contain all of the information set forth in the
Registration Statement or the exhibits and schedules filed therewith. For further information with respect to us and the securities covered
by this prospectus, please see the Registration Statement and the exhibits filed with the Registration Statement. A copy of the Registration
Statement and the exhibits filed with the Registration Statement may be inspected without charge at the Public Reference Room maintained
by the SEC, located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the
operation of the Public Reference Room. The SEC also maintains an Internet website that contains reports, proxy and information statements,
and other information regarding registrants that file electronically with the SEC. The address of the website is http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and, in accordance therewith, we file periodic reports, proxy statements, and other information with the SEC. Such periodic
reports, proxy statements, and other information are available for inspection and copying at the Public Reference Room and website of
the SEC referred to above. We maintain a website at http://www.alt5sigma.com. You may access our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed pursuant to Sections 13(a) or 15(d) of the Exchange
Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the SEC. Our website and the information contained on that site, or connected to that site, are not incorporated into and
are not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ke_003"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC&rsquo;s rules allow us to incorporate by reference information into this prospectus. This means that we can disclose important information
to you by referring you to another document. Any information referred to in this way is considered part of this prospectus from the date
we file that document. Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of
the securities by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained
in this prospectus or incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this prospectus the following documents or information filed with the SEC (other than, in each case, documents
or information deemed to have been furnished and not filed in accordance with SEC rules):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025015469/alts-20241228.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 28, 2024, filed with the SEC on March 28, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025025004/jan-20250329.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the quarter ended March 29, 2025, filed with the SEC on May 13, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025025405/jan-20250513.htm" STYLE="-sec-extract: exhibit">May 14, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025027114/jan-20250521.htm" STYLE="-sec-extract: exhibit">May 21, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025028621/jan-20250530.htm" STYLE="-sec-extract: exhibit">May 30, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025034268/jan-20250627.htm" STYLE="-sec-extract: exhibit">July 3, 2025</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828025035754/jan-20250509.htm" STYLE="-sec-extract: exhibit">July&nbsp;23, 2025</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our Common Stock is filed as <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-ex41_182.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to our Annual Report on Form 10-K for the year ended December 28, 2019, filed
    with the SEC on April 6, 2020.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
all documents filed by us with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, after (i) the date of the initial
Registration Statement and prior to effectiveness of the Registration Statement and (ii) the date of this prospectus and before the termination
or completion of this offering, shall be deemed to be incorporated by reference into this prospectus from the respective dates of filing
of such documents, except that we do not incorporate any document or portion of a document that is &ldquo;furnished&rdquo; to the SEC,
but not deemed &ldquo;filed.&rdquo; Any information that we subsequently file with the SEC that is incorporated by reference as described
above will automatically update and supersede any previous information that is part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written
or oral request, a copy of any or all documents referred to above that have been or may be incorporated by reference into this prospectus,
excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. Written or telephone
requests should be directed to ALT5 Sigma Corporation, 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119, Attention: Corporate
Secretary; telephone: (702) 997-5968.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ke_004"></A>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, including the documents we incorporate by reference into it, contains forward-looking statements within the meaning of Section
27A of the Securities Act, and Section 21E of the Exchange Act, the Private Securities Litigation Reform Act of 1995 (the &ldquo;PSLRA&rdquo;)
or in releases made by the SEC. Such statements include, without limitation, statements regarding our expectations, hopes, or intentions
regarding the future. Statements that are not historical fact are forward-looking statements. These forward looking statements can often
be identified by their use of words such as &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;outlook,&rdquo;
&ldquo;could,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; and &ldquo;assume,&rdquo; as well as variations of such words and similar
expressions referring to the future. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act, and
the PSLRA with the intention of obtaining the benefits of the &ldquo;safe harbor&rdquo; provisions of such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in or incorporated by reference into this prospectus are largely based on our expectations, which
reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently
known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain
and involve certain risks and uncertainties, many of which are beyond our control. If any of those risks and uncertainties materialize,
actual results could differ materially from those discussed in any such forward-looking statement. Among the factors that could cause
actual results to differ materially from those discussed in forward-looking statements are those discussed under the heading &ldquo;Risk
Factors&rdquo; below, those discussed under the heading &ldquo;Risk Factors&rdquo; and in other sections of our Annual Report on Form
10-K for the year ended December 28, 2024, as well as in our other reports filed from time to time with the SEC that are incorporated
by reference into this prospectus. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
for information about how to obtain copies of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
readers are cautioned that the forward-looking statements contained in this prospectus and in the documents incorporated by reference
into this prospectus are not guarantees of future performance, and we cannot assure any reader that such statements will be realized
or that the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied
in the forward-looking statements. All forward-looking statements in this prospectus and the documents incorporated by reference into
it are made only as of the date of the document in which they are contained, based on information available to us as of the date of that
document, and we caution you not to place undue reliance on forward-looking statements in light of the risks and uncertainties associated
with them. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new
information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ke_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk
Factors&rdquo; contained in, or incorporated into, the applicable prospectus supplement, any related free writing prospectus, or other
offering materials, as applicable, and under similar headings in the other documents that are incorporated by reference herein or therein.
Each of the referenced risks and uncertainties could adversely affect our business, operating results, and financial condition, as well
as adversely affect the value of an investment in our securities. When we offer and sell any securities pursuant to a prospectus supplement,
we may include additional risk factors relevant to such securities in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ke_006"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma Corporation (formerly known as JanOne Inc.) and subsidiaries (collectively, &ldquo;we,&rdquo; &ldquo;us,&rdquo; the &ldquo;Company,&rdquo;
or &ldquo;ALT5&rdquo;). Through our Fintech segment, the Company provides next generation blockchain-powered technologies to enable a
migration to a new global financial paradigm, and, through our Biotechnology segment, we are focused on finding treatments for conditions
that cause chronic pain and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2024, the Company acquired ALT5 Sigma, Inc., and on July 15, 2024, changed its corporate name from JanOne Inc. to ALT5 Sigma
Corporation. ALT5 Sigma, Inc., is a financial services and Fintech holding company. ALT5 Sigma, Inc. was created by financial industry
specialists out of the necessity to provide the digital asset economy with the best practices of the industry and state of the art over-the-counter
trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, the Company operated its discontinued legacy businesses through its Recycling Subsidiaries, consisting of: (a) ARCA Recycling,
Inc., a California corporation (&ldquo;ARCA Recycling&rdquo;), (b) ARCA Canada Inc., a corporation organized under the laws of Ontario,
Canada (&ldquo;ARCA Canada&rdquo;), and (c) Customer Connexx, LLC, a Nevada limited liability company (&ldquo;Connexx&rdquo;). ARCA Recycling
and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services
for utilities and other sponsors of energy efficiency programs. Connexx is a company that provides call center services for recycling
businesses. On March 9, 2023, we entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation,
a Delaware corporation (&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling
Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in or accessible from our website is not incorporated into this Registration Statement on Form S-3 and the included
prospectus, and it should not be considered a part hereof. We have included our website address herein solely as an inactive textual
reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s legal address is located at 325 E Warm Springs Road, Suite 102, Las Vegas, NV 89119, with subsidiary offices in Newmarket,
and Montreal, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Fintech</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: &ldquo;ALT5 Pay&rdquo; and &ldquo;ALT5 Prime.&rdquo;
ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency
payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or
ALT5 Pay&rsquo;s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros,
and British Pounds Sterling) automatically or to receive their payment in digital assets. ALT5 Prime is an electronic over-the-counter
trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets
with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access, mobile phone
application named &ldquo;ALT5 Pro&rdquo; that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime&rsquo;s
FIX API, as well as through Broadridge Financial Solutions&rsquo; NYFIX gateway for approved customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma, Inc., has four wholly-owned subsidiaries, ALT5 Sigma Canada, Inc., ALT5 Securities, Inc., ALT5, Inc., and Fortress II
Holdings <FONT STYLE="letter-spacing: -0.2pt">Ltd. </FONT>d/b/a <FONT STYLE="letter-spacing: -0.1pt">MSwipe</FONT>. ALT5 Sigma Canada,
Inc. has four wholly-owned subsidiaries, ALT5 AI, Inc. (Canada), ALT5 Pro, LLC. (Saint-Vincent and the Grenadines), UAB ALT5 Sigma Prudentia
(Lithuania), and ALT5 Sigma Prudentia s.r.o. (Czech Republic), formerly Cypherlynx s.r.o.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma, Inc. develops, commercializes products and services based on four key fundamental principles of 1) Safety, Security and Trust,
2) Accessibility 3) Regulations, and 4) Transparency:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safety,
Security and Trust</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
and deploy products and services that increase our clients and customers&rsquo; trust in our organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accessibility</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
and deploy products and services that are easy to use, accessible everywhere and with no barriers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deploy
and deploy the best practices in the industry to comply with KYC, KYT, AML reporting and always be at the forefront of all regulatory
requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transparency</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
and deploy the best practices in financial reporting, as well as best practices in communication of all material events for all stakeholders,
<U>i.e.</U>, customers, shareholders, suppliers and employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Background</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Corporate
History and Organizational Structure</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma, Inc. was formed and incorporated in the State of Delaware on March 5, 2018 under the name Buttonwood ARCA Inc.&nbsp;On March 28,
2018, it filed a Certificate of Amendment with the State of Delaware changing its name to ALT5 Sigma, Inc. It entered into a Share Exchange
and Reorganization Agreement on March 21, 2018 with Soci&eacute;t&eacute; AVA Inc., a Canadian corporation, and as a result Soci&eacute;t&eacute;
AVA Inc. became its wholly-owned subsidiary. On March 28, 2018 Soci&eacute;t&eacute; AVA Inc. changed its name to ALT5 Sigma Canada Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 14, 2019, ALT5 Sigma Canada Inc. acquired 100% of Miningcrypt Inc., a Canadian crypto currency mining company, and on November
25, 2019, Miningcrypt Inc., changed its name to ALT5 AI Inc.&nbsp;On October 31, 2020, due to a severe storm, the mining equipment suffered
fatal damages and the mining operations ceased.&nbsp;ALT5 AI Inc. is intended to be used to hold intellectual properties and develop
machine learning and or artificial intelligence software.&nbsp;ALT5 AI Inc., does not currently have any assets and is not currently
operating.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2020, ALT5 Sigma Canada Inc., formed a wholly-owned limited liability company named ALT5 Pro LLC in the country of Saint-Vincent
and the Grenadines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2023, ALT5 Sigma Canada Inc., formed a wholly-owned corporation in the country of Lithuania named UAB ALT5 Sigma Prudentia
and has applied for a cryptocurrency exchange license with the Central Bank of Lithuania.&nbsp;The application was filed and is pending
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2023, ALT5 Sigma, Inc., formed a wholly-owned corporation in the State of New York, by the name of ALT5 Securities Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2023, ALT5 Sigma Canada Inc., acquired all of the shares of a company in the Czech Republic by the name of Cypherlynx s.r.o.&nbsp;Cypherlynx
s.r.o. has limited operating history and is licensed in the Czech Republic to operate a cryptocurrency exchange. A name change to ALT5
Sigma Prudentia s.r.o. is pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2024, ALT5 Sigma, Inc. was acquired by JanOne Inc. (now known as ALT5 Sigma Corporation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2025, ALT5 Sigma, Inc., formed a wholly-owned corporation in the State of Wyoming, by the name of ALT5, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 9, 2025, ALT5 Sigma, Inc., acquired Fortress II Holdings Ltd. d/b/a MSwipe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organizational
Structure Chart</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="chart_001.jpg" ALT="" STYLE="height: 419px; width: 750px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Executive
Summary</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma, Inc., is a financial services and Fintech holding company. ALT5 Sigma, Inc. was created by financial industry specialists out
of the necessity to provide the digital asset economy with the best practices of the industry and state of the art over-the-counter trading
of securities. ALT5 Sigma, Inc., owns four distinct wholly-owned subsidiaries, ALT5 Sigma Canada Inc., ALT5 Securities Inc., ALT5,
Inc., and Fortress II Holdings <FONT STYLE="letter-spacing: -0.2pt">Ltd. </FONT>d/b/a <FONT STYLE="letter-spacing: -0.1pt">MSwipe.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma Canada Inc. provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment,
and custodianship of digital assets through its wholly-owned subsidiaries. ALT5 Sigma Canada has four-wholly-owned subsidiaries, ALT5
AI Inc., ALT5 Pro LLC, UAB ALT5 Sigma Prudentia, and ALT5 Prudentia s.r.o.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma Canada group of companies&rsquo; products and services are targeted at business-to-business (B2B) only and not a retail clientele.&nbsp;The
global target market for ALT5 Sigma Canada group of companies are banks, broker-dealers, funds, family offices, proprietary trading firms,
liquidity providers, financial information providers, and merchants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business
Model/ Revenue Model</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company obtains its revenue from initial installation fees or setup fees, monthly maintenance fees, spreads, and transaction commissions
and fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Our
Clients</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and services are marketed to banks, broker-dealers, funds, family offices, proprietary trading firms, liquidity providers, financial
information providers, payment processing partners, and merchants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a total of approximately 1,900 corporate clients&rsquo; customers located in 50 countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Product
Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ALT5
Prime</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Prime is an electronic over-the-counter trading platform, enabling registered and approved customers to buy and sell digital assets.&nbsp;Customers
can purchase digital assets with US dollars, Canadian dollars, Euros, and British Pounds and customers may sell digital assets and receive
US dollars, Canadian dollars, Euros, and British Pounds. ALT5 Prime is available through a browser-based access, mobile phone application
named ALT5 Pro that can be downloaded from the Apple store and Google Play store, or through the company&rsquo;s FIX API as well as through
Broadridge&rsquo;s NYFIX gateway to approved customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on their geographic location, registered and approved customers may buy and sell a number of digital assets including, but not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Symbol</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Symbol</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Symbol</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AAVE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aave</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DASH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SNX</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetix</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apecoin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOGE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dogecoin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SOL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solana</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardano</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polkadot</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUSHI</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sushiswap</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALGO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Algorand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ETH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ethereum</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRUMP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official
    Trump</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATOM</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cosmos</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FTM</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fantom
    / Sonic</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRX</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tron</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoCrypto</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HKD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HongKongDao</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNI</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uniswap</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVAX</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avalanche</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LINK</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chainlink</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USDC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD
    Coin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin-Cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LTC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litecoin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USDT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tether
    USD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BNB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BNB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decentraland</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UST</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TerraClassicUSD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BSV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
    SV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATIC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XLM</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stellar</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BTC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MKR</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maker</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XRP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ripple</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BTCN</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BitcoinNote</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MXN</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moneta
    Digital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTZ</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tezos</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QNT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YFI</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yearn.finance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DAI</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dai</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHIB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shiba-inu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Prime screen sample:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_003.jpg" ALT="A screen shot of a graph&#10;&#10;AI-generated content may be incorrect." STYLE="height: 252px; width: 453px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ALT5
Pay</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Pay is a crypto currency payment gateway enabling registered and approved global merchants to accept and make crypto currency payments
or integrate the payment platform into their application or operations using the plug in with WooCommerce and or the company&rsquo;s
checkout widgets and APIs. Merchants have the option to automatically convert to US dollars, Canadian Dollars, Euros, and British Pound
or hold the digital assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Pay screen sample:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_004.jpg" ALT="A computer and a phone&#10;&#10;AI-generated content may be incorrect." STYLE="height: 261px; width: 393px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability
    to offer multiple digital assets</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accept
    fiat deposits (USD, CAD, EUR and GBP).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    24/7</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supported
    order types including market, limit and stop</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    backend control through customizable administration dashboard.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endpoints
    supporting connections to trading interfaces, API, and related user-directed systems</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    trades for clients</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrated
    system to document customer KYC for onboarding process</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automated
    trade confirmation email and customized Monthly statements</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Connect
    to FIX, Binary, WebSocket, REST and custom APIs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability
    to place edit and cancel limit orders into order book via API</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Run
    reports, transactions, treasury</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlimited
    Accounts per user</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlimited
    user profile</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    setting protections in force to prevent unauthorized account activity, including unusual withdrawal requests.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal
    Service interaction utilize separate authentication contexts and are not exposed to the Internet.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    platform data is replicated and backed up in real-time.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    website data is transmitted via encrypted transport layer security (TLS) connections (<U>i.e.</U>, HTTPS).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Built
    in protection against brute force denial of service (DoS) and distributed denial of service (DDoS) attacks and active whitelist/blacklist </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cold
    Storage Wallet Management.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">management control.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Encrypted
    User Information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    Factor authentication.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
Features</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 2%">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
    available views, including price chart, depth chart, order book and recent trades ticker.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%">&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    11 available trendlines styles including rays, angles and arrows.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Live order book displays buy and sell orders with live spread calculation.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18
available pitchforks styles including pitchforks, Gann boxes, and Fibonacci&rsquo;s.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Six chart styles including line, bar, area and candles.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9
available brushes including ellipses, triangles and rectangles.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability to set custom chart durations ranging from one minute to years.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12
available test box styles including flag marks, arrows and price labels.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Ability to customize color and styles of bars, borders, wicks, price lines, backgrounds, and grid.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14
available pattern descriptors including cypher, ABCD, and Elliott formations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
    scale styles including auto, percentage and logarithmic.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9
available forecasting markers including bars, ghosts, spreads and areas.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability
to report block trade Integrated ability to save current chart view to jpeg.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300+
available icons to markup charts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58
available indicators, including linear.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Custom area measurement tool to find duration percentage change and price change Automatic calculation of fees included in order
    price.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     Regression curves, moving averages and oscillators</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
custom user reports including trade activity, transaction activity, and treasury activity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&#9642;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability
to draw custom trendlines, pitchforks, and more that scales and move with chart</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Competition</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
digital assets market for our ALT5 Prime and ALT5 Pay products and services is a relatively new industry and only a handful of companies
have emerged as recognized brands providing exchange or trading platforms such as Coinbase, Kraken, and Binance.&nbsp;These platforms
target the retail digital asset investors but currently account for the largest trading volume in dollar equivalent and number of coins
traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that some of the leading financial institutions license or buy the technology and services necessary to be able to effectively
and quickly provide these services to their customers and prevent the attrition of assets under management due to the movement of same
to digital assets investments and whereby the ALT5 products are services are highly advantageous for these customers as they provide
a best-of-breed solutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Market
Size</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and services are designed for banks, broker-dealers, funds, family offices, proprietary trading firms, liquidity providers,
financial information providers, and merchants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
main target market and focus are FINRA-registered broker-dealers and global merchants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the most recent information from FINRA, there are 3,712 broker-dealers registered and under FINRA&rsquo;s supervision, representing
629,112 registered representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 2024, the U.S. equity markets remain the largest globally, with a market capitalization of approximately $63 trillion, accounting
for over 50% of the global equity market&rsquo;s value (<I>Morningstar)</I>. This reflects significant growth from previous years, with
the U.S. market adding nearly $11 trillion in value in 2024 alone. In comparison, the global digital assets market experienced substantial
growth in 2024, with its market capitalization nearly doubling to approximately $3.91 trillion by mid-December, before consolidating
at $3.40 trillion (<I>Crowdfund Insider)</I>. Bitcoin continues to lead the digital assets market, maintaining a significant share of
the total market capitalization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
project that 3% of assets currently allocated to U.S. equities will transition to digital assets over the next 36 to 60 months. Based
on the current U.S. equity market capitalization of $63 trillion, this 3% shift represents approximately $1.89 trillion. Such a reallocation
could increase the global digital assets market capitalization to approximately $5.29 trillion. Given that average trading volumes of
digital assets have been around 19% of the total market capitalization, this would correspond to daily trading volumes of approximately
$1.0 trillion globally and $380 billion in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further believe that retail and institutional investors will continue to seek advice, trade execution, and safekeeping of their assets,
including digital assets such as Bitcoin, through their FINRA-registered broker-dealers. Therefore, we anticipate that our main target
market, FINRA broker-dealers, will aggregate 90% of the daily trading volume, representing $342 billion of daily trading volume or $124.8
trillion in annual trading volume and potential revenues of $8.64 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a McKinsey report, the global payments industry revenue reached $2.1 trillion in 2021. If calculated at an annualized growth rate
of 9%, global payments industry revenue is projected to reach $3.3 trillion in 2026. Specifically, the crypto payment gateway market
size is expected to reach $4.12 billion by 2029, growing at a CAGR of 16.8% from $1.19 billion in 2022, according to Maximize Market
Research Private Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Looking
ahead, the Boston Consulting Group (BCG) projects that global payments revenues will continue to grow, albeit at a moderated pace. BCG&rsquo;s
Global Payments Report 2023 forecasts an annual growth rate of 6.2%, with revenues expected to reach $2.2 trillion by 2027 (<I>BCG Global)</I>.
This adjustment reflects a combination of market dynamics and macroeconomic factors influencing the industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the realm of cryptocurrency payments, the market is experiencing significant growth.&nbsp;<I>Future Market Insights</I>&nbsp;projects
that the crypto payment gateways market will expand from $1.29 billion in 2023 to approximately $4.85 billion by 2033, representing a
compound annual growth rate (CAGR) of 14.1% (<I>Future Market Insights).</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
growth is driven by increasing adoption of cryptocurrencies and advancements in payment technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sales
and Marketing</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALT5 Sigma Canada group of companies has outsourced a portion of its sales and business development to resellers. It is our strategy
to target its primary market through conferences, tradeshows, direct mailing. and other digital advertising. We intend on concentrating
our marketing efforts in the United States and Canada, as well as establishing partnerships in other markets, such as Europe, and Asia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Revenue
Model</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ALT5 Sigma Canada group of companies generates revenue through three main line items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Installation or a one-time setup fee, which may vary depending on size and depth of installation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Monthly maintenance, which may also vary depending on the size and depth of installation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Transaction fees, which range from 0.25% to 5% on all transactions, buy and/or sell or payment processing depending on industry and volume.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Historical
Transaction Volume, Revenue, Profit</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
ALT5 Sigma, Inc., transaction volume reached a cumulative of $4.5 billion since inception and more specifically was $39.0 million in
2020, $442.0 million in 2021, $743.0 million in 2022, $1.1 billion in 2023, and $2.2 billion in 2024. These operations generated $0.7
million in revenue and a $4.3 million in net loss for 2020; $3.5 million in revenue and a $12.3 million in net loss for 2021; $9.1 million
and $0.5 million in net profit for 2022, $11.9 million in revenue and $3.4 million in profit for 2023, $15.5 million in revenue and $0.5
million in profit for 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Biotechnology</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing,
partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment
of pain and addiction. JAN101 (formerly known as TV1001SR) is a potential treatment for PAD, a vascular disease that affects more than
8.5 million people in the U.S. and more than 60 million people worldwide. We expected to commence Phase IIb/II clinical trials for the
treatment of PAD in 2025. We are also working with a novel formulation of LDN that we call JAN 123, which includes a biphasic release
of the product. The release properties of JAN123 provide for an immediate release of a portion of the product with a slow, sustained
release of the remaining product. Importantly, the rapid release of LDN has been reported to lead to vivid and lucid unpleasant dreams,
which should be eliminated with the formulation of JAN123. Initially, we expect that a single tablet of JAN123 will be administered orally,
once a day before sleep, with eventual titration up to two tablets before sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth quarter of our 2024 fiscal year, our board of directors determined that we would form a new subsidiary and capitalize it with
JAN123 and certain of our other biopharma assets. Accordingly, we incorporated a Nevada corporation known as Alyea Therapeutics Corporation
(&ldquo;Alyea&rdquo;) and expect to build upon and complete the capitalization of Alyea during the first half of our current fiscal year.
In that context, our financial statements for the 2023 and 2024 fiscal years will show some, if not all, of our biopharmacy segment as
a discontinued operation. On May 21, 2025, we disclosed that June 2, 2025 would be the record date for a transaction involving our formal
separation from Alyea and that the scope and method of a partial or full disposition of its interests in Alyea, whether as a split-off
or a spin-off or another related transaction, would be subsequently disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses
can be mounted. The National Institutes of Health (the &ldquo;NIH&rdquo;) defines chronic pain as pain that persists beyond the normal
healing time of an injury or that persists longer than three months. It is estimated that chronic pain affects 100 million individuals
in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease,
and cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment
and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden
for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public
health problem in the United States that costs society between $560 billion and $635 billion annually. Despite the magnitude of the pain
problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by
the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended-release generic corticosteroid, five were variants
of aspirin, and two were variants of other existing drugs. We are developing a novel product candidate designed to overcome the limitations
of current treatment options for patients with PAD who suffer from chronic pain. According to a research study by Stanford University,
more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the source and presenting patients and physicians
with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad. Given the properties of JAN101,
we have made the strategic decision to focus initially on pain associated with PAD by treating the underlying cause of PAD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Chronic
Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NIH defines chronic pain as pain that persists either beyond the normal healing time of an injury or longer than three months. We believe
that chronic pain represents a significant public health crisis. It is estimated that chronic pain affects 100 million individuals in
the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and
cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment
and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden
for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public
health problem in the United States that costs society between $560 billion and $635 billion annually. Chronic pain is the leading cause
of long-term disability in the United States, and approximately 23 million adults in the United States experience severe pain over a
three-month period. Globally, the prevalence of chronic pain is even larger, with over one billion people worldwide affected each year.&nbsp;Common
types of chronic pain include those of neuropathic and inflammatory origin and may involve the skin, muscles, joints, bones, tendons,
ligaments, and other soft tissues. Chronic pain is associated with a variety of clinical conditions including, but not limited to, arthritis,
spinal conditions, cancer, fibromyalgia, diabetes, surgical recovery, visceral injury, and general trauma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
is a necessary protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective
responses can be mounted. Pain is signaled by specialized cells in the peripheral nervous system called nociceptors, or pain-sensing
fibers. These pain-sensing fibers normally transmit information about stimuli that approach or exceed harmful intensity from different
locations in the body to the brain, which registers this information as a sensation of pain. In the case of tissue injury due to trauma
or infection, pain accompanies the associated inflammation, persists for the duration of the inflammatory response, and aids healing
by inhibiting use of the affected body part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
also can modify the central nervous system, such that the brain becomes sensitized and registers more pain with less provocation. This
is called central sensitization. When central sensitization occurs, the nervous system goes through a process called wind-up and gets
regulated in a persistent state of high reactivity. This persistent, or up-regulated, state of reactivity lowers the threshold for what
triggers the sensation of pain and can result in the sensation of pain even after the initial injury might have healed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there is dysfunction in pain signaling, injury to the nervous system, or an unhealed injury, pain becomes no longer just a symptom, but
a disease in itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Soin
Therapeutics</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5
Sigma Corporation acquired Soin Therapeutics LLC, a company focused on the development of a novel formulation of low-dose naltrexone
(&ldquo;LDN&rdquo;) for the treatment of chronic regional pain syndrome (&ldquo;CRPS&rdquo;) in 2022. CRPS is a rare pain disorder, characterized
by a complex set of symptoms, affecting approximately 200,000 patients annually in the US. There are currently no approved treatments
for patients with CRPS. Prior to the acquisition, Soin Therapeutics received Orphan Drug Designation for the product, which provides
a variety of incentives for developing the product in this indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN123</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Generally</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN123
is a novel formulation of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for
an immediate release of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release
of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially,
a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before
sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Naltrexone</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naltrexone
was first synthesized in 1965 and approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan.
Later it was approved for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to ReVia. A depot
formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid
dependence in 2010. Typical oral doses are 50 to 100 mg daily, with a once-monthly intramuscular formulation also available. At these
doses, Naltrexone has been shown to function as a nonselective opioid antagonist with a high affinity for &micro; opioid receptors, which
decreases addiction cravings (Schumacher, Basbaum et al. 2017, Opioid Agonists &amp;amp; Antagonists.&nbsp;<U>Basic &amp;amp; Clinical
Pharmacology, 14e</U>. B. G. Katzung. New York, NY, McGraw-Hill Education). However, there is a risk that patients who are non-compliant
with oral naltrexone may experience opioid intoxication simply by skipping doses of naltrexone. Oral bioavailability is also variable
from patient to patient, largely due to first-pass metabolism. Thus, naltrexone is pharmacologically effective, but may be ineffective
in a real world setting without counseling and strong patient support (Minozzi, 2011, Oral naltrexone maintenance treatment for opioid
dependence.&nbsp;<I>Chchrane Database Syst Rev</I>(4), CD001333). There are also multiple generic Naltrexone tablets available on the
market for oral administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Low-Dose
Naltrexone (LDN)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compared
to the standard dose, LDN is defined as a daily dose of Naltrexone of 1 to 5 mg, which is 10- to 100-fold lower than the dose used to
manage substance use disorders (LDN Research Trust, Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.&nbsp;<U>Med
Sci (Basel)</U>&nbsp;6(4)). Off-label uses of Naltrexone at lower doses have been explored based on a different mechanism of action for
the treatment of inflammatory, rheumatologic, and neurologic conditions. These include multiple sclerosis, fibromyalgia, Crohn disease,
chronic fatigue syndrome (CFS), and, more recently, CRPS. At the low doses used for these conditions, Naltrexone is thought to act as
an immune modulator. Some speculate that this effect is related to reduced neuroinflammation in the case of disorders like CFS (Cant,
Dalgleish et al. 2017, Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets following Stimulation with Ligands
for Intracellular Toll-Like Receptors.&nbsp;<U>Front Immunol</U>&nbsp;8: 809).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
suggests that, at low doses, Naltrexone antagonizes TLR4 on activated glial cells without the previously mentioned function as a mu-opioid
receptor antagonist (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone LDN).&nbsp;<U>J
Neuroimmune Pharmacol</U>&nbsp;8(3): 470-476.). TLR4 has been shown to be a key mediator of microglial activation, which has been identified
as a causal mechanism of neuropathic pain in CRPS. Microglial activation is associated with the release of pro-inflammatory cytokines,
reactive oxygen species, and prostaglandins, which amplify the inflammatory response (Carniglia, Ram&iacute;rez et al. 2017, Neuropeptides
and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases.&nbsp;<U>Mediators of Inflammation</U>&nbsp;2017: 5048616).
Thus, LDN presents a promising therapeutic avenue for the treatment of CRPS, a condition in which TLR4 upregulation is a primary pathway,
through attenuation of glial activation and direct targeting of TLR4 activity (Del Valle, Schwartzman et al. 2009, Spinal cord histopathological
alterations in a patient with longstanding complex regional pain syndrome.&nbsp;<U>Brain Behav Immun</U>&nbsp;23(1): 85-91. By downregulating
the inflammatory cytokine release, LDN should be beneficial for CRPS patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
patients suffer from severe debilitating pain, and even light touch or benign stimulation elicits extreme amounts of pain. Microglial
cells and glial cells oftentimes are involved in this pain-signaling pathway. By reducing glial cell activation, Low-dose Naltrexone
can treat this pain syndrome. Another potential mechanism of action of LDN treatment on pain is a paradoxical upregulation of opioid
signaling. It is noted that, when taken at bedtime, the short-acting low-dose Naltrexone binds to receptors, which leads to a brief blockade
of opioid receptors between 2 and 4 a.m. This blockade is believed to upregulate vital life elements of the body and cause an increase
in endorphin and enkephalin production. This increase in endorphins and enkephalins will likely cause a decrease in pain that the patient
experiences overall. Therefore, LDN leads to transient opioid receptor blockade, which triggers a positive feedback mechanism that increases
the production of endogenous opioids (endogenous endorphins and enkephalins) and opioid signaling (Ludwig, Zagon et al. 2017, Serum [Met(5)]-enkephalin
levels are reduced in multiple sclerosis and restored by low-dose naltrexone.&nbsp;<U>Exp Biol Med (Maywood)</U>&nbsp;<B>242</B>(15):
1524-1533; Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.&nbsp;<U>Med Sci (Basel)</U>&nbsp;<B>6</B>(4)).
Together, these mechanisms may work to alleviate pain associated with CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interestingly,
low-dose Naltrexone also has effects on the peripheral nervous system. In the peripheral nervous system, it was found that low-dose Naltrexone
can modulate T and B lymphocyte production. And it was noticed that low-dose Naltrexone could reduce interleukin 6, interleukin 12, and
tumor necrosis factor alpha in the periphery regarding peripheral nervous systems. CRPS patients often have an increase in inflammatory
cytokines and may often note an increase in interleukin 6, 12, and tumor necrosis factor alpha. By reducing these inflammatory cytokines
back to a normal state, it is predicted that low-dose Naltrexone could treat the actual disease state of CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, low-dose Naltrexone has a very specific mechanism of action that will distinctly treat CRPS through inhibition of inflammatory
cytokines, glial cell activation, neuroinflammation, and increase of endogenous enkephalins and endorphins. In other words, low-dose
Naltrexone is not just treating the symptoms with this medication but also treating the underlying disease state and process specific
to CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Chronic
Regional Pain Syndrome (CRPS)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS,
also termed reflex sympathetic dystrophy (RSD), is a chronic, orphan neurologic condition that typically affects the extremities after
trauma or nerve injury, and can cause severe pain. As the most common and prominent symptom of CRPS, the pain is often deep inside the
limbs with a burning, stinging, or tearing sensation. Sensory changes are also common and may include increased sensitivity to painful
stimuli, feeling pain from stimuli that are usually non-painful, and in some instances, sensory loss (<I>e.g.</I>, numbness). In addition
to pain, patients commonly experience an affected extremity that is warm, red, and swollen, at least initially. As CRPS progresses, it
becomes refractory to sympathetic nerve blocks, conventional analgesics, anticonvulsants, and antidepressants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
is a rare neurologic disease. It is a painful progressive condition and is listed in the rare disease database of the National Organization
for Rare Disorders (NORD). CRPS is subdivided into two categories: type I and type II CRPS. In CRPS type I, there are no nerve injuries
or lesions identified. CRPS type I is also known as &ldquo;reflex sympathetic dystrophy,&rdquo; and it comprises about 90 percent of
all cases of CRPS. CRPS type II (causalgia), on the other hand, is diagnosed when there is evidence of nerve damage. As described in
the NORD, it was found that CRPS type I developed in 5.46 persons out of every 100,000 per year and the incidence rate of CRPS type 2
was 0.82 persons out of every 100,000 per year, giving rise to a combined incidence rate for both CRPS types I and II of 6.28 per 100,000
person-years (Sandroni, Benrud-Larson et al. 2003, Complex regional pain syndrome type I: incidence and prevalence in Olmsted county,
a population-based study.&nbsp;<U>Pain</U>&nbsp;<B>103</B>(1-2): 199-207; Goh, Chidambaram et al. 2017, Complex regional pain syndrome:
a recent update.&nbsp;<U>Burns Trauma</U>&nbsp;5: 2.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underlying cause of CRPS is not well understood. In most cases, it occurs after an illness or injury that did not directly damage the
nerves in the affected area (Type I). In some cases, it occurs after a specific nerve injury (Type II). The exact trigger of CRPS after
an injury is not known, but it may be due to abnormal interactions between the central and peripheral nervous systems and/or inappropriate
inflammatory responses. There are multiple factors that may contribute to CRPS development, including immobilization, alterations to
the nervous system of the body, and inflammation. Genetic factors and psychological factors, such as anxiety, depression, and anger,
may also contribute to the symptoms of CRPS. However, there is no evidence that CRPS is a disease that can be caused by genetic factors
alone, and the role of psychological factors in CRPS development remains unproven.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
is treated by approaching it from different areas: physical therapy (PT), occupational therapy (OT), medications for pain management,
neuromodulation through implantable devices, and/or nerve blocks targeting the sympathetic chain. Neridronate and zoledronate D,L-lysine
monohydrate (ZLM) has been designated as an orphan drugs for the treatment of CRPS in 2013 and 2015, respectively. However, neither of
them has been approved. Thus, there is no current FDA-approved drug for CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Studies of LDN on CRPS</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDN
has been widely used for chronic pain and inflammatory condition and has been shown to alleviate symptoms of pain in patients with chronic
pain. A number of case studies have also reported positive effects for LDN in the treatment of CRPS. Chopra et al. reported 2 patient
case studies with CRPS who experienced significantly less pain with 4.5 mg daily LDN treatment (Chopra and Cooper 2013, Treatment of
Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone (LDN).&nbsp;<U>J Neuroimmune Pharmacol</U>&nbsp;8(3): 470-476). The remission
of pain and dystonic spasms in Case 1, as well as remission of all CRPS symptoms (including fixed dystonia) in Case 2, provide evidence
that a multi-modal interventional approach, which includes low-dose Naltrexone (a known glial attenuator), should be considered as a
treatment option for the treatment of CRPS patients, particularly those patients with dystonic movement disorders. In another CRPS case
study, Sturn and Collin found alleviation of pain symptoms as early as 2 days after beginning LDN therapy, with significantly less pain
at 4 weeks (Sturn and Collin 2016, Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients.&nbsp;<U>Int
J Pharm Compd</U>&nbsp;<B>20</B>(3): 197-201). Weinstock et al reported alleviation of pain symptoms within one month of LDN treatment,
with complete remission of CRPS leg symptoms by 16 months (Weinstock, Myers et al. 2016, Identification and Treatment of New Inflammatory
Triggers for Complex Regional Pain Syndrome: Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea.&nbsp;<U>A A Case Rep</U>&nbsp;<B>6</B>(9):
272-276). In a recent case study, an CRPS patient was able to discontinue gabapentin and amitriptyline via the use of LDN, while simultaneously
achieving superior pain relied (Soin, 2021, Management of pediatric complex regional pain syndrome with low-dose naltrexone.&nbsp;<I>Pain
Medicine Case Reports, 5</I>(3), 109-113). LDN has been reported to have benefits related to other symptoms of chronic pain syndromes
as well, including dystonic spasms, CRPS flares, energy, sleep disturbances, and mood.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systematic
literature review of LDN use showed that the most commonly reported AEs with LDN use were dizziness, vomiting, nausea, and vivid dreams
(Soin et al. 2021, Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review.&nbsp;<U>Pain
Physician</U>&nbsp;24(4): E393-E406.). Other reported AEs included headaches, abdominal pain, gastrointestinal issues, peripheral edema,
restlessness, falls, somnolence, irritability, hematological abnormalities, urinary infection, difficulty concentrating, anxiety, sleepiness,
hot flashes/sweating, tachycardia, depression, muscle and joint pain, fatigue, tinnitus, heartburn, dry mouth, and joint pain. Another
systematic review also evaluated occurrence of adverse events (AEs) and serious adverse events (SAEs) with LDN use and found that only
mild AEs reported among the included studies (89 studies), including nausea, vomiting, and dizziness (Bolton, Hodkinson et al. 2019,
Serious adverse events reported in placebo randomized controlled trials of oral naltrexone: a systematic review and meta-analysis.&nbsp;<U>BMC
Med</U>&nbsp;<B>17</B>(1): 10). Although 119 patients reported at least one SAE in the naltrexone study arm, meta-analysis found no difference
between occurrence of SAEs in naltrexone and placebo groups. Furthermore, secondary analysis found only 6 AEs that were statistically
significant: decreased appetite, dizziness, nausea, sleepiness, sweating, and vomiting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Efficacy
of low-dose naltrexone treatment on CRPS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Author
    (year)</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms
    alleviated</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
    to alleviation of symptoms</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEs
    and SAEs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chopra
    et al (2013)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">swelling,
    allodynia, color change, temperature change, some weakness, blisters, skin ulceration, dystonic spasms, dysesthesia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dystonic
    spasms, CRPS flares, energy, pain tolerance, sleep disturbances, pain, mood</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt;
    2 months</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    mg/day</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sturn
    et al (2016)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    days</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5
    mg</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinstock
    et al (2016)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe
    leg pain, episodic pain in arms and nose, asymmetric and shiny skin with fluctuating temperature changes, color change, edema, IBS,
    atypical chest pain and fatigue, edema, blue discoloration, tenderness, joint hypermobility with EDS diagnosis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leg
    and bowel symptoms; all CRPS pain, bowel symptoms, and fatigue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt;
    1 month</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    mg/day</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Orphan
Drug Designation</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
orphan disease is a rare disease affecting fewer than 200,000 people in the US. It is often a serious or fatal condition for which there
are no effective therapies. In 1983, the Orphan Drug Act was passed to incentivize companies to develop drugs for patients with rare
diseases. Orphan drug designation provides incentives to companies, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits for qualifies clinical trials</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from user fees</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Potential
    for seven years of market exclusivity after approval</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given the small number of patients with a disease and the severity of the disease, approvals are often granted with fewer and
smaller trials, saving costs and time. JAN123 was granted Orphan Status for the treatment of CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Development Plan</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDN
can be rapidly developed in the US via the 505(b)(2) regulatory pathway. This pathway is used for candidates that contain drugs that
are already approved but come in a dosage form or delivery system that is different than the original, approved product. In this case,
JAN123 fits these criteria perfectly. LDN has the added benefit of being developed at a much lower dose (&lt; 5 milligrams) compared
to approved naltrexone products, which are 50 milligrams per tablet. Therefore, it is likely that product development will consist of
the following general steps:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
    and approval of clinical batches of LDN tablets prior to clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I pharmacokinetic study(ies) to confirm the release profile of LDN; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    single Phase III study to demonstrate efficacy in CRPS.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
protocol synopsis of the development plan is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of study</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 74%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I: The Pharmacokinetincs of LDN in the fed and fasted state of a Single Oral Dose of LDN, 4 mg</FONT></P>
                                                                                          <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
III: Double-Blind Placebo-Controlled Trial of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome (CRPS)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
    Phase</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I: The Pharmacokinetincs of LDN in the fed and fasted state</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
III: Registration/Efficacy Study to hopefully facilitate an NDA application for the use of low-dose naltrexone to treat CRPS</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I: To determine pharmacokinetics of single oral low-dose naltrexone in healthy participants in fasting and fed state</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase3: The primary objective is to assess the efficacy of low-dose naltrexone in treating complex regional pain syndrome symptoms (CRPS).</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to conduct a double-blind, randomized, placebo-controlled trial to treat CRPS using low-dose naltrexone.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Efficacy:</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1- Assess daily NRS (numerical pain scale 0 &ndash; 10) scores through the 3-month study</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2- Study the possible changes or improvement in the Brief Pain Inventory (BPI) and Oswestry Disability Index (ODI) over the three-month study</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Safety:</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will also monitor safety labs on enrollment and termination of the study. However, we would like to point out that this drug has been available and FDA approved at much higher doses (50 &ndash; 150mg or higher) orally with a long-standing proven safety track record. The drug has been available with multiple different embodiments, route of administration and at much higher doses for quite a long time and the safety of the drug has already been extensively established and published.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigational
    product</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN123</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Design</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1: Single-center, dual-arm, cross-over, open-label study</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3: Study Description</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to conduct a randomized, double blind placebo controlled trial to treat Complex Regional Pain Syndrome. The study duration will be three months long. Patients in the treatment group will receive a single tablet for the first month of a 2mg dose of Naltrexone. Then, after 1 month, the patient will take 2 tablets for a total of 4mg for months 2 and 3. Study conclusion will be after 3 months.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients in the placebo group will take a single tablet for 1 month followed by 2 tablets for month 2 and 3.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A total number of 200 patients with a 1:1 randomization will used. Since CRPS is an orphan disease, we will likely have to use a total of 25 clinical sites or more to be able to adequately recruit the study.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety labs will be completed prior to first dose and upon study completion.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For clinical efficacy, we will be assessing daily NRS (1-10) pain scores, a brief pain inventory (BPI) at enrollment and at months 1, 2, and 3 (study completion) and Oswestry Disability Index (ODI) at enrollment and at months 1, 2, and 3 (study completion). Statistically significant improvement in pain scores or any scales in the BPI or ODI are desired outcomes.</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Treatment
    Regimen and Route of Administration</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 74%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study Drugs are as follows:</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I: Single Oral dose of JAN123, 4 mg given on separate days with and without food separated by a washout period of no less than 7 days</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III: Patients will be dosed with either the low-dose naltrexone or placebo for three months. Initially for the first month patients will take 1 tablet at bedtime (typically in the evenings) for the first month and then increase to 2 tablets for month 2 and 3. Specifically the Naltrexone will be 2mg tablets, such that for the first month with the 1 tablet per day the patient will be on 2mg doses and subsequently increase to 2 tablets in the evening for a total of 4mg.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration
    of treatment:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I: One day for each dose. Two doses of 2 mg each, in total, separated by a washout period of no less than 7 days.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III: This will be a 3 month trial or approximately 90 days. Upon enrollment, patients will be on either low-dose naltrexone or placebo for 90 days.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant duration is expected to be 121 days, and at the conclusion of the study (approximately day 90 post-treatment) patients will come in for a final site visit to complete remaining surveys and within 7 days of completion the patients will obtain final safety labs which are anticipated to be a complete blood count and a comprehensive metabolic panel. Since Naltrexone is non-opioid based and does not have withdrawal issues, patients can immediately discontinue the therapy without concerns. As referenced earlier, the safety of Naltrexone orally is already well established and our tested doses are low.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Centers</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1: Single Center Clinical Trial</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3: Multicenter Clinical Trial</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likely 25 total sites. Keeping in mind this is an Orphan Disease state and recruitment may be quite difficult, we feel the need to have 25 clinical sites to enroll 200 patients.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical sites will be likely Pain Management Centers, both academic and private practice facilities that have access to patients who suffer from CRPS and also include local PIs who have the skill set and ability to properly diagnose CRPS.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local or regional clinical trial coordinators will be assigned to each site as well.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrolling participants are those who meet the diagnosis criteria of CRPS. Typically, CRPS is diagnosed using the Budapest Criteria. Age range of 18 - 65 for enrollment, negative pregnancy test, and stable therapy for 3 months.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subjects:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I: Adult male and female healthy subjects, 18-65 years of age, satisfying all inclusion and exclusion criteria.</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III: Patients diagnosed with CRPS (Complex Regional Pain Syndrome), Adult male and female patients, 18-65 years of age.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Subjects</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I: 10 patients</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III: 200 patients</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Endpoints</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase1:
    Primary Outcome Measure:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PK
    profile for low-dose naltrexone (Time Frame: Day 1: predose and at multiple time points after low-dose naltrexone administration).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Cmax&nbsp;(Maximum observed plasma concentration)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Tmax&nbsp;(Time to reach maximum plasma concentration)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    AUC0-t&nbsp;(Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable
    concentration)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    AUC0-inf&nbsp;(Area under the plasma concentration-time curve from 0 hour extrapolated to infinity)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    CL/F (Oral clearance)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    Outcome Measure: Improvement in NRS pain scores over a 3-month time period.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
    Outcome Measure: Improvement in Brief Pain Inventory and Oswestry Disability Index (ODI) or other verified pain scales.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of Study will occur upon completion of the 90-day trial of the low-dose naltrexone or placebo. It is expected that patients will
    complete all required surveys and testing requirements of the study.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
    termination is also a possible way to end the study due to issues such as side effects, adverse events or patient desire to withdraw
    from the study, among other reasons.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safety
    Assessments</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard
    clinical evaluation and objective measures will be employed to monitor and assess safety during the conduct of the trial. Furthermore,
    the results of safety assessments will be used during the trial to monitor and protect the safety of enrolled subjects. Strict subject
    and study stopping criteria will be implemented to protect the subject&rsquo;s well-being.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition of Naltrexone is off-patent and generic versions of the drug are available at 50 mg doses. LDN has been routinely compounded
in compounding pharmacies and used clinically off-label. However, the 4.5 mg compounded tablets are associated with sleep disturbances,
manifested in vivid and lucid unpleasant dreams. For these reasons, JAN-123 was developed as a biphasic release, orally available tablet
to reduce the likelihood of unpleasant dreams. A provisional patent was filed in December 2020 and converted to a PCT application in
November 2021 (Pub. No. US 2022/0202807 A1). US Patent number 11,752,143 B2 issued on September 12, 2023.&nbsp;The issued claims in this
patent cover the use of the biphasic LDN formulation for treatment of patients with chronic pain. In addition, claims are made to the
titration of the LDN for treating chronic pain. While there is no guarantee that the pending applications or future pending claims will
issue, the issued US patent will provide protection of JAN123 through 2040 and the Orphan Drug Designation provides 7 years of market
exclusivity after drug approval in the event that there are any challenges to this patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Trade
Secrets and Other Proprietary Information</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed
methods for more efficient manufacture of the biphasic LDN. We seek to protect our proprietary information, in part, by confidentiality
agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Soin
Purchase Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022, we entered into a Purchase Agreement (the &ldquo;Soin Purchase Agreement&rdquo;) with Soin Therapeutics, LLC. Under
the Soin Purchase Agreement, ALT5 Sigma Corporation acquired Soin Therapeutics and its LDN product, now known as JAN123. This all- stock
transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up
to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be issued
to or transferred by Soin Therapeutics at any given time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Team</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony
Giordano, Ph.D.,<B>&nbsp;</B>our Chief Scientific Officer, joined the Company in December 2019 from the Cleveland Clinic, the No.2 rated
hospital in the country, where he served as Senior Director of Special Projects in the Business Development group. Dr. Giordano has extensive
experience in drug development, having served as Vice President or President of seven different biotechnology companies he co-founded,
including companies developing platform technologies, a cancer vaccine, and Alzheimer&rsquo;s Disease and cardiovascular therapies. He
has managed numerous clinical trials and the launch of a medical food product. Dr. Giordano has also served as an Associate Professor
and Assistant Dean of Research and Business Development at LSU Health Sciences Center in Shreveport, Louisiana (&ldquo;LSU Health Shreveport&rdquo;),
at which he led the licensing efforts at the campus and at Abbott Labs, where, in addition to serving as a Senior Research Scientist,
he was involved in technology assessment activities. Dr. Giordano has a Ph.D. focused in Molecular Genetics from The Ohio State University
and completed Fellowships at the NIH National Cancer Institute and the NIH National Institute of Aging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN101</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Generally</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101,
formerly known as TV1001SR, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood
flow to the extremities, such as those with vascular complications of diabetes or PAD and treats pain. A conclusion from a round of human
studies found JAN101 prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium
nitrite. In a previous study of patients with PAD, a 40 mg BID treatment with immediate release sodium nitrite led to a statistically
significant reduction in reported pain, while an 80 mg BID treatment had a more pronounced effect on bioactivity and Flow Mediated Dilation,
a measure of vascular function. However, a number of subjects in both treatment groups reported headaches and dizziness following treatment.
Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect. JAN101 was tested
in a bridging study of diabetic neuropathy subjects and, during that bridging study, the subjects did not report headaches or dizziness.
Subjects in this bridging study also reported less pain following treatment and improvements in bioactivity (quantitative sensory testing,
a measure of nerve function) were similar to the PAD study, where the 80 mg dosing group had the greatest improvement in Flow Mediated
Dilation. The ability to alleviate pain with BID treatment of JAN101 offers promise for a new non-addictive, non-sedating treatment of
chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Studies in Humans JAN101 Attributes</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well-established
    safety profile</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excellent
    bioavailability</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of induced tolerance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-narcotic</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101
does not mask pain, but instead treats the cause of pain by improving tissue and vascular function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Benefits
of Sodium Nitrite on Vascular Health</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
initial research studies, sodium nitrite effectively restored ischemic tissue blood flow and was effective in a wide range of pathologies
involving alterations of angiogenesis &ndash; development of new blood vessels &ndash; including diabetes, wound healing, and tissue
necrosis. Beneficial effects include enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis. There is also a strong
association between reduced circulating nitrite levels and cardiovascular diseases in humans. We describe some of the associations and
beneficial effects of sodium nitrite/nitrite below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plasma
nitrite levels are negatively correlated to cardiovascular disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_005.jpg" ALT="A graph of different sizes and numbers&#10;&#10;AI-generated content may be incorrect." STYLE="height: 171px; width: 367px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_006.jpg" ALT="A graph of a number of numbers&#10;&#10;AI-generated content may be incorrect." STYLE="height: 290px; width: 572px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
nitrite levels were inversely related to number of cardiovascular risk factors a subject had and decreased plasma nitrite was associated
with decreased flow mediated vasodilation (FMD) and increased intimal medial thickness (IMT) (both are indicators of vascular pathology).
Kleinbongard, et al. (2006) Free Radic Biol and Medicine 40:295-302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plasma
nitrite levels are reduced in diabetic and PAD patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_007.jpg" ALT="A graph of a number of columns&#10;&#10;AI-generated content may be incorrect." STYLE="height: 253px; width: 325px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
is a well-known stimulator of endothelial nitric oxide synthase activity, an enzyme that enhances nitric oxide (NO) production, which
leads to increased plasma nitrite. In the study by Allen, et al., these authors revealed that baseline plasma levels of nitrite were
less in patients with diabetes mellitus (DM) or DM + PAD. Importantly, increases in plasma nitrite levels were not observed in either
DM, PAD, or DM + PAD patients after supervised exercise. These data reveal that baseline nitrite availability is compromised in DM patients
and that supervised exercise is unable to increase plasma nitrite levels but actually results in a decrease<B><I>&nbsp;</I></B>in nitrite,
highlighting a physiological efficiency of this molecule. Allen, et al., Nitric Oxide 2009 20:231-2377.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Skeletal
Muscle Nitrite and Metabolite Levels are Reduced in Critical Limb Ischemia (CLI) Patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_008.jpg" ALT="A comparison of different colored bars&#10;&#10;AI-generated content may be incorrect." STYLE="height: 266px; width: 385px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skeletal
muscle nitrite, nitrosothiol (RSNO), nitric oxide-heme, and cGMP are all significantly reduced in CLI (the most severe form of PAD) patients.
Diabetic patients with CLI show even further nitrite reductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, nitrite levels in various cardiovascular and vascular diseases appear to be inversely related to the severity of the disease
in humans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    nitrite levels are associated with higher level of heart failure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    nitrite levels are observed in diabetic patients with PAD and are not compensated by exercise; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    levels are lower in the muscles of patients with critical limb ischemia and are further reduced in diabetic subjects with critical
    limb ischemia.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the association between low levels of circulating nitrite and human diseases, supplementation with sodium nitrite has been studied preclinically
in animals. Below are summaries of some of the more important findings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    angiogenesis</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulates
    wound healing</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevents
    tissue necrosis</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
Arya, et al.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Selectively Increases Ischemic Tissue Vascular Density in a NO-dependent Manner</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_009.jpg" ALT="A collage of images of a graph&#10;&#10;AI-generated content may be incorrect." STYLE="height: 529px; width: 382px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
sodium nitrite therapy increases ischemic tissue vascular density in a NO-dependent manner. A and B show representative images of CD31
(red) and DAPI nuclear (blue) staining from sodium nitrite and sodium nitrate ischemic gastrocnemius muscle tissue at day 7. C and D
report the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 for 165 &mu;g/kg sodium nitrite and nitrate treatments,
respectively. E and F demonstrate the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 from 165 &mu;g/kg sodium
nitrite plus carboxy PTIO. (Scale bar, 150 &mu;m.) n = 10 mice per treatment group. Kumar D., et al., PNAS; 2008; 105:7540-7545.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Augments Arterial Perfusion of Ischemic Tissue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_010.jpg" ALT="A close-up of a graph&#10;&#10;AI-generated content may be incorrect." STYLE="height: 284px; width: 584px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
sodium nitrite therapy acutely increases ischemic tissue blood flow and stimulates arteriogenesis. A and B report 165 &mu;g/kg sodium
nitrite-induced acute changes in blood flow of chronically ischemic tissues at various time points with or without cPTIO, respectively.
C reports the number of arterial branches between PBS and nitrite therapies. D and E illustrate vascular casting of the arterial vasculature
in ischemic hind limbs of day 7 nitrite or PBS-treated mice, respectively. *, P &lt; 0.01 vs. sodium nitrite. N = 10 mice per treatment
group. Kumar D., et.al., PNAS;2008; 105:7540-7545.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Restores Diabetic Ischemic Hind-Limb Blood Flow and Promotes Wound Heal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_011.jpg" ALT="A close-up of a rat&#10;&#10;AI-generated content may be incorrect." STYLE="height: 389px; width: 379px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 99pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unilateral
femoral artery ligation was performed on 18-20 week old male Db/Db mice. Mice were randomized to PBS or sodium nitrite (165 &mu;g/kg)
therapy twice daily via I.P. injection. Laser doppler flowmetry was performed at the indicated time points. Increased wound dehiscence
was noted in the PBS treated animals at day 7 but not in nitrite treated animals. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Increases Diabetic Ischemia Induced Angiogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_012.jpg" ALT="A graph of different colored and black numbers&#10;&#10;AI-generated content may be incorrect." STYLE="height: 303px; width: 519px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
therapy prevented ischemia mediated endothelial cell density loss in normal C57BL/6J ischemic limbs. Nitrite therapy significantly restored
endothelial cell density in ischemic limbs of diabetic mice to normal C57BL/6J levels compared to PBS therapy of non-ischemic and ischemic
conditions. These data suggest that nitrite therapy may be useful in attenuating microvascular rarefaction due to loss of nitric oxide
that is observed during metabolic dysfunction (Frisbee JC AJP Integr Comp Physiol 2005 289(2):R307-16; Stepp et al Microcirculation 2007
14(4-5): 311-6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
Nitrite Therapy Restores Ischemic Hind-Limb Blood Flow</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_013.jpg" ALT="A graph showing the amount of nitrite therapy&#10;&#10;AI-generated content may be incorrect." STYLE="height: 316px; width: 398px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
were performed to determine whether nitrite mediated therapy would be effective in tissue that had been left ischemic for 5 days after
femoral artery ligation. Femoral artery ligation was performed in C57BL/6J mice and the animals randomized to either PBS or sodium nitrite
therapy 5 days after artery ligation. Treatments were given b.i.d. via I.P. injection. Ischemic limb blood flow was measured using laser
doppler flowmetry. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
nitrite therapy increases SPY angiogram arteriogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_014.jpg" ALT="A collage of x-ray images of a human foot&#10;&#10;AI-generated content may be incorrect." STYLE="height: 513px; width: 380px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
nitrite therapy increases SPY angiogram arteriogenesis. Representative temporal SPY angiogram image stills (3&ndash;6s) are shown at
11 days following ligation and 6 days after beginning therapy (either PBS or sodium nitrite).&nbsp;<I>Left</I>: PBS control angiogram.&nbsp;<I>Right</I>:
sodium nitrite angiogram following injection of ICG.&nbsp;<I>n&nbsp;</I>= 5 animals per cohort. Circles identify limb anatomical regions
of vascular blush, whereas arrows indicate perfused vessels that progressively occur over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bir,
et al., Am J Physiol Heart Circ Physiol 2012;303:H178-H188.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Prevents Tissue Necrosis in Aged Db/Db Mice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_015.jpg" ALT="A collage of images of a rat's hands&#10;&#10;AI-generated content may be incorrect." STYLE="height: 233px; width: 441px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
sodium nitrite (165 ug/kg) or control PBS therapy was stated 5 days post-femoral artery ligation in nine-month old Db/Db mice. Nitrite
therapy significantly prevented tissue necrosis (panel B) compared to control PBS therapy (panel A). Panel D reports tissue necrosis
severity as a function of degree of limb and digit involvement. Nitrite therapy, but not PBS control or sodium nitrate, significantly
prevented tissue necrosis. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nitrite
and Hind Limb Ischemia Summary</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sodium
nitrite has long been known to be a potent vasodilator (transiently increasing blood vessel diameter) that can lead to a drop in blood
pressure when given acutely. The above studies indicate that chronic administration at low doses promotes angiogenesis, unlike one-time
nitrite therapy, which does not stimulate angiogenesis. In addition, these studies and a large number of other studies not reviewed above
show:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    therapy is very specific, acting only in damaged, ischemic tissue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
    nitrite therapy effectively restores ischemic tissue blood flow;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    therapy is effective in a wide range of pathologies involving alterations of angiogenesis including critical limb ischemia, heart
    failure, and tissue necrosis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    supplementation has had positive effects in various diabetes models, including diabetic nephropathy and diabetic wound healing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    effects center on enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustained
    release nitrite therapy, unlike immediate release therapy, does not lead to vasodilation or a drop in blood pressure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN
101 is designed to treat diseases associated with poor vascular function. The following table summarizes our current product candidate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_016.jpg" ALT="A yellow box with black text&#10;&#10;AI-generated content may be incorrect." STYLE="height: 72px; width: 441px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a research study by Stanford University, more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the
source and presenting patients and physicians with better and safer treatment alternatives, we expect to minimize opioids at the prescription
pad.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Peripheral
artery disease</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peripheral
artery disease (&ldquo;PAD&rdquo;) is a general term for conditions in which arterial blood flow to the limbs is partially blocked. When
there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also
known as &ldquo;intermittent claudication.&rdquo; In many patients, pain and fatigue are relieved through rest. Roughly half of patients
with PAD are asymptomatic. The most common cause of PAD / intermittent claudication is atherosclerosis. Diabetes, chronic kidney disease,
hypertension, and smoking are all risk factors that can increase the likelihood of PAD. In atherosclerosis, fat deposits (plaques) build
up along arterial walls, resulting in a reduction in blood flow in the legs. This same process can cause strokes if the arteries leading
up to the brain are affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the high rate of asymptomatic patients, prevalence figures vary widely. Some estimate that up to 200 million people worldwide have
PAD, ranging from asymptomatic disease to severe. Prevalence increases as a function of patient age, rising sharply after the age of
60. Thus, in countries with an aging population, it is expected that the prevalence of PAD will only increase. There is also a strong
ethnic and racial component to PAD prevalence, which may be due to cultural differences in diet and exercise, along with genetic differences.
Some suggest a prevalence of eight to 12 million in the United States alone, with roughly one-third experiencing pain when walking, which
improves upon resting. The diagnosis of PAD usually begins with patient complaints of pain in the extremities. If the patient is already
being treated or monitored for diabetes or other risk factors, then the physician will check for a weak or absent pulse in the extremity.
Decreased blood pressure, poor wound healing, and whooshing sounds (via stethoscope) in the legs are also tell-tale signs of PAD / intermittent
claudication. Angiograms, electrocardiograms, and ultrasounds can also be used to image and confirm the diagnosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_017.jpg" ALT="18870" STYLE="height: 349px; width: 582px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1: Ethnic-specific prevalence of PAD in men in the US, by age. NHW = Non-Hispanic Whites,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AA
= African American, HS = Hispanics, AS = Asian Americans, AI = American Indians. Source: (Criqui, 2015)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
non-drug treatment of PAD / intermittent claudication may be divided into four general categories:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lifestyle&nbsp;</I>&ndash; Primarily changes in diet and
smoking cessation.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise&nbsp;</I>&ndash; Patients who walk, cycle, stretch,
or swim can experience marked improvement. Formal programs involving treadmills and track walking (usually three to five times per week)
are frequently provided to patients. However, if the pain is triggered by exercise (claudication) and is significant, it can discourage
the patient from exercise.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Angioplasty&nbsp;</I>&ndash; A procedure by which the affected
artery is stretched with a balloon-like device. This procedure has limited effectiveness and is reserved for severely blocked arteries.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Bypass Surgery&nbsp;</I>&ndash; Arteries that are beyond
angioplasty can be bypassed entirely. This procedure is typically reserved for cases where the blockage is considered very long (~10
centimeters) and nearly complete.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underlying condition is not addressed by surgery. Surgical approaches will not, in the long run, improve exercise capacity and walking
distance. Only exercise itself, coupled with lifestyle changes and drug approaches, has this benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription
drugs for the treatment of the underlying PAD may be divided into multiple categories, depending on the underlying condition and severity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cholesterol-Lowering Agents &ndash;</I>&nbsp;Statins and
bile acid sequestrants.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Antiplatelet Medications&nbsp;</I>&ndash; Aspirin and related
drugs, such as clopidogrel. Cilostazol also has antiplatelet properties.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Antihypertensives&nbsp;</I>&ndash; Patients with underlying
high blood pressure can and will receive any number of medications to reduce blood pressure, such as ACE inhibitors and diuretics.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diabetes Therapies&nbsp;</I>&ndash; While a substantial
portion of PAD patients may have pre-diabetes or fulminant diabetes, it is unknown if aggressive treatment of diabetes has a positive
effect on PAD.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pain&nbsp;</I>&ndash; To our knowledge, no drugs are specifically
indicated for PAD-associated pain. Pentoxifylline, for example, is indicated &ldquo;&hellip;for the treatment of patients with intermittent
claudication on the basis of chronic occlusive arterial disease of the limbs.&rdquo; (Sanofi-Aventis U.S. LLC, 2010). However, the evidence
supporting the effectiveness of pentoxifylline is mixed. Short-term courses of NSAIDs, such as ibuprofen, may be used, provided the patient
is not on another anticoagulant, like aspirin. Non-drug pain relievers, such as TENS and massage therapy, may also be used in these patients.
Opioids may also be used, which creates a risk for addiction and potential misuse at the medicine cabinet by family members.</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-3_018.jpg" ALT="" STYLE="height: 270px; width: 420px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lack of any truly effective treatment of PAD, along with encouraging early trial results using JAN101 on both improving vascular function
and reducing pain in PAD patients, has created an opportunity potentially to treat this large unmet medical need. By improving vascular
function, JAN101 has the potential to reduce associated pain and improve PAD patients&rsquo; quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Strategy</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
focus is to develop and commercialize novel, non-opioid, and non-addictive therapies to address, safely and effectively, the significant
unmet medical need of chronic pain or treat conditions that cause pain. The principal elements of our strategy to achieve this mission
are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License,
                                            acquire, develop, and create novel, non-opioid and non-addictive therapies by leveraging
                                            our understanding of pain biology to address the large and growing problem of pain.</B>&nbsp;While
                                            innovation in medical sciences has led to exciting new treatment options in many disease
                                            areas, pain has seen limited innovation in recent years. We have a deep understanding of
                                            the pathophysiology of pain and diseases that cause pain. We intend to leverage this understanding
                                            to bring innovation in the pain treatment paradigm through targeted acquisitions of companies
                                            or assets in development. Our advisors and doctors have years of collective experience in
                                            leadership positions at institutions and substantial scientific experience and understand
                                            the complexity of designing and executing clinical trials for and developing therapies.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leverage
                                            our management team background and expertise.&nbsp;</B>We have assembled a team with extensive
                                            experience described above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Current
Therapeutic Approaches to Treating Chronic Pain and Their Limitations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NSAIDs</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the most widely used therapies to treat chronic inflammatory pain are non-steroidal anti-inflammatory drugs (&ldquo;NSAIDs&rdquo;).
NSAIDs can have significant side effects that include gastrointestinal bleeding, gastritis, high blood pressure, fluid retention, kidney
problems, heart problems, and rashes. On April 7, 2005, the FDA announced a decision to require boxed warnings of potential cardiovascular
risk for all NSAIDs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Corticosteroids</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corticosteroids,
or steroids, also possess anti-inflammatory properties and are commonly used in the practice of pain management, either systemically
or locally, depending on the condition. Steroids work by decreasing inflammation and reducing the activity of the immune system. While
steroids are commonly used, they may have numerous and serious side effects. These side effects may include allergic or hypersensitivity
reactions, increased risk for infection, adrenal insufficiency, diabetes or decreased glucose tolerance, hypertension, loss of bone density,
and loss of joint cartilage volume. In addition, steroids should not be administered when there is an infection present because steroids
can inhibit the body&rsquo;s natural infection-fighting immune response. Also, if a joint is already damaged or is subject to chronic
deterioration, intra-articular, or IA steroid injections are not likely to provide any long-term restorative benefit. For the above reasons,
IA steroid injections are generally recommended to be administered no more often than every six weeks and not more than three to four
times per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Opioids</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioids
are some of the most widely prescribed therapeutics for chronic and acute pain, and sales of these drugs have quadrupled between 1999
and 2010. According to a National Survey on Drug Use and Health report, in 2016 more than one-third of adult Americans were prescribed
opioids and 230 million opioid prescriptions were written that year in the United States. Opioids act by binding to specific receptors
located on neurons in both the central and peripheral nervous system throughout the body including in the brain, spinal cord, and other
nervous tissue. Although they can be effective in providing pain relief, the increased medical use of opioids has been accompanied by
an increase in the abuse and misuse of prescription opioids. In addition, for most patients, chronic opioid use is a poor option due
to an intolerance to the many side effects, including nausea, vomiting, drowsiness, and constipation, and the propensity for opioids
to become less effective with long-term use. According to the Centers for Disease Control and Prevention (the &ldquo;CDC&rdquo;), almost
two million individuals abused or were dependent on prescription opioids in 2014. CDC figures show that the number of opioid-related
overdose deaths has quadrupled between 1999 and 2010, and currently approximately 40% of opioid overdose deaths in the United States
involve a prescription opioid. This increase in prescription opioid-related deaths in the United States prompted former President Trump
to declare the opioid crisis a national Public Health Emergency in October 2017. Opioid abuse has become an epidemic in the United States,
ranking as the nation&rsquo;s second most prevalent illegal drug problem. These major issues create the need to find new approaches to
treating chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Approach to Treating PAD and Chronic Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unmet medical need for treating PAD and chronic pain reflects the historic failure to develop novel classes of analgesics with comparable
or greater efficacy, an acceptable level of adverse effects and a lower abuse liability than those currently available. Some of the reasons
for this include the heterogeneity of chronic pain and its related conditions, and the complexity and diversity of the underlying pathophysiological
mechanisms for pain. However, recent advances in the understanding of the neurobiology of pain are beginning to offer opportunities to
identify new drug targets and develop new therapeutic strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology
of pain. Pain is variable. For example, it can be inflammatory or neuropathic in nature, and it may be localized to a specific area of
the body or it may be generalized throughout. We believe that the most effective way to treat chronic pain is through therapies that
specifically target the origin of the pain signal. We strive to maximize JAN 101&rsquo;s potential based on its unique mechanism of action
related to the origin of the pain signal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic
Neuropathy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background:</B>&nbsp;Sodium
nitrite has been reported to be effective in reducing chronic peripheral pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:</B>&nbsp;To
evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained-release formulation of sodium nitrite (SR-nitrite) in patients
suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported previously by
subjects receiving the same doses of an immediate release formulation. Study Design: Phase II, single-center, randomized, double-blind,
placebo-controlled clinical trial. Setting: The Ohio Pain Clinic and Kettering Medical Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Methods:</B>&nbsp;Twenty-four
patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks. The primary objective was to determine whether
headaches would be reduced using SR-nitrite. The primary efficacy endpoint was the mean difference in the change of the Neuropathic Pain
Symptom Inventory (NPSI) pain score from baseline to that reported after 12 weeks of treatment. Secondary endpoints included changes
from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short-Form McGill Questionnaire, daily patient reported
score for neuropathic pain, changes in HbA1c, PulseOx, and quantitative sensory testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results:</B>&nbsp;The
number of subjects reporting adverse events and the number of adverse events did not change with dose. There were no reports of treatment-related
headaches. Although no significant differences were identified in patient responses to the questionnaires, a trend was observed. In the
NPSI assessment, patients in the 40 mg and 80 mg dosing groups reported a 12.7% and 22.0% reduction in pain, respectively, compared to
an 8.4% reduction by patients in the placebo group. A trend was also observed with the BPI total severity score. However, the 40 mg dosing
group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores, where the mean of
pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by
subjects in either of the other two groups. Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance
and Nerve Sensory Velocity. No changes were observed in HbA1c levels or PulseOx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations:</B>&nbsp;Small
sample size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conclusion:</B>&nbsp;Sustained
release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium
nitrite. In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant
reduction in reported pain. Similar trends were observed at the end of the trial period for most of the pain questionnaires used in the
study. The 80 mg BID treatment had the more pronounced effect on bioactivity (quantitative sensory testing), which was similar to the
PAD study, where this dosing group had the greatest improvement in Flow Mediated Dilation . The ability to alleviate pain with BID treatment
of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JAN101&mdash;Regulatory
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sodium
nitrite has been previously approved as one of the active components of cyanide poisoning antidote. This means the approval path for
JAN101 is likely through a 505(b)(2) (&ldquo;NDA&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JAN101&mdash;Commercial
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use third-party providers and manufacturers to support the commercialization JAN101, if we are successful in obtaining
FDA approval. We believe that we can promote JAN101 to the patients suffering from PAD in a cost effective manner. We anticipate our
commercial operation will include outside sales management, outside sales support, distribution support, and an internal marketing group.
Additional requisite capabilities will include focused management of key accounts, such as managed-care organizations, group purchasing
organizations, and government accounts. We intend selectively to partner with third parties with vast experience in the space, as we
have been partnering for every aspect of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Competition</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies,
intense competition, and a strong emphasis on proprietary products. We are currently focused on the development and commercialization
of our asset pipeline of novel, non-opioid, and non-addictive therapies for PAD. The number of patients suffering from chronic PAD is
large and growing. While we believe that JAN 101 and our Chief Scientific Officer&rsquo;s development experience and scientific knowledge
provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biotechnology,
and specialty pharmaceutical companies that market or develop therapeutics to treat chronic pain. Academic research institutions, governmental
agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors
may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research
and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved
products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales,
marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. The key competitive factors affecting the success
of JAN 101 (as well as other subsequent product candidates), if and when approved, is likely to be its efficacy, durability, safety,
price, and the availability of reimbursement from government and other third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
competition exists in the PAD pain field. Although we believe our approach to developing novel treatments for pain is unique from most
other existing or investigational therapies, such as NSAIDs, corticosteroids, and opioids, we will need to compete with all currently
available and future therapies within the indications where our development is focused. With respect to JAN101, the main classes of marketed
products that are available for the treatment of PAD pain include NSAIDs and opioids. Furthermore, numerous monoclonal antibodies targeting
nerve growth factor, or NGF inhibitors, are in clinical development, including two product candidates in Phase III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of companies developing or marketing therapies for the treatment and management of pain that may compete with JAN 101, including
many major pharmaceutical and biotechnology companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to
operate without infringing or otherwise violating the proprietary rights of others. We endeavor to protect our products using a combination
of intellectual property protections and available government regulatory and marketing exclusivities afforded to new medicines. For example,
we endeavor to protect our products by, among other methods, filing United States and foreign patent applications related to our proprietary
technology, inventions, and improvements that are important to the development and implementation of our business. We also use other
forms of protection, such as confidential information, trade secrets, and know-how, and trademarks to protect our intellectual property,
particularly where we do not believe patent protection is appropriate or obtainable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proprietary nature of, and protection for, JAN 101, processes, and know-how are important to our business. Our policy is to pursue, maintain,
and defend intellectual property rights, and to protect the technology, inventions, and improvements that are commercially important
to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Trade
Secrets and Other Proprietary Information</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed
methods for more efficient manufacture of sustained released sodium nitrite tablets. We seek to protect our proprietary information,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors,
and commercial partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>License
Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2019, we entered into a Patent and Know How License Agreement (the &ldquo;License Agreement&rdquo;) with UAB Research Foundation
(&ldquo;UABRF&rdquo;), TheraPAD, and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College,
acting on behalf of LSU Health Shreveport, together with UABRF and TheraPAD collectively, the &ldquo;Licensors&rdquo;). Under the License
Agreement, the Licensors have agreed to grant to ALT5 Sigma Corporation an exclusive, worldwide license, including the right to sublicense,
to the Licensors&rsquo; patent rights and know-how related to the Licensors&rsquo; sustained release formulation of sodium nitrite. Under
the License Agreement, we have agreed to pay a non-refundable upfront license fee and certain milestone payments upon the achievement
of certain milestones of up to approximately $6.5 million and certain royalty payments and annual license maintenance fees. The License
Agreement requires us to use commercially reasonable efforts to develop and commercialize JAN101.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Commercial
Operations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have any marketing and sales organization dedicated to the Biotechnology segment. We have retained global rights to
JAN-101 and JAN123, and, if either of them or one of our potential subsequent product candidates is approved by the FDA to market in
the United States, we expect that our sales force will be supported by sales management, internal sales support, an outside marketing
group, and distribution support. We intend to invest in our commercial capabilities prudently by focusing our marketing efforts on the
physician subspecialties that treat patients. These physicians include, but are not limited to, pain management specialists, rheumatologist,
surgeons, and sports medicine physicians. We will also evaluate licensing and partnering with third parties to help us reach other sales
channels and geographic markets inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Government
Regulation</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements
upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing.
These agencies, and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling, and export and import of product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>U.S.
Government Regulation of Drug Products</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDCA&rdquo;) and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable
United States requirements at any time during the product development process, the approval process, or thereafter, may subject an applicant
to a variety of administrative or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending applications, withdrawal of
an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension
of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal
penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with
                                            the FDA&rsquo;s good laboratory practice (&ldquo;GLP&rdquo;), regulations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an Investigational New Drug Application (&ldquo;IND&rdquo;), which must become
                                            effective before human clinical trials may begin;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            by an institutional research board (&ldquo;IRB&rdquo;) at each clinical site before each
                                            trial may be initiated;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well-controlled human clinical trials in accordance with good clinical practice
                                            (&ldquo;GCP&rdquo;) requirements to establish the safety and efficacy of the proposed drug
                                            product for each indication;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of a new drug application (NDA);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA inspection of the manufacturing facility or facilities at which the
                                            product is produced to assess compliance with current good manufacturing practices (&ldquo;cGMP&rdquo;)
                                            requirements and to assure that the facilities, methods, and controls are adequate to preserve
                                            the drug&rsquo;s identity, strength, quality, and purity;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity
                                            of the clinical data;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of user fees and securing FDA and approval of the NDA; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                            with any post-approval requirements, including the potential requirement to implement a risk
                                            evaluation and mitigation strategy (&ldquo;REMS&rdquo;), and the potential requirement to
                                            conduct post-approval studies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pre-clinical
Studies</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential
safety and efficacy. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical
data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some pre-clinical testing may
continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result,
submission of an IND may not result in the FDA allowing clinical trials to commence. Clinical holds also may be imposed by the FDA at
any time before or during clinical trials, due to safety concerns about on-going or proposed clinical trials, or non-compliance with
specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.
Through the 505(b)2 regulatory path, the FDA allows a sponsor to rely on well documented, published studies to support the clinical development
of the product. The FDA has indicated that it will accept published data in support of the Company&rsquo;s development program for JAN101
but prior to filing an NDA would require the Company to complete developmental and reproductive toxicology studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Trials</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing
for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives
of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical
trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution
participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution.
Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov
website. The information contained in, or accessible through, this website does not constitute a part of this Annual Report. We have
included this website address solely as an inactive, textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: The drug is initially introduced into healthy human subjects or patients with the target
                                            disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution,
                                            and excretion and, if possible, to gain an early indication of its effectiveness.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            II: The drug is administered to a limited patient population to identify possible adverse
                                            effects and safety risks, to evaluate the efficacy of the product for specific targeted diseases
                                            preliminarily, and to determine dosage tolerance and optimal dosage.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            III: The drug is administered to an expanded patient population, generally at geographically
                                            dispersed clinical trial sites, in well-controlled clinical trials to generate sufficient
                                            data statistically to evaluate the efficacy and safety of the product for approval, to establish
                                            the overall risk-benefit profile of the product, and to provide adequate information for
                                            the labeling of the product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase IV clinical trials as a condition of approval of an NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with
unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized
by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial
may move forward at designated check points based on access to certain data from the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase II, and before an NDA is submitted. Meetings at other times may be requested. These meetings
can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for
the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase
II clinical trial to discuss Phase II clinical results and present plans for the pivotal Phase III clinical trials that they believe
will support approval of the new drug. ALT5 Sigma Corporation submitted briefing materials in 2021 describing the previous research and
development activities and planned clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of product candidates and,
among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug.
In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the IND is active and before approval, progress reports summarizing the results of the clinical trials and non-clinical studies performed
since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the
FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk
to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and
any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator
brochure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Review and Approval Process</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, pre-clinical, and other non-clinical studies and clinical trials, along with descriptions of the manufacturing
process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to
the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial
user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other
things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve
the product&rsquo;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (the &ldquo;PDUFA&rdquo;), guidelines
that are currently in effect, the FDA has a goal of 10 months from the date of &ldquo;filing&rdquo; of a standard NDA for a new molecular
entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the
FDA has approximately two months to make a &ldquo;filing&rdquo; decision after the application is submitted. The FDA conducts a preliminary
review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts
it for filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee; but, it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or
more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing
of the drug with prescribing information for specific indications.<B>&nbsp;</B>A Complete Response Letter indicates that the review cycle
of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes
the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional Phase III
trial or other significant and time-consuming requirements related to clinical trials, non-clinical studies, or manufacturing. If a Complete
Response Letter is issued, the sponsor must resubmit the NDA that addresses all of the deficiencies identified in the letter, or withdraw
the application. Even if such additional data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria
for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor
to conduct Phase IV clinical testing, which involves clinical trials designed to assess a drug&rsquo;s safety and effectiveness further
after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products that already have been
commercialized. The FDA may also place other conditions on approval, including the requirement for REMS, to assure the safe use of the
drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without
an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use,
such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products. Marketing approval may be
withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Food and Drug Administration Safety and Innovation Act (the &ldquo;FDASIA&rdquo;) made permanent the Pediatric Research Equity Act (the
&ldquo;PREA&rdquo;), which requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication,
new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric
assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of
the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials
for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is
ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs
to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit
the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Special
FDA Expedited Review and Approval Programs</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat
a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially
superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on
a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of
the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required
user fees upon submission of the first section of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate
therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review
of 10 months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from
the &ldquo;filing&rdquo; date, rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two
months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation
are also likely to be considered appropriate to receive a priority review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful
therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and
well-controlled clinical trials that establish that the drug product has an effect (i) on a surrogate endpoint that is reasonably likely
to predict clinical benefit or (ii) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that
is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, including taking into account
the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted
effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
under the provisions of the FDASIA, a sponsor can request designation of a product candidate as a &ldquo;breakthrough therapy.&rdquo;
A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions,
such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval
of a breakthrough therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities
for our initial (or subsequent) product candidates, as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Post-Approval
Requirements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user program fee requirements
for any marketed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing
testing, including Phase IV clinical trials, and surveillance to assess further and monitor the product&rsquo;s safety and effectiveness
after commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state
agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements
and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to
use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply
with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of
post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.
Other potential consequences include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may
be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have promoted off-label
uses improperly may be subject to significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>The
Hatch-Waxman Amendments</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, added two pathways for FDA drug approval.
First, the Hatch-Waxman amendments to the FDCA authorized the FDA to approve an alternative type of NDA under Section 505(b)(2) of the
FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials not
conducted by or for the applicant and for which the applicant has not obtained a right of reference from the data owner. The applicant
may rely upon the FDA&rsquo;s findings of safety and efficacy for an approved product that acts as the &ldquo;listed drug.&rdquo; The
FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support the change from the listed drug. The
FDA may then approve a new product candidate for all, or some, of the label indications for which the branded reference drug has been
approved, as well as for any new indication sought by the 505(b)(2) applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
the Hatch-Waxman amendments to the FDCA also established a statutory procedure for submission and FDA review and approval of abbreviated
new drug applications (&ldquo;ANDAs&rdquo;) for generic versions of branded drugs previously approved by the FDA (such previously approved
drugs are referred to as &ldquo;listed drugs&rdquo;). An ANDA is a comprehensive submission that contains, among other things, data and
information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications, and stability of the generic
drug, as well as analytical methods, manufacturing process validation data and quality control procedures. Premarket applications for
generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness.
However, a generic manufacturer is typically required to conduct bioequivalence studies of its test product against the listed drug.
The bioequivalence studies for orally administered, systemically available drug products assess the rate and extent to which the active
pharmaceutical ingredient (the &ldquo;API&rdquo;) is absorbed into the bloodstream from the drug product and becomes available at the
site of action. Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption
of the generic product and the listed drug. For some drugs, other means of demonstrating bioequivalence may be required by the FDA, especially
where rate and/or extent of absorption are difficult or impossible to measure. The FDA will approve the generic product as suitable for
an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the
innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator
drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose
claims cover the applicant&rsquo;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then
published in the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the
Orange Book or a 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on
which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product
for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV
certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved
NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a &ldquo;section viii&rdquo; statement
certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify
to a listed method-of-use patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the referenced NDA holder and patent owners assert a patent challenge directed to one of the Orange Book-listed patents within 45 days
of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30
months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement
case that is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent
exclusivity listed in the Orange Book for the branded reference drug has expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Marketing
Exclusivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a
five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for
a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA
may not approve or even accept for review an abbreviated new drug application, or ANDA, or a NDA submitted under Section 505(b)(2), or
505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right
of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification
of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively
provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than
bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the
application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification
for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs
or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or
obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness. Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity
provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical
trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake
the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity,
except in certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Coverage and Reimbursement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory
approval. Sales in the United States will depend in part on the availability of adequate financial coverage and reimbursement from third-party
payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed
care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our initial or subsequent
therapeutic product candidates can be subject to challenge, reduction, or denial by payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement
rate that the payor will pay for the product. A payor&rsquo;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be available. Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement
for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals.
Third-party payors may not consider our initial or subsequent product candidates to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Healthcare
Reform</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict
or regulate post-approval activities, and affect the profitable sale of drug product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality, and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March
2010, the Affordable Care Act, formally known as the Patient Protection and Affordable Care Act (the &ldquo;ACA&rdquo;), was enacted
by Congress and signed into law by the President. It substantially changed the methods by which healthcare is financed by both the government
and private insurers, and significantly impacted the United States pharmaceutical industry. The ACA, among other things: (i) increased
the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals
enrolled in Medicaid-managed care organizations; (ii) established an annual, nondeductible fee on any entity that manufactures or imports
certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in
some government healthcare programs; (iii) expanded the availability of lower pricing under the 340B drug pricing program by adding new
entities to the program; (iv) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
(v) expanded the eligibility criteria for Medicaid programs; (vi) created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (vii) established
a Center for Medicare &amp; Medicaid Innovation to test innovative payment and service delivery models to lower Medicare and Medicaid
spending, potentially including prescription drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects
of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under
the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; Additionally, on January 22, 2018, former President Trump
signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including
the so-called &ldquo;Cadillac&rdquo; tax on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health
insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to
providers of two percent per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Healthcare Fraud and Abuse Laws and Compliance Requirements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. The United States laws that may
affect our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration,
    directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal
    healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or
    entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors
    that are false or fraudulent;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making
    false statements relating to healthcare matters;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the federal Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also
    imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, which among other things, requires certain manufacturers of drugs, devices, and biologics
    that are reimbursable by a federal healthcare program to report annually to the United States Department of Health and Human Services
    information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests
    held by physicians and their immediate family members; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">similar
    federal laws and state law equivalents of each of the above federal laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Regulation
Outside of the United States</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that our initial or subsequent product candidates, if and when approved, are sold in a foreign country, we may be subject
to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to
healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market our future products in the European Economic Area (the &ldquo;EEA&rdquo;) and many other foreign jurisdictions, we must
obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing
Authorization (an &ldquo;MA&rdquo;). There are two types of Marketing Authorizations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee
    for Medicinal Products for Human Use of the European Medicines Agency (the &ldquo;EMA&rdquo;) and which is valid throughout the entire
    territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products,
    orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the
    treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, and auto-immune and viral diseases. The
    Centralized Procedure is optional for products that contain a new active substance not yet authorized in the EEA, or for products
    that constitute a significant therapeutic, scientific, or technical innovation or that are in the interest of public health in the
    EU; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are
    available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized
    for marketing in a Member State of the EEA, a National MA can be recognized in another Member State through the Mutual Recognition
    Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously
    in various Member States through the Decentralized Procedure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Data
and Marketing Exclusivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or
biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized
in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the
EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period
can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains
an authorization for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are
held to bring a significant clinical benefit in comparison with existing therapies. In Japan, medicinal products approved for administration
to a patient via a new route of administration qualify for six years of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Trials</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the
International Conference on Harmonization (the &ldquo;ICH&rdquo;) guidelines on GCPs. Additional GCP guidelines from the European Commission,
focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical
trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative.
The sponsor must purchase a clinical trial insurance policy and, in most EU countries, the sponsor is liable to provide &ldquo;no fault&rdquo;
compensation to any study subject injured in the clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion
from an IEC. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an
investigational medicinal product dossier that contains information about the manufacture and quality of the medicinal product under
investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State
in which the trial will be conducted. Under the new Clinical Trials Regulation (Regulation (EU) No 536/2014), which took effect on January
31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application
and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information
submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees.
Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements
also apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recycling
Segment &ndash; Discontinued Operations</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholly-owned Recycling Subsidiaries in our Recycling segment included ARCA Recycling and ARCA Canada, which recycle major household appliances
in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency
programs, and Connexx, which provides call center services for the recycling segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ARCA business was disposed of on March 8, 2023. The business started in 1976 as a used appliance retailer that reconditioned old appliances
to sell in their stores. Any old appliances that could not be sold in ARCA stores were sold to scrap metal processors. In the late 1980s,
stricter environmental regulations began to affect the disposal of unwanted appliances and ARCA was no longer able to take appliances
that contained hazardous components to scrap metal processors. At that time, ARCA began to develop systems and equipment to remove the
harmful materials so that metal processors would accept the appliance shells for processing. ARCA then offered their services for disposing
of appliances in an environmentally sound manner to appliance manufacturers and retailers, waste hauling companies, rental property managers,
local governments, and the public. In 1989, ARCA began contracting with electric utility companies to provide turnkey appliance recycling
services to support their energy conservation efforts. Since that time, through March 8, 2023, ARCA provided services to approximately
400 utilities and other providers of energy efficiency programs throughout North America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, when we disposed of our recycling business, we had contracts to recycle, or to replace and recycle, major household appliances
for approximately 100 utilities and other providers of energy efficiency services across North America. ARCA operated 17 recycling centers
in the United States and Canada to process and recycle old appliances according to all federal, state, provincial, and local rules and
regulations. We used United States Environmental Protection Agency (the &ldquo;EPA&rdquo;) Responsible Appliance Disposal (&ldquo;RAD&rdquo;)
Program-compliant methods to remove and manage hazardous components and materials properly, including CFC refrigerants, mercury, polyurethane
foam insulation, and recyclable materials, such as ferrous and nonferrous metals, plastics, and glass. During our operations of the recycling
business, all of our facilities complied with licensing and permitting requirements, and employees who process appliances receive extensive
safety and hazardous materials training.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Disposition
of our Recycling Business</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2023, the Company entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation
(&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting
of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The
sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement (the &ldquo;Disposition
Transaction&rdquo;) was consummated simultaneously with the execution of the Recycling Purchase Agreement. Our Board of Directors unanimously
approved the Recycling Purchase Agreement and the Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
economic aspects of the Disposition Transaction are: (i) we reduced the liabilities on our consolidated balance sheets by approximately
$17.6 million (excluding those related to the California Business Fee and Tax Division, as discussed below); (ii) we will receive not
less than $24.0 million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling
Subsidiaries&rsquo; future performance; and (iii) during the next five years, we may request that VM7 prepay aggregate monthly payments
in the aggregate amount of $1 million. We also received one thousand dollars for the equity of each of the Recycling Subsidiaries at
the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year
payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&rsquo;
aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&rsquo; aggregate gross revenues
between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000
for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions,
or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 19, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VM7
may prepay, at any time and in total, the estimated aggregate of the future monthly payments. That amount will be an amount equal to
the then-present value of the estimated future monthly payments, discounted at the rate of 5% per annum (the &ldquo;Prepayment Price&rdquo;).
Furthermore, VM7 will be required to pay the Prepayment Price upon the earliest of (i) Mr. Johnson holding less than 75% of the capital
stock of VM7, (ii) VM7 selling substantially all of its assets, (iii) VM7 holding less than 50% of the capital stock of the Recycling
Subsidiaries, or (iv) the Recycling Subsidiaries selling substantially all of their respective assets. Upon payment of the Prepayment
Price, VM7 will have no further purchase price payment obligations to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
terms of the Disposition Transaction are: (i) we have the right to appoint one member of VM7&rsquo;s board of directors until the sooner
of VM7 having paid the Prepayment Price or having tendered all of the monthly payments; (ii) Mr. Johnson&rsquo;s annual salary as Chief
Executive Officer of VM7 shall be $400,000, prorated, for the remainder of the 2023 calendar year, and then adjusted annually to an amount
equal to 1% of the Recycling Subsidiaries&rsquo; aggregate gross revenues, until the sooner of VM7 having paid the Prepayment Price or
having tendered all of the monthly payments; and (iii) we will receive additional payments from VM7 (that are not related to the on-going
monthly payments) that relate to certain taxing agency issues. Upon settlement of the continuing dispute between ARCA Recycling and the
California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to us 50% of the
amount of the reduction between the current assessment and any such settlement. The payment will be memorialized by a three-year promissory
note with interest at five percent per annum. The first payment under the note will be on the last day of VM7&rsquo;s fiscal year in
which the settlement occurs and the remaining payments each year thereafter. If ARCA Recycling receives a refund from the agency for
payments previously made, it shall pay to us an amount equivalent to 25% of such refund after reduction for the legal fees payable to
counsel for this proceeding. ARCA Recycling and Connexx are due to receive from the Internal Revenue Service two payments in the aggregate
amount of approximately $931,000 in connection with the Employee Retention Credit provisions of the Coronavirus Aid, Relief, and Economic
Security Act and the Taxpayer Certainty and Disaster Tax Relief Act of 2020. Those payments are to be tendered to us within 10 days of
receipt by ARCA Recycling or Connexx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
secure VM7&rsquo;s obligations under the Recycling Purchase Agreement and pursuant to a Stock and Membership Interests Pledge Agreement
dated March 19, 2023 (the &ldquo;Pledge Agreement&rdquo;), Mr. Johnson pledged to us all of the capital stock in VM7 (&ldquo;VM7&rsquo;s
Capital Stock&rdquo;) and VM7 pledged to us all of the equity interests of the Recycling Subsidiaries (the &ldquo;Subject Securities&rdquo;).
Under the terms of the Pledge Agreement, upon an Event of Default (as defined in the Pledge Agreement), among other remedies in our favor,
we may foreclose on any or all of VM7&rsquo;s Capital Stock and the Subject Securities. We may also cause the ownership of VM7&rsquo;s
Capital Stock and of the Subject Securities to be transferred to us automatically, pursuant to an irrevocable transfer entered in our
favor, as referenced in the Pledge Agreement. In the event of an automatic transfer, all of the monthly payments previously made by VM7
pursuant to the terms of the Recycling Purchase Agreement will then be characterized as contributions to the capital of the Company without
dilution of the Company&rsquo;s capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties have made customary representations, warranties, covenants, and indemnities in connection with the Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Recycling Purchase Agreement contains certain representations and warranties that the parties made to each other as of the date of the
Recycling Purchase Agreement or such other date as explicitly referenced therein. The representations and warranties were made solely
for purposes of the Recycling Purchase Agreement and (i) are subject to limitations agreed by the parties in negotiating the terms and
conditions thereof, (ii) may not be accurate or complete as of any specified date, (iii) will be qualified by the underlying disclosure
schedules, (iv) may be subject to a contractual standard of materiality different from those generally applicable to investors, and (v)
may have been used for the purpose of allocating risk among the parties thereto, rather than for establishing any matters as facts. Information
concerning the subject matter of the representations and warranties may change after March 8, 2023, and subsequent information may or
may not be fully reflected in ALT5 Sigma Corporation&rsquo;s public disclosures. For the foregoing reasons, the representations and warranties
contained in the Recycling Purchase Agreement should not be relied upon as statements of factual information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the closing of the Disposition Transaction, VM7 determined that, after expending significant amounts of time and resources, it was
unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, we were advised
that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because we did not receive all of the economic
benefits of the Disposition Transaction and understand that we will not receive any future benefits of the Disposition Transaction, we
determined to fully impair the approximately $5.3 million carrying value of the Disposition Transaction on our balance sheet. We also
determined not to exercise any of our remedies under the Recycling Purchase Agreement so that we could maintain our focus on our clinical-stage
biopharmaceutical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Corporate
and Other</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate and other segment consists of certain corporate general and administrative costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Employees</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 1, 2025, the Company had 27 employees, all of whom were full-time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_001"></A>DESCRIPTION
OF SECURITIES WE MAY OFFER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue from time to time, in one or more offerings the following securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of Preferred Stock, which may be convertible into shares of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">debt
    securities, which may be senior or subordinated and may be convertible into or exchangeable for shares of Common Stock or shares
    of Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
    exercisable for debt securities, shares of Common Stock, or shares of Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rights
    to purchase any of such securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">units
    composed of our debt securities, shares of Common Stock, shares of Preferred Stock, and warrants, in any combination.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains a summary of the material general terms of the various securities that we may offer. The specific terms of the securities
will be described in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or
other offering materials, which may be in addition to or different from the general terms summarized in this prospectus. Where applicable,
the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials
will also describe any material United States federal income tax considerations relating to the securities offered and indicate whether
the securities offered are or will be listed on any securities exchange. The summaries contained in this prospectus and in any prospectus
supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable,
may not contain all of the information that you would find useful. Accordingly, you should read the actual documents relating to any
securities sold pursuant to this prospectus. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information
by Reference&rdquo; for information about how to obtain copies of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any particular offering, the initial offering price, and the net proceeds to us will be contained in the prospectus supplement,
information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating
to such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_002"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of terms of our Common Stock and our Preferred Stock is based upon our Articles of Incorporation (our &ldquo;Charter&rdquo;)
and Bylaws (our &ldquo;Bylaws&rdquo;), currently in effect, and under Chapter 78 of the Nevada Revised Statutes (the &ldquo;NRS&rdquo;).
This summary is not complete and is subject to, and qualified in its entirety by reference to, our Charter and our Bylaws. For a complete
description of the terms and provisions of our Common Stock, please refer to our Charter and Bylaws, which are filed as exhibits to Registration
Statement of which this prospectus forms a part. Throughout this section, references to &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo;
refer to ALT5 Sigma Corporation. and its subsidiaries. We encourage you to carefully read these documents and the applicable provisions
of the NRS.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 200,000,000 shares of Common Stock, par value $0.001 per share, and 2,000,000 shares of Preferred
Stock, par value $0.001 per share, of which 34,250 shares are designated as Series B Preferred Stock, which has a stated value of $1.00
per share (our &ldquo;Series B Preferred Stock&rdquo;), 17,000 shares are designated as Series I Preferred Stock, which has a stated
value of $262.00 per share (our &ldquo;Series I Preferred Stock&rdquo;), 1,000,000 shares are designated as Series Q Preferred Stock,
which has a stated value of US$2.594 per share (our &ldquo;Series Q Preferred Stock&rdquo;), and 200,000 shares are designated as Series
S Preferred Stock, which has a stated value of $300.00 per share (our &ldquo;Series S Preferred Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 29, 2025, we had 20,142,951 shares of our Common Stock issued and outstanding, 34,207 shares of our Series B Preferred Stock issued
and outstanding, 17,000 shares of our Series I Preferred Stock issued and outstanding, 578,258 shares of our Series Q Preferred
Stock issued and outstanding, and 100,000 shares of our Series S Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized and unissued shares of Common Stock and Preferred Stock are available for issuance without further action by our stockholders,
unless such action is required by applicable law or the rules of any stock exchange on which our securities may then be listed. Unless
approval of our stockholders is so required, our Board of Directors (our &ldquo;Board&rdquo;) does not currently intend to seek stockholder
approval for the issuance and sale of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued and outstanding shares of our capital stock are fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting,
Dividend, and Liquidation Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of our Common Stock is entitled to one vote for each share issued and outstanding held on all matters to be voted upon by the
stockholders. Upon liquidation, dissolution, or winding up of the Company, and after all liquidation preferences payable to any series
of Preferred Stock entitled thereto have been satisfied, our remaining assets shall be distributed to all holders of Common Stock and
any similarly situated stockholders who are not entitled to any liquidation preference or, if there be an insufficient amount to pay
all such stockholders, then ratably among such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive,
Conversion, or Other Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of Common Stock do not have any preemptive, conversion, or redemption rights. Our shares of Series A-1 Preferred Stock do not
have any preemptive or redemption rights and each share of which is convertible into 20 shares of our Common Stock. Our shares of Series
S Preferred do not have any preemptive or redemption rights and, subject to the provisions of the Certificate of Designation in respect
of the Series S Preferred Stock, each share of which is convertible into shares of our Common Stock at a conversion price of $1.66 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
Action; Special Meetings</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
actions can only be taken at an annual or special meeting of our stockholders. Our Bylaws provide that special meetings of the stockholders
may be called at any time only by (i) our Chief Executive Officer, (ii) two of the members of the Board, or (iii) upon a written request
of stockholders holding 10% or more of the capital stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
of Directors; Removal; Vacancies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws specify that the number of directors is to be determined by a majority vote of the Board. Our Board is currently composed of four
directors. We do not have a classified Board. Pursuant to our Bylaws and the NRS, a director serves until the regular meeting next following
or closely coinciding with the expiration of his or her term of office and until his or her successor has been elected and qualified,
or until his or her earlier death, removal, or resignation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newly
created directorships resulting from an increase in the number of directors and vacancies occurring on our Board for any reason may be
filled by a vote of a majority of the directors then in office, although less than a quorum exists. A director that is appointed or elected
to fill a vacancy shall hold office for the remaining term of his or her predecessor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
of Liability and Indemnification</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter provides that none of our directors and officers shall be personally liable to us or our stockholders for damages for breach
of fiduciary duty as a director or officer, except for liability for (i) acts or omissions that involve intentional misconduct, fraud,
or knowing violation of law or (ii) for authorizing any distribution in violation of Section 78.300 of the NRS. Our Bylaws provide that
any officer or director who is made a party or witness to an action, suit, or proceeding, whether civil, criminal, administrative, or
investigative, by reason of the fact that he or she is or was one of our directors or officers or serving at our request as a director,
officer, employee, or agent, shall be indemnified and held harmless by us to the fullest extent authorized by the NRS. The right to indemnification
shall include the right of advancement of expenses to the extent permitted under the NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Listing
and Transfer Agent</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;ALTS.&rdquo; The transfer agent and registrar for our common
stock is EQ Shareowner Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of our Charter, our Bylaws, and the NRS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the NRS and our Charter and Bylaws could make more difficult the acquisition of us by means of a tender offer or otherwise,
and the removal of incumbent officers and directors. These provisions are expected to discourage certain types of coercive takeover practices
and inadequate takeover bids and to encourage persons seeking to acquire control of us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice of Stockholder Proposals</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
proposals must be submitted to the Chairman of our Board, our Chief Executive Officer, our President, or our Secretary not less than
120 days before the one-year anniversary of the date on which we released our proxy statement in connection with the previous year&rsquo;s
annual meeting of stockholders. In the event that our annual meeting date has been changed by more than 30 days from the date of the
prior year&rsquo;s annual meeting, written proposals must be submitted within a reasonable time before we begin to print and mail our
proxy materials. To be in proper form, a stockholder&rsquo;s written proposal must be in compliance with Rule 14a-8 under the Exchange
Act and must include: (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting
such business at the annual meeting, (ii) the name and record address of such stockholder, (iii) the class or series and number of shares
of our capital stock that are owned beneficially or of record by such stockholder, (iv) a description of all arrangements or understandings
between such stockholder and any other person or persons (including their names) in connection with the proposal of such business by
such stockholder and any material interest of such stockholder in such business, and (v) a representation that such stockholder intends
to appear in person or by proxy at the annual meeting to bring such business before the meeting. This provision could make it more difficult
for stockholders to submit proposals for consideration and nominees for director at an annual meeting of our stockholders<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
Combinations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;business combination&rdquo; provisions of Sections 78.411 to 78.444, inclusive, of the NRS prohibit a Nevada corporation with
at least 200 stockholders (at least 100 of whom are stockholders of record and residents of the State of Nevada) from engaging in various
&ldquo;combination&rdquo; transactions with any interested stockholder for a period of three years after the date of the transaction
in which the person became an interested stockholder, unless the transaction is approved by the entity&rsquo;s board of directors prior
to the date the interested stockholder obtained such status; or after the expiration of the three-year period, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 98%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    transaction is approved by the entity&rsquo;s board of directors or a majority of the voting power held by disinterested stockholders
    of the entity, or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid
    by the interested stockholder within the three years immediately preceding the date of the announcement of the combination or in
    the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock
    on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher,
    or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;combination&rdquo; is defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or
other disposition, in one transaction or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate
market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal
to 5% or more of the aggregate market value of all outstanding shares of the corporation, or (c) 10% or more of the earning power or
net income of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, an &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, owns (or within three years,
did own) 10% or more of an entity&rsquo;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control
attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity
to sell their stock at a price above the prevailing market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Acquisitions
of Controlling Interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada&rsquo;s
&ldquo;acquisition of controlling interest&rdquo; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition
of a controlling interest in certain Nevada corporations. These &ldquo;control share&rdquo; laws provide generally that any person who
acquires a &ldquo;controlling interest&rdquo; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested
stockholders of the corporation elects to restore such voting rights. These laws would apply to us as of a particular date if we were
to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times
during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation,
unless our Charter or Bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws
provide that a person acquires a &ldquo;controlling interest&rdquo; whenever a person acquires shares of a subject corporation that,
but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third,
(2) one-third or more, but less than a majority, or (3) a majority or more of all of the voting power of that corporation in the election
of its directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction that took it over the
threshold and shares that it acquired within the 90 days immediately preceding the date when it acquired or offered to acquire a controlling
interest become &ldquo;control shares&rdquo; to which the voting restrictions described above apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_003"></A>DESCRIPTION
OF PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our Preferred Stock may be issued in one or more series, and our Board is authorized to determine the designation and to fix the number
of shares of each series. Our Board is further authorized to fix and determine the dividend rate, premium or redemption rates, conversion
rights, voting rights, preferences, privileges, restrictions, and other variations granted to or imposed upon any wholly unissued series
of our Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issuance of shares of a series of Preferred Stock, our Board will adopt resolutions and file a certificate of designation with
the Secretary of State of the State of Nevada. The certificate of designation will fix for each series the designation and number of
shares and the rights, preferences, privileges, and restrictions of the shares including, but not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    voting rights, if any, of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    rights and terms of redemption;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dividend rate(s), period(s), and/or payment date(s) or method(s) of calculation applicable to the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends on the Preferred Stock will accumulate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution, or winding
    up of our affairs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if applicable, upon which the Preferred Stock will be convertible into Common Stock, another series of Preferred
    Stock, or any other class of securities, including the conversion price (or manner of calculation) and conversion period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provision for redemption, if applicable, of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for a sinking fund, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidation preferences, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    limitations on the issuance of any class or series of Preferred Stock ranking senior to or on a parity with the class or series of
    Preferred Stock as to dividend rights and rights upon liquidation, dissolution, or winding up of our affairs; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, preferences, rights, limitations, or restrictions of the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms listed above, we will set forth in a prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, as applicable, the following terms relating to the series of Preferred
Stock being offered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares of the preferred stock offered, the liquidation preference per share, the conversion rights, and the offering price
    of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures for any auction and remarketing, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    listing of the Preferred Stock on any securities exchange; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of any material and/or special United States federal income tax considerations applicable to the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
B Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series B Preferred Stock do not have any dividend rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series B Preferred Stock do not have any conversion rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series B Preferred Stock do not have any redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series B Preferred Stock are not entitled to any preemptive rights in respect of any securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series B Preferred Stock do not have any voting rights, except to the extent that voting is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary, the holders of Series B Preferred Stock
shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the Stated Value ($1.00
per share) for each share of Series B Preferred Stock before any distribution or payment shall be made to the holders of any security
junior to the Series B Preferred Stock, and if the assets of the Company shall be insufficient to pay in full such amounts, then the
entire assets to be distributed to the holders of Series B Preferred Stock shall be ratably distributed among them in accordance with
the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no protective provisions in respect of the shares of Series B Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
I Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series I Preferred Stock shall be entitled to receive dividends on an as-converted into-Common Stock basis contemporaneously
with the declaration and payment to the holders of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series I Preferred Stock is convertible into 100 shares of our Common Stock to a maximum of 12.5% of each holder&rsquo;s initial
shares of Series I Preferred Stock on a quarterly basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series I Preferred Stock do not have any redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series I Preferred Stock are not entitled to any preemptive rights in respect of any securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series I Preferred Stock do not have any voting rights, except to the extent that voting is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence of any liquidation, dissolution, or winding up of the Corporation, either voluntary or involuntary (a &ldquo;<U>Liquidation</U>&rdquo;),
each holder of Series I Convertible Preferred Stock then outstanding shall be automatically converted into shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no protective provisions in respect of the shares of Series B Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
Q Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series Q Preferred Stock do not have any dividend rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series Q Preferred Stock is convertible into one share of our Common Stock to a maximum of 12.5% of each holder&rsquo;s initial
shares of Series Q Preferred Stock on a quarterly basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series Q Preferred Stock do not have any redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series Q Preferred Stock are not entitled to any preemptive rights in respect of any securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series Q Preferred Stock do not have any voting rights, except to the extent that voting is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, each holder of Series
Q Convertible Preferred Stock then outstanding shall be automatically converted into shares of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no protective provisions in respect of the shares of Series Q Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
S Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022 the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&ldquo;STLLC&rdquo;) by way of merger.
In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company&rsquo;s
Series S Convertible Preferred Stock to Amol Soin, M.D., the sole stockholder of STLLC (&ldquo;Dr. Soin&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series S Preferred Stock have no dividend rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Soin may convert up to $10 million of value of the Series S Preferred Stock into shares of the Company&rsquo;s Common Stock from and
after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the
closing of the acquisition of STLLC. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional
$17 million of value of shares of Series S Preferred Stock at a rate of five percent of the gross revenues that the Company receives
in connection with sales or license revenue from STLLC-related products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Soin further agreed to certain restrictions on the maximum number of shares of Series S Preferred Stock that he may ultimately keep or
that he may convert into shares of our Common Stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares
of Series S Preferred Stock into shares of the Company&rsquo;s Common Stock in an amount such that, upon any such conversion, he beneficially
own shares of the Company&rsquo;s Common Stock in excess of 4.99% of the Company&rsquo;s then-outstanding Common Stock and (ii) during
the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Preferred Stock into
shares of the Company&rsquo;s Common Stock, he will not dispose of any of such shares into the public markets in an amount that exceeds
five percent of the daily trading volume of the Company&rsquo;s common stock during any trading day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of Dr. Soin exercising his initial conversion rights in respect of up to $3 million in value of his Series S Preferred Stock, Dr.
Soin and we agreed that we will tender to him $3 million. As of the date of this Registration Statement of which this prospectus forms
a part, Dr. Soin is owed $2.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series S Preferred Stock have no redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series S Preferred Stock are not entitled to any preemptive rights in respect to any securities of the Company, except as
set forth in the Series S Certificate of Designation or any other document agreed to by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series S Preferred Stock has one vote. The holders of Series S Preferred Stock vote together with all other classes and series
of Common Stock and Preferred Stock of the Company as a single class on all actions to be taken by the holders of Common Stock of the
Company, except to the extent that voting as a separate class or series is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Preference</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a voluntary or involuntary liquidation, dissolution or winding up of the Company, the Holders of Series S Preferred Stock have preferential
rights to holders of junior securities and shall be entitled to payments in an amount equal to the Stated Value for each share of Series
S Preferred Stock that is eligible to be converted into the Company&rsquo;s Common Stock at such time, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
first obtaining the affirmative approval of a majority of the holders of the shares of Series S Preferred Stock, we may not directly
or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Preferred
Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Preferred Stock, but excluding a stock
split or reverse stock split or combination of the Common Stock or preferred stock; (iii) effect an exchange, or create a right of exchange,
of all or part of the shares of another class of shares into shares of Series S Preferred Stock; or (iv) alter or change the rights,
preferences, or privileges of the shares of Series S Preferred Stock so as to affect adversely the shares of such series, including the
rights set forth in the Series S Certificate of Designation; <I>provided</I>, <I>however</I>, that we may, without any vote of the holders
of shares of the Series S Preferred Stock, make technical, corrective, administrative, or similar changes to the Series S Certificate
of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of
shares of the Series S Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_004"></A>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information we include in any applicable prospectus supplements or any related free
writing prospectus or other offering materials, as applicable, summarizes the material terms and provisions of the debt securities that
we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may
offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus
supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from
the terms described below, the terms set forth in the prospectus supplement or any related free writing prospectus or other offering
materials, as applicable, shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell from time to time, in one or more offerings under this prospectus, debt securities, in one or more series. These debt securities
that we may issue include senior debt securities, senior subordinated debt securities, subordinated debt securities, convertible debt
securities, and exchangeable debt securities. We will issue any such senior debt securities under a senior indenture that we will enter
into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture,
which we will enter into with a trustee to be named in the subordinated indenture. We use the term &ldquo;indentures&rdquo; to refer
to either the senior indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture
Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;), as in effect on the date of the indenture. We use the term &ldquo;debenture
trustee&rdquo; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary description, together with the additional information we may include in any applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, does not purport
to be complete and is subject to, and qualified in its entirety by reference to, the form of indenture filed as an exhibit to the Registration
Statement of which the prospectus is a part, as it may be supplemented, amended, or modified from time to time, as well as the notes
and supplemental agreement relating to each series of debt securities that will be incorporated by reference as exhibits to the Registration
Statement that includes the prospectus or as exhibits to a Current Report on Form 8-K if we offer debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture does not limit the amount of debt securities that may be issued thereunder, and each indenture provides that the specific terms
of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture,
if any, relating to such series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the debt securities issued under the indentures as &ldquo;discount securities,&rdquo; which means they may be sold at a discount
below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be
issued with &ldquo;original issue discount,&rdquo; or &ldquo;OID,&rdquo; for U.S. federal income tax purposes because of interest payment
and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities
issued with OID will be described in more detail in any applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will describe in the applicable prospectus supplement, the related free writing prospectus, or other offering materials, as applicable,
the terms of the series of debt securities being offered, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title or designation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate principal amount and any limit on the aggregate principal amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    maturity date or dates on which principal will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    form of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    applicability of any guarantees;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities rank as senior debt, senior subordinated debt, subordinated debt, or any combination thereof, and the terms of
    any subordination;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a
    price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration
    of the maturity thereof, or, if applicable, the portion of the principal amount of such debt securities that is convertible into
    another security or the method by which any such portion shall be determined;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to
    accrue, the dates interest will be payable, and the regular record dates for interest payment dates or the method for determining
    such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our
    option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those
    redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous
    fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities and the currency
    or currency unit in which the debt securities are payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple
    thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    place or places where payments will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities of that series shall be issued in whole or in part in the form of a global security or securities, the terms
    and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities;
    and the depositary for such global security or securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the indenture will restrict our ability to pay dividends or will require us to maintain any asset ratios or reserves;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    other than the full principal amount thereof, the portion of the principal amount of debt securities of the series that shall be
    payable upon declaration of acceleration of the maturity thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will be restricted from incurring any additional indebtedness;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to
    declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the provisions relating to satisfaction and discharge of the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt
    securities issued under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and conditions upon
    which the election may be made;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts
    of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    restrictions on transfer, sale, or assignment of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, preferences, rights, or limitations of, or restrictions on, the debt securities, any other additions or changes
    in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax
considerations and other special consideration applicable to any of these debt securities in the applicable prospectus supplement, related
free writing prospectus, or other offering materials, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
or Exchange Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in the applicable prospectus supplement, related free writing prospectus, or other offering materials, as applicable,
the terms on which a series of debt securities may be convertible into or exchangeable for shares of our Common Stock, shares of our
Preferred Stock, or other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion
or exchange is mandatory, at the option of the holder, or at our option. We may include provisions pursuant to which the number of shares
of our Common Stock, shares of our Preferred Stock, or our other securities that the holders of the series of debt securities receive
would be subject to adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidation,
Merger, or Sale; No Protection in Event of a Change of Control or Highly Leveraged Transaction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, applicable to a particular series of debt securities, the indenture will contain covenant
that restricts our ability to merge or consolidate, or sell, convey, transfer, or otherwise dispose of our assets as an entirety or substantially
as an entirety, unless we are the surviving corporation or the successor to or acquirer of such assets (other than a subsidiary of ours)
expressly assumes all of our obligations under the indenture or the debt securities, as appropriate. In addition, we cannot complete
such a transaction unless immediately after completing the transaction, no event of default under the indenture, and no event that, after
notice or lapse of time or both, would become an event of default under the indenture, has occurred and is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable to a particular series of debt securities, the debt securities will not contain any provisions
that may afford holders of the debt securities protection in the event we have a change of control or in the event of a highly leveraged
transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Events
of Default Under the Indentures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable to a particular series of debt securities, the following are events of default under the indentures
with respect to any series of debt securities that we may issue:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to pay interest when due and our failure continues for a period of 90 days; <I>provided</I>, <I>however</I>, that a valid
    extension of an interest payment period by us in accordance with the terms of any indenture supplement thereto shall not constitute
    a default in the payment of interest for this purpose;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable
    whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established
    with respect to such series; <I>provided</I>, <I>however</I>, that a valid extension of the maturity of such debt securities in accordance
    with the terms of any indenture supplement thereto shall not constitute a default in the payment of principal or premium, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant
    specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice
    of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders
    of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    specified events of bankruptcy, insolvency, or reorganization occur as to us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency, or reorganization)
necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default
may constitute an event of default under any bank credit agreements we may have in existence from time to time. In addition, the occurrence
of certain events of default or acceleration under the indenture may constitute an event of default under certain of our other indebtedness
outstanding from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of at least 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us
(and to the debenture trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities
of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and
premium and accrued and unpaid interest, if any, on all debt securities of that series. Before a judgment or decree for payment of the
money due has been obtained with respect to debt securities of any series, the holders of a majority in principal amount of the outstanding
debt securities of that series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in
principal amount of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events
of default, other than the non-payment of accelerated principal, premium, if any, and interest, if any, with respect to debt securities
of that series, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect of principal,
premium or interest that had become due other than as a result of such acceleration). We refer you to the prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating to any series
of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal
amount of such discount securities upon the occurrence of an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be
under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of
the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place
of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture
trustee, with respect to the debt securities of that series, provided, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability
    or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver
or trustee, or to seek other remedies if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder previously has given written notice to the debenture trustee of a continuing event of default with respect to that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,
    and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount
    of the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders
    of a majority in principal amount of the debt securities of such series represented at such meeting) other conflicting directions
    within 60 days after the notice, request, and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the applicable
indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modification
of Indentures; Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the debenture trustee may change the applicable indenture without the consent of any holders with respect to specific matters, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evidence the succession of another corporation to us and the assumption by any such successor of our covenants in such indenture
    and in the debt securities issued thereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add to our covenants or to surrender any right or power conferred on us pursuant to the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    establish the form and terms of debt securities issued thereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evidence and provide for a successor trustee under such indenture with respect to one or more series of debt securities issued thereunder
    or to provide for or facilitate the administration of the trusts under such indenture by more than one trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cure any ambiguity, to correct or supplement any provision in the indenture that may be defective or inconsistent with any other
    provision of the indenture or to make any other provisions with respect to matters or questions arising under such indenture; provided
    that no such action adversely affects the interests of the holders of any series of debt securities issued thereunder in any material
    respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue,
    authentication, and delivery of securities under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add any additional events of default with respect to all or any series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    supplement any of the provisions of the indenture as may be necessary to permit or facilitate the defeasance and discharge of any
    series of debt securities, provided that such action does not adversely affect the interests of any holder of an outstanding debt
    security of such series or any other security in any material respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make provisions with respect to the conversion or exchange rights of holders of debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    pledge to the trustee as security for the debt securities of any series any property or assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add guarantees in respect of the debt securities of one or more series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    change or eliminate any of the provisions of the indenture, provided that any such change or elimination becomes effective only when
    there is no security of any series outstanding created prior to the execution of such supplemental indenture that is entitled to
    the benefit of such provision;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for certificated securities in addition to or in place of global securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    qualify such indenture under the Trust Indenture Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to the debt securities of any series, to conform the text of the indenture or the debt securities of such series to any provision
    of the description thereof in our offering memorandum or prospectus relating to the initial offering of such debt securities, to
    the extent that such provision, in our good faith judgment, was intended to be a verbatim recitation of a provision of the indenture
    or such securities; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make any other change that does not adversely affect the rights of holders of any series of debt securities issued thereunder in
    any material respect.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with
the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series
(or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities
of such series represented at such meeting) that is affected. However, the debenture trustee and we may make the following changes only
with the consent of each holder of any outstanding debt security affected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending
    the fixed maturity of the series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the principal amount, reducing the rate of, or extending the time of payment of interest, or any premium payable upon the redemption
    of any debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the principal amount of discount securities payable upon acceleration of maturity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impair
    the right to institute suit for the enforcement of any payment on any debt security when due;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, adversely affect the right of a holder to confer or exchange a debt security; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the percentage of debt securities, the holders of which are required to consent to any amendment or waiver.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series
(or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities
of such series represented at such meeting) may on behalf of the holders of all debt securities of that series waive our compliance with
provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may, on behalf
of the holders of all the debt securities of such series, waive any past default under the indenture with respect to that series and
its consequences, except a default in the payment of the principal of, premium, or any interest on any debt security of that series or
in respect of a covenant or provision, which cannot be modified or amended without the consent of the holder of each outstanding debt
security of the series affected; <I>provided</I>, <I>however</I>, that the holders of a majority in principal amount of the outstanding
debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from
the acceleration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discharge,
Defeasance, and Covenant Defeasance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can discharge or decrease our obligations under the indenture as stated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may discharge obligations to holders of any series of debt securities that have not already been delivered to the trustee for cancellation
and that have either become due and payable or are by their terms to become due and payable, or are scheduled for redemption, within
one year. We may effect a discharge by irrevocably depositing with the trustee cash or government obligations, as trust funds, in an
amount certified to be enough to pay, when due, whether at maturity, upon redemption or otherwise, the principal of, and any premium
and interest on, the debt securities and any mandatory sinking fund payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, we may also discharge any and all of our obligations to holders of any series of debt securities at any
time, which we refer to as defeasance. We may also be released from the obligations imposed by any covenants of any outstanding series
of debt securities and provisions of the indenture, and we may omit to comply with those covenants without creating an event of default
under the trust declaration, which we refer to as covenant defeasance. We may effect defeasance and covenant defeasance only if, among
other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    irrevocably deposit with the trustee cash or government obligations denominated in the currency of the debt securities, as trust
    funds, in an amount certified to be enough to pay at maturity, or upon redemption, the principal (including any mandatory sinking
    fund payments) of, and any premium and interest on, all outstanding debt securities of the series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    deliver to the trustee an opinion of counsel from a nationally recognized law firm to the effect that the holders of the series of
    debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the defeasance or covenant
    defeasance and that defeasance or covenant defeasance will not otherwise alter the holders&rsquo; U.S. federal income tax treatment
    of principal, and any premium and interest payments on, the series of debt securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of a defeasance by us, the opinion we deliver must be based on a ruling of the Internal Revenue Service issued, or a change
in U.S. federal income tax law occurring, after the date of the indenture, since such a result would not occur under the U.S. federal
income tax laws in effect on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may discharge or decrease our obligations under the indenture as described in the two preceding paragraphs, we may not avoid, among
other things, our duty to register the transfer or exchange of any series of debt securities, to replace any temporary, mutilated, destroyed,
lost, or stolen series of debt securities or to maintain an office or agency in respect of any series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Global Securities and Book Entry System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities of a series may be issued in whole or in part in book-entry form and will be represented by one or more fully registered
global securities. We will deposit any registered global securities with a depositary or with a nominee for a depositary identified in
the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials and registered in the name of such depositary or nominee. In such case, we will issue one or more registered global securities
denominated in an amount equal to the aggregate principal amount of all of the debt securities of the series to be issued and represented
by such registered global security or securities. This means that we will not issue certificates to each holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
and until it is exchanged in whole or in part for debt securities in definitive registered form, a registered global security may not
be transferred except as a whole:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the depositary for the registered global security to its nominee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    a nominee of the depositary to the depositary or another nominee of the depositary; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the depositary or its nominee to a successor of the depositary or a nominee of the successor.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials,
as applicable, relating to a series of debt securities will describe the specific terms of the depositary arrangement involving any portion
of the series represented by a registered global security. We anticipate that the following provisions will apply to all depositary arrangements
for debt securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ownership
    of beneficial interests in a registered global security will be limited to persons that have accounts with the depositary for such
    registered global security, these persons being referred to as &ldquo;participants,&rdquo; or persons that may hold interests through
    participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    the issuance of a registered global security, the depositary for the registered global security will credit, on its book-entry registration
    and transfer system, the participants&rsquo; accounts with the respective principal amounts of the debt securities represented by
    the registered global security beneficially owned by the participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    dealers, underwriters, or agents participating in the distribution of the debt securities will designate the accounts to be credited;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ownership
    of beneficial interest in the registered global security will be shown on, and the transfer of the ownership interest will be effected
    only through, records maintained by the depositary for the registered global security for interests of participants, and on the records
    of participants for interests of persons holding through participants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some states may require that specified purchasers of securities take physical delivery of the securities in definitive form.
These laws may limit the ability of those persons to own, transfer, or pledge beneficial interests in registered global securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as the depositary for a registered global security, or its nominee, is the registered owner of the registered global security, the
depositary or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the
registered global security for all purposes under the indenture. Except as stated below, owners of beneficial interests in a registered
global security:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not be entitled to have the debt securities represented by a registered global security registered in their names;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not receive or be entitled to receive physical delivery of the debt securities in the definitive form; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not be considered the owners or holders of the debt securities under the relevant indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for the registered
global security and, if the person is not a participant, on the procedures of a participant through which the person owns its interest,
to exercise any rights of a holder under the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand that, under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a
registered global security desires to give or take any action that a holder is entitled to give or take under the indenture, the depositary
for the registered global security would authorize the participants holding the relevant beneficial interests to give or take the action,
and the participants would authorize beneficial owners owning through the participants to give or take the action or would otherwise
act upon the instructions of beneficial owners holding through them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will make payments of principal and premium, if any, and interest, if any, on debt securities represented by a registered global security
registered in the name of a depositary or its nominee to the depositary or its nominee, as the case may be, as the registered owners
of the registered global security. Neither we nor the trustee, or any other agent of ours or the trustee will be responsible or liable
for any aspect of the records relating to, or payments made on account of, beneficial ownership interests in the registered global security
or for maintaining, supervising, or reviewing any records relating to the beneficial ownership interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the depositary for any debt securities represented by a registered global security, upon receipt of any payments of principal
and premium, if any, and interest, if any, in respect of the registered global security, will immediately credit participants&rsquo;
accounts with payments in amounts proportionate to their respective beneficial interests in the registered global security as shown on
the records of the depositary. We also expect that standing customer instructions and customary practices will govern payments by participants
to owners of beneficial interests in the registered global security held through the participants, as is now the case with the securities
held for the accounts of customers in bearer form or registered in &ldquo;street name.&rdquo; We also expect that any of these payments
will be the responsibility of the participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary for any debt securities represented by a registered global security is at any time unwilling or unable to continue as
depositary or stops being a clearing agency registered under the Exchange Act, we will appoint an eligible successor depositary. If we
fail to appoint an eligible successor depositary within 90 days, we will issue the debt securities in definitive form in exchange for
the registered global security. In addition, we may at any time and in our sole discretion decide not to have any of the debt securities
of a series represented by one or more registered global securities. In that event, we will issue debt securities of the series in a
definitive form in exchange for all of the registered global securities representing the debt securities. The trustee will register any
debt securities issued in definitive form in exchange for a registered global security in the name or names as the depositary, based
upon instructions from its participants, shall instruct the trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Concerning the Debenture Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes
to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture,
the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct
of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given
it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the
costs, expenses, and liabilities that it might incur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
and Paying Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we other indicate in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, we will make payment of the interest on any debt securities on any interest payment date to the person in
whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record
date for the interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated
by us, except that unless we otherwise indicate in the applicable prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, we will make interest payments by check which we will mail to the holder.
Unless we otherwise indicate in a prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, we will designate the corporate trust office of the debenture trustee as our sole paying
agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the
debt securities of a particular series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities
which remains unclaimed at the end of two years after such principal, premium, or interest has become due and payable will be repaid
to us, and the holder of the security thereafter may look only to us for payment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to
the extent that the Trust Indenture Act is applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subordination
of Subordinated Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment
to certain of our other indebtedness to the extent described in a prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 29, 2025, we had the following debt securities outstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Secured Revolving Line of Credit, as amended, with Isaac Capital Group LLC, dated February 7, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Promissory Note, as amended, with an otherwise unaffiliated third party, dated February 7, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Promissory Note in favor of an otherwise unaffiliated third party, dated February 7, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Promissory Note in favor of an otherwise unaffiliated third party, dated February 7, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Promissory Note in favor of an otherwise unaffiliated third party, dated March 4, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_005"></A>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants to purchase debt securities, shares of our Common Stock, shares of our Preferred Stock, or any combination of these
securities. We may issue the warrants independently or together with any underlying securities, and the warrants may be attached or separate
from the underlying securities. We may also issue a series of warrants under a separate warrant agreement to be entered into between
a warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants of such series and will not assume
any obligation or relationship of agency for or with holders or beneficial owners of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to the warrants that we may issue. The summary is not complete. When
warrants are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing
prospectus, or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which
these general provisions may apply. The specific terms of the warrants as described in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials will supplement and, if applicable,
may modify or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of warrants in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to all the provisions
of any specific warrant document or agreement, which we will file with the SEC for incorporation by reference into this prospectus. See
&ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; for information on how to obtain
a copy of a warrant document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we refer to a series of warrants, we mean all warrants issued as part of the same series under the applicable warrant agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe the terms of any warrants that we may offer, including but not limited to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    total number of warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which the warrants will be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency or currencies that investors may use to pay for the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the warrants will commence and the date on which the right will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the warrants will be issued in registered form or bearer form;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    with respect to book-entry procedures, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the minimum or maximum amount of warrants that may be exercised at any one time;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the designation and terms of the underlying securities with which the warrants are issued and the number of warrants
    issued with each underlying security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date on and after which the warrants and the related underlying securities will be separately transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, a discussion of material United States federal income tax considerations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the terms of redemption of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    identity of the warrant agent, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures and conditions relating to the exercise of the warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the warrants, including terms, procedures, and limitations relating to the exchange and exercise of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the warrants in one or more series under one or more warrant agreements, each to be entered into between a bank, trust company,
or other financial institution as warrant agent, and us. We may add, replace, or terminate warrant agents from time to time. We may also
choose to act as our own warrant agent or may choose one of our subsidiaries to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant agent under a warrant agreement will act solely as our agent in connection with the warrants issued under that agreement. The
warrant agent will not assume any obligation or relationship of agency or trust for or with any holders of those warrants. Any holder
of warrants may, without the consent of any other person, enforce by appropriate legal action, on its own behalf, its right to exercise
those warrants in accordance with their terms. Until the warrant is properly exercised, no holder of any warrant will be entitled to
any rights of a holder of the warrant property purchasable upon exercise of the warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form,
Exchange, and Transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the warrants in registered form or bearer form. Warrants issued in registered form, <I>i.e.</I>, book-entry form, will be represented
by a global security registered in the name of a depository, which will be the holder of all the warrants represented by the global security.
Those investors who own beneficial interests in a global warrant will do so through participants in the depository&rsquo;s system, and
the rights of these indirect owners will be governed solely by the applicable procedures of the depository and its participants. In addition,
we may issue warrants in non-global form, <I>i.e.</I>, bearer form. If any warrants are issued in non-global form, warrant certificates
may be exchanged for new warrant certificates of different denominations, and holders may exchange, transfer, or exercise their warrants
at the warrant agent&rsquo;s office or any other office indicated in the applicable prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the exercise of their warrants, holders of warrants exercisable for debt securities will not have any of the rights of holders of
the debt securities purchasable upon such exercise and will not be entitled to payments of principal (or premium, if any) or interest,
if any, on the debt securities purchasable upon such exercise. Prior to the exercise of their warrants, holders of warrants exercisable
for shares of Common Stock or shares of Preferred Stock will not have any rights of holders of the shares of Common Stock or the shares
of Preferred Stock purchasable upon such exercise and will not be entitled to dividend payments, if any, or voting rights of the shares
of Common Stock or the shares of Preferred Stock purchasable upon such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
warrant will entitle the holder to purchase for cash an amount of securities at an exercise price that will be stated in, or that will
be determinable as described in, the applicable prospectus supplement, information or document incorporated by reference, related free
writing prospectus, or other offering materials. Warrants may be exercised at any time from the initial exercise date and time through
and including the close of business on the expiration date set forth in the applicable prospectus supplement, information or document
incorporated by reference, related free writing prospectus, or other offering materials. After the close of business on the expiration
date, unexercised warrants will become void. Warrants may be redeemed as set forth in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
may be exercised as set forth in the applicable prospectus supplement, information or document incorporated by reference, related free
writing prospectus, or other offering materials. Upon receipt of payment and the warrant certificate properly completed and duly executed
at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement, information or document
incorporated by reference, related free writing prospectus, or other offering materials, as applicable, we will forward, as soon as practicable,
the securities purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised,
a new warrant certificate will be issued for the remaining warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_006"></A>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock. These rights may be issued
independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the
rights in such offering. In connection with any offering of such rights, we may enter into a standby arrangement with one or more underwriters
or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed
for after such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
series of rights will be issued under a separate rights agreement that we will enter with a bank or trust company, as rights agent, all
of which will be set forth in the relevant offering material. The rights agent will act solely as our agent in connection with the certificates
relating to the rights and will not assume any obligation or relationship of agency or trust with any holders of rights certificates
or beneficial owners of rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to rights that we may offer. The summary is not complete. When rights
are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general
provisions may apply. The specific terms of the rights as described in a prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify
or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of rights in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the rights agreement
and the rights certificates. We will file each of these documents, as applicable, with the SEC and incorporate them by reference as an
exhibit to the Registration Statement of which this prospectus is a part on or before the time we issue a series of rights. See &ldquo;Available
Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference&rdquo; above for information on how to obtain a copy of
a document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a distribution of rights to our stockholders, the date of determining the stockholders entitled to the rights distribution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a distribution of rights to our stockholders, the number of rights issued or to be issued to each stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price payable for the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock upon the exercise
    of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and terms of the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock that may be purchased
    per each right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which the rights are transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the holder&rsquo;s ability to exercise the rights shall commence, and the date on which the rights shall expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering
    of such rights; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the rights, including, but not limited to, the terms, procedures, conditions, and limitations relating to the exchange
    and exercise of the rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions described in this section, as well as those described under &ldquo;&mdash;Description of Debt Securities&rdquo; and &ldquo;&mdash;Description
of Capital Stock&rdquo; above, will apply, as applicable, to any rights we offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_007"></A>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units composed of (i) our debt securities, (ii) shares of our Common Stock, (iii) shares of our Preferred Stock, (iv) warrants
to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock, or any combination of these securities,
and (v) rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock in any combination. We will
issue each unit so that the holder of the unit is also the holder of each security included in the unit. As a result, the holder of a
unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may
provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to units that we may offer. The summary is not complete. When units
are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general
provisions may apply. The specific terms of the units as described in a prospectus supplement, information or document incorporated by
reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify
or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of units in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the unit agreement,
collateral arrangements, and depositary arrangements, if applicable. We will file these documents with the SEC for incorporation by reference
into this prospectus, as applicable. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
for information on how to obtain a copy of a document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
    securities may be held or transferred separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the units will be issued in fully registered or global form; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable provisions described in this section, as well as those described under &ldquo;Description of Debt Securities,&rdquo; &ldquo;Description
of Capital Stock&rdquo; and &ldquo;Description of Warrants,&rdquo; will apply to each unit and to each security included in each unit,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_008"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the applicable prospectus supplement, information or document incorporated by reference, related free writing
prospectus, or other offering materials, as applicable, we intend to use the net proceeds from the sale of securities for general corporate
purposes, which may include capital expenditures, working capital and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_009"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities through underwriters or dealers, through agents, directly to one or more purchasers, through a rights offering,
or otherwise. We will describe the terms of the offering of the securities in a prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials, as applicable, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any underwriters, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities and the proceeds we will receive from the sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    underwriting discounts and other items constituting underwriters&rsquo; compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    public offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    securities exchange or market on which the securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
underwriters we name in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, are underwriters of the securities offered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of securities may be effected, from time to time, in one or more transactions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    transactions (which may involve crosses) and transactions on The Nasdaq Capital Market or any other organized market on which the
    securities may be traded;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement, information
    or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which a broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    &ldquo;at the market&rdquo; to or through a market maker or into an existing trading market, on an exchange or otherwise; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    in other ways not involving market makers or established trading markets, including direct sales to purchasers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices
relating to the prevailing market prices, or at negotiated prices. The consideration may be cash or another form negotiated by the parties.
Agents, underwriters, or broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in
the form of discounts, concessions, or commissions to be received from us or from the purchasers of the securities. Dealers and agents
participating in the distribution of the securities may be deemed to be underwriters and compensation received by them on resale of the
securities may be deemed to be underwriting discounts and commissions under the Securities Act. If such dealers or agents were deemed
to be underwriters, they may be subject to statutory liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also make direct sales through subscription rights distributed to our existing stockholders on a pro rata basis, which may or may
not be transferable. In any distribution of subscription rights to our stockholders, if all of the underlying securities are not subscribed
for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more underwriters, dealers,
or agents, including standby underwriters, to sell the unsubscribed securities to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
or all of the securities that we offer though this prospectus may be new issues of securities with no established trading market. Any
underwriters to whom we sell our securities for public offering and sale may make a market in those securities, but they will not be
obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity
of, or continued trading markets for, any securities that we offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents
may, from time to time, solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement,
information or document incorporated by reference, related free writing prospectus or other offering materials, as applicable, any agent
involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated, any
agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the securities covered by this prospectus
may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
underwriters are used in an offering, securities will be acquired by the underwriters for their own account and may be resold, from time
to time, in one or more transactions, including negotiated transactions, at a fixed public offering price, or at varying prices determined
at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter
or underwriters at the time an agreement for the sale is reached. The applicable prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials will set forth the managing underwriter or underwriters, as
well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities, and will set forth the
terms of the transactions, including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus,
and the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other
offering materials will be used by the underwriters to resell the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required,
we will set forth in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or
other offering materials, as applicable, the name of the dealer and the terms of the transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others.
These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities.
To the extent required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will describe the terms of any such sales, including the terms of any bidding or auction
process, if used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents,
underwriters, and dealers may be entitled under agreements that may be entered into with us to indemnification against specified liabilities,
including liabilities incurred under the Securities Act, or to contribution to payments they may be required to make in respect of such
liabilities. If required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will describe the terms and conditions of such indemnification or contribution. Some of the
agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us, our
subsidiaries, or affiliates in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the securities laws of some states, the securities offered by this prospectus may be sold in those states only through registered or
licensed brokers or dealers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person participating in the distribution of Common Stock registered under the Registration Statement that includes this prospectus will
be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation
M, which may limit the timing of purchases and sales of any of our Common Stock by any such person. Furthermore, Regulation M may restrict
the ability of any person engaged in the distribution of our Common Stock to engage in market-making activities with respect to our Common
Stock. These restrictions may affect the marketability of our Common Stock and the ability of any person or entity to engage in market-making
activities with respect to our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, and penalty
bids in accordance with Regulation M under the Exchange Act that stabilize, maintain, or otherwise affect the price of the offered securities.
If any such activities occur, they will be described in the applicable prospectus supplement, information or document incorporated by
reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
securities we offer other than shares of Common Stock will be new issues of securities with no established trading market. Any underwriters
may make a market in these securities but will not be obligated to do so and may discontinue any market making at any time without notice.
We cannot guarantee the liquidity of the trading markets for any securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_010"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the applicable prospectus supplement, Lucosky Brookman LLP, will provide opinions regarding the validity of any
securities offered by this prospectus. The legality of the securities for any underwriters, dealers, or agents will be passed upon by
counsel as may be specified in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_011"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Registrant as of and for the years ended December 28, 2024 and December 30, 2023, incorporated by reference
in this prospectus, have been audited by Hudgens CPA, PLLC, an independent registered public accounting firm, as stated in its
report incorporated by reference herein, and have been incorporated in reliance upon the authority of such firm as experts in accounting
and auditing. This report on the consolidated financial statements contains an explanatory paragraph regarding the Company&rsquo;s ability
to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="form424b5_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>ALT5
SIGMA CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Up
to $1,000,000,000 of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>A.G.P</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>August
11, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Y /H# 2(  A$! Q$!_\0
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M'XO^(GA'4[2Y6>V$4G^;0/C5\;@ !\;?C+P .?BM\0&/  ZMXC)[>PR2<#.
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M A4FDAOHOB;\0['4;-?%%DT15DE^''A*U\4_$B)I'CMKFZ\*V>E/,DVJ6RN
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M=J6N6,?A;Q-=0F.=_!WB'Q%91RJ+M@0#_(D/(_PQG\.<9]#G&<'..:_T*?\
M@U0_;FD^,_[*7C+]C#QOK*3^/OV3=534_A^ES<*VH:U\ _B)J5_J6CP)YSM<
M7O\ PKGQXWB7PM,T*+::/X2UGX:Z2JQL!O\ \^"^T[5-&U'4=$US3+W1=;T6
M^O-)UK1M3@>UU+1]7TRZFL-3TK4K60"2UU'3K^VN+.]M7&^WGA:-SO#JGZ&?
M\$H_VW;S_@GS^W;\$/VA[J\N+?X=)K9^'?QRM(9)A#?_  2^(,]CI'C:ZGMH
M'1]0F\%2Q:1\3='T_<HO_$/@;1[)G6*XF# '^N75+4O^0=?_ /7E=?\ HB2E
MT^ZMKZRM;VRNK>^L[R"*[L[VTN([JTO+2Y19[6[M;F)GBN+>Y@DCFAFC=XY(
MW5HW="K%-2_Y!U__ ->5U_Z(DH _Q&=%_P"0/I7_ &#K+_TFCK]=O^"%/_*7
MG]A+_LJ?B?\ ]5'\1J_(G1?^0/I7_8.LO_2:.OUV_P""%/\ REY_82_[*GXG
M_P#51_$:@#_5]HHHH **** /Y6?^#NK_ )1W_ 7_ +/6\!?^J._:#K_/%K_0
MZ_X.ZO\ E'?\!?\ L];P%_ZH[]H.O\\6@#^^W_@S[_Y--_:__P"SG](_]4]X
M&K^O.OY#/^#/O_DTW]K_ /[.?TC_ -4]X&K^O.@ KSOXH:KXF\/_  ^\=:[X
M'\/7'BSQKI?A3Q!>^$O#%M-;02^(/%$&EW,FA:0)KVZLK2%+[51:0S2W%W;0
MQ0&2229$#D^B4UHT8$,B,"<D,H()'0D$$$CU-72G[.K1JN$:BI5J565*;DJ=
M6-.K3JRI5.1J7)55+V4VFI*G4J\C4FFN?%T)8K"XG#0K5,-+$8?$4(8FDHNM
MAIU\/B*$,304[P]OAI8AUZ/M$X>UITW)63/XL[C_ ()Q_M[7]Q<7^I?L^^,-
M0U&_N)K[4+^Z\1_#Y[F]O[N1I[V]G9O&6XSW=P[SSL>7D;<V6&:@_P"':_[=
M'_1N7BG_ ,*+X??_ #95_:F%4  *H       '   &  . !TI<#T'Y"OZ6I_2
MGXZI4X4J?#_!U.E3A&%.G##YY&%.$8QC&$$LU2C&,81C%**248V2LDOXJG]!
M'PSJRE4J\8<?5:DYSJ5*DZW#CE4JU)U*M6I)O*7>=6K6K59N[;G6J-MN3;_B
MI;_@FQ^W.BL[?LY>+"JJ6(7Q!\/W8@#.%5/&#.S'^%55F9L* 2:^8?B)\*/B
M=\(M6@T/XI?#[QC\/=5N?,%E:^+_  ]J>B?VCY1*ROI5Q?6\5IJL4)*!YM-G
MNX4WHQDV$NO]^A53U4'Z@5YW\4OAA\/_ (O>"-8\ ?$KPGHOC#PCKD317VC:
MS;H\/F;)/*OK&Y4"ZTK5K,N\^FZQILUKJ>FW06ZLKJ"=%<>OD_TK<_IXZC+B
M#AG*,1EC=L2LFKYCA<PA!V_>4%CZ^.PE><-9+#SC0==VI*O!R@UX'$/T"N%9
MY;7EPIQQQ%A,XA3E/"QS[#91B\LK5(QDU2Q$\NPV!QN%A5:4)8JG+$1P\;U7
MAJBC-'\"."<#MC!(QZ$\9R1VYXS@''2OOK_@GU^V;K?[)?Q?L8=:U&[N/@GX
M]U*STSXEZ')<2&TT:2X:*SLOB+I5OMECAUCPXC+_ &N(8XWUOPQ%=:7*+B\M
MM!GTCSC]M3]F+4/V3/CSK_PR:ZO-5\*WL*^*OAUK]ZD7VK5O!6JW%U#9P:A-
M %MYM:T'4;34= U>2!(4NIM/BU7[+91:K;6D/R4P4EPRA@0 <@'((P5P>"#G
MH3@]#P<C^M<5A>&?$KA#V=14\SX=XHRJ%3#UU'DJ*CBX<V'Q5&4HRJX/'8+%
MJ$FX.-?#XK!8C#NHXRJQG_G]@<5Q?X.>(:KT?:9%Q=P7G[HXFE%RJTY5\+BZ
M5#$83$Q?L88_+LUPE2-.<'!X?%X/,<+B*4'.%"=/_0IL;B&ZMH[FWFCN()U2
M6&>)TEBFADC22&:*6/\ =RQ2Q,DL<B$JR.I!SFKE?GI_P2Y^+-Y\6OV,OAA=
MZO=27FO^!6U;X7:U<RR&628^"K@6?AUWD8EY)7\%2^&6NII0LLUV;B:0,\C2
M/^A=?Y7YYDV)X>SK-LAQG-]:R?,<9EU9SBH2G+"XBI2C4<%I!UJ7L:W*O=BJ
MR4;143_=G@[B3"<8\)\-<68"#IX3B/(LJSJC2<G)T/[0P5#$5<-*4DG.6%Q+
MQ>%E-J\Y89S^V%?Q-?\ !VU^W*L&F_!7_@GMX%UHBXUF6Q_:#_:"BL;A1C1-
M+N;[2?@KX&U)K>>59(M5\0P^)?B'J^DWL%M<6D_@_P"'&KP33V>I/%)_97\3
M_B1X+^#OPX\>_%?XC:W;>'/ /PT\&>)O'WC37KO<;?1_"OA'1[O7-?U*1$#2
M2BSTVSN)A#$KS3NJPPH\KHI_QZ?VP?VG?&7[:'[4?QT_:E\>?:H==^,_Q U;
MQ18Z1=W)NV\)^#8EAT;X>^!X)]Q$EMX(\!Z9X<\*Q2J(_M)TI[QXHYKF11Y1
M](?-](55AA@"/0C(_P CMZ=J[_X4?"[QQ\</BG\-_@Q\,]);7OB'\5_''AGX
M>>"M'#^3'?>)/%FK6NC:6MU<D,EEI\%Q=K=:GJ$H,&GZ=!=7D^V*!W3^AQO^
M#4'_ (*E!B!XJ_8_8 D!A\8/B/@CU!;X&(Q![%D0D<E5/  /YHO*C'\"?]\@
M_P Q1Y<?_/-/^^5_PK^ES_B%"_X*E_\ 0T?L@?\ AX/B-_\ ./H_XA0O^"I?
M_0T?L@?^'@^(W_SCZ /@O_@B1^V^/V"O^"AWP<^(VOZJ-+^#_P 4;AO@+\=3
M)/';Z?;?#_XC:A86^E^+K]Y8Y8K>'X;^/;7PGXYU"\CB>_?POHOB71;)T;6F
M!_U>%P JY!*@#' (P!V!(& 1TXY&."*_S>)/^#3[_@J1+')%)XF_8_9)$>-U
M/Q@^(V"KJ58''P/Z$'H>#T8$9!_O%_8#\%?M,_#7]D+X$_#7]K_4/!NM_M!?
M#CP1:> /''B?P'XBU3Q5X>\7V_A"XGT/PEXK&MZUH/AG5KO7==\&V>@WOB_[
M=HUH1XO?7&M&N[%[>]N #^ C_@Y?_8@;]EC_ (* ZC\:O"NCFP^$G[9FG:C\
M6=+DM;;R=.TGXPZ-/I^E?&_0%+2-ON-3U.^\._%*:YF:W^U7'Q$U6SL[=8="
M8O\ SLLHD4JPRK AE/=6!5UY!P2I(!(.#@E3C!_U1?\ @O/^PV_[<_\ P3N^
M*WAOPMH8U?XS?!**3X_?!-((?,U34?%7@'3-2D\1^"M-,5O-=377Q"^']YXK
M\*:98I)#;2^*;[PS?W99-,0I_E<12I/&DL;;XY%5T8 @,K*&!&?8\^ARIY!
M /\ 30_X-L/VZ'_:X_X)]:!\+O%VJF_^+_['=YI?P.\6FZN/.U'5_AS'IC7G
MP-\8R)M+BVO/!EI=^ );FYF>\U'Q'\,O$FI3*D=[!G^@?4O^0=?_ /7E=?\
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M?P591PL]O8CX??$6T\5>&=.T4R?;K3P?'X-U&YMK6WUNQ1_]6"OR8_X*N_\
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MV6O^",WQ)\87^G>*/VG-3C^'/A*(PW;_  X\-ZC9ZK\0=>CRC_9-8UZQDO-
M\'64H'E74=A-KVO,K3Q :!>B&\3^D#P%\/?!_P ,/"6A^ _ 'AS2/"?@[PS8
MQZ;H/A_1K9;6QT^T2225@H \R>YN;B66]O[ZZDGOM0U"XNM0OKFYO+B:>3^<
MO&'Z0&58/+<=PWP)CUF><XZGB,)C,^P<TLORBA5A.CB'@<9:V/S"JI5J%&IA
M*?U;!1J5JU2MB9O!>R_L;Z._T3.(,VSC+^,?%/)ZV2\.9=7HYA@.&,SH4J6;
M<08NA.C7PW]IY9",?[,R2$U"MB:&.5/,<TJ4J6&AA<-ET\Q^M=?;QB./:%"C
M<3M4 * 0,!0I("A0 H& H     J>D  Z#'TI:_AI)))*]DDM6V_FVY-MN[NY
M-N]VVVV_]2DK)*R26R22271)))))65DEML%%%%,84444 %%%% !1110 4444
M %%%% !1110 4444 %!( ))P!R2>@'J:*:Z[D9<XW KGTSP#VSCJ!D9Z9H #
M(@!)= %ZDL !SCDYXYXY[\=:"Z#&649&1EAR!U(YZ>]?S5_%#Q]^V#\:?AW^
MQQ\4O@'\?/%GPX^,?[4O_!3;]IWQ%\/?#FI>*_$J_!^;X8?LX_L^?MJW7P%_
M9Y\:>%+"\@ME^$?Q<T3]F;X?:G\;;5;.;4+?XB_$;QO\1M/MW\0Z+X;CTSUW
MPC_P4Y\-77Q)_; _:LU*^\>Z/\,/@E_P3,^!/Q"\7_LV>(M;O4U7X:?M/^$/
MVB_V[OA[\6O@Q?\ A%IQHFG_ !UN/'GP_P#"_P %=5OK"Q6[\9W&C^!3IU]J
M7AN7PO=3 '[[ET499U R!DL ,DX R3U)X [GCK2EE&,L!GID@9^F>M?S3_L6
M?M1_%&[^"?[<7[+.J?MEPZI^TE9?LNI^TW\&/VH?VA)?'WAWP;\-OB+\9/A?
M+X'^*NDW&I_&CPCI%S'\*?V<?VOM/?Q9H-FFBZCX=\'_  A^,_PL\#:=IUS#
MH,FC)T_PVU_QE\$?'NF>$_'EA_P41_9*^*GBK]G']H?1+CPE^T3^TEKW[:?[
M/_[4OQ(\)?"B?QQ;>)?A'\>KCX[?%0_"3XO?#S3O!?BKX@Z5:6W@C]GO5O&G
M@>'Q3#+\/EB\,V-OX< /Z,/,3CYTY!(^8<@'!(YY /!/KQ0'0]'4\9X8'CUZ
M]*_G-\'Z#XS^ O[#G_!-W]MOP/\ M$_M5:[\7?B#J/\ P3/T7XO>#/BS^U!\
M=OCWX"_:$T_]L3QO\!_A1\6?#DOPX^-?CWQ[X:\+^+/*^*VL?$'P-X@^'%AX
M1UCPWXE\/6MNLS>$)=4T6]P?&W_!15-#_P""E%]\2!\;/'-C\"O 7[3?@G_@
MG)KWP0CTCXC?\*DU?P[KFC:AI7Q"_:FU#4#I;_"RU\;>#_VU_''PR^ UYXEO
M=9@UG0?AC\*/B'%$+.QUV]?4@#^DWY3N(D&!R<$<#GJ0>.AZ^AJ-84QB-P,
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>chart_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (3 [8# 2(  A$! Q$!_\0
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M\*/)3_GG_P"/#_"CVL/^@2/_ (55_P#(.2I_S^J_^ 4__DS\N_\ AXQ\2?\
MI&3_ ,%"/_#;?#7_ .>A1_P\8^)/_2,G_@H1_P"&V^&O_P ]"OU$\E/^>?\
MX\/\*/)3_GG_ ./#_"CVL/\ H$C_ .%5?_(.2I_S^J_^ 4__ ),_+O\ X>,?
M$G_I&3_P4(_\-M\-?_GH4?\ #QCXD_\ 2,G_ (*$?^&V^&O_ ,]"OU$\E/\
MGG_X\/\ "CR4_P">?_CP_P */:P_Z!(_^%5?_(.2I_S^J_\ @%/_ .3/R[_X
M>,?$G_I&3_P4(_\ #;?#7_YZ%'_#QCXD_P#2,G_@H1_X;;X:_P#ST*_43R4_
MYY_^/#_"CR4_YY_^/#_"CVL/^@2/_A57_P @Y*G_ #^J_P#@%/\ ^3/R[_X>
M,?$G_I&3_P %"/\ PVWPU_\ GH4?\/&/B3_TC)_X*$?^&V^&O_ST*_43R4_Y
MY_\ CP_PH\E/^>?_ (\/\*/:P_Z!(_\ A57_ ,@Y*G_/ZK_X!3_^3/R[_P"'
MC'Q)_P"D9/\ P4(_\-M\-?\ YZ%'_#QCXD_](R?^"A'_ (;;X:__ #T*_43R
M4_YY_P#CP_PH\E/^>?\ X\/\*/:P_P"@2/\ X55_\@Y*G_/ZK_X!3_\ DS\N
M_P#AXQ\2?^D9/_!0C_PVWPU_^>A1_P /&/B3_P!(R?\ @H1_X;;X:_\ ST*_
M43R4_P">?_CP_P */)3_ )Y_^/#_  H]K#_H$C_X55_\@Y*G_/ZK_P" 4_\
MY,_+O_AXQ\2?^D9/_!0C_P -M\-?_GH4?\/&/B3_ -(R?^"A'_AMOAK_ //0
MK]1/)3_GG_X\/\*/)3_GG_X\/\*/:P_Z!(_^%5?_ "#DJ?\ /ZK_ . 4_P#Y
M,_+O_AXQ\2?^D9/_  4(_P##;?#7_P">A1_P\8^)/_2,G_@H1_X;;X:__/0K
M]1/)3_GG_P"/#_"CR4_YY_\ CP_PH]K#_H$C_P"%5?\ R#DJ?\_JO_@%/_Y,
M_+O_ (>,?$G_ *1D_P#!0C_PVWPU_P#GH4?\/&/B3_TC)_X*$?\ AMOAK_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M +*W]*=36[_[K?TJ9_!/_#+_ -)9,NG^)?F?FC^U#_RD/_X);?\ 82_;+_\
M6>5K],*_,_\ :A_Y2'_\$MO^PE^V7_ZSRM?IA6C_ (>&_P"P:/\ Z<J$T_M_
MXW_Z3 ****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ^#/@Z%8=)D\.^ OASX"LH-&L--ET>>\^M_^"0/C/QA\0_\ @F5^QYXP\?\
MBWQ)XS\9>)?A,;K7_%_BC6+S7?$VL7Y\0^(;;[=JFL:I+=W=]>"*.)!/=RRD
M+#%'RB!1^;=M_P $SV_X)W_MC_LZ?'?]F77_ -J_XX>$/VA_#/QB_8K_ &JH
M/C+\5O%_[0^O>%/!OC/PGJ'Q)_9]^(>GZAXB4WGA;PAX(^-'@Z^T#Q'=R-=6
M.G0?%^\O85L3=ZO_ &MRW_!+']O_ .)WP1^ '[(7[$?Q!_X)K_\ !0C1/$_A
M2WTWX3>)?BO??!S1[/X4:'?7WBS5@WBV^UI_$L=_%X2MH+Z*]O=1.E12Q6HE
M<V8"<],N5T9JC.#GBHY=.E*2J*5..$QN:86M2:GRPA[?"O"UY\MU4<Z=O9J#
MI&=*FXT*\GJZ>*5DI049JKE]%U(Q25W&GC</BZ<')MTHR4&Y-J<N3\>?\$F/
M['_;G_9__9LLO^"F_P#P5U3P/\:/V:OVPOC7XGOU_;.GAUVQ\7?!?XJ?L@^&
MO!UEH#P^ (],T[P^^E_'KQT=8TV73;F2[NK/PK+9WFG1Z5?PZO\ KQ^W)XR/
M[$O_  2W^.VL:1\1/%U]=?!K]F63P)X?^*WQ#\3W6K?$*YU1M L?AWH_Q \5
M>*[.T34]9\;176I0>)=1U;3]._M/4M9ADGL;![N2&!MWXF>#_%5W_P %0?V/
M_'UGX=UB[\#>&?V*/V^O#/B'Q7;Z=<RZ#HGB/Q9\8_\ @GYJOAG1=3U-(S:V
MFI^(M-\%^*[S1+":5+C4;;PYK4]JDD>GW31?0O[4NO\ Q^\)_L_?$7Q3^R]X
M1\.?$#XW>'-'MM<\&^ ?$]Q+9:?XT32M2M+W7O"=GJ$%_IHL?$.O>'(=5L/#
M-Y=7D5C!XBETPWV;3SA7'&JWA*?/:3D\;&JO9OF4*69SITH.-KZ45"*D[JWO
MJ-O=+45/%2G:Z@\'4HQ=2,(J=3"RG5@YM.-Y3Y5)M<J?*W>-S\/?^",#_LM1
M?&+XD:'\-OVUO^"GGQK^.6D_!G0SK?PB_P""AFK_ !5T'0_$'P\NO$6C64?[
M2GP$\ _%OX6?#S5M9\"Z_P",M-O?#FG^(I)_^$AT"W==$\5>%]"DU_2[C4O6
M/^"O/C^/2?BK^RM\*/CY^V3\;/\ @GS^PO\ $S0/BRWQ+_:-^!>K?\()K7B+
M]H+3+[P)8_!SX%^-OC]_PCGBBP^!O@;Q!X2U?XF^-+C7/$>GZ+HWB^Y\"Q>&
M;KQ)IFI?91+T7[,WQ%^.'[=?[=?PJ_:K\1?LC_M"?LA?"']EC]FS]H;X/7*_
MM)VNA^&/B'\3OBU^T'XY^ ^M7F@>&?"^AZIK4VI?#[X=^'O@C<7E]XHN[RV@
MU7Q7KFDVNF6KC1YKN3V7]NCXL?M<?LR?&3P+\</!/P/^)_[9/[%_B7X.>._A
M)^T+^R_\'M%^'&M^/O!/C^_U[1-?\)_'K1M \3Z7::[\2/#FH^%K?Q=\,_'7
M@F'Q7:Z186-_I>OPZ!J%^+Q)]*JE.M04X).,%:E4DJE*=.G5JNC54J7+R5?8
M36(PL)RDZ;JU(8KZPW25-4FE[>T;J48I[-*K.FO;1>JN\/42I.:O"I.+E!15
MSY0@@O/V:?V"?V@?$OC7]N[XS_MQ_L6'X@?L[7W[,W[0'P>^-W@SQE^U]IFA
M>*/CE\)_"VN^!=?^.VF:?H_PX\<>&=/^(FH6$1\0PZY<:U<_"K4O%?A.[M+.
M]33UF]C_ &HO^"VO[/W[)OQ$^-WA&]_9^_;(^-?@7]F&R&E?M(?M'? _X,1>
M,_V>?@Q\2-5\,Z9XU\/_  A\8>/[GQ+IK3>.7TOQ!X4@\72Z!I>KZ#\-M0\<
M>%+'QOJVGSR>)3X9_+_4_P!F_P",'C[]E;_@H[\7O@U^POXX_8Q^#G[1_P 0
M_P!A6[^#'[%S^$_#?ACQMK^O_"7]HSX/:E\6_CWJ/P?^'UTWA[X>2>+]%M,7
M.F:;)9ZAKF@^$)?%6KJMS<?:&S_VMOBO\>/V1?@/_P %F?V5?#/[*GQ,^/WA
M?]H7XD_MF?'WP5^T_P##K6/ =Q\ / ?A+X_^!-*\1_%SPW\?/$4GB>;4_AO\
M2/@%K&IZ_H%UX'U338=<\;Z3'X(GT;3?+\1VLLG3.G4=/#PIN->M6KTX.#Q$
M*34ITN'XRC45&"<\3"EBL9[65.%)34%"ES5J5:F)4Z?(ZR4G4CB*\'*7)%0I
M7G4G*+YE*%.#H4Y_O&^?GC&*;NE^I_QA_P""X7P2^$/BGQ!X(D_9J_;'^*_B
M+P;\(_@5^T%X_MO@3\'H_B?;?#GX%?&?P?J'C>]^*7CO5-#UI-'\/>'OAMI>
MF7-GXFAN=0;6M;U..X'@[3-;TVPU'4K3TW]G/_@KK\ OVD/VB-.^ _AOX9?M
M(> /#GC_ .&7C3XM?LW_ +2/QE^%$OPT_9[_ &K/ WPWG\)7OCKQ!\!_$FO:
MU!XI\1Z9H6@^-=#\507VK>$]#M-9\(?:O$4%Q9V$NCMK?QG\._@I\69?!/\
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M/>%]-T13X9FCN=+UBZO-:&J0:I_;"ZW-K#-<7&M#5?M%W]O^WM(;A;D7$J;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHI7UMK]SM]^WX@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,F6**K^<_\ SRD_[X/^-'G/_P \I/\ O@_XT<\/YE_Y-_\ (AK_ "R^Y?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*0_:+_GUBO\ P2_\CZ ^TQ?[7Y?_ %Z/M,7^U^7_ ->OG_[!^TQ_T-'P#_\
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M!_P4^_\ "I_8K_\ H(:^P/L'[3'_ $-'P#_\(/XB_P#SRJ/L'[3'_0T? /\
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M\?\ _#N_XI_])8/^"GW_ (5/[%?_ -!#2_\ #N[XJ=/^'L/_  4]QV_XJO\
M8J]^H_X8BXX^O)Q[U]?_ &#]IC_H:/@'_P"$'\1?_GE4?8?VF!_S-'P#]_\
MB@_B+C_U96#TI<V,ZXW!/M\*U^5'43]E_P! ^(_\$2_^3/D)?^"=_P 5F/EC
M_@K!_P %/1G _P"1K_8KSR!R#_PQ#V#9X/;H,5P7PU_8I^,/Q*\%Z1XTOO\
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MP?M,?]#1\ __  @_B+_\\JGS8W_H-P/W0_\ E(?NO^@?$?\ @B7_ ,F?'_\
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M(/XB_P#SRJCV5;_H*P7WR*]HO^?6*_\ !+_R/H#[3%_M?E_]>C[3%_M?E_\
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MM?E_]>C[3%_M?E_]>OG_ .P?M,?]#1\ _P#P@_B+_P#/*H^P?M,?]#1\ _\
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M8K_P2_\ (^@/M,7^U^7_ ->C[3%_M?E_]>OG_P"P?M,?]#1\ _\ P@_B+_\
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M/KSGG.<^IFI)II-;-)KT?]?+8U3O>UUJUKY?UH%%%%, HHHH **** "BBB@
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MO"?^#*O_ ,S!SO\ Y]5O_ %_\F?J717Y:?\ "MO^"O'_ $=5^QI_XCC\0/\
MYY%'_"MO^"O'_1U7[&G_ (CC\0/_ )Y%'L:?_07A/_!E7_YF#G?_ #ZK?^ +
M_P"3/U+J-OOCZ+CZ[O3Z?YXK\N/^%;?\%>/^CJOV-/\ Q''X@?\ SR*3_A6_
M_!7@$'_AJG]C)B.0K?LY?$$ D9."1\2-P!X!*\@$D<XJ)X>G-./UW!J_5U*M
MMX]L-Y#4W_SYK/R4%OT^V?9'[,__ "272CCG_A)_BKWZ9^+OCK.>?TYYXQ7O
M\0'EKU[]R.Y[#&/RK\D_"7P0_P""K?@_1HM!\/\ [47[',&E0W>L:C%'<?LY
M_$)IUN=>US4O$&HL6;XAQCRIM2U6]D2+8HMXU@C4MEF;I1\-O^"NX "_M5?L
M9@=@/V<?B!C\,?$C%:8BE2J8S&5H8[!N.(Q%>M!>UKIJ-6LZB4E]62YK-7LO
MG:QG!S5.G"5&LG"$(OW8M7C!)I-3=TF?J7@>_P"9_P :,#W_ #/^-?EK_P *
MV_X*\?\ 1U7[&G_B./Q _P#GD4?\*V_X*\?]'5?L:?\ B./Q _\ GD5G]77_
M $&X/_P;7_\ F<KF?_/NM_X!'_Y(_4K ]_S/^-&![_F?\:_+7_A6W_!7C_HZ
MK]C3_P 1Q^('_P \BC_A6W_!7C_HZK]C3_Q''X@?_/(H^KK_ *#<'_X-K_\
MS.',_P#GW6_\ C_\D?J5@>_YG_&C ]_S/^-?EK_PK;_@KQ_T=5^QI_XCC\0/
M_GD4?\*V_P""O'_1U7[&G_B./Q _^>11]77_ $&X/_P;7_\ F<.9_P#/NM_X
M!'_Y(_4K ]_S/^-&![_F?\:_+7_A6W_!7C_HZK]C3_Q''X@?_/(H_P"%;?\
M!7C_ *.J_8T_\1Q^('_SR*/JZ_Z#<'_X-K__ #.',_\ GW6_\ C_ /)'ZE8'
MO^9_QHP/?\S_ (U^6O\ PK;_ (*\?]'5?L:?^(X_$#_YY%'_  K;_@KQ_P!'
M5?L:?^(X_$#_ .>11]77_0;@_P#P;7_^9PYG_P ^ZW_@$?\ Y(_4K ]_S/\
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M , C_P#)'ZE8'O\ F?\ &C ]_P S_C7Y:_\ "MO^"O'_ $=5^QI_XCC\0/\
MYY%'_"MO^"O'_1U7[&G_ (CC\0/_ )Y%'U=?]!N#_P#!M?\ ^9PYG_S[K?\
M@$?_ )(_4K ]_P S_C1@>_YG_&ORU_X5M_P5X_Z.J_8T_P#$<?B!_P#/(H_X
M5M_P5X_Z.J_8T_\ $<?B!_\ /(H^KK_H-P?_ (-K_P#S.',_^?=;_P  C_\
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M'O\ F?\ &ORU_P"%;?\ !7C_ *.J_8T_\1Q^('_SR*/^%;?\%>/^CJOV-/\
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M/_091_\  :W^8<TOY'_X'2/TQP/?\S_C1@>_YG_&OS._X98_X*#?])2M<_\
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MJ>G_ -859K\S1^RU_P % \#_ (VDZYT'7]COX!?_ "6>?7ZBE_X9;_X*!_\
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M (4UF5>J\XS]W('UQ^M/V$?+R]ZOK_Y= JEW9._]>A7\D?W_ /T.CRA_?_\
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M?^!8C_YJ#G?G^!4\D?W_ /T.OE7]N,_\87_M;\8_XQN^,PZYP?\ A77B!L
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M>_\ ,C\OW_3_ .O1Y?O^G_UZDHHY8_RQ^Y?Y!9>?WO\ S(_+]_T_^O1Y?O\
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M'>&-0\77OASP]:QR3ZGXEU'2]+#7HT'1K6)[S5KV"*9K2U4S&)P#CY_\0_\
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M3M7\0_'SX&_#CXL^%O'K:K\)OC=\6]'\5PZW\8OAI\6_%7AC6?&O@7PQX_\
M"^AZ1H^EH?"XL_%6GV.GZE'G_P#!03XH_&31/$7_  66M_AI\9/'G@SQ'\/_
M  9_P3(7X37^E^.?% TCX3>-?%WQ2T*VNM4T7PY:Z];:3H,FM3WEI<>,=(L+
M?34\=:,TNF>)QJ6FWTD4F%:NZ<HI4N>$Z5:M&7O*452I99)*4.2\75K9G3I4
MY7]G5A%5Z,ZM*HF;-<E.G4JM*$_;<\J;53D5'%XW"MP]Z]1R>$5115I14YTI
MQ56E*+_H3\:?&^S\"_$NU\"^(? OQ&@\,CX*_%+XXZ_\;8/"=S>_!CP?I/PL
M\0> M'O? OB7Q38RW5[:?$[Q+IOC>Y\6^#O"<&E3S^(/"G@7X@:K:3/+X;>R
MN>-^''[5'ACXMW?[-^I?#CX>_%OQ=\,/VG?@@GQZ\#_&[3_!4EG\+_#GA'5/
M#_AGQ3X.TKXBW^J7MEKG@_Q;XZT#Q3:7_A?0+O19[B8V.IVFHMI]W:&)_P 2
M_BQ^S5>_"SXEC]CJ3]IS]L/QWX&\;?\ !(+_ (*=?$OQGX[\>_M$>*=>^+6K
M_$"_^/G[%5[:>*;7Q.+>RT#1=0\*Z?XC\0^%O!$>D^$[/3_#/A'6]=T*VL7M
MM?\ $!U7X[^#OC'X@_L/?LC?\$U_$GPG^)?QD\42Z7_P11_:'_:<LO#OQ'^*
M'B[QUX?F^)FK_!7X+>-/#EI-X9O99] NO!GPVU36'T_X8>%;O0KFP\#^%K<^
M'=(D@M9KV6=1KT;5X_%*A.M"FU2<I5_8SS2G5NM/9NI6R^BUS.27.N9QC2E)
MQ&%65/#S3C!8JI0^*;C"E[:C@*J4Y.+C&"6+E[225U&DY14ISY5_9'D^G^>?
MZ8_/'')H&.GIZCT_S_A7\B/_  3N?]J;P'^U9^QQXDTZZ_X*]^,_#?[1_P#P
ME6F_MFWG_!0&[\.^(OV=]<.K_ GQC\4_#GQ)^ ^G+K\\?PIU71/BEX=TW1-(
M\,>$+6;3=0^&GB.ZTZY2W@\-64<_$_\ !/KQE\;/V?\ ]M+X-P_\% /BQ_P5
M&\-?M#_'WQUXE\%Q?$OQ)\:/"7[07_!)_P#;"\3^-X-;U+P?I/P=L?"?ANVT
M7X.VU_I=]X?U7X4Z)H]MHDO@A=+C\#O?S*VI1OW*D_:QH.4?:RCB(NT92BL3
MA:BHSIP:5Z].HW*="K1YI5:2J5(4YQHUU3SYY.G6J*G)J"P\J,'*'M*M.O0J
M5;RBI-4JD)TI4I4YM-N5*7,E42?]B5S)$LDFY=S(L988))5SL'R@%F()!4*"
M21A58\5\Z_L[?M-^"_VC=?\ VEM \'^'?%>A7?[+_P"TCXH_9A\=3>*+?18(
MM=\;>%?A_P#"[XDWFO>$SHVLZRUUX0O=$^+.AV]A=:P-&US[;8ZI'>Z):)';
M2W'O%NDT<*>=@DR,0HC$6%* Y>/:I4[N2""5Z$\$U_(M\3[+XE>(Y/VG?AU\
M+?C=\5/V>==^+?\ P=.^!_A;K/Q/^#?BJ?PIXYTOP7XM_8Y_9_A\76>GW)AO
M=)U)K[28)!8:7XFTG7/#B:[!HVK7^D7S:3;1KP1FY2A.$8OVL8*G!234+U(1
MYN>FI*;E":J^['W5%T]7>4;:5IVWI2F[I->TY?:<L6K-I3<$HO7W:E.3M:<8
M_P!AF1D<<G/48[#UZ]NGIUX(IU?R"?$V[_:#_8:L/V[?V,?A'^V3^T[XM\-:
MS\9/^"<G@;X<_'/X_P#Q)/QA^/'[/^E_MC^)/$/A;XQ:EX(^)7B.RMI(Y5MO
M"HF\'S:I82Q>&==UU[_3DBU(_;W_ &K_ &(OV61^QC\4/B_\#K+]N[]H#]J#
MP[XG\)?#_P")?ASX'?M7>/K;XQ_&GX,>;JGB_P *>)?B'I'Q6N[C3_%M_P##
M3XM:C8V-C9^#-7\.VVA^'?%?A#Q+J>@:Q*WB+6K*/I3YZ2JT7"I"I3<J&LDZ
MDH4H8B49\L)*E!X>:=*K4:C5J1=*'-:4HXQKQ]].]Z=649I1F_W3K4L-2JQ:
M@HRE.O4E[2DO>I4H.K/24.;]4**K6I+00,26+01MN8*"3M&3A5102220JHHR
M $0 *+-5>_?YZ?U^AT=6NS:^YV_01NA^A_E4;_<;Z/\ ^A"I&Z'Z'^51O]QO
MH_\ Z$*4MEZO_P!)&MX_XO\ (_+3_@FW_P E(_X*O?\ :4[XA_\ K)W[&]?J
M%+]U_P#KF?YU^7O_  3;_P"2D?\ !5[_ +2G?$/_ -9._8WK]0I?NO\ ]<S_
M #IXO_>:G_7I?^F8'-1_AT?^OC_]/53\[/V.?^3R?^"MW_9UO[/?_KO#]D"O
MTAK\W?V.?^3R?^"M_I_PU9^SU_Z[Q_9!S_2OT?9E4+GH64#ZD\'\.N?6ML5)
M1J7?2CA=M]<+AO\ ,VAM\Y_^ER%<D*QQDJ"5 X)PIXSSR3G!QZ<5\^^ /VFO
M@?\ $SXY?&_]FWP9\0-+UWXW_LV:7\*]8^-_P^M;#6HM0^']A\:=#UCQ)\,Y
M-2U2XTZ+PYJ-QXIT#1;W65TS0=9U?4M#TR71;OQ%:Z0OB/15O?7_ !3XFT'P
MCX>U_P 5>*-4L=#\->%]&U;Q'XBUG4IE@T_2- T33I]2UC5K^5_EBLM.TZUN
MKRYF<;8X(9&/0Y_B&_8"_P""C/[-5Y^VO^R)^TEIU[\4_#_[0/[>/Q^_;&\'
M?MBV/CCX-_%32/"=AX(_:VU_PMK_ .Q'X<M?BUXF\(:+\/=>C^ EI^SY^SC\
M!O#8\/ZE<6M[%\2/'OB/2+VYL]1UF2^YJ;=2NZ,>;GY(1:LU%3KU)TZ2OUDW
M"3:TY8.,M7*,9*I-4Z,Z\E)4X1J2<XI.\:-%UZJ2;5_<5HVO>=T^6,92C_9K
MX)^.?PR^(_C3XN_#KP1XICUWQE\"_$>B>%?BGH8T3Q%I\GA7Q!XF\/V_B?1-
M.-[J^E:;INN-?Z#<PZ@MSX:O=7LX4D\BXGBNE, _.7]J;_@N[_P2L_8H^-_B
MW]F_]I[]JZU^&GQI\#6OAJ\\5^"H?@I^T3XYFT2#Q?X;TWQAX=%WKOPZ^$?C
M'PLTVH>%]>T/5H[6UU^ZN8+>^A%[#:3.8!<_87+G]N'_ (*UE@,C]H;X(+TP
M<#X!>'0.V#G ;'4G!/K5G_@M9/-!_P $\?&<D,LD<D?[2G_!/AHY(Y&1T(_X
M*'?LKGY64AE(Y&000"<'BN6E6YHT9I35.L\/'DF[S4Z^)KX93<WRV2=#VCC:
M\E-15K7>LTH5J]#1^RG-*6W\.CA*S:5FDY?6W#1Z>S;N^:R^C?V+?^"AW[(?
M_!1#P-XJ^)O[&_Q@A^-'@GP5XH7P5XIUB'P-\2_ ,NB^)GTNVUN/3)](^*7@
M[P-K-QYFEWEM>)>6>GSV!CD\L7)E#*OSMXH_X+@?\$Q?!O[6UM^PQXF_:@MM
M/_:FNOBYX2^!%M\*X?@U^T-JCR?%CQOK>D>'/#7A%O&^E_":[^'$4VI:WK^D
M:>VK2>+_ /A'].>X-QJ>KVEM%=26WZI3.CAOM'[R);D95EW(NV1\?+T91@<'
M<#M&.1BOYG?^$E_X*??\$M/"/C;]HGXRM^Q=XG_8LOOVL/$'COX__#KP5/\
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M1/!.ES_!C3+CQ%XH\;K)J-UXO\%Z=8RW>H_1'_!43]J']ISP'\6?$5A\(?\
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M.^+PNC7^TX+?SQV'_P OQ03O[*M=6_<5/_;7^IM?L3_\F;_LE_\ 9LOP&_\
M54^$*^E+K[G_  %_Y"OFO]B?_DS?]DO_ +-E^ W_ *JGPA7TI=?<_P" O_(5
MF_XS_P"PBK_ZER*C_P N_6G^<3\P]8_Y3)?#C_M''\2__6C_  /7ZC5^7.L?
M\IDOAQ_VCC^)?_K1_@>OU&KHJ?PLO_[%U#_T]BB(;U/^OC_)!1116184444
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MZ<V)G"$972>B<X^JN]/=3]^HK\(?!?\ P68_97_9[_9:_8NN_P!MCXQ>(O\
MAHSXN_L#_LQ?M.^*+7P[\'?%GBCQ%\1)/B+X)\/0>,/%7AWPU\*_!]UI+W0\
M8'Q)KWB+PWX:TRTL?">A?:-6&GZ9H,<6WZT^,'_!6']@KX#? KX+_M$>+_C9
M!K/PU_:*LUU/X('X<>%?%WQ-\8_$O3$MX+G5M3\,> ? ^BZWXPO;#PQ%-$?%
M=U_8R1>'9V^RZJUO=,L)VJPJ4JM6E*-W2Q%?#.2=XRK8;$8O"58IVTMB<'6I
M*^KMMS)Q65*HZL*<U%)5*,*UN;5*I3H5XV32;C[&O&;EI:VJ46I'Z545Y;\%
MOC1\+_VAOA;X%^-7P6\9Z+\0_A;\2?#UGXH\%>,_#UQ]JTC7-&O'DB$T+E4E
M@NK:YAN;'4-/NHX;[3=2M+S3[^WM[RUN(8_4O3G_ .OG_P#74*^ST?5;_HNZ
MZ+<U3N%%%%, HHHH **** "H)/\ 6)]%_P#1T53U!)_K$^B_^CHJ3V8GL_1_
MDS\YO^"5G_)J?B'_ +/@_P""I_\ Z\^_:]K]')/NG_=/\UK\X_\ @E9_R:GX
MA_[/@_X*G_\ KS[]KVOT<D^Z?]T_S6HJ?Q*W_7V?Y#C\$/\ KVOR1^47_!)W
M_DGG[:__ &E;_P""DWZ_M/\ C85^IDHX'08,F">V(1CZ8'(Z#%?EI_P2;_Y)
M[^VM_P!I7/\ @I-_ZU!XVK]3E#.C*, D'8Y&2K>6 #^!(Z]..#DUIC8\^8XA
M7LG&*;M>U\/@U?I^9%)N-"#23?)4LF[;SKQ=G9ZI-NW6UO-?A;^WG9?$:\_X
M+ _\$@;7X5:YX'\.^+3\#?\ @J$UIJGQ$\)^)_''AN*T7PE^S%]MCN-"\*>,
M? >I2W=S$!!#=R>)K*UM6=YFAO[H6UE<>R_M,_M%?M$_L[?"_P#99\%^/]8\
M#6'QU_:H_;(\/_LUZW\7/ _ARZL/!7@;P1XL\6>,=<TSQ-X8\.^)M=\67NGZ
MM<?#G2=*\.Z)8^)O$6N#3/%6KW=^MQ.(X$;W#XN_\$^M"^,/[7'P<_;)U7]H
M_P#:7\*?$;X :=XHT'X0^$?!NJ_ J'X6^#/#?Q'TO0=&^+F@1^%_%'P#\5ZI
MK]G\5M.\,Z5'XJU+Q7XF\0^)]-D@M)_ NN^"Y])T.;2OHO\ :%_9K^$O[47P
MHU7X._&SPLWB7P;J=]H&OVZV&L:QX>U[PSXO\(ZM:^(?"7CCP5XJT*_L/$?A
M/QIX6\06EKK6@^(](U&#4;/4+<&:2ZMYKJ&XPHPE3IX52]FY4,1BIU8I*7[K
M$8Y8IISDK3Y:4$HQ<+<TFK2LFRI'FE4:FK3H0A2DU+W*RPTJ$)I1E%VA.2DT
MFE)12YHK?\7_ -I+]HK]J+]ESXQ_MF?LG_"_XV>*-5TRP_X)A?$']O\ _9R^
M*OQ,T31?BWXZ^!?C;X->,-9\.>//AKK][XJ,LWQ3\,_$5[73M6\&:CXV.KZK
MX%O)]?TV)-9T2QT32[+YE_:$TO\ :)\??\$R/V.?VE/B[^V%\>?&.O?M.>,_
M^"/&O:CX-\*W^E?"/PQX"UGQ]XC^&UK\6!X=O/AKI^A^(O$FF_$6+Q;!K.JV
M7C+5?$2:7XVTK_A(M ?2[9M-TC0OW'\0_L%^$?%GPK^-?@'Q5\8?CIXC\??M
M!_"*S^ GQ-_:3U/7/AC_ ,+\O_@[92Z_'!X T"^LOA):?"GP?I)TOQ?XSTV>
M]\+?"32=?FN_%FN>-'U=_B9<6OCBPXG5O^":'P7\5?L->%O^"?OCOQU\;_&O
MP=^'^B?#30/AKXQOO&?ACPI\9OAUI?P1OO#=]\%7\)>/OA?X"\!6ECK'PKD\
M(Z!#X;\2:EX;UCQ+?KIZ7/BS7/$VI32WU;IM*ERM2Y:^7SFGHZE*CB\=7Q=3
MF:;@YX?$8:@J27+/ZNI-RE-1C$%4<KRG#VB6.;M#DY8SP&!H49<\7%2]EB\/
M4Q?+96=>48R24W/Y"\<C]KKQ3_P4?\;_ +%GA']MOX@_"KX*-^QC\.?CCX"N
M/#GPW^'_ (L^)7@SQ9I?QMF\)WUMK'Q"^)>F>,M1^(5GXQT[PV\7BZZ\20O?
M_P!E:A/IFC76BQ-J-S?\GX>^,7_!0_\ ;*L/%GQV_96UGX%_#9/@U^V'\<OA
M!<O\2?VI_&L/@FU^&'[.G[2?B/X8^//AU\=_V6]&_9'UW1=(\6>._A3X.?QG
M;^(+CXV1_$/PMK?C?0?%6@>--$\$267@V']%/#G[ GACPS^U7HO[76F?'S]I
M2Z\<:'\(M+^!$7@WQ-XP^'7C#P#JGPNTJ\N]<AT'Q!>>)/A7J/Q6UB\N?&-_
M>>-]1\4S_%)/&=WX@N)(&\1IX=*Z"/'M1_X(W?L9WW[67BK]KZRTCXM>$/&/
MQ*\0Z5X[^-/PK\!?'#XC^#/V;OC_ /$SP[?B_P! ^(?QM^"&@:]9^'/'VLV%
MU&MUJ&@7TT'P]\7W=]K-]XY\%>)M2\0>(KS6,:,IP>&YY^UMA\3&K4E0BKUJ
M>98K$T*DX3?7 5J6!]GS*4UA_:RDTXTH.<?>JS7)H\(H1Y9*\'@:.&KP7+S-
MKZS2EBW))PYJ[@U&2=6?@4?[67Q+\!_MT6WP5_:9\0_&_P#9PU/XE_M(MH/[
M./CJ]\.VOCG]B/\ :H_9_;0-6O?"/P:\&^-M&BU?1_@]^TI<7<6I:MK\/C2+
MP-X]U>;P^MII'B#Q)HFN:-I-M%^S[^U1\7T_;%\$_LY?M4ZE\<OV>OVBO%/Q
M%^..J6W@WQMH5CXV_9._;?\ A!X-\#_$2Y\"7?[&/Q3T*QU/PEX/\1?#?PTO
MP\^)WCSX6S7OP]^*$EA+K3?$W2/&>JV$&K:=^A2?L/\ PVD\;:3XFU?Q3\6/
M$O@_0?BG>?'C1/@CXP\>P^,/A3I'QVN=4O=7A^*6F_V_X>O?B3I]WI5YJ%U<
M:#\/K'XD0_!?0;VXEUW2OAA:^)"VKM)X-_8?^'O@WQC\-O$H\;?&/QCX=^"F
MN:WXS^!WPP^(OQ%D\:>"O@Y\1/%7A/Q]X!\4^/\ PEK&IZ*OQ4\0:[JW@CXH
M>//"FF:5\3/B5X[\"?#OP]XANM,^%'@OP/;I;Q6^D)7]BVW*\:RJM\T5K47)
M;G<I/W;\S;22:MS/F;N3<I5=%%6I<CM\/+"5[)627,T^5-MM-MKFL?&7_!=<
M.G_!.7QPX&V1OC7^RTSIS(J'_AHCX<E_+9UW*$(&P@JZ'+;8W+*,[]N<_P#&
MU3_@B$.&#^+_ -OXDY.5'_#,FC*0,$ K)NPP<-G=@$  '[+_ &WOV&?"G[=W
MPVTWX/\ Q'^+OQO^'/P]M?$OAWQ=K>C_  8USX;>'9_%FN>#M>T_Q3X.N-;U
MCQI\*OB)K]I%X7\2:59:Q9V?A75O#5MJ4\2VOB*+7=-1+&/S'XG?\$VT^+WQ
M=_9N^._BS]L?]L-OB=^R=IVOV_P<\1Z3J7[+.EI::QXU\*Q^"OB5XH\3:%%^
MRFWA_P 5ZU\2_#,":1XCM]=TZ\\-Z<LCW_@KP]X/U(+>#/#KV-=UG9N&+]V"
M4ES4X9;4P,:G/;3F=7G46G%*"ASMMN$8NG]9IJFIV4,/B:7/RJ5Y5\3A,3LI
M)JSPK@[2;;GS?9<9>D_\%(R1^P#^VOMWL5_9@^-8Q&X63CX?ZX,(Q20*S+G&
M4<9P=A&:_$7]IC1_VM5_X-U?'-YK7Q%_9MN_AD?^"7WA5V\/Z3\%/BY8^.G\
M-GX+^%Q#8KXOU#]H6_T./7H;22(OK$G@N73I;Z%V30/[/E,$7]#?[4W[/.G_
M +4WP-\<? /7OB+\3/AEX1^)FB7_ (5\:ZO\);KP-IOBW5_"&MVLVG>(O"T6
MK>/? 7Q$L=(T_P 0Z;<S6-[J.BZ3IOB>TA8OHOB+2+G]_7ROXL_X)J^#O&_[
M#T?[ 'B7]HO]I^^^![>$X_AEJVJMKOP,C^)6O?!ZUTZUT;3OA#J7BU?V?OL:
M^$M+TFRM+*VUO2=$TGXE7%I;+9ZIX^U.TEEC>(4_9^V3<7[26!A3]W6:P4L3
M*;YK2C34XXB23:EI3=G>3<=J4^5X>;LXT<3C,57B])1CBZ.&IQC'2\I1EA[Z
M<OQ)R7N)2\@N_C1XK\9?M+?L9_L':-XB\8?#;P3XQ_8"^('[4_Q3\:>%6U#P
MUXO\:6W@76_@?\'/A_\ "KP%\2K2>._\&W%EK?Q+UOXE?$*\\->5XJ2W\,^!
M])CU&RT#Q1K]GK'YB?MG?M!_%KQU^P[_ ,%1OV:/C#K5_P"/==_8Q_;$_98^
M%_AGXT7&B6FBW_Q1^&/Q"\??!7XI^![?Q1;:3!;Z7J/CSP#9:]<^#?%&LZ9!
M"/$<6GZ+KM];+K6HZC)-^YFJ?\$_/ >O^"/V>=&UWXO?'/5?C#^R=)X@;]GG
M]K-M9^%VG_M(_#>U\4V$?A_Q%H(O]'^$FF?!_P ;>$_$?@FUTKP5XH\'_$?X
M/^,/#/C'2O#OAO7_ !KIOB/Q]H6C^+;' ^.G_!-+X/?'C]G[Q3^SGJ'Q ^-/
MP_\ "OQ)^)&F_%[XR>-?AUXE\#VWQ2^,_P 2-,NM!OU\4_$+Q;XW^&_CF%[J
M35/"GA>\M['P=HW@W2=%T_P]HGA3P[8Z-X(TG3_"]OI54:DJSE-.$\15G&/L
MXQ:]IF^"QV%J.T^;]Q@\+4I*4N?VGM%*]*,'?*FITXT(<R484*;LHMM5J6!S
M##5).HU>4<36QM.JJ7N1INCRM5;Q<?/_  G\7/%/[3/[9_[3/[,VA_$;Q=\)
M_#7[%OP__99U6!/ >H6VE^(/&'Q:^-_A7Q-\2;#QEXJG>UGEUSX;^%?#5AH7
MAZQ^&.K)+X1\8ZX_C2;QM8:W;1>'[;2?Q>_83^-?[0/P4_X)P?\ !NI9?"WX
MJIX/\ _&S]HS1/@5\<O :>"O#VJW7Q(\->)?&?Q?UXI'XLU6*;5O"5G8W7A:
M9KFTT&.TN-5@U 6EU=+:QO:3?O-X]_X)K_!SXA_&3X5_M$ZEX[_:$\,?'7P!
MX*\,_#'QS\3/A;\:];^#FO?M'_"WPM<WFI:7\//VC+'X6Z=X4\+^.O#L>OZA
M=>(?.\.Z#X%UV&^6+2;'6M/\+2W.B'Q[1O\ @C!^RYX$^'W[)OPD^$/C;]HC
MX._#C]C;XSP?M#?";PKX4^*6E^,+&_\ C+;V4-@OB[Q5-\:_ _Q6OQI[QW/B
M*0?#WP;>^#OA;;7?BC7-4L/ =OJ=S97FF;QJ4XR:G&<N7$9?B)KF_=U?JF(X
MBG6NE%Q4JL,WP-13Y9U(QR]4ZCG"K2J49I04**IV@HJC2A2LDY0?U#+\+4CS
M7YK2KX2M76L(Q>(<8P4HU)5?S%^,W[0/[?\ +\'/^"W'CFU_;>\5>$?$/_!-
MOXI:QX^^!#_#_P"#?P>TG2O$.@^"_@GHGQ@TWX6?$;3-=\+^*#XA\!7<]Q<:
M%K2VESIVO:N\]UJ&N:WJ5E%:Z-!]Y?M2_M2^)]/_ &HOA5\,?C1\8C^QU^R[
MXW_8D\2?&KP3\:K/QYH_PRL_B1^V"GCSPGI]I\(#\1/$,EM:+/\ #/P+=VOC
M;2?A!]OMG^-,'C74[B_TCQ3HWP^UJPM?5-<_X)&?#;Q'X3_;;\%:O^TQ^UK<
M:!_P4'UG^V?VDH5\3?L_P7&K++H3^$-6T;PA-#^S8A\':+K_ ('ATGP5JL&D
M&&Y;0='LY[&[T_7Y]8UG5_A?]L[X!_&[PA\;?A=ID6F?\%@_%O@'X;?L\> _
M@?\ #;]I+]@?]H+X50>/OB=>/XI\2ZOX[TG]J'X8W6@>%_"WA"_\)RZ?\/\
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MN=-E.F2_$#X:_$:Y\'Z7=PQ^'O$=GKT+:HGV'\*/@)X&^!/PAT+X*?!VSO/
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MA?Q9H^J:P^M6VO65W%>6>K65A>6DB-"R'Q3X2?\ !(KX"_!;X-?M!?"OP?\
M%;]J*Z\>_M.Z!X>\*_$;]J#Q3\9O$?B7]H^U\*^!9KN7P'X5\)?$75%GG\)>
M'O"%M>:K!I6G:7!;1W,^NZS?W[75]>1R1?K8/4@9_E^-+1&*@E&"48QI4J"4
M59>QH*:H4M/L4?:5/9K[*G))\KL'+%)Q27*Y3FUT<ZBA&I)]W-4Z:F]I<D;I
MV3&(0RJ^-I91\O/!/S$<@'(.>H'T%/HHIC$;H?H?Y5&_W&^C_P#H0J1NA^A_
ME4;_ '&^C_\ H0I2V7J__21K>/\ B_R/RT_X)M_\E(_X*O?]I3OB'_ZR=^QO
M7ZA2_=?_ *YG^=?E[_P3;_Y*1_P5>_[2G?$/_P!9._8WK]0I?NO_ -<S_.GB
M_P#>:G_7I?\ IF!S4?X='_KX_P#T]5/SK_8Y_P"3RO\ @K?Z?\-6?L]?^N\?
MV0<_TK](&57&"..".V,=/I7YP?L<_P#)Y/\ P5N_[.M_9[_]=X?L@5^D-;8E
M)U+/5.CA=/3"X;_@?<;0V_[>G_Z7(^0_VY?V<_$7[6W[*_QQ_9G\-_$>;X42
M?'3P<GPT\0>-[;1SK=U9?#OQ-K6D67Q6T.SL5NK+_3O&7PR?Q=X+L[UKA1H\
MWB./5_+N5LFM9N9_;+_8Y\+_ +5G[(?CG]E/2]2C^&MGJ'AKPI;_  H\3:;I
MKWD'PF\<_"_5M&\4?"/QAI&CV]Q8K*O@+Q+X:\-ZE:V%O<VD<T=@EFL\2Y=/
MN+ ]/\]/Y<4W!!X "XZ8'J,]^A';'8]<C'+4CSQY+6O4A6;2LG.FXN+=G&7-
M[D+.^G(MM;B2C)2M?EA*"6NBG=2LKVLU*:=XNZE)/1GX&^._^">7_!3[1OVA
MOCY\<OV3_P#@HS\'?@!HO[1EY\.O%'CWP3XC_9#LOBK*WCOP5\/]*\$ZGK&E
MZWKOCVVN=/TK5IK">_L])CMW^PP2VUO/+=7%O)-+]W_M+?LG?$7]J7]BS1?V
M:_B#\7=);XEC7?V5/%OCGXP67@8V>D>)_%?[/?QY^$'QN\5ZGI_@2TU*%=#M
M_'UW\,+S2['3XM3N8/#C:XDZ_P!H1:?Y=U^@.#P=HP"V1@@\ @%5R0<X'Z=3
MT0(P<L-H!STX)R.IXP26P3Z<X^\V59<D8QIJ,8251*48N5X3J5::@U>SC4J2
MDF[6;35FE8O)S<Y^]*2LY1NN9\E*G*5375RC1IQ5^D5KNY59(@8G=%Y,F_D$
MK@,23M!&>X/LQX/2OPS@_P""1WQ=D\<Z9\,O%G[<WQ!\:?\ !./0?C!X>^/N
MF?L?>(_AYX=UOQCJ/C#PA\5;7XR>%/A=XL^/^JW%]XJU[X :#X^L-'UR#P3+
MIRZW?1:#IGA^[\1-HXEMI?W6*M@ $$#D[@0I4YP..N._/'!]*>1D8&TY]1D'
MIR>?ZFBGS0J*O%2C5E[&3N](/#UO;T;-/F4Z59>VIR@TXU+23322)Q4HN+BF
MFJBT2YTJD'2J)-II*=-N$OYH-Q>A\B_MG?LD^#_VSO@?J/P?\6>)O%_P]U6#
MQ1X0^(GPX^*_P]NK>Q\?_"/XJ^ -<M?$W@3XD>#;FZAN;6/6?#NM64,WV>[@
MFLKZTDNK"\C:"X<5\5_L\_\ !.W]I:R^/WPU_:$_;U_;AU;]L;7/V>G\7I^S
M9X.T/X-^%/@KX'\$ZEXRT.3PEJ7Q-\:Z?X<N-1OO''Q6?P==ZKX:AUR>[T_0
MK#3]9U9M/T:">^=Q^Q^#ZC\O_KU&4Y+#!.",$<#@=/?Y1C_]5.$'%23<7S.;
MM)<RYI4_9<S36K=-\DKWO#W6VDFG+EDK.#LE:R5KKG53E6NB<XJ5E9<VNC;;
M_D<_;.^&NC?\$L/AM_P3OM=2_:P^)_[*WQ+^"_PK_:>^%>G?\%!_#W[+FN_'
MS]G&\\*_$OXL?#KQMK?[._[0_P *M LO$WB#1=3\=W&H:#XI^!6O3:E;V<?Q
M ^&6L+&+Q;N^M;3Z&_X)C_L,>.?&G[/W[/WQ=\2^,_C!I,/A#_@H]\=?VVO#
M6I_M$>!)=!^-GQO^'_C/0-4\#Z'XC\>>%81H\OPXUCQS+<7GC/2M.O=*B?3O
M#,^CVO\ 944$ULR?TFWD;[ I*E=RG#H)(SAPW*-A6)QA6.6C8A@"1@^)>*/C
MOX.\(^--4\'ZCJ%L/^$*\#ZC\3_BSXJU'5M,T;PE\(_AYIUO>W$?B'QOJ]]*
MJ63ZK#IVI76EZ<D1<Z1I&JZYJ%QIVE67VJ9PK3A]8J2=.K7E*=>35*+DUA\3
M_:4DI2@E%TZV)51RG)VJ5.9-R;4,94Z<G2BJ3C"G:%E;I26$IIV?.U+#.4*<
M$VE2YX)1;U^)?B%_P3OUOQS\#O\ @K%\)++XI:?IUU_P4KUWXB:WI&LWGA6_
ME@^$1\;?LD_"/]FJ&#5+)-81O& L=1^&-[XIN9;*YT436>MVNE0*DVGO?7?C
M7Q^_X):?M!_$#X]_&;X@? ;]O;QI^S?\(_VM?A[X&\"?M8> -!^$_A#QEXX\
M13_#/P)>_#SPQK7P>^(_B61[KX6IJGAR^FL_$NGG3=8MV+7-]HWV#4[ZYG;[
M3\)_MOZ1XNT[P1XRT_\ 9W_:;M/@W\3O$?PM\.?#+XU7?@KP5-X8\7R?%SQ7
M9>$O"NOS^!--^(E_\>/ /@H7FIVFH:IXR^*OPB\">'[/0KJSU6.^N(=0L%N_
MJB#XF>"9H=8GB\4>%IH_#E['I>ORQ^)]$:#0[Z=_+M[+6I?M872KV>0-!':W
MGERR7"/;QB1T)7&$'A8PH.%11H1E2I\_[V2C@HK"7J-<[5Z=1J2DXS3]WWW:
MV\ZEY.K[5--Q;DI.]ZU2-6#IRBVI>TGAH5$XN46Z-.:M'E<O$?V,?V<KC]EO
M]E#X$_LU:QXEM?'LOP8^'6D_#E_%$.ES:1;>)-/T.*2QL;RZT>\NM0DMI;K3
M%MXK^"6[N(I+D7$BD12K&OY.7G_!'/\ :6T3PW>?LI?"W_@I9\7OAW_P35UL
MZUI\O[.,?PY\+:[\:? _P\U>ZN9_^%"_#+]I34;A_$^B_!6TTV2+PM8:=K.G
M:MXJTOPG-J&B6WB H;26W_="3XG>#X=%U'Q%)XC\+1:!I%X]CJ^MR>*-(CTG
M2KV*86]Q::GJ1G-G974,SK$UK<SQ7(F9$:)&<9X'XV_'[2/@W\'O&?Q<'AR[
M\=)X;\(:WXM\->$/#OBCP'HFM?$AM'TB\UP:+X-U7QUXF\*>$[B^O=-LS>6T
MU]K]M92VTD;Q7$KL(&JK*,I8BMB73J1G[..(C*#G3DN58BE&<>249TU[3VD%
MRRA%N:;<54@9TW%0I4:+<'!RC1?-:I"<:RI3M>49*;JU^23=I7JJ5[OF7YI_
M%K_@ES\8K;XYZ?\ $K]BC]LOQ%^QCX \3_ [X8?LV_&/X>^'?A7X2^(&H'X2
M?!S3M0TCP ?@7XM\3$W7PH\:Z3HVIW6F?VX]IKMHLJ6VK1Z<VHQ&:3IOV)/^
M"9.I_L?S?L4++\9?^%D6O[&W[-/[7/[-BW-_X6N](UGX@:=^T7\?_@I\7O!_
MB>YNSJ]Y!87O@CP]\)E\,^(XC;74?B;6=6;6=/.CV]FVGS?H5\-/C]X2^*?P
M_P#A=XQTIM.TG7?BY\*_"GQ4\,^ M9\0Z5!XHCT?Q=X9TWQ'9QW5I#)/=F"Q
M75K6RU34K:PGAM9A+<+#+$JEMKX6_%'1OBKH>K:MI-IJ>AZMX7\3ZKX#\<>$
M?$"V,?B/P3XX\.3QIK/A?7(M+O\ 4]-:X2RNM-UW2=3TV_OM'\1>&->T#Q/H
M5]?Z)K-A=S%2G5E[C<92]LW.=1S4U7ISQF'=2$X)MRH_VGCH1<I-MUYN+J12
ME3'.G*$&H<U-4%34;)15"3H*,-8WA2F\LP\8IVC?#PLDTW/\@/&O_!)+XJCP
MM>:S\$_VL&^$?[1GA#]NWX__ +:_P3^)TOPITWQIX'\/3_'C2+?POK7PY^('
MP\UW5)(O%]A:^&A>VZ:W97^CWD6H26][9BW1;B&6IX6_X(T^-+KP;^V3I?QF
M_;1^)?Q:^)_[5'Q"_9@_:'\+_M!CP1X7\.?%/X&_M._LP6^DW?@OXB>!K2"*
M7PE#X7T37_"/@ZT\(^#4TFR.D^"K+5?"&HZOJ%OJLFIP_O)"I:-3N'((/RY(
MW$C@GGOSDG//3BIHU;DL0?EVG'0G)_AZ9QC/'?&>M:8?FHJ]*3C'EBJ227)2
M@HX).E333M%ULMP>)LU).>'HM_"XS;7.H1DE)4FTW.-YSDYXJISJ46MXXS%4
M7=W]G6JQUC)*/X*Z3_P2#^+7Q(G_ &D/%G[77[9_B'XV?$W]JS]C_3_V7_B'
MXO\ "7PQT;X;Z=X*N_#_ ,2-0\<>%?$'PG\'076H:#X<\-:-'- ^H>&=2@U.
M\\3>(9M6U;5=3>VOK73;3H?@-_P30_:]\(?M.?L\?M9?M-_\%!=0_:.\:_ +
MP%\9?A/:>$;/X':!\,OAQ;_#7XC>']"L-*O/#7ACPSJ4KV_Q$LM6\+:-J_C#
MQ%J\VL6_BFTL+31K'2=)2UM7K]RRCY.& &,*,'T'4Y/3 QP>F3D]$92=V"5X
M(]0. Q/7))/ S[]*B*<81IPC[)4Z2P]"*4(TJ,5#'4U4I1@E*#<<RQR<KRDW
MB:U]9W3J>\Y3E!3NEI9.;498>:I:^ZH.>%P_NV4;TH;)24OE+]G32?CK/^S=
MX7\.?M&>-;3XB_&&31/%.B>*/B3I?@&+X:0>-K.75-=T[P[XUD^&T=W=KX*N
M=:\/#1M3E\+/>&^L1<1PZE%8ZE_:%E9?%O[)O_!,O4_V:O'/[''C2Y^,%AXN
M@_95_9F^-?[/=SIJ>#;K19?&=W\5?B;;_$"'Q3;W$VL78T2+18+;^RYM-E@O
M6OI&^U1W5NF(3^NK6L^#F<DEB0=IP"2Q!*@\8)Y X)Y !J2.WRH\PAS@X(&!
MT .<Y(8\C@D'&<'!S,O:MU)PIJ'MJ,:4Z=HJ$4J&*HMKE;:O]<KM\CNE)\LE
M*W+--./N24I1O6E*4_>]ISSI\G-&3:YZ<:-/DFUI&G!+6.OXJ>*O^"3_ (FO
M?A':67PX_:3U#X2?M.?"[]M_]JS]M_\ 9T^/_AWP'INMV?P_\2?M1^+_ (K:
MEKWPP\:>!/$-Y=V?CGX=:MX,^*VH^!?'MK%J.DWVNV-M%J&GW.CS1;![1^SK
M^Q7^T5\ =)T35G_:]U;XE_&3XD?M!VGQP_;*^)GC?X=V=YIOQGTF'P;%X03X
M4?"?P;'JPT3X#^#]%L]+T*/PY_8$5[<V<5A>2ZC+J-]J,EPGZC"$J6("D,A#
M#G.=I P2>02<<\CUQ@*XQ-M"G8<L2QVD#D#)&#P2>F <=<YZE.$J=*,'#GC3
MIPISAS-SJJC3P-*"4W**<)0RW .K&=N:>%I2LFI.I4DI7C:3DX2C&K*UX1E4
MQ-63DVW+VD:N-QE6BU=1J5ZDW[TERU8C(4S*V&R<\8^4_= & ..N1R>3QG ^
M6/VX^/V+_P!K7_LVWXS?^JZU^OK!HY", C?CAB"0,8[X')P!T)(+>]?)_P"W
M'_R9=^UK_P!FV_&7W_YISK_?O710BEC,-9)*6*P4K+9-X[#WBNMHMO5]6_(F
MS5&LF[I4*D8\VLVHN*YI/JY637S[FU^Q/_R9O^R7_P!FR_ ;_P!53X0KZ4NO
MN?\  7_D*^:_V)_^3-_V2_\ LV7X#?\ JJ?"%?2EU]S_ ("_\A4/^,_^PBK_
M .I<C2/_ "[]:?YQ/S#UC_E,E\./^T<?Q+_]:/\  ]?J-7Y<ZQ_RF2^''_:.
M/XE_^M'^!Z_4:NBI_"R__L74/_3V*(AO4_Z^/\D%%%%9%A1110 4444 02D[
MU /49QQC^(9)SGJ0.G4CW%?F3_P5H^)'C7PC^Q;XZ^'WPP:\/Q<_:9\3>!/V
M4/A>VG>0]_9>)?V@_%%K\.[W7HX)"=T/A?PUJ>O^([Z1D>*&UTZ2696B245^
MG+JS'*E1QC)!W=3P#G ^I!P3D<BL^2Q/+J8PRN60JFTC<SEAE<D.6D9S)SEB
M654?+GGKTW5@X6<J;FE6A&3C4J4;Q<X4III1E+DIQ:;7-!UX-Q]HFJA.5.7M
M/=E.#4Z-DO=E%IP<FTU=2?,W9VY(O5QC;^7/5/V&/BS_ ,$JOCO^P/\ M92_
MMM_M&?M5?"KP3\4O '[!?Q&\)_&?2/AU:^%_A)^SK^TO-IGPV\,>)M!O/!^B
M:!-I.A>$/C;I'P4AOI-3?5(K32+V619;2(:C/<UOV ?^"T?_  30_91^%FN?
MLD_'3]I3_A!?V@O"?[:W[?7A[7OAV?A/\9_$EU8ZQX]_X*!?M&>)/!]BNN^%
M_A[K/A>\DUC1/%'AV]1[/6YX[:6\>SOI+6ZM+J"+^GO5+NWTE!/J5YI]O;J\
M4,D]V5@A'FR*8E>2><B1V:-FWR-%$BP375Q*([9@,S^WM!=H5CU7P^QN',4#
M?VCHLD\\RRQ(XMV6=?/F#SPB8)YK+>7*1[RPC2X%6J59Q5:%;EIQ5.-KJI3I
M3S"AB%!2BJG[N$Z-:I!13]S&.--5*M2=*GC*-/FO.RE.K"4ZCNX3DJ&(C4J2
M2LY*4)25:4K/EA&57ECRS/S9_:)5Q_P5?_X)O%E.1\&/VVE=XTD,(<Z%\+]J
MF7:RQ[]K"-78-)M;:#@X^N?VP;N_TW]EOX]:C9?L_P ?[5<EA\+O%U]-^SA)
M<V=J/C5IMK9++K/P_MC?Z9K-K>:AK^D+J%OIND3:9>+K>H&UT@1[[Z-T]T@O
M;*]NIEM[VSN+FWFCBN[>&\CN[NQFD8;H[RU@F>2V=, $S!,Y+1 (OS]*T+X"
M[]NQB3(I4-M&S.0Q=<.HVDL"1Q(&5E4&*<%)PC%R<8>WFKWY;5L?'$1O9I.3
MC"?(TY))[--II1DZJJ32C+V486BU=2A0K03C\+3O*/NVNN?<_FN^#O[37[%O
M[3/[;OP'_:1_8?\ A]JOA7X*_L4?!#]J#4_VS_C!I7[-'C7X'^'O!VD:[X#T
MZVT+X!^(].O_  +X3U?QG\1/#7B'3)O&.H>!/#FA^)9O#,'ARYO()%GN4CG_
M &(^,WQ4\"_&W]@7XV_%SX8^)8/%WPX^)'[)_P 6?&7@;Q/:6=]80:_X8UWX
M2>)+_2]2AT_5+2PU6T-Q;R!VL]1L;:_@='BN;:&:*6./Z\OK*XGL[N"#4+G3
M7FB<1W^GI8F^L97#(;VW%]9W]D]U&&W1R7]G>Q.Z@RV\JC:W*:79^&OAOX8T
MS1H9K?0O#6BVVFZ5!<ZOJ=O$AFO;N'3K);B^U!HXGO=6U:_M;2,2-(;[4[N"
MWMH(GE@C-3@\1A*U%TYP4\&\.G)\\D\7&JZE*&LI+V4L1[)4U!)<JC"+@Y3-
MHS=+$8>K!J4J>)IXB,8)IR]A*E4BI*UVXRIJW173CK'E?\[O_!+?0]+U3]K7
M]AW7M4T:&?4M-_X-O?V'["PO[^P+R:=;Z[XOT0ZU80RW,.+:2^2QM8]0M\I/
M)!"L4Z>4[*WQ/^R)\;/AE^P5K7[&/[:7[3GA_P 4>&_V69OV>_VP?V;='^-G
MAWX7>*O'?AC]G_XK3_MQ^._%T6C^*-.\!>'O$&N>#=.^*OA._P!+TO0=;&D)
M8ZE<^'F\/V;S9EBB_LF2U>-5$:QQDJN"\0; 7:2FV,Q;3N&\D/L661\*5 J*
M[2*UB::XN[>TM$):;[242W8,@4!W<K#S.P9&*Y+MMC57P:TEB5BZ^,J3@\,L
M7B\;C%3YFXRJ8S'9WCI22C%.]&KF\'&=HN,X4ZKV36*IV6%Y=5A\*L,W!M)J
MEEU+"TKN\7^]CA:4$FK_ +V,9-1C4Y/SD_8P_:M^$MU\/_V8/AS+\#=1_8L\
M8_M3Z?\ M1?%?]GG]EGQ!X+U#1->7X4_"[XJKKNO^.?%^F>'M"@\,?"[Q+XY
M\-_$_P $_%?5/ .MW=CJ&GZE\0K_ $2TFU?4M%UG['^FL;LZ0G+'<4)W*4."
MV>5(!'&, @$'@@<XSX[>26=O,*M(BDY=2JD,%1U*$-N,DL:3-<Q" '8D4195
MN =-8G4+D@E7!.T$ C=V7L,L6P22.,LQR:M\KGSI5$YRE-W<G&-XTX<J4I2D
MOX?,HMRM*<YI\L^2-QM9)*R26FBLVN9QTTO!S<'HD^72Z2;LT445104444 %
M%%% !4$G^L3Z+_Z.BJ>H)/\ 6)]%_P#1T5)[,3V?H_R9^<W_  2L_P"34_$/
M_9\'_!4__P!>??M>U^CDGW3_ +I_FM?G'_P2L_Y-3\0_]GP?\%3_ /UY]^U[
M7Z.2?=/^Z?YK45?XE;_K]/\ ($[0A_@BOO2/RC_X)-_\D]_;6_[2N?\ !2;_
M -:@\;5^J\"@IDYX/;_=';\:_*C_ ()-_P#)/?VUO^TKG_!2;_UJ#QM7ZLV_
M^K_'_P!E6ML7KF.*3U3A!-=&O8X/1D4TG2I7Z*=O7VM;7\6/V XZX'(R>AYX
MP1T.<_ACIQ3B W'/![?G_+^>*=16?*E9)*R::5MFOQ^^]NG8NR^]6?W6_+^F
M,V*&#<\ ^OZ_X=/2HW@1E*D$Y YW8/!SUX/<D\U/11**:=TG>U[ZII:VM=?G
M\@:3T:35K6>JMI=/NG97\M"J557*@9P4."3G)]/PSC'OUK$O]?T+2]IU+7=&
MTX?9Q<YO]5L+11;S2-%%<DW-Q$3;S31M"DH^1G'EJ20V-F4D-+CJ57&,YR <
M?=#$'TPK'@X!Z'\@/VW_ (/_  D^(W[>_P#P2CN_'_PM^''CNYE^)7[6'AQY
M_&O@7PMXKNI?#L'[(?Q3UZ+PX+C6-)O';0UU^TLM>_LK]]IYUBSM=1A3[1!;
MS&%;VL5=_O*L(S:6MJ.#Q6)=M='+V$8):WYK79,K+F:6M.$)JROK*K3IN-OY
M6I>\MFDDTC]=TG26&*>.:&:":"*XBECDBDBFB=0XFBE1BDD+H0Z2*61D(8,0
M:Y6U\<>&]5CT^?1O&?A748M7VC2'T_7]%OTU1I);<1KIK6][*+YG1GV"U,I?
MS%"Y8IG\+_A[*_P8_;A_;^_9H_9N270OV>?%'PB_9TGA\#^$[_48O OPA_:V
M^,WB'Q=X5\:Z!\)+.QODT/X7:[K_ ,);'_A:'B7P7X3M+"QL=:T.V\7G3;._
MU*[CU7R/Q_\ LSG5?VT/^"J_AOX/_L*_L<?M-7?_  R_^Q@S^'OCEXLMOA%=
M3^,)_AS^T/;:0=%U33_@'X[M]0UKQ#+H]@=9\7WGQ(^$M_ITFGZ"8?$&EW-C
M#X@T^IJ7LZ>(474YL!]<ITHSBHU)2AA,32P\N:5J<Y3J>QESQTASP;2<DJE2
M56->'/5@X\W[R.G)3Q-:.%YXM)ZT93C.FU?DOS--;?TGW&J:=I:67]KZKIVG
MM?W]II-HU_>6UD+[5;UVBLM.M%N)8OM&H7L@$=K90[[FX<%(HW85HATC/#JJ
MD$MD@'!SACDC"@AL%L X(X(./R#_ .">WQ5\(?'[]F;]@'Q=H?Q3^(GQ<\!?
M"[]D#P7X_P#%/Q;^,&B3Z!\1_&GC73?#DGP<@\4_%O1M4UWQ<;'Q;/J_@[XI
M^*+^9_%7C)AKGAZ76+'QQXMM98/$>K>(?##XS:OX'_X*7^"OB?X@\*?'+P5\
M/O\ @H1X)\3_  /\0M\4O!GB;P]\/=$^.?P.DUWX@?LQV7@C5]=NH_#B7WQ4
M_9]7XL:5JB>$PT'B35_AOX>U-[276-8O;PN=%4ZK@VY>[44OB5^1OZO#K)>V
M=[*SC'EO5<$XMPG)PE**M)3DG%6MS1D_:K1N/N<KO9N[E^[Y]C]3/VOOV@?%
M7[+W[/GQ%^/?A_X1>(/C9#\+=!O/&/B?P'X0U[3]"\87?A+1+&34?$%UX235
MM-OK'Q'XAM(87&F>&&DTR35Y<01W]O+L#W/V6/VD/!'[7?[/?PM_:/\ A;?7
MQ\%?%SPI;>)-(LM4M([;7=!O))IK/5_#7B&Q)W6/B#PQK%M>Z'K5E*JR0:A8
MS)(B9"G(_;5GDC_9,^/LB;87C^&/B2;S)<M"GEVF2TBL-_EH4 =F100-Q&"2
M/Q0\"WWCS]B_]KS]J/\ X)E?#]-<\-^%OVZM23]I_P#8GU[2=/O[>S^%=O\
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MNH13][6VOOS]K+7^]4]]]Y:[E7;TNR.3K'_UT_\ 9'K\O?\ @L5_RCL^._\
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MZ_+W_@FW_P E(_X*O?\ :4[XA_\ K)W[&]?J%+]U_P#KF?YT\7_O-3_KTO\
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M]HMO\Q_L4_MUZYXT^%&F#XPS>*/B[\5-<^._[=>CN?A1\)+?0=7T#X#?LO\
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MB=?7IQSZ$5+119=4GOOKOO\ ?MZ:;:!9?TEWO^>OX[ZC!&@4+L3;C&S:NW&
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M445!1')UB_ZZ#_T!Z_+W_@L5_P H[/CQ_P!ASX ?^M+_  ;K]0I.L7_70?\
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M8_\ \*LM_P#F<.3$?\_<+_X#6_S/C;_A[3_P31_Z/>_9U_\ #BZ/_P#'*/\
MA[3_ ,$T?^CWOV=?_#BZ/_\ '*^R?^%=?#[_ *$'P1_X26A__*ZC_A77P^_Z
M$'P1_P"$EH?_ ,KJ.? ?R8__ ,*LM_\ F<.3$?\ /W"_^ UO\SXV_P"'M/\
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M /'*/^'M/_!-'_H][]G7_P .+H__ ,<K[)_X5U\/O^A!\$?^$EH?_P KJ/\
MA77P^_Z$'P1_X26A_P#RNHY\!_)C_P#PJRW_ .9PY,1_S]PO_@-;_,^-O^'M
M/_!-'_H][]G7_P .+H__ ,<H_P"'M/\ P31_Z/>_9U_\.+H__P <K[)_X5U\
M/O\ H0?!'_A):'_\KJ/^%=?#[_H0?!'_ (26A_\ RNHY\!_)C_\ PJRW_P"9
MPY,1_P _<+_X#6_S/C;_ (>T_P#!-'_H][]G7_PXNC__ !RC_A[3_P $T?\
MH][]G7_PXNC_ /QROLG_ (5U\/O^A!\$?^$EH?\ \KJ/^%=?#[_H0?!'_A):
M'_\ *ZCGP'\F/_\ "K+?_F<.3$?\_<+_ . UO\SXV_X>T_\ !-'_ */>_9U_
M\.+H_P#\<H_X>T_\$T?^CWOV=?\ PXNC_P#QROLG_A77P^_Z$'P1_P"$EH?_
M ,KJ/^%=?#[_ *$'P1_X26A__*ZCGP'\F/\ _"K+?_F<.3$?\_<+_P" UO\
M,^-O^'M/_!-'_H][]G7_ ,.+H_\ \<H_X>T_\$T?^CWOV=?_  XNC_\ QROL
MG_A77P^_Z$'P1_X26A__ "NH_P"%=?#[_H0?!'_A):'_ /*ZCGP'\F/_ /"K
M+?\ YG#DQ'_/W"_^ UO\SXV_X>T_\$T?^CWOV=?_  XNC_\ QRC_ (>T_P#!
M-'_H][]G7_PXNC__ !ROLG_A77P^_P"A!\$?^$EH?_RNH_X5U\/O^A!\$?\
MA):'_P#*ZCGP'\F/_P#"K+?_ )G#DQ'_ #]PO_@-;_,^-O\ A[3_ ,$T?^CW
MOV=?_#BZ/_\ '*/^'M/_  31_P"CWOV=?_#BZ/\ _'*^R?\ A77P^_Z$'P1_
MX26A_P#RNH_X5U\/O^A!\$?^$EH?_P KJ.? ?R8__P *LM_^9PY,1_S]PO\
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MO+5_[KAR8C_G[A?_  &M_F?&W_#VG_@FC_T>[^SJ?8?$71\GZ?O:^9_VO_\
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M@JP!! ^E)T+J N,D,O)P,D<?R]*2U@BMH(8((D@ABC2.*")%CAAB152.**-
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MXT_\,;\;?_F H_X?,?\ !/W_ **GXT_\,;\;?_F K]/-[_WF_P"^C_C1O?\
MO-_WT?\ &CZY@?\ H$Q7_A3+_P"=X>SJ?\_Z?_@I_P#RP_,/_A\Q_P $_?\
MHJ?C3_PQOQM_^8"C_A\Q_P $_?\ HJ?C3_PQOQM_^8"OT\WO_>;_ +Z/^-&]
M_P"\W_?1_P :/KF!_P"@3%?^%,O_ )WA[.I_S_I_^"G_ /+#\P_^'S'_  3]
M_P"BI^-/_#&_&W_Y@*/^'S'_  3]_P"BI^-/_#&_&W_Y@*_3S>_]YO\ OH_X
MT;W_ +S?]]'_ !H^N8'_ *!,5_X4R_\ G>'LZG_/^G_X*?\ \L/S#_X?,?\
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M-G_S TW_ (?+_P#!/W_HJ?C3_P ,;\;?_F K].]S_P#/1_S_ /K4N]_[[?\
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M_0)BO_"F7_SO'[.I_P _Z?\ X*?_ ,L/S#_X?+_\$_?^BI^-._\ S0WXV_\
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M&=2*M"22NW9P3UDW*6K:>[=ET+3<4DGHB2BBBD(**** "BBB@ HHHH ****
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M ,=H_P"'K'_!-_\ Z/:_9W_\.'I7_P =H^J8_P#Z \;_ .$>)_\ E0>UH_\
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MWZ>^?Y_YY.?SU_X>L?\ !-__ */:_9W_ /#AZ5_\=H_X>L?\$W_^CVOV=_\
MPX>E?_':3P6->^"QK_[E,5^D$'MJ/_/VC_X-B?H5\W]W_P ='^%'S?W?_'1_
MA7YZ_P##UC_@F_\ ]'M?L[_^'#TK_P".T?\ #UC_ ()O_P#1[7[._P#X</2O
M_CM+ZCC?^@+&_P#A)B__ )$/;4?^?M'_ ,&0/T*^;^[_ ..C_"CYO[O_ (Z/
M\*_/7_AZQ_P3?_Z/:_9W_P##AZ5_\=H_X>L?\$W_ /H]K]G?_P .'I7_ ,=H
M^HXW_H"QO_A)B_\ Y$/;4?\ G[1_\&0/T*^;^[_XZ/\ "CYO[O\ XZ/\*_/7
M_AZQ_P $W_\ H]K]G?\ \.'I7_QVC_AZQ_P3?_Z/:_9W_P##AZ5_\=H^HXW_
M * L;_X28O\ ^1#VU'_G[1_\&0/T*^;^[_XZ/\*/F_N_^.C_  K\]?\ AZQ_
MP3?_ .CVOV=__#AZ5_\ ':/^'K'_  3?_P"CVOV=_P#PX>E?_':/J.-_Z L;
M_P"$F+_^1#VU'_G[1_\ !D#]"OF_N_\ CH_PH^;^[_XZ/\*_/7_AZQ_P3?\
M^CVOV=__  X>E?\ QVC_ (>L?\$W_P#H]K]G?_PX>E?_ !VCZCC?^@+&_P#A
M)B__ )$/;4?^?M'_ ,&0/T*^;^[_ ..C_"CYO[O_ (Z/\*_/7_AZQ_P3?_Z/
M:_9W_P##AZ5_\=H_X>L?\$W_ /H]K]G?_P .'I7_ ,=H^HXW_H"QO_A)B_\
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M:GT4<D>WXR_^3"[^\****H04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q
M'Q(/_%O_ !Y[>"_%'O\ \P*_/3\:R/A-G_A5_@'T_P"$+\-=?^P7:=,?U_#N
M:UOB01_P@'CO!Y/@WQ2 ,9Y&@ZAQ^F>WZYK&^$Q"_#'X?ITSX,\.?3/]E6A
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M3"R[1_\  *?_ ,K/._\ A4OPQ_Z)WX!_\(KPU_\ *VD_X5+\,>?^+=> ./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P 5?_U&9^J,?W%^E/ID?W%^E/K&/PQ_PK\D6MEZ+\D%%%%4,**** "BBB@
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MZ9 ;?3;![^XDO+E-.LE=K?3K1KF>:2.SL(K:Q@,C?9;:%&*G?. P(C!.XL6
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MQ]'_  T__P %1_\ I%1X$_\ %B'PS_\ G'T>QK]\-_X54/\ Y8'M8?\ 3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGXD?\ )/\
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MOC;_ ,1!_9@_^9BC_AEW]OC_ *2G>-O_ !$']F#_ .9BG[&G_P!!>&^[%?\
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M ,S%'_#+O[?'_24[QM_XB#^S!_\ ,Q1[&G_T%X;[L5_\RAS5/^?57_P&G_\
M+3]*@J@G@=!V&/Y9XQ^M&T'J/<9'(R.@]..*_--OV7_V^%5B?^"IWC? [K^R
M!^R^2,\ _P#(M8/)'8$=,'OH?\$X_BU\;OB;X+_:1T+X[?$F+XL>*/@9^V)\
M>?@+I'CT>#/"_@2]U[P?\-M;M-.T.YU?0/!UI8Z!%JS13N+R>QLK=)G(81@$
M4>QCR3J1Q%"K[-P4H0=92_>3=-<JJ4::=FO>L[I23U3=AU%&4(SA.'.JC4I)
M<JY(>TES.,Y<MX[75KII'Z/44BXVC!R,#!]1CK^-+69J%%%% !1110 4444
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MBR?"[_PO?"__ ,M*/^%^_ S_ *+)\+O_  O?"_\ \M*T]A7_ .?-7_P54_\
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MQWRRF/?)Y2 G8C'L:UWECC!9VP ,DX)P,9Z $]/Z#J17\RW_  6#^-7C:?\
M:1TC5?A7XYN/##?\$N?A-H_[??C;0['Q/::#)\4]?U[QI8^&;GX4:C87E[$-
M>MG_ &?-&^+?B:PTR.UDEN-;FT:WA+3S1H(ESNKAJ7UATU6J2C.=1Q<:=&-.
M4ZU=WCK[!>RDE\,G62E*"2DCV:<:CA!3=.+ER\TO>FFE"BWS^Y[:<E!S=O9I
M<VUS^DR;5H+>2VC>)O-N%G*1M+&)3Y"V[.(XB?,G(6X7/E*X7 $ACWJ3)/JE
MG;>7Y\UO 9"0OVF[@M0/O;]IG9 ^ -QV9_+K^-W[1/C6/Q=_P5'_ ."+NO\
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M2H!&QRS8Z#/''KT. 1CJ1ST[U^7'_!,0X'_!0$  Y_X*;?M=*0>A#>*K# _
MG)X.,<<\C]2YO]4Q]<C\,_\ V(/UK\M/^"8F/^-@/.?^-F_[6_'_ '-6G?7\
M>G3%:T6W0QKDVW!8)Q<M6N;'3A+5)?92M?9ZK6Y$HI3H127*Y8BZZ/\ V=[W
M?]?E^J"8VKC@8%.ID?W%^E/K*+O&+>[2;]6E?\6:K9>B_(****H84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHFE9 +&3^RM.^5@?N'%N#@="">1ZC(/2F-#_  KU!^Z.Q^GX?2J\R[5DP ,
M< 8ZL#CTY)Y/7KUSBEJHSO>_LYM?O:]U91[ST:]1.+YH+G?O5:?_ "ZH6M=W
M3_=IV?5[JRMNS\P/^";ZB/XA_P#!2B-5153_ (*"?%%(E1654C'@[P"4C6/>
MT2A >/*2)3G<RERSM^I QD^V01^6/T'^<5^77_!.+_DHW_!2DGC/_!03XHY(
M]O!W@( ]/8+^%?J*.N[U[?EC],_G77C6WBIM[N&'O)MR_P"87"JUY7=VE;5Z
M6TM%*V.$M["'+MS5>D5;]_B5M%12VMMMKO=MU%%%<YU!29 ZD#\:6JL[HC#?
MT9>N!@!=V3D_4 ?[3*!DD"@"SD>H_,49Y(!''Y^_]/QXKQOXE_'OX(_!;PMK
M_CCXO?%GX>?#+P=X2U*QT?Q-XG\=>+M#\,:)HFLZE;07VFZ-J&HZO>VEM#J]
M_97-K>6>E^8VH3V=U;W"6WDSQ.W9^#?'/@OXB>&-'\<^ /%?A[QQX,\36,>J
M>'?%OA+6=/\ $7AO6]-DY2\TO6M)N+O3KZW9E9!);7$B^8KH2&0@2Y64W;2,
M4[O9WZ?(=OZ^=EZ=_P!#H[CY57=WDCW8)R "S/( %).T@2$< !<_=SG^?3P#
M_P $<OV?/VN_'W[2/[4O_!3?]ENQ\;_'7XO_ +0?CP^"- \7?$#6=3_X07]F
MWP!/!X&^"WAVUA^&_C&'P_;1>(/#FD7?CB\T]K[5+^(^*(+;4SI^HPW>FVW[
MQ-\0/!(\8VGPZF\3:&/B!J'A;4_'>G>"VOK8>)[WP9HFM:7X;U3Q5:Z,S_;9
MM"L=<US1M*GU-(3;17NJV%N\BR7,2M;U77_#NC"RGUK5M)T>._U.VT>PEU2Y
MM=/2^U74CY=AI%D]T\9N=2OY _V73[?S+FX*R-%$WENR8RI*<:E16A.=">'5
M6?,G1C4M&;HQ4H\LJ\;4G)VDHI132<D9MR4O9<[C9SK1Y5I.4(2E34Y6;:A4
M7.XQOS)V:M%'\IF@_ ?_ (*=_LII_P $RM0\ _L,^+?VP/$7_!.#Q+_P4A_9
MIT_15_:1_9Q^$8^(?[./Q#?X8>&?V4?B_:>,_%WC#5)([34?A7I%CX<OO#FJ
M^$=*\90^)?!'B6;Q%H?ABP;P[)XF_>/]EOXT?M6?'_X0?$O4/VI?V(M:_8C\
M>VEUK7ACPE\.=6^/WPI^/\WC70[GPPTMGXHMO%'PS33]%T-GU*>729]%U<1W
M,,L'VLW+6$J3CZUU?Q9X%T'Q#X1\-ZQKF@:-XG\?SZQ:>"M$OIK.RU;Q;?\
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M;H<NHD%],@N[4R3K\6?#?X._\%1/VE/$G[!O[-_[67[''PV_9K^"?[ ?QO\
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M/YX1T?X>>(OV??\ @HWXE\4?L^?LT_M+?M(Z%^UU^U9I7[7WAO\ :.^+VE?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_2.#]A'_ ,1*^ O_ ,P='/@N^,_\$X;_ .2"V([4?_ Z_P#D?7H^+OPHP/\
MBY_P\_#QKX;Q^'_$SH_X6[\)_P#HI_P\_P#"U\-__+.OD+_AU%_P2^_Z1P?L
M(_\ B)7P%_\ F#H_X=1?\$OO^D<'["/_ (B5\!?_ )@Z.?!=\9_X)PW_ ,D%
ML1VH_P#@=?\ R/KW_A;OPG_Z*?\ #S_PM?#?_P LZ/\ A;OPG_Z*?\/.?^IU
M\-__ "SKY"_X=1?\$OO^D<'["/\ XB5\!?\ Y@Z/^'47_!+[_I'!^PC_ .(E
M? 7_ .8.CGP7?&?^"<-_\D.V([4?_ Z_^1]>_P#"W?A/_P!%/^'G_A:^&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;_P\7B__ .2J/^%#Z7_T4;X[?^'B\7__ "71R8;_ *"JW_A!B?\ YM#FK_\
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MQG/Y\?3O_D5^5W_!-&T73?&7_!1C2DGN[Q-)_;X^)EC'?:G<S:AJ]['%X/\
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MV_TV F],@LE$T.Z_\NW-XWV%/,W7@2T#73-;"3;;(\[8B1G7YB_:-_:=T/\
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M:6+K[#]L@%\MHVH&R\R+[:VG";[.;]++S/M)L3<8A^V>5]G,S+$)#(P6H?\
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M ]!^7YTM% 679?<O\ANT?7Z@?X<GZU!-]U\9Z#\#N4YR>F.<>G08XQ9JM/\
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M3E)R[V225]DN[;;>_G8I_?\ U_P^FW30****H"";_5-]3_,U^67_  3#Z_\
M!0'_ +2<?M;_ /J5Z?7ZFS?ZIOJ?YFORR_X)A]?^"@/_ &DX_:W_ /4KT^M*
M'\#,O\.!_P#5A5,Y_P 6A_BK_P#J,S]48_N+]*?3(_N+]*?6,?AC_A7Y(M;+
MT7Y(****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ22Y;1YJ<8Q<7>.EU%-R;?/SRE/7FESN3:M=U)3G+=6=Y3FWH[<S2TL?C?\
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M\(Z-X9ATWQ?XUT#P;7],(2 998T7<V]L*O$F2=Y[F0DG+XW$<$D 4X&)00,
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M.+_OI?\ &C='_P \XO\ OI?\:GZQ#_GQEO\ X)G_ /+ Y7_S]J_^#8'YF?\
M"=_\%B?^C6/^":/_ (GC^TW_ /2\J/\ A._^"Q/_ $:Q_P $T?\ Q/']IO\
M^EY5^F>Z/_GG%_WTO^-&Z/\ YYQ?]]+_ (T?6(?\^,M_\$S_ /E@<K_Y^U?_
M  ; _,S_ (3O_@L3_P!&L?\ !-'_ ,3Q_:;_ /I>5'_"=_\ !8G_ *-8_P""
M:/\ XGC^TW_]+RK],]T?_/.+_OI?\:-T?_/.+_OI?\:/K$/^?&6_^"9__+ Y
M7_S]J_\ @V!^9G_"=_\ !8G_ *-8_P"":/\ XGC^TW_]+RH_X3O_ (+$_P#1
MK'_!-'_Q/']IO_Z7E7Z9[H_^><7_ 'TO^-&Z/_GG%_WTO^-'UB'_ #XRW_P3
M/_Y8'*_^?M7_ ,&P/S,_X3O_ (+$_P#1K'_!-'_Q/']IO_Z7E1_PG7_!8G_H
MUC_@FC_XGC^TW_\ 2\J_3/='_P \XO\ OI?\:-T?_/.+_OI?\:/K$/\ H'RW
M_P $3_\ E@^5_P#/VK\JL#\S/^$Z_P""Q/\ T:Q_P31_\3Q_:;_^EY4O_"<_
M\%B_^C5_^":7_B>'[3G_ -+RK],MT?\ SSB_[Z7_ !HW1_\ /.+_ +Z7_&E]
M8@ML/EB_[@3_ /EH<K_Y^U?_  ; _,S_ (3O_@L3_P!&L?\ !-'_ ,3Q_:;_
M /I>5'_"=_\ !8G_ *-8_P"":/\ XGC^TW_]+RK],]T?_/.+_OI?\:-T?_/.
M+_OI?\:?UB'_ $#Y;_X)G_\ +!<K_P"?M7_P; _,S_A._P#@L3_T:Q_P31_\
M3Q_:;_\ I>5'_"=_\%B?^C6/^":/_B>/[3?_ -+RK],]T?\ SSB_[Z7_ !HW
M1_\ /.+_ +Z7_&E]8I_] ^6=OX$__E@<K_Y^U?\ P; _,S_A._\ @L3_ -&L
M?\$T?_$\?VF__I>5'_"=_P#!8G_HUC_@FC_XGC^TW_\ 2\J_3/='_P \XO\
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M)H_^)X_M-_\ TO*OTSW1_P#/.+_OI?\ &C='_P \XO\ OI?\:/K$/^?&6_\
M@F?_ ,L#E?\ S]J_^#8'YEMXZ_X+%E3M_98_X)H@XXS^WA^TZPSCN%_X)Y!C
MSS@<X!'O7:?\$]/@3\;O@CX)^/M]^T):_"?2?B%\=/VJOC3^T#/H'P8\=>,O
MB1X+\-:=\3]5LM3LM A\7^./A=\(-;UF[TX02PW-ZO@FQLK@>7-:R,KM'']_
M&2- 6.P*#R/0[LC!!]>X_A&.3UFAD256* <-M)'9L'+ \]CC///'M2=>4HSA
M"&&HJHZ7-+#T91@U3J>T:<G.7+-NUME;XDU9"=-<T9.<YN%W'FGS)-JVJ2LW
MM;MNG=EA3E5/JH/Z4M%%,L**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGXD?\D_\
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MHEUH_@F\FU+Q#JV@Z39Z7H6O:A9>(M<GEU6UF&C:1J*V!N-0-K:S?@3\0O\
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MINO_  Z^$_PUF^(2V>O6_AUY[WPI\2;UWTC3==\"ZU;6M]H,6J3W<LCOIUU
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MPU9^$M;U76O#>FW5_=WVBS:!XZTWP]XB@N]*FN8[2ZL;B"8>PQ_ZR7U^7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=ELKONPMU>N[UUU=M?71:[NRNW96JK96BC:MI;*O7Y88P.&#*,!1]T@,.P8
MCD TYK6W)8FV@;<VY@8H^7)!9SE>6)2/+').Q/[HJQ11973MJKV?572BVNS<
M4HNUKI).Z22$DMDETT2VNW;;:[;MW;>[=XQ%&-N(T&T[E 11@X(R..#[C!X'
M.,Y>  20.3C)^G3^9/U)I:*$DM%HNW;R79>7J,@F_P!4WU/\S7Y9?\$P^O\
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M\)?ASXL?29_"/@2.WU4^&?%_B[1]<33;MTE2ROY+!;6\,4WV6:;R9-GW</\
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M*T4\%_;SQ7^F6$J_.?\ P]*_X)D?])&/V$?_ !+O]G[_ .>%1_P]*_X)D?\
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M_P F?=U%?"/_  ]*_P""9'_21C]A'_Q+O]G[_P">%1_P]*_X)D?])&/V$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_X4)\"O^B*_"/\ \-KX,_\ E+111[:M_P _:O\ X-J__+ Y(?R0_P# (_\
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M (;;P9_\I:**/;U_^?U;_P '5?\ Y:')#^2'_@$?_D0_X4+\"_\ HBOPC_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
.HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>forms-3_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #\ <4# 2(  A$! Q$!_\0
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MD]23^-&3ZG\Z ))%DA($@=21D#-1Y!]3^-!)/4D_4TE "Y'H?SHR/0_G244
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MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(W;ZTM(W0?6@":W7=<1JRNZD\JG
MWC]*GMHPR,3!,^&ZHV,>WUJ&W.+B,LS@9ZQ_>'TJ2 J$;=).IW<!!P?K[TP+
M!B4;_P#0[K..,OT^M5K2/>2#%+(<C_5G%22-^Z)CENC)Z,.*CM2N\[Y)4&>L
M0S0P'WB*JJ4@FB)/)D;.:KQC(<%225^7;VJ2XQ\NTS'D_P"L%1)U))8#'5:3
M&E=BF&502RD#UQ3?F/K4KLFP@22$^AJ++#I214TD]">5!(%\B*48'S;FR#]*
MK\U;46ZJ/,EN%)'9:J<TR7;H1M]XT4-]XT4")(]WF?+C.3BICYV?NKG\*CA5
M6=MW SUJ;RX?[[8^E)LWIQ;C<AD#C <"FC.>.M3/''QM)/UH$<9!R<>E%Q.F
M[D39Q\V*T6.H! 3%%MP,?*O2J12/(Y)'>K!BL\$K<2$CID47)<&A]ZET$#W"
M(JMTVXZ_A5;38DFOX(Y%W(SX(]:?.(!&#%*[,>H8=*@M)S;7$<R@,R'(![TF
MFT[&>(3<&H[V.J_L73_^?9?S-']C:?\ \^R_F:R_^$FG_P"?>+\S1_PDT_\
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M.> 3Q5! 3P.M4C"IT$P?6C!]:<R[?IVI1&Q7/&/K00,P?6C!]:>T;(N3TIM
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M#@#GK0)6&/0-G';- #&W$DMG/<FEC+HVY"RMV(IS3LW4#KGBGK=2* !@ >U
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M[%1$8YF;H(R"?RI\EHZN$6> OP&!(&TFEJ%BF#SVH+<]JM_97?'V:1)L':P
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M]/UHV-Z?K2AU'_+,'FG+(F#E .<].E QNQL#C]:38WI^M2/(A4 (,YJ+/L*
M%V/Z?K2A&ST_6FY]A0#ST% A=C>GZT;']/UI,^PHS["@8NQ_3]:4HW'';UIN
M?84I/3@4 &Q_3]:-C^GZTF?849]A0 X(W/'ZTFQO3]:0'KP.E&?84 +L?T_6
MC8_I^M)GV%&?84 .*/GI^M)L?T_6@GGH*3/L* %V-Z?K2[&P>/UIN<=A0#QT
M% "[']/UHV/Z?K29]A1GV% "A'ST_6@H^>GZTF?84I//04 &Q_3]:-C>GZTF
M?849]A0 [8V.GZT@1QTX/UI,\=!UHS["@0X!QN_VNO/6@(V1Q^M-S["E!Y'
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M2[%&3_6-]:*)/]8WUHJPO<L6F/,?YMHSUJV53_GXS6?'PY^7=R>/6I692?\
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MU-*'(/))IO2B@!=QQU-&YO4TE% A=S>II2Y.,$CCUIM% QVYO4T;F_O&FT4
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>=L_WCFJ>: _>=T4I/]8WUHHD_P!8WUHJS)WOJ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>forms-3_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $% 8D# 2(  A$! Q$!_\0
M'@   0,% 0$               0%!P$" P8("0K_Q !D$  ! P,!! 0(!P@)
M#PD)   !  (#! 41!@<2(3$305%A" D4(C)Q@9$5(T)TH;&S,S92<G:2P=$6
M.$-38H*3PM(7)#1497.#A**CLK3#T^$E)BA$8V1UA908&2<U1F:5I/'_Q  <
M 0$  04! 0               0(%!@<(! /_Q  _$0 "  0!"00&!PD! 0
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M)"T=1*Q+%;?_ )':^SR=GU+*@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A"
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MX +1;7!IROU5!>:..Z^4U=1TNZZ!S(>DW-PN<'#(]'//J3M-J+5C0##I5KW
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MN!/XY*J1>7-X^>_^2_XJGEK?PW_R06(%Y%RH.92(5K>/GO\ Y,(-<P<Y)/S
M@L+E0<0D/ES/WR7\P*OES?PY?Y,(+"W"TJ325Y?KDW<W,/M_3LD; 7N:8XQ'
MNE@:.#N.3Q_"[EM'EK?PYOS&JGES <[\I[BT<4)0SG^ROSDQ73F[/)/-1*(I
M>D.]NC/(<5K5TK&>=Y\I_BA"3RA\/JX4=7X9UHCI8A'-2FU053@P-WY1(#G/
M7YI:,]R]KNMWK*\-O#:<'^&U*1G'PA:_2Y_N:]R?E.]90I*81U(P@\ 4((7V
MDP_#5\NEDHH*&T.K9H8I+Q4R/Z::H^+<(H]QKBUIC#=[. <GO*34=TM=HU/)
M-4O?;:V:XQQ1T4(D<V$[DL8CG<6[O1E[FY;&2W.,< HGVX[?W:+VDZII)[)I
M&BMMMND-+%=M3:MGMTE162443ST4;(7[NY&68(/ Y/,E;7IO:MJ7:#8(J:Z4
MMHL54R^U=%64-1=9ZF"6H@J&"/H*D,!W2YS'!FZ!@$< A47-T]?I&:JO=NKJ
M6S4,,SVU<5+*]S6S,>6N8W? (=C#P1PPX '@GRSZ2FIM-W.U4531RV^2D?<'
MW6*:03RN=$X,^*D;N$EAX\'!O$^EA+FSQVZRUUANUCI)9V5XN3V5;Y*;RH],
M#+52- ?B!A/ Y.]N@8 3!K&TROJ:IYHJR_24]D,EMK+4)Z6!S7$C+8V.(C8U
MAPX DO.. RK/3X324T]U,N%YS\]&G79>%_&Q<YV(U$^2I$R)9JYNVJ^^PHNF
MF;GJC2S;K146[65DT$M:?A4PM9&)&L,;&'@1N1;Q+VY.\ TGJF[1=8:[3E-)
MT38J<.?'3 2ND+H&N+8G$N\[>+0"0>()P5S_ '2.ST%ZH'V*1MTJZZ3=K(WB
M>YEX9T9C>87[K6O:_>#1GS0.!X84\;.'U,^B[755CX)*NLC-7*ZGIO)V%TA+
MSYF3QX\2>)/'AE7A%L9L855:T*Y"DX,\<A^UPTU^4]/]C*N&MF7WF6;YN/K*
M[D\<AP\'#39_^YZ?[*5<-[,FXT99NWR=OUE9;DYVF+@:_P M.PP<>A(]L] )
MS39;/0"<UMN5LG/<W:9QTA"%SN=C@A"$ (0A "$(0 A"$ (0A "$(0 I4\';
M[Y[K\Q'VC5%:E/P=^&I[K\Q'VC5?<#[QE<3%<J>YJGAU1/2J%1 X+>9RH5'%
M<[[9FXVE5X[:&F/^D%T1R7/NVQF[M#G=^%;Z?_2>L>QK1)@?M+Y,V#D2_P#T
M8U[#^:-'' *HXJT=G4J@+&[FZ+%5[3>!"#-X*6S,>:"+6[)<<# FD7BRO:+P
M%HFUG@G[.87YW9+9+$<<\&:0'ZU8<7TRH>)<J'1'%P)X%#*> W"2,@!W,=J/
M()QS#0.]V%K\>RFUQN:YM7<0X#!<VH.7#JR<=P65FS2CCIYXC<+D_I-SSWSD
MN:6\B/U+$B]#Y\'U'X+?>J"@GX\&^QR;[-HT6:Y15;+G6SA@<#%-)EKLCL]?
M%;&,CO0BXV?!\_8/SD"@G'R1^>G/)[$9/8@N-?D,XY-'YRM-%/CT![PG89ZU
M1WHE!<UBNH9PT_%_Y06IW2CF\X;F<]X4@W#T2M0N?I%"3R'\.^QR67PS+9/+
M(U_PE+:ZMK6@Y8.D:S![3YN<]Z]N_E.]:\7?&*_MQ-''_NMJ_P!8*]G*FJBI
M,F9^X'.P#@G)]B%)F5#R*1_#5%^_C\QWZD?#5%^_C\QWZD(.)_"0\%;4^UC:
M'JHUVSV75.G*J\4]YMU9;]5PVN5KVT45.]DC'Q/)&8\@Y'-2ML@V2:KLUO9=
M]1Z;IZ2ZS:AN-:;-%=Q(VGIZES0'.E#=V7#&G+< DD'(QA= ?#=#Q'3C\QWZ
ME47BBY^4 #\5WZDL3J(:OVR34M-5W[]C;8J&@\KIZJV4L=QDBC,@<WI9'M^2
MX-;PP>>>'%9-%:(UMIJV6^2X6BW7&JML_24T4%Q<R1Y#)&-,DK]X.8UC]T,Q
MPR#G@I8N.K;/:(&S5M?'31..Z'R @9X=W>/>E4EXHH9'L=4-#FG!&'</H4V9
M-R/7:9U;'1SV&VM@M%!%5>5TMUCJRZ;<WP]T#VC!.\XO&]D #'!2!8J04ELB
M;Y&RWR29GEIXW[[62O)<_P [K\XGB@7V@_MEOYKOU*AOUO'_ %IOYKOU)8@<
M$)O_ &06_P#MIOYKOU*G[(;=_;3?S7?J2Q!PWXY$_P#1OTW^4]/]C,N']FOW
MG6;YLU=O^.0_:W::/5^R>G^QE7#^S7[SK-\V;^E99DUVB/AU-?Y:]B@][H2+
M;/0"<TV6ST G-;;E;)SW-VF<=(0A<[G8X(0A "$(0 A"$ (0A "$(0 A"$ *
M4_!XXZHNOS$?:-46*4_!XX:HNOS$?:-5]P/O&5Q,5RI[FJ>'5$]*HZU15'!;
MS.5 '+V* -N QKXG^YT/^F]3_CFH"VY#&O6=]LB^T<L>QOL\+]I&?9%=YOW7
MT-!0C'4JAI*Q5,W=8  O9;P&'EW@B:"+3Q%!5 $=T\B\: .T%>S/B_79\%#9
M_P >4-4,_P",2*R8J[REQ_,]]%MO@2W65TS'U1H::SU$36.=!FM='(]VZ=T$
M'@#G&3GD5L>FJCI:1Q/1L<=QSXXY>D8QY8"YK79X@.RB@=T&]Y5<HJMO4'1-
M9CN2^.>DQADD '8TA8J7D4[P[1[T \^(]ZPAT!Y&,^T*XLC+'8#"?6A%C(@<
M0F)U1?&2NW;13/AZG-JL$^S"=X(G/;F2)T3L\@\D<D(,^%:?1*MZ$=KQ_&*H
MZ+@?/<!ZT)0@N/!I6GW3F[N3_J&YQVIK>D%5+O\ !O01=)CUXY+1KGJBC$;I
M7&K9'G=)?3'@4*CR[\8L/^F'H[YK:O\ 6"O:+DY_'K7BQXP^<3>&!HXM<7CR
M:U DC&#Y0>"]I_E.]:%( D=:,]Z$GKZQEOHJBJEWC%!&9';HR2!SP@0VZCU?
M;-*1PR7&H,73$B-K&%[G8&7$ =0'$GJ"S.U1:V4PJ'W"!D+A'AY?P._DL_.Q
MP4?ZSK;#K.2VS,N\MIKHB8&/EI'..)B&%I:>1SC![0>I+HZS0])9*>W5%6'P
M4<D5*#('->9(B0W/;Q)X]>5;I4=2ZF.&9"O1V5GX^'ZGLC@D*3!% WG^*Y_H
M;9%5V34F,.I+@(\;O2,#@TNY8WAS..2J-8V-K78NU)NLX$B0'&"1];2/8M;9
MJ?1-"'@U'Q?2AQ9)&]S&2LZ^YW#Z0F^.700AJ*BE8^I9'Y\DL(>0.DE.<YZM
MYV2.0X*XI^!XTK&\2:LM$49>^YT[& N!+GXXM +O<"/>G1C]YH<#D$9"CV6V
M:-=9F!L5346W+W,W'/+,M !QD]XX=>#V+:;;J:WU5P-L@Z431-QAS,  #.,]
MN.H\>" >LGV(R<J@XH]J$'!GCDOVM^F_RGI_L9EP[LU^\VS?-6KN+QR/[6_3
M?Y3T_P!C,N'=FOWG6;YJU9=DUVB/AU-?Y:]B@][H2+;>#![$YILMHRP)S6VI
M>R<]S=IG'2$(7.YV."$(0 A"$ (0A "$(0 A"$ (0A "E/P>?OHNGS+_ &C5
M%BE/P=^.J+K\Q'VC5?<#[QE<3%<J>YJGAU1/2$(6\SE0J.:@/;L,:\ISVVMG
MVKE/C1G*@;;O]_%%WVT?1*5CV-K[,O>1GF1>C%/_ )B^1'H.%<'JU"P].QO,
MO:]>R7B^'[W@H:#X< VL'_[$B\:@O8WQ=C^D\%#1([)*YO'YP]6?$W_"7$]M
M'MO@=+MF@+0"T>Y!%(\<6-/K:L?D4F.&Z?:J>22\?-!]JQ@O)D\FHG9\R,?Q
M58^AHRTEC&[W<K#3R#]S*H8GM^20@%'P7!\D$>HE'P8P>B^5OJ>4FWG-^4\>
MTH$SQG#W(184B@<WE43#^/E6NHY@/[+D^A8VU,@_="CRN4 C>!]806$%?%5M
M<0*HDD')+1QXK4[FVMWC\>P^MBVFX54CFY)&1U@+4[E52 GCE"3RH\8B)1X8
M.C>E(+_);5DM&!_9!7M/\IWK7BQXQ"1TGA?Z,<[GY-:_]8*]I_E.]:%(+#52
MM@I9Y'L,C&-)+ ,[W<LR17<AMKK'$@ 1'.]R 0@0.,D[V2R:<WY&G(<Y\1<#
MG/OR$EHK+2T3-V+2[!YYDR]T;R'$DDY<3UICU3:;Y6W9]?9+U3Q->V)C#Y66
MEC.3F[O%A!]/>P7=06&DT[JU]MKHKCJ^&LFGIY808@V%C7.]![=T9:0>'-?;
M,AM>Y&<;4:6+<+#IIFX7%V[\5C)YG';R5S*>-G2!FFP-\8< (?.&<\?:M+MV
MEM9VZF,8U5'.2P8)G& 1CEO-)Y=?:<I;4Z9U156BLICJF(5,KXW1RL=NB(!Q
MW]W''B#UYXA3F+>AG>1L\D8DI/)GZ=WZ=O*$F+<''/ 9X(MS:6GN#6? K;=-
M(U[FR[L?G=;@2WCW]^%HCM*Z^Z2.0:KHV2P%K6.!+@> Z3(/ DGB-[.,^Q;G
M9H:JD;9::NK/+JZ-LW2REP<7\#QX 8ZOJ410J%:PG<V/CVJJH.7<JKXDG!?C
MD?VM^F_RGI_L9EP]LT^\ZS?-FKN'QR/[6_3?Y3T_V,RX=V:_>=9OFK5EV37:
M(^'4U_EKV*#WNA(MM] )S39;/0"<UMJ5LG/<W:9QTA"%SN=C@A"$ (0A "$(
M0 A"$ (0A "$(0 I3\'C[Z+I\R'VC5%BE/P>?OHNGS(?:-5]P/O&5Q,5RI[F
MJ>'5$]*H5%4=RWF<J WD5 ^WEN-:V\_W-/VJGD#MX* _"#JX*36-J=/*(P^W
M.:"X=?2K'<>B4-)=^#7S,[R+TXLDONQ?(C_.<H6!EPI)?0J8CW;P"SL+9.+7
M!WJ.5A"F0O4S?.:_% O87Q<,N_X*6D_X-5<&_P"?<O'K=([5Z^>+6?GP5].#
MJ9<;@/\ .G]:MF).\I<3U4FVSJ1E7+CCND>I7"N<.;&^]96LIG@>B3U\57R2
M%W+..XK&R[:S&*_MC]Q5XKF$'(>$>0,).'.'TJPT P<2>\(-!D%9$1S=[0J^
M40.SDM]H6 4+P/2:5::.4=0/J*"XJQ3N_>S[E1U/"X.\UOL*1FFD'.,E8WQ.
M#3\6X>Q 8[A1Q8.&D'UK4;G1LWCQ(3_7.+0>+A[5JMQF>"X;[O>A)Y7>,4B$
M7A@:,:"3_6MK/'YP5[/U54RE.7-D=O.Q\7&7GZ%XN^,0<7^%_HLDY/DUK_U@
MKVH)PYWK0I$7PK#CT*G_ -._]2H;K3G(+*C'(@TS_P!27 GJSE-3-4VB0N:;
ME!&X.+-V5X8<@D'@>K(/%2$KF%WP(/2MS/\ \>?Z*L+["/\ J$8/_AY_H)13
M:LM-5(QD=R@WWL$C Y^[EIY$9Y\0?I5E7K*S4)C$]TIHQ+O;AW\M.Z<.XC(&
M#S"7%AON-WTK::=D]9%2TT4CBT.DH\9((!."WM(X]ZSSU6G*>5\<M' '-."!
M;W.'O#,%+9;U9*F2)LM;0S/<0(Q)(QW$\L>M5J-4VFCIG3/N,)AC>(G.C.^&
M..0 0W)'(\^Q3=6&D;6UNF'<11P _P#AS_Z"44ERL5(\OIHHZ=Y&"Z*C>PD>
ML,2YFH;<^ S-N-.Z(%K2\2@@%QPWWG@%;#JBTSN<UETI7%N<_'M&,$CGGM!'
ML2XL U%;\?=W>V*3^B@:AM_]L8/][?\ J2VFKH:QKC3U$<X:<$Q2!V#WX67?
M=V_2J= ."O'(_M;M-_E/3_8RKA[9K]YMF^:M7<7CDOVM^F_RGI_L9EP[LV^]
M"S?-6K+LFNTQ\.IK[+7L4'O="1;;P8$YILMGH!.:VU*V3GN;M,XZ0C*IO#J(
M/J7.YV.50KF1OD]!CG_BM)2J*S7";[G0U+_5$[]2 1H3O%I"]S8W;94#/X3=
MWZTKBV?7V0_V&UGX\K0@-=0MMBV8WE^-YU-'ZY2?J"5Q;*:QWW2OIF?BM<4!
MH_-"D*'9.W/QUS)'8R']92MFRJWM'GUM4X]VZ$!&6.&>I"E$;,+6TGXR9P[7
MN_4KCH&VTS012&;CU'/UH"*\A (/6I5=IVWTD8D-J#6G@"0%2(T$9;N4<4;#
MRDW<M]X" BYD;Y#AC'//\%I*E#8&\6[45TEJSY+&:( /F\P$[[3CBLLE7%"7
M!C:8@8PYIX'VG"RQ5C)&LZ1XBX\<0AX'/KS^A>VBJ71SX:A*^:6O$Z*'$:29
M21.RB5KDO2ZHM$!PZXT^?X+M[ZDG.M+,"0*S?_%C=]:B!MV$<KPZ0O9QP(QN
MN]?)6LJJFJB?(PR;K!O.<'M Q[3]2RR+*VK>S!"N?YFOY?[/<.ATQS8GR_(F
M ZSMG4Z60#L;_P 5$VW32\VT6>T5EE=''5T;9(I(ZIVZU[''(P1GCE)*6=]4
M]S3(UH WLR![O9AN5?;YYR[H:=Q=*X\,O8P=?$%_)6BLQVKKI3D3;9K\C(<,
MR4P["ZB&II\[/5];WD45>R_5=(<FTMJ!VTU0QQ]QPF2NLMWM#]VKM%PI3SST
M#B/>W(70=!?Q 'LK'2S/:=TB,A[LYZL#!]Z<H;_2.,F^:BG#>+G3M:SAZB02
ML>3:,SUZSE^*^&!Y:*V2%PX$.+FX]ZE[99X8.UK9#:(K3H[7U5;;5'(Z5E!N
M030ASCEQW7M/$E2 Z6S7+S'OI:MQYA\!<#[=TINK=FVEZS[M9;<XN&<L#6''
ML(4YS:M<A)+4C=K'XU3;U:RWRRMT]?&-QEM;: S>_C1N'U*1+#XXO6T! O.S
MK3UP9\IU#634[O9G> 7-M5L)TU)GHZ&KI#SS3SOQ^D)FJ=@=#O$4][KX'8R&
MRADGUX5))WE8?')Z9F+6WG9M>Z)N?.?07**?'J:X#/O4CV/QM.Q&XAHK'ZHL
M[CS\JM?2M;[6//U+RQJ-A%WCWC2WRFGQP GIW-^K*:*C9'JVER6P4-6WJZ*H
M+2?80@/:RR>,/V 7EC>CVG6RE<X [EPIIZ<CU[S,?2I-L/A#[-M2L:ZU[0=*
M7#>Q@07F#>/L+@5\^%5HO5%)DSZ<JRT?*@W9/J3+54LE+GRVUU5,!USTI ]Y
M" ^F&BO%/<&"2EDAJHSR?3S-D!]H)2QT@RYN?.&,@<QGDOF9M>KJBU$.M]ZK
M+<YO+R:KEAW?5ND+?K)X26T^S'_D[:3J2/ #<?"KY.'4,/)Y(18^A:XENZ<_
MY2TZZ,8XN\UN1S!"\6[%X?6WJPAH9K^IK6M^37TT4P/T!;I8_&B;8+8^/X1I
MM/WR-HQN3TKX<^LM<A(Y>,5:T>&%HT, QY+:N7S@KVD^4[UKY]]L6W&O\(3;
M+HG5]RM5+9JI\U%1FFHY'R1XCJ<!P+N/'/)?01\IWK*%)@EG>R4,8UKLC>\]
MV ..$PU.F+.^>>6>VT+YJD^>Z2;C(?:G&]V:&]0FFJH/**9P!<P/W<D'(6OS
M;,K1*=_R:H;,/N<AJ23&>T! A;/I^SS4S&2T%"Z&D8&@FH^YM&<9/9YV>/:D
M\FF-.U-#11OH+?)20EXI_P"N<M!<07;ISQ))5O\ 4ULQCZ'R&<1;V_T8J.&\
M>!)'7U<^Y$>SBS->]YH9W;S2W<=.-WCC.&\@> X\^]"4*8=)6.&IA>+;2B9O
M&,NJ"2,<. )ZL#W+/'IRV4PK'"@B8V9X,^:CAD'('=SSCO39#LVL]/$Z*.CJ
MV,):[ J>(<W."'<P>)]?7E9F:"MS)GS]!6&=QR9'S!Q)P1Q!X?\ ][D%S*=%
M6.:"=CK7 ^&4MZ1O3DM)!)!]8R2%@;L\L38)&FTL?%)@N+JC>R=[(.3UY X]
MR3LV96J.G9"UER;$P[P8VI &<C!..>,=?>$.V;4,L3&25%T( <"&SAK'9!'H
M]760.H\D)0^6*Q46G&U$=!2"$3'?>WRC>R0,9&>X_4GJ*3I8VOQ@. .%J-!H
M*BH+@*QGESI(W[\(<\'H^[.<G/7D^Q;93M+(&-<-TAH!'8A2<(>.0&?!MTZ>
MS4U/]E*N'=FWWGV?YLU=Q>.._:V:>_*>G^RE7#NS;[SK-\V:LNR:[3'PZFOL
MM>Q0>]T)$MGH!.:;+;Z 3FMM2MDY[F[3.;;/7T5'#&UUIH:L!HRYS<O/>3E;
M)0ZIL[0 ZV"E/;'$UP_6H3;/+&<LD<P]QPE<%^KH.'3;X['C*YW.QM)/E+J"
MTU'"*LB8?P7#</TIR:>D;O,>'M/6UV1]"Y\BU.XGXZ '//HSCZ"G*AU5#&X&
M*HEIG]N2$!.!&#CD@ X)P<>U1C0:XN+ !'7-J6CY,F')?'K!DLA=64(E)X'H
MY7-'NSA"3?2YK,EQ _&("PR7"EC].IA;ZY M<I-26"0Y?3^3N_[6(N'OXI\I
M:^V21[\$U-NY ):6C!0%_P +4AY3!_XC2[Z@JMN4<F=R*H?ZH2/KPE3'AS?-
M<'#M:4 ]_'O0"5M;,XX%#/CM<6M_2J&>L)(921M[-^<?H"5A5Y(!(!7/;G^M
MF$\_2=A7,CK0P@UC& \"(XL9'M*49[T9" 0FU-$;HXVTY:>)$T ?D]N<Y"1M
ML+61.CDIXJD.=O%[9>C?Z@2"GK/>@<.OZ4!K\EN?1S'R6&MAA(XCI<GV.;Q^
MA-K*(4SG.D$$KLG=;51' _.QE;ED(SD8/+LZD!IM/32LD!\YT1])M-*8\CLZ
MU9&9*:J=*RF$9;Z(F:*@#WC]"VZ2@II3E\$9/;NX/T+"ZT4YXM=+&>K=>2![
M#E"#4Y&QTM0'-F,W$.)9$8!VD#"OKH7NB;6GH8FRN(:SRMLKSZVDY6POLF<[
MM0#W21_I"2S6&0\XH)>PAQ:?<0I VUDIJC$^D=4RB.(-E>VC;$QGM8?K6%D<
M4%(V=GDL<P?@E\SC(1U8:1@A+Y+?5PL>QC*F)K_3W)'8/L:>/M5]MM]/2539
MY+E2Y8<MCK*9V<]GGC!4!"*DJ:RI,K635S\#?:RE8 W/(G/#"61ZDN._' V>
M*DW1NN\K+B,]IWL\?4DE51U-1<9! V.9[CG%!'N@M[L<%3X)GHX97>034[FD
M$.J)0UPY\@[TL]R$CE3ZM?!*\538:YX/*!@&?40!]*64FH.DF'E=$V@@>W>;
M))(\\.H8:"M:FJ9;A,75-2T2'#-PP\?7YH&>"QN\G?&Z&"#RE[7DLE+GL)'8
M >2 V<:IM1+F.=4,<#^ ' >W@G'RFD,3725;(MYN]B9I:0._!(6HTHK:-L^7
MFGA#1TC6MC>2#RQGC[@FV0P!V.-1N$$M>W=]Y" W@:>M-_A?O,M-<6\XWOB+
MCZMX E-]PV%VBLI34/TM'T)..EIVD 'L\QQ30ZNFW<T;8J".08DCCJ"03VG>
M[>Y)J22-LF\:RJ-0XY(C'H^HAR 27'8588P>CCK[?^+,YH'L<%KM9L3C;GR6
M]U+.P31M?](4@TNT'4E%*X6^[3TSW#H\R2;OF]GG$C"QSZYN3#(^X/HJ]YP
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(YS/FX(=Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>forms-3_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "K 6\# 2(  A$! Q$!_\0
M'0   00# 0$               $%!@<"! @#"?_$ %L0  $"!0(" P8/"0H.
M P    $" P $!081!R$2,1-!LR(W46%ULA05%B,G,C4V<7)S=(&QM @7)"4F
M,T)VTC1%56-E@Y&AP<)&4E-45F2"DI.4HJ/1X4-$8O_$ !8! 0$!
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M0 &\.-MS+4Y0I%;*N-LLH&X(W W&\!K6I=C%T,SJF9:9E'9.8,L^S-(X5H6
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MB?GZ9+34XQ@-O.(RH8.1_0=_%&=-M*E4MYEZ6DFT/L-J9;>4,K2A2N)203N
M3OB(K>&L<A9]<F::](3,RB39EWYM]LI :0\YT:" =U;XSB-6X==Z-;MYFW5R
MTPZXVEA4Q-#"6F>F)#>_7 )<:<:[V5C^#*@/,BS4C BGINZ*=7M?;3:DG7'%
MR].GPL*96@#= V*@,_1%P)SUP&4$$$ 0000&!YF.3:7[KW:.KU15+[0J.M#R
MCDJFC%7NP<_RAJ7;JC,6>''Q\_###>^]"3\\E>V3#^,[@;[F&"]Q^(DC_7)7
MMDQJH[!0/JC*,4QE&8$,57JD_>BZ_2Y>V43[<LI +TVQT:F&CQC/$D]TH\((
MQRWBU"(3AC0H!O[[C3\Z%+FIJ6<>"GGN%MIQIKI""B73D@G@WS#Q7IK4!C1V
MJB;DI*;G%2<[TYGG^C=2SPJZ,D(!!7P\_'%S\ $1S4D8T\NCR9,]FJ ;M$>\
M_97D:4[),:E\=\_3KY:>^SQMZ(]Y^RO(TIV28U+Y[YVG/R\]]G,!/^ *&^\(
M$ =0C(<H6 @>F7NK>WEE?9HB>1 M,?=6]_+*^S1$\'* 6""" (((( @@@@$)
MP(U9JJR<DMIN9FF)=;IX6TNNI25GP $[F-E0RDXBIM5=!V=3J[+U%RK.2(:E
M4RO1H02$A+R7>).%#<E(&%!0\4 NM))N_2W Y7$GL5Q8ESG\F:O\T=\PQ3VJ
MUIR].U&TQJ29VINO.7" 67Y]UQA/K"]TM%7 GZ!X8N&Y\)MFK^#T([YAB=#5
MIBG.GUN\_P!PM<OBQNTFTF:16JE4T3LX^]/\'3-O+26^Y'"G "1C C4TO[WU
MN_,6OJB4Q1 =0!B\; \HN]@J)XCVL0/4'WYV#Y1>[!43P>UV@,H((( @@@@"
M""" (3J,+"=1@&BHVK2*K.LSL[396;G&,=$\\T%*1C<8./#OXHU6;"M]E<NM
M-(DRXP26UK:!4DY)SD^,D[YQ$7O36>4LVX7:8Y3G9L2S<N]-.I=0@H0\YT:.
MC0=W3G<@<H2Y=9Y:W;LE*0Y3U*D7 UTM54^D,MK<44I0$C*B<CP0&-R=_>R0
M<D>EM0Y_[$68!C,4X_=4G<&OEJ-2S4VA<O3Y]*S,2JVDG= V*N?*+3KE=D[<
MI$U4Z@\&).61TCKA!.!\ YP#C!$2&IE**0H,U$@@8_ '>OZ(\V-5*+,H4II%
M0<"5%"BF0=V4#@CES@)A"Q'*-?U)K=6-,86^B=Z(OAF8EUM%2 <<0XAOO$CY
MP&*HY-IQQ5[LSR]451S_ ,=4=9'KCDVF[5>[>H^J*H\OEU1F!PZO"<0PWOCT
MA3U#T9*]LF'Y/@VWZX8+V/XB22!M.2O;)C5'8*><91B.?T1E&8$) &2<0T5>
M[Z+09EF7J-4E))][=MM]X(4H9QG!ZL[9Y9AV4,C$0*_])F[^JLE,3=6?9D6$
M=&Y30RTMB8'$% N!2>(X(V&<#F!F-!\.H=M<,Z17:?\ @>/1'X2GUO)QOOX=
MOAC3O6JRM8TQN*;D)EJ<EG:7,E#S*PI*O6U<B(A0^YHHB5R"TU.=2NE9]*\(
M:Q*9<XSD</KFYQW><#ERS&S=>DM(H>E%=DQ,U%SH).=F2XW.N,=(XXE2U%2&
ME)21GD,8$!)=$>]!97D:4[),:E\]\[3KY:?^S&-O1$YT@LHG^!I3LDQIWQWS
MM.OEI_[,8"PH2 <H# 0/33W4O;RTOLT1/8@6F?NK>WEI?9HB>P!!!! $$$$
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M,Q#I?4^R&TK#-R4A S@]',(&_C\<.='ONWJ_.&4IE:D9Z9X2OH9=Y*E\(YG
M@'^"$'*%@$(R(;*E;5)K#S+T]39:<=9W;6^T%E.^>OJSOB'2$@*FUH&+OTL
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M5(ITS9M:#\M+(:<X4H(R!@_I0]??"J(_P,KG^XC]J \-0??G8'E![L%1.TD
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;;@8QB%Y0"<(\$)P)WVYQE! 8\"?!&4$$!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-3_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $B CP# 2(  A$! Q$!_\0
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MULD03]T<B@"Q1110 4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)NJN=4E"9\M/SJ:UOGG.&11]* +]%%% !1110 F>:*#0,T 'X48I":",C!H
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M/ I.E+U% %.;4;6)MLC\_2G&:VGASMW)]*>UM;NWS1*3ZXJ.\5(K<A!@>@H
MKPG3A)^[4;OI4&IR8Q\B%?\ =J&S91,><?6IM0)P,%6^E $UHW^CY 3Z;:I[
M]UWCRDZ]0*MVK V_;/O5,.1=]".?PH TI7M%C'VA0?\ @-+;R62C,*@?\!JO
M>L#$,D'Z4W37RV"O'TH N'4[0/M+_-]*L(ZRC<G2FFT@9MQB4GZ5(J*@PHQ0
M N:,#UHHQ0 N:#CO1VJM<7:VXRR,WTH L'I\M9-_:SLVX*"!4ZZM"5)V,*J7
M%^]T<1,4'O0!7W[P(PGS5HV-O/& 64 5GAPO0KO]:LV^H-&<2.2* -FBL]M8
MA!QM:K,-TDX^4$?6@"Q13<'UHW<XP: %HYHHH /K2$C&2301GUH/3 - %.YO
M8%4IN^:LP02&3S=@*>M6;O3Y3)YFY,4U+M OE'[W2@ EF2X3RXL[AV-+ PL^
M;A0![4P1O;MYDC+M/I2L!>G$)Y]Z -2"ZBN!F(Y_"IOK5.TMVMUP[*3[5<ZT
M )2TE+0 4&BB@!-P]Z7M32V!GTJE+JT43[3&Y_"@""]U":W?"L*M6%T]RF7(
MIT:07:[S$I^HIDMS;V/2,_\  10 M]<O;KE"!]:JV.HSSR8<C'TJQ#=07YP8
MC_P(5*Z06J[A$/PH LC/K250CUB%Y-@1P?I5Y6W+D4 .-%(#GM2T +124M !
M1124 %%(>E4YM3CMVVLCGZ4 7:*@M[I;D956'UJ>@!:*2EH **** .6\37DD
M"X\H8/J*Q=/BANF#2K&3GI6YXG8K$?FX]US7&VLT(N1\[AL^E 'IFFQK';@1
MHJCVJ2XMC,.)"IJGHCEK8?,6&*TS["@# N_"RZ@W^DS;A["F0>$DM!BUG*?A
MFNB /K2XH YMO!]N\GFM*QF_O8J:+PV5D#37!<#H,5O8HQ0!6%G 8MA0X KD
MO$%A;12@K%@YZUVQZ&N1\2_ZP?6@#7\.#%B .E:W'>LKP[_QXBM:@!/H*"?6
ME%!H 8[;%R%S5(ZG^\VM"V/4BKV![U'-;K,NTG% &?>^7*F4&#_LBHK%1SO+
M?\"%78]*CC;=N8_C3;JTMCCS)2GT- &=<J1/\I?'^R*N'9]E[YQZ<U/#;0+%
MA')'J35<6UL)\_:,M_=S0!6LU!E)?>1[U?EOX[< 1Q%C["I9;%9T SM'J*+>
MQ2V.02_UH ?;71G7)C*_6IZ,<>U)MYH <*#Q1VJG?7R6$9=U=\=@,T 6\^M,
MD,;C:66N.N/B/8I*8GL;L]LA#5.;QSHJG?):WP_X": .MFTP.^X3@>U4KF,0
ML%+,?H*Y5OB#I1;,=I>E1_LFC_A8>D2=+.\)'JIH ZI@HC! ;\JD@B%PN#(4
M^HKDA\0M)(P+.\_[Y-!^(FD ;?L5YG_=- '<0:>L39\\-]:OJ4 QN7\*\X7X
MA:*?EEMKU?HIJU!XYT9/GAM;Y_JIH [\$'I2UQ]G\0[&ZD$8M+I,^L9KJK6Y
M2ZA$B @'U&* )<&CA:#]:8\T40S(ZH/5CB@!X]<U3NM1^SG A9OH*7^U+!C@
M7UOGT\P5!=:O;Q#Y+BU/UE% $JW)N823$RUEE"+KHXY[BK\&K0/'N:XMB?02
MBJL^J0S/L,ULH/?S10!/>X, YS]*;IHVG(#_ (BH=]G:C>MY [>AE%6;;5X)
M!AIK91[2B@"674S%-M,+$>H%7(IA,N0I'U%9<FM6Z3;5GM6]S**N+J=GLS)=
MVR_]M10!;H!JM'J-E*<17<#'T$@-6%(/(P1Z@T .HHSZ44 !II13U53]13L"
MD/ X&:  8'08I"H;JH/X53GNKF-L)#D5-;2RRC]['MH F"JOW5 _"C /49^M
M0W$DT0S%'O\ QJ*"ZN)&Q)!C\: +0C4'(C7\J=0"3U&*7% !CWHHS2T %%%%
M !24M% "4TQHW50?PI]% #0H7H /I2TM% "4M%% !1110!YHVL7=]Q+* O?<
M*N:=I^G7$H\VZ8/[=*Z_^QK ]+9*5-'L8VRMNH- $EC!';0A86W+ZU9IJ(L8
MVH,"G4 +1FD_&@Y/7I0 N?:C-)TZ"CGO0 I^[7(>)/OCZUUW537)>)!^\'UH
M U_#I_T$5KUD^'1BQ%:U  **!0:  G%( #SBBHYIU@7+ GZ4 171NA_J I^M
M519R3@M=(N1Z5-'JD4C[0KC\*=<7\<289'.?:@#+EN6MY/+CV[?>K4=DLT?F
M*B>95=K1IV\U'*KZ$5:MK]82(V5R?7% $EN+Y6PP78*OKTYZU6DOXXUR5?\
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MX\_$B(_\P74#_P !JM+XWLYCE]%U$'Z4 =XA0CY"N/:H;FY, RL9?Z5QL7Q
MM[<8CT343[XJ3_A9,1_Y@M__ -\T =1;W\L[8-N4'J:N\CJ:XO\ X6/'VT6_
M/_ :;_PLJ,-C^Q-0'_ : .VSZ"C/N*RM(UL:N@86LT/L]:NP>E "XHQ11F@
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MV.PJ7%(4##!Z4 82^)XQ*4DM95QW-++XAW#-O#OQZUJ-I]LQRT0-02:+9/\
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M8S5>YF:&,E<9]Z (YKB5$RML6/IBF6US+,V'MMGU%5K?49Y)MI9<5KH25!-
M!@#H!2_6B@'- !D49HHH ,T444 -;D8YJE+I0F?<9I![9J]^-*1QQUH C@@$
M";0Q;ZU#<V0N>KLOTJ.X:^5OW*J11%>-&N;LA3[4 /M[%;4Y61F^M32Q"92"
MQ'TJNUXTP_T3#'WIMO)?%\3(H% #8]($<N_SG/MFM!1M7'/XT#WZTO- "8%+
M0.:,4 %+24M !2&EI#0 AZ<5FW.HF"3!AW5I'D8K(O+*:23*QY_&@"_:7)N%
MSLVU9Z=ZIV$+Q)AUQ5O/I0 ZBDI: "BBB@!*6BB@ HHHH 2C%+10 F**6B@!
M#TKD?$OWQ]:ZX]#7(>)?]8/K0!L^'?\ CP%:U9/AW_CP%:U "T444 %%%% !
M1110 4444 %%%% !1110 4444 %(:6DH 2D9 XPPR*=2T 5A8P*VX1C-3J H
MP!BG4F* "EHHH **** "BDI: "DI:* $J&X>-(SYHR*DD0NI )'O69/8RQDR
M><[C^[0 07-DTN(XMK>I%::D%>.E8PD:X/E^2T9_O 5>M;-X>3,S>QH M\^H
MIPI./QI10 M%%% !1110 F/:D/-+0:  <51O;%[D?(R@^XJ]52YNV@Y6(M]*
M (;"PEMCF1U_ 5H54M+QKD_/$4^M7* $P!2YHI: $I:2EH **** "DI:0T !
MX&:IS:E%"V&#?E5OH,UGW5ZL;X-L7]\4 6X+M+@?*#^-38JM:3"9>(BGX58Z
M4 .HI*6@ HHHH **** "BBB@!*,T&D'IS0 UYDC&9'51[FHTOK:0X2>-CZ U
MFZEH\UPQ>*4G_9/2L^WT"[$X=]J ?W: .I/*\5R/B96WCCO70/I[/ $:=QQU
M!K,?PC!-+OENIW]BU %KPX?] %:]5K2T2RB$<2G [YJQ]>* %S2TE ^M "T4
M44 %%%% !1244 +124M !1110 4444 %%%)0 M%)10 M%)FC- "T444 %%%%
M "4M%% !1110 E&*6B@!N .P_*E^@I:* &_A2BEHH **** "BBDH 3K2T4M
M"?A2$4ZDH 0 >E+12T %)2T4 %%%% !1110 4E+24 '6DVCN :6B@!-OIQ2T
M44 %+24M !1110 4444 %%%% "48-+10 F**6B@!,44M)0 <"C -%% $$UR(
M!DHS?2J)UQ V#;3?E6KC/4"DV)_=7\J ,W^VX\?\>\WY4G]N1?\ /O-^5:>Q
M?[J_E2;%_N+^5 &=_;4>/^/>7\J!K2'_ )=YORK1VC^ZOY4R5XHD)?:!]* ,
MF3Q591/M=) ?I4\>NPRKNCBE8?2J,]QHKS_OH<MGKBM:R:S,0^S[0OI0!!_;
M<?\ S[S?E0-:C/\ R[R_E6B%4] OY4%47^$?E0!G?VW'_P ^\WY4?VW'_P ^
M\WY5HA5/\*_E2[%_NC\J ,W^VX_^?>;\J/[:C_Y]YORK2V+_ '1^5&Q?[H_*
M@#-_MN/_ )]YORH_MJ/_ )]YORK2V+_='Y4%%_NC\J ,W^VD_P"?:;\J1M;B
M1=S02@>XK2"#^ZOY5'<>2L1,RC;WXH R4\4V4DFQ5DW?2K/]M1]1;S$?2J=O
M-HKW6(T'F9]*W$5-HVJN/I0!G_VW'_S[S?E1_;4?_/O-^5:6Q?[H_*C8O]T?
ME0!F_P!M1_\ /O-^5']MQ_\ /O-^5:6Q?[H_*C8O]T?E0!F_VW'_ ,^\WY4?
MVW'_ ,^\WY5I;%_NC\J-B_W1^5 &9_;<?_/O-^5+_;<?_/O-^5:6Q?[H_*C8
MO]T?E0!F_P!MQ_\ /O-^5(^N1QKN:WF ]<5I[%_NK^55;V>WAC*SIE?84 4(
M_%-E(VU5D+>F*G&M(>EO,1]*J6EWH\<W[I KGU%;49CD3<@4K]* *']MQC_E
MA+^5']MQ_P#/O-^5:.U3_"OY4NQ?[H_*@#,_MN/_ )]YORH_MN/_ )]YORK3
MV+_='Y4;%_NC\J ,S^VX_P#GWF_*C^VX_P#GWF_*M/8O]T?E1L7^Z/RH S1K
M<9_Y82_E2?VY'G_42_E6EL7^ZOY4%4'\ _*@#-_MN,_\N\WY4R7Q#;0C,D4B
MCW%:NU<9V#\JS-0N;%%(NH_E_P!V@".'Q+:W'^JCD;Z"IO[:3_GWF_*HM+GT
MN1O]"4 _2M8HO7:OY4 9W]MI_P ^\WY4?VTA_P"7>;\JT0JG^$?E2[%_NC\J
M ,W^VT_Y]YORH_MN/_GWF_*M+:O]T?E1L7^Z/RH S?[;C_Y]YORH_MN/_GWF
M_*M+8O\ ='Y4;%_NC\J ,W^VX_\ GWF_*C^VX_\ GWF_*M+8O]T?E047^Z/R
MH S?[:0_\N\WY57E\4V<+;9$D!],5L[5 ^Z /I6+?-HJS_Z25WYH FA\003C
M,<,I'TIYUI!_R[S?E4]@UF\?^BA=OTJT57NH_*@#._MN/_GWF_*C^VX_^?>;
M\JTMB_W1^5&Q?[H_*@#-_MN/_GWF_*C^VX_^?>;\JTMB_P!T?E1L7^Z/RH =
M129'J*,CU% "T4F1ZBC(]10 M%)D>HHR/44 +129'J*,CU% "TE&1ZBC(]10
M 8HHR/449'J* %I*,CU%&1ZB@ HHR/449'K0 5!<VB7*$/G\*GR/6C(]: .?
M?PP7EW>> OIBM*STJ*U P235W\11GW% "X & **3(HR/:@!:*,^XHR/44 %%
M&1ZBC(]10 4AYI<CU%(6P/6@  QU--FC6:,HW0UR&M?VNU]FRF=%ST[5%<ZQ
MK=E"JRV[R'U2@#H(_#MO%<>:H^;.:U47RUQZ5Q^FZ_?@[KJ&0+Z-5J\\53QC
M_1;5G/IB@#J!S1GU%<A#K.N78W?95C'O4PU+6@I+1*<=A0!U-)NKB)M;U:27
M;L:#W:K\6N7\$/\ JOM3>B4 =3FFL^*XY_%&JL^/L#0^S"K$?B#5&3"V@)]:
M .J!/6C.:QM+N=2N6+7:*B^E,U75[RU;;;P<?WC0!N<CM67JND2:B,+<>56-
M+KVIM;'9%N?_ &:ATB76;RYW73/&N>AH U-/\+_8Y-[RK*?<5NQJ$7:  /85
MEZC?WEE"!!#YK8ZUCG5=98;V@8#T% '6YYQFG<UQP\2:M$</:KM]QS5:Z\1Z
MJ_S6\$C'^Z!0!W6: :X[2/$.JSRA+VQ:%?[QK>U.2X:TWVAPV* -.BN%@U+6
MH9CYQ=ES^%23^+M2MY JV32#V% ';45R4?B:^N5&;0P'U:EN=3U4IF!U8^@H
M ZMAD8K*U#1Y+Y2OG!5/J*P[?7=44XF@(/\ >-6)?$.H1)N2%9?84 :&F^&X
MM.?=YA8^U;(&!@5R]MK>L7:DBS$6/[U5)_$NK6\^Q[?(]0* .THK+TK4I+R(
M&6-E/O6GGWH 7/K1FF_7%+GZ4 +2TF?<49'K0 M(<T9'K1D>M #9$$B%22,^
ME<_>>"["]G\V1Y=V<_>KHL_2DXH HZ=I4>FH%A8D>]7Q29 I<^] "T4F1ZBC
M(]10 M%)D>HHR/44 <SYC_WV_.CS'_OM^=%% !YC_P!]OSH\Q_[[?G110 >8
M_P#?;\Z/,?\ OM^=%% !YC_WV_.CS'_OM^=%% !YC_WV_.CS'_OM^=%% !YC
M_P!]OSH\Q_[[?G110 >8_P#?;\Z/,?\ OM^=%% !YC_WV_.CS'_OM^=%% !Y
MC_WV_.CS'_OM^=%% !YC_P!]OSH\Q_[[?G110(/,?^^WYT>8_P#?;\Z** #S
M'_OM^='F/_?;\Z**!AYC_P!]OSH\Q_[[?G110 >8_P#?;\Z%D?=]]OSHHH E
M).W.3FE@);.XD_6BB@!& +\@4NQ1T4#\*** (W8@\$_G0&;^\?SHHH & ;[P
M!^M+& A^48^E%% #W^8?-S]:CR1TX^E%% #6D<'[[?G4@)9?F)/UHHH :H ;
M@8ITK$+P2*** (XG8GEB?QJ96.>IHHH C8 OR,U.J@#@ ?A110 R0U"KMNQN
M./K110!*.>M*%7^Z/RHHH :X!'(J.,8;BBB@!\G(YHB '8444 .=B#P2/QH*
M@C) -%% #68J/E)'TJ/S'S]]OSHHH =YCX^^WYTSS'W??;\Z** '>8^/OM^=
M)YC_ -]OSHHH 7S'_OM^=)YC_P!]OSHHH 7S'_OM^='F/_?;\Z** #S'_OM^
K='F/_?;\Z** #S'_ +[?G1YC_P!]OSHHH /,?^^WYT>8_P#?;\Z** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-3_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #] 44# 2(  A$! Q$!_\0
M'@   @(" P$!              @!!P8) @0% PK_Q !K$  ! @4" P,$"0P*
M# H(!P ! @, ! 4&$0<2""$Q$R)!"111=146(S(W.&&SM!<8)#,T0EAQ<G:!
ML38Y0W-T=Y2RP]$9)2A$4F*1EJ'2T]0F*35&4U56A)7!14AD96>%AK6BHZ3$
MU>'C_\0 %@$! 0$                   $"_\0 )1$! 0$  @$$ @(# 0
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M3_T=R%D/[5-*?Q<,?1DP#*:%? M87J&1^81&<Q@VA7P+6%ZAD?F$1G, 1!Y
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M42F)J3;OLBS./%J7*G D!E6X=\$*VCQ,9U=>C4Q=.J-7K[\XTW2:C:;UN+:
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M1UY_[AF/WM7ZC'W2<YCX3P*I1](!42VH #QY& 63R;'Q6:+ZRJ7TI<-'"Y<
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M>TKGGFWE+IC=PT9^:9IJ"3M#+06EM*@/OMI/RPW5AREP25J4UBZ9Z3J=P(:
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MK)7<X\*;*_[C%26%7).N^4)E'Y*Z)NZFDV"\DS4ZPVTML^=([@"&6ACQZ'K
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MOJ+C_H&/I#<:FI-NFLT6@S99JBBIF8>6D2S3"!V;A&$SX1N<!Y9F59,J>XG
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MPD6U-W7:M2K5#EI2S*19M-EI:Y:&[.NMJO=U"^_,M(Y!T.8/,Y]]\L&#P<*
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MFPW+2[*;;D2&VT)"4I!*"3@ #)),-5)2[$G*M2TLTAB7:0&VVFD!*$) P$I
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MA162$8QRQG/..A2-+M7K5M:KV11M)[T-F7=YL_=*INCLJG@^#E[S-0.U*/\
M!W<\=8W*;1Z(,03&F::T)OVNT*2T_J^D^HHTSH#\U/4(RE)EA53,/ 9\X).P
MIR#R3SZ8AHN&'0;4FV>#VW:*[;'FMU2-X>SJ:/59A,JI;"'DG"E85L)"3@$'
M_3#[$1. (EFDZ*SJ)H[J/K9.*KE>I%*MV8IDNB5I=(9J/G1<*YAIQYUUW8D
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32E$DQDP&(F+MOJB,01,$$U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-3_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* 8$# 2(  A$! Q$!_\0
M'@ !  $$ P$!              8!!P@) @0% PK_Q !?$  ! P,# @,#!@4)
M$@L)   ! @,$  41!A(A!S$($T$4(E$)%2,R87$6=8&SM"0W.$)2<Y&RT1<E
M*#,T-39%56)R=)*5H;'2TR9#4U9C=H*#A)3!&"=&5V2%D^'P_\0 ' $!  (#
M 0$!              $'! 4& @,(_\0 0!$  @$# 04#"04&!04       $"
M P01!082(3%!47&Q!Q,4%30U88&1%C)3<J$B)#-2P>%#1&*BT51SDK+P_]H
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M8ZR%H;P!N6$X_;<9/W]QF'WOK]\PIO<R58"NT6V\R+%YS,K+RGVXY>2HME(
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MD\'%""T=SZ[PM;6QV &F;8W,=9?MCTA[>9K2+A[.L;<#8O<TH@ J&"#\:O\
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MQ^J/[VLO,4Q0%GNDNMH6E=#PK9>YL@S&5+"0(TN0L-Y]T..J;^D7CNH  D\
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MEXA"6T)4-OEK3R=QSG/I6-'27QD>(7Q6:Q^:=*:+TX7HC(5*F-SKA"AQ6R2
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M%\Z_WGYU2U$6I:64F+'9V%2DI*CN84<X[$=CQ69#6]1AEQK-9)S@MUX=?"-
M\,U@NMGTCJZ[/1;E)3+>5<H\=U86$[1@A"0!BKM?@]?_ /G4[_Y!G^2I,D<5
M\WVO-:6C) 4DC([C-:FK6J5INI4>9/F^T@PEN_@EZ6:KU?>I#O4ZXKN\RY+<
MD1VG(@VR'W%N;$CR^<DJ  SVP>U57\F]H:>W<8]LU]>53H:@TZ%B,M+#A 4
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M/*CZ5#]1^&^[ZHB1HLZZVEZ+:[E(N$!AV(ZI#X>E!Y;<@!8)2 D) 01SA1[
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;2&@PLEY2DAL*RE"4DX ![8J9TI0D4I2@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-3_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (1 7X# 2(  A$! Q$!_\0
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M6TK("P"<'!^D5B(E.(:<;2LI0YCF![<'M6=<;I<-1SDNS'G9DA0"$E1Y''L
M%8#K2FU%"@4J!(*5#!!KEUZL7/32DW%<9YP:5"2CJ:+HLMR(\AYLX6@\@K /
M?[]7J8ZD<R2M ROB4!7K>6<X]WTUC*.!BK<D>VJ[G)QTYV,K"Y*J&%&J445
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MX\JQBPM*>100/?BKT2GD-+;2XI*%?.2%$ _6/;5VDJ44_6B]UMV__4:VGV/
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MF_E#E)2E7NS^RCK#[L3?Y==)2@"KV_(U954T KK)K=ZP:>>A6](C3'7>:YB
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M)](1Q 7[>/T5U@^!+3QVOW(&<_U;C=__ +-72OJMU33M:M132>=GE9>[P_\
M95@HOZDCI(>P^^/XZ^9WQ#)SOSN0?9]DMS_+':^F)7E]\?QU\T?B$DN?;PW(
M8*STOLFN:N('M]+=KCTU%YU>-C8)?3;-M5;KJJ:&U/AM*8Z5K4DA15@J&//'
M;L??7K:+5;G671,N"V%J4&PVR$G)SYJR1@>W(_T4G2Z2>PXX[=JS[5=%6\2
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M2?N$]^Y3'Y+Z^3SJBI2C[35>I1E1DX5%AK^?8WRIQC34LY;_ )O[F&"../\
M30A7K=^X]];JRVMV07E^C)>PTK"7 H9)[#CCS5[A]%:J4E"7G$H2M* <87YC
MZZ2MZE.FJDEA2X]_<TO&,H]))2)*BPM:T_M5+[*^_@G^.M]=IUZN&E("I<]J
M1;F7"AE@O)4ZV>^<I^</K-)Q#66^7-/SL<<]_K^JLYUJ QS"'7I!Z:2A92$
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M 1BNOCOC6_4-^@LZ.<GLQ+A=+/$::N\9J8_,MY3Z1U&G"D-,JY@(<4HY(PH
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M('62[)7QY+(7D?M4X'D,#%>FI=!6;5LJP2;G&+SUBG)N4 I<4@-/I0I 5A)
M(XK4,'MWH"+6A?')?-Q-O]3Z@L>B$W"Y1G8+EML,4S')BHDEQY*77D]#U@ S
M\]CFV5%2.64$E[M,[_Z?E;?Z+U#=93#3NI8#TUA%O0ZZU\C'7(?2"M"5#BA"
MNRD@Y3C -85G\)&W&G[1<[=:X-TMS4YUAT.Q+U,;>A]%QUQE$5P.\HZ$+?>(
M0T4I^55V[UBZT\*^F-4VO;K3[3DRU:8T<M_H08,IYIYYMR(Y'X>D)6' "'%%
M1))7D@GO0%;AXM]%0M9ITZJ+?%M&8U;W+VB!_4YF0N&9O26Z59"A'',^K]'<
MY%-SMCXYX]QNVI;7KVU1]/W&S6B+?WH]O4ZZMB N );SSR'$I4@-E;;.,94M
M0P,=ZVU^\"6FM0Z[@WB3>9GQ)'<84[:BIY2Y26X*X>'7B_W6IM>%.\ X4@)Y
M8IQ]0^&?1%\N5^O'Q:&[_> "_.<6MP*4F"N$D*;*@%-EE?%3>0E> 3W ( TK
M?B=@7W;G<C4%JT]>;?=-&6ERY/VK443T1;A]$<DL@%*E@I6E ]9.<9]X("(T
MUXS9E@]'A[C:9:B76ZVBV7JR-Z5>7-%T3.<Z345M#H;*7POL03Q(RH'L0%EM
M-X4+/MYIO7%CN=UD:C@ZMCMPIS;P<02PF*J.4=13KCBB4K5ZQ7D#BD8"17O;
M_!IM=;[!<+4FUW*1Z:J"I5PEWJ8].9]#4%0PS(6Z7&0R1E ;*0,F@,>U>,;1
M%[U5IW3L"+>)%VO#KT=;"H[3*H#K4CT=YI\..))6AT%*DM=0C&?+!.YV4\4^
MA-^[M=+?I.5)?>@M&2%2&TI3(C]9;(>1A2B$E;:P L(5@ \<$$^*?"/MF@6!
M(M$OIV925L-FY2"E]:97I87(RL]=77RX2YR)).>W:M]MEX?-#[07:[7'2=I5
M:WKDE+;K8DNN,M-)<<<2TRVI12TV%NK4$(  Y=NW:@'&HJB1Q %5H HHHH H
MHHH KR?D-L)"G%I0DJ"05'&23@#ZR2 /IKUIO=XMLG=R(.FVX\EN*_9]16V^
M!3I7Q4F-(2ZM "3W4I(*1RR 3F@%XE0R![2<??J]*P!49]V/"[?]Q=P;EJ:+
M>H-M$^W1[?,B/I7(:E,M.-.=#!1EEM:D.)64+/-*\*0:;?;=_<78_P 6>TFT
MMRU_*U+IFX:-E.2;<]&2&6GF.82MI9^4\T#YQ.!V\L8 G$*K5$]Q5: ****
M*H3@56K5CU%?50"=F[BZ>M\MZ*_<V@^RHH<2A*U\5#S!*01D>T>RFZU5KV[/
M:T3.T_J"WIL[, ($&>ET-/OE3O+D$LE8P UZW, =_55DX6VU:0+/>< #^KUT
M/_\ 6.TLN(SY4!'J'N%J466<U<;ZIRY>FA4>3;XB$(*$K4$^J4K"6UH#)<3E
M2@5/<5#U<>&G-P-8)F2Q<;VPE@1&C'<<9"U*?+A+X<"6QY$(2UY#IE6>2L&I
M%\$^X4G]9V^^W.P/QM-7>)8KLM2>E.EP/36D 'U@6N:,Y';YPQY]Z PANII8
MN]'XW:+W#GT^FYRXYQG''.,]J2NX6NOC:+"CZ;U(FUN%XJ?D=-0PD)/$$*97
MR258RD $CL%)SFDHO2>\8UHB!]L[2QDFW*?$S[!SS".JE);_ *]\LD*\_,4\
M^C8%ZMVG8D74=VC7R\("Q(GQ(7H;3N5DIPSS7QPDI'SCG&>V< !F4[EZM%]>
M?E7."ECT-89C6]A2HH=Z*AEQ2T=17RP;*3ZOJ+6%))2#6FCZZUHW=V>6HI:K
M<'"D]1EH*+:5(Z!4>C\]0+W7XX "6^ 22K,FB@'V"J=,#W?@H!$Z1W"MST")
M%N%W8?N;CBFRM+*VDN$K5PQD8&1Q[9\SC)I<#R[TF-PVQ]C0& 1Z=!\Q_P#K
MC-*<# P* K1110!1110&/-ELP(KTF0ZAB.R@N..N'"4) R23[  ":2UTW;T;
M9+=IZ=<-36N%%U"IM%I=D24H$TK2%(Z>3W!"DG/D.0R1D5OM262-J2P7*T3&
MFWXD^,[%>:>;#B%H6@I(4D]B""<@]C3)ZE\.%\O&E=!:?C:MMK-MTH820U-T
MZB2J8U'8:1TU*+H*4J<:#AXXSA"5<DI(4 \.F-;6+6+,MRPW>'=VX;ZHLA<-
MT.!IU)(4A1'[8$$$?16]'<"H">,78O[2_ABUKJNWZENC5Z@W:#,M*[3*DVYF
MWJ?FQFGREM#Y"U.@E2RK(Y**DA)))G7IQU;]AMSBU*6M<9I2E*.224 DD^V@
M-C116KU/?6],Z;NMX=;6\U;XCLM;:" I8;0I9 SVR0GVT!M**9.Q^)5F][>P
MM1MZ>FL2);")"8LE1C-(2XHAM*GWT-CFH!1"4I5W&,]TDY&K?$=;M)HG2WH(
M>MD)QD.OB<RAPH5%,IQ8;)SZC900G/K\E$$!)) >2BD)HG<X:O<C1C;U0YBV
M'W7<2$/,H6S(Z#B$.)^?A7?E@#!'O[+-V6U&QU7D-Y\N:@/KH#V*L''MJSDD
MGS[GM2,W3^.KQHJXP])7B-;;\Z61'DK?2G@ \@N=R%>;8<'E[>V/.DS=8>M+
M6FWICWV)J*(P\TA3:9*(,AU/[9QQPA84$G"@@8) (.2<T [74P#Y8]]52O*L
M?1FF*F0]PDWN:\F8S*AKEO+2EN]H:^3*U+2,%!Q\B4QP/VJ@7?;3G:048L%$
MBX2E-S9#+!>CO3DOI84&P"VE0P#@\B58RHDD]N( "I)P*H5X]M8QND0#O+8'
MT]4?ZZ9O1MCW$LFBK>F]:OB7R[E@R+A%+C;2UO=! Z#,@# 27$K)64#NL$8"
M<$!["X![1[JHESEV!!^JF/N\#<-<N&Y"ND<L-P&&7H_QHA!<<Z92L9XD9ZJD
MN\_,I:*.W/LJM*(O:;A E726B.W'<FMRFU7-+Z9&>F&GP !Q"N"U!'[0*QYY
M- .2.XJM6,N)=;2M"@I*AD$'(/WZOH HHHH HHJASQ./.@*U@76^6^R(87<)
MT>"A^0W%:5(=2@./.*"&VTY/=2E$  =R33&;U[[:@T)N3:-.Z1BVK4D]Z%Z3
M,L<V6U!Z:"[P0Z9BW0&\X4$M])?(CV4JM0Z15OOH30UQFVYS3=P@WBUZC$*Z
M1PX_$=C/I<6R?[E9 6CD/8H^PXH!87+<K2=FNDVV3]3V:%<H,(W&7#DW!EIZ
M/%'F^XA2@I#0]JR D>^HIZOO=MU'\)!L?=+1<(MTMLK1EU<8FPGDO,O(Y/84
MA:24J'T@TY^X7AKN6X6O+M?;C(TY(ARK,+>B*NVO-.ETK:+KCCS+J%JYI90V
M#RY(2E(3[>3"6O;*3ME\(ELK;YNI[QJ>6K1=Q#LBZ2ENI2I/73\DE1)0DC&<
MDE1'(DJ)) G^/*JU1(PD49% 5HI*ZXUO'T/&M[KL5Z8N9),9IID@'D&G'3Y^
M?JM*  [DX \Z3,3?[3<W43=JCLW!U2VU+,DL!"$$-R%E)2I05G$20/F^:1YA
M050#H5:OYBOJIIIGB*LT&1&9>M5Q#CW8<"R0DAI#R@?E/8TZA7T]QYCNY=IN
M2+M;A*0R['2LJ'3? "TD**3G!(]F?/VT G=K?U(O'W=NGY8[2RI&[6_J1>/N
M[=/RQVEE0".W@O<W3>U6M;O;9"HL^!99TJ,^E(46W41W%(5A0(."D'!&.U0J
MVPD>(+7.VVD]2/;H7[JWBTQ;@KIW6P,IRZTE?9M<$J2/6^:HDCR)S4R=_?V#
M=Q?WN7+\E=J)OAZT]=U[#;;K;TI>Y3:M.6\I>;TK9'DK'HZ,*"W)'-0_QE *
M/F0#VH#W&B]]C<A/.Y>H?2PR8X<^/-/?I?(*(QZ!CS [^=)'>Z^^(+:S:;56
MK6MT+]U;1",E'6N-AD(SR2.[;<$*4._D"#]-//\ 8[>O\#;[_P!#K#_M%-#X
MN;!=&?#7N(](TQ>832+4LJ??TQ9HR$>NCN7&7RXD9P,I!/>@.@EN=6]#86LY
M4IM))]Y(!/\ '636':!_4Z-_XI'_ %1690"9W#_6XG_/H/Y8S2FI,[A_K<3_
M )]!_+&:4U %%%% %%%-[O9N8_M5HUR^Q8#5YDH>0RW:B\XV_,4I*\-,!#;B
MENGCD)XD$!62/, .%5, 4TVC-V5;V;6WZ9IZ)>](:@99?@N1+U;BB9;)H:RG
MDTH\7,<DJ&#@^1(.13-[A77>AW1VSL;2C&H472$U%;OJELC,B<J(PMGTE2NZ
MHX49(>.4@+"0>^* W7PFW]A=KO\ SBU?]IQJDCICMIZV?YJU_P!1-<V/$G/W
MP7X-MQ4ZVB&7:W=01!-EW]TLRHZ?38N##:0CBXR7P0 HI 1@IY>SH.O7^F-"
MZ;L9U+J.TZ?])BM]!5UG-1>J4H3RX]10SC(SCRR* 6*SA"CY8%:./:7IL1*G
M+G-*74Y4G+?'!\QW1Y4RFMO$%,3?WDZ3UYL\]92A :5>M4*;DE13ZV0WE.,Y
MQ@^5:S2WB#O1N=M3>-<[*L67JI$HP-5N+D)9S@],+PDJ]V3B@) .Z73(8Z#T
M^4ZQV'2<Z2D]O+L48[5YG1T=1&9+Y.4G)0S^U!"?[7[ 3CW9-8NEMTM&ZRG+
M@:?U=8K]-0@NJCVRYLR7$H! *BE"B< D#)]XI54!I8NFA$;2ABX2F4('%*6^
MD D>X (["M7*L,:5JR$S/2FZ)$%]2?36T.<?E6?+U0/]%*ZM%(_7K"^Y[_\
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M2ES@4P?C)O+%FVVM,QZ>]&0W?(I$1A7!V<L(>*64+Z3A0I) >Y #CT<E0 -
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MMA37%U)*BE25#BI1R!Z^/T]+<7PSNEU# 9AWQY4AY9:882B%%477GD_*,,I
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M5\FTSBWJ!?25&\ON6U/3C\VPR.FA,=WT,)$#"H@2%YX!!_2$'O:#Z\GF% 4
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M7B4V]TD&-5N/6'5S6Y^&FM)N36PC;7^UE;64J']M"_40S^D#R\QM]D=Y-O\
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M2^2N([#D0.U 9&C-)QM%646N)(G2VDNN/*D7*6N2^XM:U+4I3BR2<E78>0&
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MPAIEM#32$A"$(2$I2D>0 '8 >Z@*0H;$&(S'CM-L,-(2VVTTD)0A*1@)2!V
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MG[O+M@M"'5(?@6Y4EJ4)04EPI;=6CD&!S2XRXT\5M*Y)0L(4MNIHE(/F,T
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M$]AWJ+.DO!I=-3^'C3ND=33!IN\IA6F%.<MCQ+C;$1E_#8(&.0=E/>KDI*
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MLUEKB=:).I]0)B15,6%IYN''C1DK#21U25J62XM2B<#N ![2 [-%%% %%%%
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M%U:?50\M*1@$#L$@?>K=#15F&<15#Z>NY_.K$VY_4"1]T9OY0Y2HH#0C0]E
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M]4=\9'LQDU(K;3?/0&[ZYR-$ZOM.J%00@R1;)(=+(43Q*L>6<'\% ; ;;6L
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MRYT9#;R$.J*0X.0QZJ%+0 K]MDD 8I1L'.X<D^6;4W_*KJR%HZ5;DA,6;#C
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M'<=Z3.C/%$]J9^U,1]IM?Q(,UU+:;E,BPDQVDE1!<61**@D'.2 3V\JYS,[
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ML;E+3]CEO"3 U;:V8Y'02!TFW)J5(1V]5*DI(& 0,8H!2C74']T"P_PFRO\
M9*1.^6M83^S.O4)UQ9)2U6&>E++>XDB2I9,=P<0T8J0LGV))&?+-.MS?_P#H
MFZO_ $SM'^WTA=^%/_:1W"S'W,; T_<#RF:PM;C(_0[GZ8A,U2E)]Z4I)([
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M'8TT6_&Q#F^S%KM4O4";/I]GF9S,>U1Y$R024\>C(>2KT8@!7K-IY]QA0P*
MKH#1SNN/#PQIG5,:3!7=K:_%FLA+S#C8<6Y\U+V7&^R@0E>2D8'LK62_"]:K
MCMBG0TN]S)5J5,<FO//18Q>4ZZMQ;ZFU%L]%:E.J*7&PE37[0BE1=A!\/VQ]
MP<M$:9<8&E[4ZZQ'ERW'GG0VE2@E3RRI2B?><G%-NKQ'ZC=V9L.J8=JL3]_D
M7I=F?MCDUQ FN(D.,XAC!)4YT^8*R$MHY+45!&" ROC-\'NAM(>%;<F]K^,+
MQ<+7'3/M3LZ4>4(IP@)!3CJ]EK)4YR*B>Y[4GO'..,_PNGD&D(@74K?4LMML
M)%NBY=<> Y1T(&5*D('-I(+B 5) K=>-/Q2M7+P\;M:+O&F;JW>)#)C1U6J.
MF9%:C*>6&9+\A#BD-I7T5C!PM*@0I R"=/XX4EV\^%)E)4%O,W!ALMX#P6N#
M$2DLE7J)=R1P4[\DE6"YZ@50#?*PME*$N)E<W(K28S+RI*Y:E-9;CM,K]64[
M(2"XU%<(;N"$JD2"EQ !RD(R@A"'%X995S#?,*3UB$OA1^<VXKY!,D^O)=28
M;@#* H^<Q+C4&:YR6EIEAZ2[Z8I+K'38(;>](0V>HN.5D&2VP"^Z[Q5#^0"J
MHA80M25%*BATQR'&UA14VV'7,E. 7RV0''$_(*C\&V?T4%4 J=@4K/C&VK=5
M#?2E5OU&GTQ5N:;:6I*&0IE,D'FXXR?4<C$=.(KY%HJ0,UTH=<#2"I2N*0,E
M1]@KF9X>Y+2O&OMBP&X*7A9;P^>FT\)(;<C,J;"EGY(L<<=!"?ET-^K(P[FN
MB&Y_['6J,C/]2I?L_P#J%T!Y:GW$MVG=/S;DPE5_=CHYIM]I?85)?[@80''$
M)SWSW4/*FR/BK2)*6#M9KPNELN@<+7\T*"2<^G^]0_#7+O93:?0NA=N;%N)K
M/25NUM:M?6QK3UHM$5KJ2;1<$CI*G2 2 AM2T*5R!)PH' I6_P!"YI"1I]/A
MK;L]D1NVPKXS7NH63\5N,<B_T0]\[ETU!K''&4D?30'6'26Y-NU+IZ-<I+#N
MFW7>?*VWA^.B2R$J4D%8;=6D9 Y#"CV(S@]J5;+J7FDK0H.)4 0I)R"/>#7$
MW>7:[0&ZV@;_ +J;?Z-M^WU@T3;G;5<M/W!CI2[G+5@)E,I!(4D%:?6/?U3V
M\ZZZ^'A/'87;@9SC3EN&??\ H9N@(S[NB<?&U?Q NIM*OL"MA4L:G%CYCT^9
MVYEAWJ?5ZN._GFMOPU%_ADK^%I'^P5H=Z+9(N?C9OJ6(D^44:"MBE"WV^TRU
M#]'RP,BXJ2D#O^T.??V%9HTI</[S:D_Z.:-_/4!L.GJ+_#)7\+2?]@K2^#54
ME?BSW\,N<;B^(5D29!O/QMR^25V$GIM\@/+'$<?+O67]BEP]MGU(!^]S1OYZ
MM?X*X;L+Q7;]LO-267$PK+E$R+!C.CY-?FB$2P/K2<GS/?- 3>4L).#]5)/<
M;=W1FT=NBW#6VIK=I>#*=Z#$BYOAE#CF">()]N!FFL\?#SL?PJ:Y6R\ZPM0@
MHZC#JFE@*GQDG"DD$9!(['VFH.W39#1%ZT"](N-D-P<:MB)"#,FR'0'/LJ7"
M*P%.$!7HP#6<?-H";T#Q@^'^WWRZW,;R:56J>&>39N3>$=-)2,8.>^<T_%HO
M4*^VB%=;=*:FVV:PB3&E,*"FW6EI"D+21YI*2"/KKG-<_"#LZQKJ1!3H.V"*
MAO6"TM#JXS%3"]&_;_VOJKQ_E4K-Q]CM%[5Z\L$C2MI>LSEOU_HZ%%Z%QE%#
M3+SR0ZV$*<*>*L#*2,8H"?:3D9JM%% %%%% 4K!N%JA7%QA<J+'DJ85U&E/-
M)66U8QR3D'!P2,CWUG$=J93?31>X.H]<[>7#2,MQFTVZ<';HPW-$?L),1960
M?TP&.W,9X]^\@=L94D!QTZ!TT%ON#3]I#K[086M-O9RIL<<(/J]P.">Q[>J.
MW:HN;DH2U\)ELLA("4)T==4I [ #+V *KK_:'?346K]87:VSI<:T7$Q'VK8F
M\(:4Y%"XI5 0 >+:V^G,RO*4JZX 6<G&DUWX1?$!JC=+1&XEFW1T]9=1:=TU
M'LJ'9EM5*<4ZI@"8M9*>*^;I<4"0#A0\J 9">B6YX@-Y"RS)<=&N9QB(9AL.
M.OK$!LNI82OU9*D-CFXV^0EEH*>9Y/@"LR+%E%,=$>+<G5E-O2T&(,9]QP>O
MZ*6PX>+O6[^CES!F#O+X%*:WTSX.'?F=J'4]ZD;N:4?G:EFB?=E*LJPF4ZGB
M4$I P E:$K2$X'(9^BM%K/P#>(.RQ8*6=>:=U&BY7%N%,9C60_)MRE\9<AW(
M'J'LIS'<X[8H# =CI3'47E.(85 0I3KR^FRW&])P'BZCUTQ^KEKTD R2\#'(
M]'"55([X+MQQ>Q6JUO-NL.JUG=BMI]AMAQ"NHG(4VWZB%#VI3ZH\AV%-(U\'
MAX@67@\WO#I9M\.^DAP656>OPZ?6[CY_3 ;]W$#MGO2CV@\&'B=V+TP_IW1>
M]>E+3:'ICL]4<Z?ZV'7,%1"EI) [>6<"@-C\*S,T? TMM)(U];KA=]&MZI6J
MZ0K2OC*>9]#>R&SS1WSC]L/KIK=41M6PM?[>6_7]QA7C>6YLA6TU[M"2BUV9
MH@8%S3Q25$I*?)M[V_67,UOX1/%)N+<],3]0;V:1N#^F[A\9V[GIM(0V_P %
M-\E)",+'%:NRLBD)9/@W-^]/:2U5IR)O)ILVW4JN5PZ]I6Z[DDYZ3J@5L^?D
MV4T!@:<AZUFZNW*B:)N4&W;AVM"5;RW2Y95"OS00X0+2.*B@])+X[H9[J1W&
M,U;X6),:X^)'8RX:,Y6_9:39-2'1=BN)Y72WI24">)2@5<NI)"UM_*+P@CYO
ME6JTCX!O$7N?MOH@7S<"UZ45IF0^W M<^UJ1*0EM\A"WW&QE]*PVE8#A5A*_
MI.5Y \ 7B*MN]"]U8V\NEF-8*85&$ANQD,(;4T&B$1^/33E*1DA(R>_GDT!/
M/<,YT!J09R?BR5_(KJ+WABCVE7AQVN+]D=<=.F;>5+&A'I(5\@COU0@AS/GR
M!/+.?;6-<-B/&%=+?*A2=^M).1Y+2V74?8PV,I4DI/<(R.Q--UISP"^(C2NG
M[=9;=O'IEJ!;XZ(L=LVEX\6T#"03GO@"@),>C63'Z@O?P=/?FZ0'B!CVE.Q.
MXY9L;J'1IRX\5G0+K'$^C.=^H6\(Q_=>SS]E,3/\+7BGA[E6K3#>OK7*M,V"
M_+=U&U:'/1(KB#A+*^^>:\Y%;^]^ OQ%:CLEQM,[>73+D*='<BOH3:7@5-K2
M4J&?9V)H"<^U:A]K3262/U'A^W/]I142=;]_'+N]C]R/_P#S>K86G83Q@V6U
M0[=$W[TFU%B,(CLH^QE"BE"$A*1DHR>P%)"=X+/$Y<=?7O6<C>S2J]07FR_$
M$V0+!A+D/*CTPCCQ!]=7K#O0#CVDY\0.I?\ REVW_P!VW*;?11'V";6C/]KV
MQ_ZCE:C7GAF\66A[?J#6]IW.L6JM0MSVK^+9;K @/S);<?T1/ *3Q&&5*[>1
MQGSK,MG@?\2T.TV>(QO1I=IBVHM/HK9L.2W\7 B(">/?@%'.?G?MLT IO@VB
M/L_\3?[_ ![^-ZIR9'OKG[MAX)O$UL_.U7,TKO7I6WR=3W%5TN:UV#J]60>6
M5#FD\?G'L.U3HT=!NUNTO9XM^FM7*^,0F&Y\YAKIMR)"4 .N)1^U2I?)0'LS
M0&[HHHH#S>;2ZVI"TA2% A04,@CZ16ADZ&T[,A-1)-BM<F*R4%#+L%I2$<>R
M<)*<#'L]U8^ZL"_W/;?4\32SQCZC>MSZ+<\E804/E!""%'L#G'<]A4<K]HO?
M27M!I>U6Y-UC7Z+=Y3DD&\1PZF*X)"H06[U,+$=7HW,9)/'U>IWH!3>/:V1+
M;X.-X%Q(S,94BV*=>4RTE!=67$94K&.1/O.34>/&\<:C\)">//F9C89Z?5#Q
M,.& T6?.1S)"?1QW>Y=,$%=+K7WA_P#$'NKMWN+HHWJTVZW:AE]%UW4TE<KG
M'Y+4IR*&.72R>GZJP/F_-'M1&X_@G\4.Z4O1,B_[B;=O*T@EU%L2S D-@)<;
M;:6%X:R<H;2,@@CS!!Q@!%/L.L1I2DMF.XAB>I+R&_0E1BV^D*>$@Y$(QC\D
M)I"A;,F,I*BYD>#@YET94SB5)0E*GPCCQC<RSQ_:!H?+^A]S&),XDASB%9_0
M'>)5)5QW$V^0<$)6+>^HMJR.*@"T0>(&,*RE6<K"U84-'HOP8>)[6&G8UUDZ
MKT=IYYY;R3;KI:W6Y#24N*0D* :/8E/42K)40L!1*?5 %WATDM/>-W;-#4SJ
MI38;HKT=-S#B1RB,$/>B>;9=!#AE9Q-R'P$@XKHQN=^QWJCVGXKEX_\ 4+J!
M.E_ SXGM([@V;6=OW'V]3>;3'DQXO.VO%L"0E*7E*'1!45<0<$X3Y)"1VIT;
MKM3XT+S:YEOE;F[9&-+8<CNA-G>!*5I*58/3[=B: B'X5>O#T>A_:T-S]RY&
MFH[6OXEV]6)&L'33TG8A[<G^CT21E7<GM2F?BZ4_H=V+9(DR_P"@N]*+D>]M
M@_9%Z?UE>J4$?I?I/,?,^;CO[:5$/X.?Q%6G16F-,6_<70ELA6%\.LRH,20S
M+E)Y*5TI+R6@I]KUL=-9*< #& *\W_!WXFH>^\26F_Z)DQIEK>?+2;.ZK34=
M39;;#:H?3Z:7UA16DA!R4+.<^8#>>*U5QN%GDR=[D(MF\;&GWV]%0K#Z]ODV
MK"N:Y"O6PZ!UC\X>SM74#P[@#83;<).4C3ENQ]7HS=0%;^#D\12]!ZBTG,W&
MT+=H-\42_-N<:3)G,()&6V)"VBMI'JCU$D#N?>:>?3&S?C,TEINU6*W;F[9H
M@6R(U"CI7:'E*#;: A.3TNYP!WH"F[$?K>-S4 ^+X,_&@+9ZL[24N_I3_5"7
MY(C+26S_ (RNQQBMY\7$?][>GOX&;U^?I#.^&GQ?+W&FZY;W1V]CZAEVMBSO
M/,6Y]*%1VG7'4#CTL9"G%]_<<5Y:_P!&>.#16C;O?8VX>E=3OP6"\BT6:UO.
M2Y1! X-)+8!5WS]Z@%]\7D_][6G_ .!J]?GJ3O@W:+/BVW^28D>%^@K*>C%L
M;]G;'R2NXBOJ4M&?/)/?S':J0MI_&Q+A,/'=O0\=3K:5EEVWOA:"1DI5\GV(
M\C6ATEX6?%OHW<'5>M8.YVWB[]J9N,U<'I-N?<2M+"2EOBDM>K@'[] /IX_O
M[%'6_P!=O_[1BU%DC_>XE>_XF1_[[+IP]R_#KXO=V-%W'2NH=R=MGK1/Z1?2
MQ:GVUGINH=3A0:[>LVG[U(\^"'Q.IM#EN^V)M[Z,J,(I @2"K@+B;CV^3\^N
M3_YO:@'3O?[)<P^SH:\_ZMOKV\1?Z\8 ]HW)T/\ RZ:9FP;'^+O56XNKHLG4
M.D;0JSKF,M7B;9741+HFY-LJE*C$(/()Z*$]P,$'SS2MU7X6?%EK.<B7<MQ]
MMU/MW:VWM):M;Z,28*@J.?TKYH([CV^7E0$^,CWU6F!V,TGXBK+K)Z1NOK+1
MM_TT8:T-Q-/VYQB0))6C@LJ4@#B$AS(SYD4_H\J K1110!5*K10%*K16IU/J
MJT:,M#EUOMRBVBV-K;;<F370VTVIQQ+: I1[#DM:4C/M4![: V3SR&&UK6L(
M2D$E2C@ >\GW5&2W>*ZXZPWC@Z<TK"C7334I<9R-<4VV6XJ8RMTH>5S]5+"$
M(0MU#Y"VG@E24E*DFL[=>^WC<N7,V]5;KSIS53JUM-,,%;UKNUJ6L=1Y<E(2
M&0$I *LI>:<*4H#@<XN.IM/M':]K+ 8$0)?E././R)G10T7G%K*UJ#: $-)4
MH\BVV$M\BI02"HT O!Y56J 8H4H)&30 3@9-,WO'XE=,[>VI^';+M;KIJY\2
M6;=; LN)=DLJ2AQEQ2#AM04I*,+4G*E)3D9!JW?K?ZS[=07+-'G2/LEDI4$)
MMZHJGH(Z#SX><1)<0A0X1W"&\\EA)"1GN-;H?8_36O)L/<*^:;;M5[NB69MQ
MMT1X*@S9*.)9F\<<@HH ['B5)4D.I46T$ .?MGJR9K32<>ZSK1,LCSCCJ!%N
M$5<5XI2XI*7%,K]9OF %A"LD!6,GS*JJQ#80D@&KZ I6!=[Y!LD3TB?+9@L%
MQ#0>D+"$<E*XI&3[22 !]-86J-8V;2+,-=XNL6UIFRVH,94E?'JON*XMM)]Z
MUJ]5(]I( [U%+46G+3XVKG&N^FKM<-._%DF&F[VZX.)?9DPTKDAB2R&EK0U*
M0OTE("NY02'4%"VS0#[;(;Y0]X4W5L6M^S7.VK!?@O)<4MA"UN)0AU2FTI0_
M\D2ME)5P"D'D0H&G4K1:)T9:M Z9MMALK*XULM["([#2W5.$(2 !E2B2HX [
MD_1Y 5O"<"@#-8=XO4#3]N?N%SFL6^"P.3LF4X&VVQG&5*)  [CN??5+K>8=
ME@NRYTAN+';&5..J  [@#O[R2 ![20/;4.-1^)*Y;DZV9B6=Z%=]*3[JUI\:
M!N6GWR]?X3W%N7(,E0^0=C+ZX<86A(0ED]0Y=;- .7K;Q5*3K]K3FW]I1KN1
M#5,BW2#$"Q(1+; 2RT%'"6VBX2AR00M+1 "@,\JD0V24)) !QW ]AIMMJ-@]
M+;2\W+0)<V9TO16I]R>ZTAN*%9;8ZF 5I1V 4ODL@)"E*XC#E)'$8'E0%:I5
M:* **** IBC%5HH"F*IS"<Y]GMH*PDX_BINMQ=V[!H^-;UW>3(@Z>N;CL)>I
MXRTF%;WP>*4O.I5EKDKDD+(X!2>*B"I((&CW]WW3M-!M[-L3!N=ZF/AM<%;B
MER([!2K,E$='KR.! 4IE*DK4A+A1DIP5GM/JJX:UT%9[W=K<FV3I;96IAL+"
M%#D0EQ 6 H)6D!8"AD!6#G&2R.RNP_V6SKCKS7+\34\B\.M/QG56]Z&M]EMT
MK86^TZK(XE+3S*2D*847 A:D+ $FT-A P/+.?OT!?5"<"@G K4ZGU+;])Z?N
M-ZND@1+=;X[DJ2\OR0VA)4H_3V'X<>^@,75^O=/:&MK\Z_7B':H[#*I"S*>2
MA732I*2H G) 4M"<CVJ2/:*;+9C?V5NSJ6[L,6EPV1$B1Z!<V(RQ'7%;4E+;
MAD*44N*>Y$\$I2IHMK2L$C--TYI%_P 4\B\1]06J0S;HCYEZ;U2M$%4NTID1
MV7%PW&05MR6'67FU@GJ)6E7%U(6T"J1VWNWECVSTG"T[IZ&(5LB<BE&>2EK4
MHJ6XH^U2E*42?>?8* 4:,\>YR:NJ@&!BK>IW(Q[<4!7J #).!37ZPW]TWI#6
M=JT_.<):GH=3\8-GJ-"0A]I@14A.5+?YO)*FP,H0%*5@ TF=Q-]-&ZHEVO1-
MKU9(A3-1L)>@:@L4M@^BKYD,K"2ODZDNHX*2E*D]PESB%=]=X7?"NWLRB;>[
M_.%XUC<GG'IKD=U2H*72LY?80I(4E;H"5JY%10IQQ"%!&!0$AD#%7U:E 30I
M7$9]E 5*@D'/LI$[I;J6O;#3,V[2P)K\=I#P@-.H2ZILO-M*=/(^JT@NI4XX
M>R$@D^5:'<C?!.D;_P#$=ELBM47AFW2+O*B,3F6"U%84A+G$K/KNY6G#?8=Q
MR4D$9:+27AJ8W)W)M6Y;FIKK>="7&#"OED:FW!X3XY6LR?0W0I*@N*2X' .2
M5I*EM$K;5Q $DM$ZJ@:WTW#O=M>;D1905Q=9R4**5J0K@H@<DA2584.R@ 1D
M$4H!6/"ALPHC,>.TAAEI ;;;:2$I0D=@ !V  'D*R* IBJT44 4444 452O.
M0^F,RMU:@E" 5*4HX  \R3[!]- 639K<".Z^Z>+;:%+4>P[ $GN>P[#VU&7=
MNRZM\0<:U*TM?[:G1DU80MB?87'I5IG-MK)]*;4\E+L=U*ELNMK2<!:%(SGF
MC0:DWQ_HA-QT;;VQ"DZ*N3LRW/72"MM_TU;/1>0YQ4D8904K0\RKB5H?;4DK
M;<!$@MG-GK1M!IQ^W6\-NNRGU29$A+"60HDG@VA"<\&FTD(0C)XI &30&?M5
MH4[=[?V33BI3TLP(Z6^3TA;P0>Y*$*<];IHR4("LD(2D$DBE?CM5:* H2$@D
M^RFLW?WVM&W:/BAB2Q(U;);;>BVE3:W'2RIS@I[I)P5A(2XKI@A;@;4E&58%
M+/<*SW:_Z'OUML5Q^*+S*A.LPYV,]%U22$J_#[?9YTSFUFQT.ZSH=YOVD9^A
MG;3Z'%AV%J_^DQY"(RS(9>?2TLH=X27'EMEPE?M4$YX@#5>'#PYJLCUQU%JP
MQ[J]<4EM,*5^C$+2EY2V'B\LX>2A*E!A:FFW6VG2VOD0,27;;2VD)2  .P H
M2@(\OPU7RH"M)K76N(FA;,)\MIQT./(CM-MX'4<6K"4<U82DJ/9/(@%7%.<J
M .PO.HX-C;494A"'./)# 4"Z[WP$H1YJ43A( '<D =S44&;?MKXV]2O*ND%Z
MV7VW1E0Y41$Q3K=RL[JPM/%UE:0EQ)+?()/486LH6%!0R!YZ?:U5XD=R[JUJ
M: VUIMB.AMA"6%.P&@T^L+"@L .JD)64K3R0]$=C 8RD+5*C1&A++M_8(UGL
M<%$.(PA*0?G..D)">;KA]9QP@#*U$J/F2367IK3D33%B@VJ(J0ZQ$90REV6^
MI]]WBD)YN.K)4XL@#*U$J)[DDUM: *M4<#WT+7P3G[U-EJC4VLINI=&/Z%:M
M%^T@],<9U!)$AM;K30RD%A74"2I*QA:<' !QE7:@&.USJ*1XA]\;7H?KB3MX
MIM^1'N]L<6A*9+*,H>9D)4/T6T^.26E-J;" %A:R2E,BMN=M8VBFY<Z0J--U
M/<T,_'-YB1?1/C-YM)0'ULI44I<4G'(I\R![  ,+:S9#3.T;]T7IP34-S@RT
MF/*F./LPX[1<+,:.A1PTRV7G2E [#F0.P #A 8H  "1@56J8Q5: **** ***
M* *M4K%"C@&F/\2'B&>VBLDMFRVV+=[[\7NR J3*;3&@+)2B.N6CJ)6EEU:E
M(#@PGDD)4I/+D -ONSK:[W!F[Z7T:J*=61&437K7=XKZ/C* 1AX0WDK;!='(
M +"E!"^*5!/(*"(\,VPFH=!)O$W4UWAS85W: ?M+,=89G'*5-39++J!T9A02
MV\$92Z4H6KY0$G*VEV;<O>O$;GWMYN8B8QZ;;V94)^+,;><^:[(:4X6VWFVE
M*:'32 I)'+/%)J0R4CCY>= 42VD#L.Q.:OHJU8)0H#SQ[: U&IM56O25ED72
M\3V;;!8QU'WU8"23@ #S))[ #N?941KE8M1>+#73[Y1(L.G& @,I]*<E1LQI
MJ78\E:!Q0W**%I=;X]9E]AY:%*24 TOM6: U-JW<>7;;I#U'):<OL*XP[RU/
MX6R!$CGK-.1V^:@W)0L)0H+0KK9)(X*(#\:-TI!T7INVV2W(4F%!8##74/)7
M$>\X'M)/L'N% 9%ATY:M.PU1;5;XMNCJ5U"U$9#2"K &< >X #W  >0%;,#%
M  3Y5:I6* %KX G!/U5%3?SQ.7-YEFR[?6YJ]-3$A<F:DK4[T$OM EAH((6V
M\.M&2^5 -/A*5\<@AP-[=RM&7-R;MS?;S=['Z>F&Q*OEGD>BFUN2G74PBJ0#
ME"G78SB$D I"D@+QR&;-BO#3 VID/76?=)NH;\])=F+D7&09#;,E84V])8*P
M7&E/H""ZGFH%2?VV.5 7[->&/3VV=S>O;KB[U=G"KH29L9#:VD%?(+6A/J>E
M%/%#DA 27."2H9R2]B4!/EY>RJ\15: HHX&<9ID/$GOA(VVA6>PVF+='+]J)
MY,:/*ML)+ZXS1=;:<=90X0A]]/5"DL E1 4LI4AM0*QWLW@MNR6AI&I[I;KA
M=8K+J6C%M3/5?45!1&$9[CU>Y]@R3V!-(N7LS,UIN5(OUVN,2Z:1FKAW>(PX
M'D7"#)8"2PAAU*^"&@KDYR3A:BZXVKDA1% )'2'A93=M:,W77%MA/R;2TFUR
MGVBA]C5#3;2!'GN@X=CRD\2AP94%CME:>/&346*U%C(88;2RTVD(0AM(2E*1
MV  '8 # Q5[: .7UYS5X&*  ,# \JK110!1110!1110%CK@:;4LYPD9[#)J*
M>L]Q-2^(+3NF[?I:<UIU^\FXS&K,S<$HG28T8):3Z4I32VVDI?=;ZT925\T+
MX\B4J096J^;6@M&@=.6+4=TU!;K%;X-[NG'TZX1XJ$/RL>746!E7WZ TFT^U
M-HVUL,5B)"B-W0PV(TR:PUQ4_P!,$(1D^L6VP>#:3G@VE"?)(I>50>VJT 44
M44 50 "JT4!3RKPG36+?$>E2GVX\5E"G'7G5!*&T 94I1/8  9)/84F-S=SK
M%M5IYJ\W]YYJ$Y-8@I]'84\M3KJ^"0$I[^W)QY 'SIB=HM;:C\15CN>D]91(
MY87$^,4:ETQ,RB.^)1Z*0%-\$DI"7&T\G5<$+2^E"\H(#>7R=!\2/B1MMEO,
M"795PUF3;7X[RG#'$.07&RZGCQ(D=%;@*"6UM&.OJ)=9;Y3(T[H.Q:7E2)5K
MM<:'+DMH;D26T?+2 @J*2XOS6K*E$J422222324V-V9MVT&A;/9PQ"?NL2.M
MF1<HT;I=<J>6\OBG^UH*UJ4&DX0DG"0   Y2?*@"L67.9@,J=D/-L,I(!<=6
M$I!)P,D]NY('WQ605@ ]^X]E1<WZ3KG>639OM5:CLTW3B94B$_+C]5T1+DR5
MME$I;#I"XRP5-N(+*N!2E04DJ2M 'EK?<(>)2?-T?M[JB;'@/Q8,]N\P)?00
MH!Y]+J6TI"''VTJ;0W*9+J5!+B..#G+H>&S9([(:#%F?N\J[SI*Q)E+><2IE
MMSB 4M!+;8([9*U)YK42I:B?+;;2;30MOK<W+D-![5$Z*P+M-ZQ>#SR$<<I4
M4HR0,(ZA2%N)0CJ%2DYIQ ,4 8%5HHH HHHH HHHH JA\C5:H?*@&3W2\0;>
MEY>OK/ ;CPI>E]/"[R;M>72S%:==Y"*A*<%;J2I)YK2.*3Q3DDD#1[([-7.?
M?+EK/<6VHE:B5+6B$]<(<5,WI!H,]9PL**$*<;PVXTC#:NDA?!*B278U=M)H
M[7MZLUXU%IRWWBY6=PNP)$MD+4P20>WO&0%<59 4 <9 (5[8P#0%$)''RJ_R
MHHH HHHH"W@G.<#/OJZBO-U7%/UG ^N@+E9]E1J\8>[=OL.F9&F5>G\UL&;,
MG6N5P7#;;<:[%M)"G?TQ*EMI]9+14Z > !\=5>+67!UQ;I>GK4SJ7;I:(\1^
M9!=;].7,?DEI(0VMQ*N(2$K0@(4I\*6I)2EHD[F+X769V\FJ=2:GD-ZIT[=8
M[:HT68"A]E]+Y<X/<0$R&V_)A:O7;0I;9YIXF@-1M/X-=+Q+?%NNM9MTUY=O
M2WIT5^^3W7@PR\ZI_H.("RVZ.3@*P$AM:FFW."5@DR8;0$HQYT-(#:.(  '8
M #RJ[EC.: ,X'?M3;;X;JJVNTB].BI8E71QMU4:,XAQU2NFD*6YTF@7%MH'K
M.% )0G*L'&#Y[[[F3]M=%KN%LM\F3(D.>B(GM0C,CV]Q8/2>DM)<0M3/4X(4
M4'D.8/E4?/#5LWK?66K9&O==,:ATP[Z?$NC5LNL@*F)E-Q$QG4\DA);!Z?KK
M3R;DM.MA3;;C1- +[PVW+=;5^L]3ZGU5_4S2DQU;46TSPZI[D""@L]PTEE*5
M% =;!#X"5D<LD21 ![8JQAE+*0E(XI P !@ ?57K0%,8JM%% %%%% %%%% %
M%%% %%%% %%%% %%%% %4/E5:* 9C>#P^)W)U$B^-7$]9;,6WSK/<DEZV3H3
M;[KRD*;!"FWN;B5H?0>:%,MX[%04YND=(VO15J5;;1%,6*7G9*^;BG%NNNK+
MCKBUJ)4M:UJ4I2E$DDDFMU5* *"H >=>4AY+"%+6>*4C)-,9,WU=W6VJOMQV
ML?,G4<5LK-M4&_34-]1Q')D+RT73TU%OGR05)X+XDG "&WDW7U_JC7Z;'M?<
MM.ZCLO58BSX 4'.HVI*%OH4ZC*D+Z+G,<>RVNH6SU&BE2_\ #MX>YNS-VU'.
ME7)N0+JF(D1V%%0'292V"XK@VE:D!(;2L-I4I">3A<4K*4CX4O#I]CT?3VXM
MZ$*'J.7:U(^+;3'=9C16WEJ<Z0#RU*0E(5GH(X-(<<>XI(*2)0T 4444 444
M4 4444 4444 4444 4444 4444 4444 4E-S-'W'6^EUVNUZEN.E)1?9?%RM
M>.N VL+X#/;"L $'S!(/8TJZ* 9+8OPXVG;AQ&H+A:;?$U<XR\Q)^)W'/0$E
MQU*UN,-+&6@XIM"^GDAHE24$))Y/6@8!%753.* "H)\SBFOWTWOB;)6.-<)%
MEN%]7)4^$1;8A*G3TF5O+("B.1"$%7!.5E(44@\32MO^M8%JMU[>80_>9=I8
M#TBUVI D30%)*DI2T#DJ4 2D>T#MFH;::LVI/$]N(WK&TK?.F1?64SG;@IST
M,QF$H468I*T+4UU8[;P"4-NM25N)7E//("LVUO>ZFY.Y[%T5"F7;:[42I:IL
M74<5+,?XL=0A3"&D>LDK;YJ0%ME29"%E2NZ<B6ULM[%K@1H<5AN-&CMI::9:
M'%#:$C"4@>P   "KHL1$9EMMMM#:6QQ0A PE*?8 !Y#Z*R: **** **** **
M** **** **** **** **** **** **** *M-750C- 1N\2%FW!U7J"#9X,&!
M]B_I5ME6JY+CJE]*YMOK46YS.#B*XD(2'T87'<XK]8?-<K:+:I6BK4Q/O2XT
M[5TB,&9\N,5B.D<U+Z<=M6$M(R05%"$=12>:QR)IQ2V#5P&!B@ )P/\ XU6B
MB@"BBB@"BBB@"BBB@"BBB@"BBB@"BBB@"BBB@"BBB@"BBB@"FOWJW<A[?-PK
M,9+MOO-^8?8M=P6SF*Q)'%+0>=/J-%:W$(05^J5D ^>"Z%8%ZL-MU';9-NNT
M"-<[?)1TWXLQE+K3J<YXJ2H$$>78T!%KP^[5ZFO^JK9K^]6F3H2\H><<OL9R
M7+4_=971905+9)1&2%<275MLD+4VV6RD!1,FM/Z1M6EUW)=I@LP?C*8Y<98:
MR [(< #CF/(*5Q23C&3DGN23M41T-H2A " D  )&, 5ZT 4444 4444 4444
M 4444 4444 4444 4444 4444 4444 4444 4444 4444 4444 4444 4444
M 4444 4444 4444 4444 4444 4444 4444 4444 4444 4444 4444 4444
+ 4444 4444!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-3_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $< D@# 2(  A$! Q$!_\0
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M(85/2BSF&MMTA'+NY(#PSN"^7))0* W+D7N!%N<.W/3&6ITQ+BH\9:P''0@
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MEXM.-C&4JRX"M0^4I.X!/2H[9[*^M=7W;03EZ=3H^!9D7://79M1O7*:XB3
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MB7VTNAF6RS:9#J4J* L86E.#R4.E8M^FR=G/]\UU_P !ROS: W$/R35FTO\
M8;C_ '?(_P LUJI^FR=G,C'U377_  '*_-JWV7TJW9V@MRTN:ENN7)3SJ?ZA
MR?DJ42/VOLH#=3%*T[_39.SG^^:Z_P" Y7YM/TV3LY_OFNO^ Y7YM ;BTJ/^
M!_'/27:$T.C5NBYC\ZR+D.10[(C+CJ[Q&-PVK /F.=2!0"E*4 J-.TG$>G<"
MM;,Q[+]4,@VUQ35N)6.]6GQ)/@\9VD;\)R3MP 3R,EU&7:7C1IG C6T>6Q+D
ML/6]39;@H"W22H $ D @$@G/+ .<C(H#4SA'K74/#?@1K1BV(EQ-,L3X#T+6
M=MCR>_=;>G1HCKQ1)0H@I83NV=T-J&CD'<%F>NQ\G21TW?I&E;\]=5RI:9$^
M)(ML6&N,\2X-RNXCLA:G G<5*!/3IYV'LT7#4EY[/NI#I"-;-/ZJ;N\A,=$Z
MTQVXJ70EA2DK9B]R@D@E!.04J^43LQ5^[)7&'6W%NWZA?U<Y;I(@JBQPY;[4
M[ #$PAWUN*0XZYWI:*6_C4X0K?X<XS0&PH'*J$<OI%8QQ,U7*T3P\U-?X;,:
M1,MEN?EL-3'TL,N.(02E+CBB A). 5$C YUK9I+MHZIOVHH=N.BF[F\;:X^[
M:K8M0GR)*&)#BTQ]RBTXT%QRR' LI65!05SQ0')Z,[_B2U7_ '[WO\<BMN*T
M_P#1>RESN 6HI+L9V&X]K*\.*CO8WM$NH)0K'+(Z''LK<"@%*4H"AZ&O+;65
MM>U7VL..^G[?JGZS%R-[C31Q7*^Z"6TP8Z#:.\W-_95+3(V]X,^K9VG&1ZDJ
M^2:\JN+TC2UI[0/'BY<9+;)U9P13J>(Q]3=I"E3OATVUI3$K#:FUI:3'3)05
M=Z$[EI!03XD@4;G-S;/,U8WI_P"I^SV9TQ)? C;M.O7 0DW+NMHW[RM+N0TY
M_8V=QZUS/ VXVDR'?JP^JM24VUOY7UF"O #I^5W7<]X#S[G^Q?*N>0Q?H^J;
M99K]-8G=IN>P'>'.M6 /@RRVC"BB/*4$I:[P-"6DA;+IRXGQ$J!'!!4U+5J0
M:23\%.VC<KCT90Y:N9 5ZTFW[BH+*TIF !D1\]ZC!&X8 V2]&=;W;5PNXAPG
M]2#6+S&N;DVO4(7O^$B$M?JC.Y6=_7.3UZFMOZTW]%Y)TW+X/:Z>T? ?M>E5
MZUN*K5!E@AZ/&*&N[0L*4H[@.1RI1]];BK7M\B?F!- <,Y;R8SWJR$.2 A1:
M0XO:E2L<@2 < G&3@U"W9BXTZSXOP-2/ZOT.K1I@SMD(+>=494=S*VG$A;2/
M"&RD;CA15NRA'(5D'%6#Q=G7*$KAU?-)6B"EDB4C4EGE3'%N[N10IIYL!..6
M""<\ZP+0I[2%\E1Y=SU5PY7:6+F]&ELL:;GH><;9D*:<[M1E$ J"%%)((&1G
M/.@-CZ5QI=R>8(^<&OI2L#ESH"PZZ5J)&E[B=)-VQW4?=?J%-Y6XF'WF?_K2
MV"L)Q^YYU \K4':CB7^WVE5OX1*>FLOO(<$NZ[4AHMY!\&<GO$_<-8+I_P!)
M ]JNT0;K9^!^N[A;)ST=B++95%V/+?<4VR$DN#Y:T* ^:NG?>W1>8VKX%RD\
M"->1Q:[9<9$AI:HNX,I?99=<Y.=$.-E)]Y'44!M9PO.N3I\_7":T^SJ /K&-
M,N/KB=SRV<W@%[L[L\L=,5F5:;S/2%W*WJN(?X#Z]:,!R4S*RN)\4N,TEY\'
MXS]HVM*CY8/+-;/\+]>QN)_#[3FKH4=V)#O=O9N#+$C'>-H<0%!*L<LC/E0&
M4UB7%B#\)\,]60_@<ZA[^U2F_@E*]IF$M*PSG(QN.!U'6LMK#^+_ *M]:W6(
MFL2Y,-5GEAYF @KD.([E>0VD$$JQT% :/< M2:DX;<+>*LNS6F1*MJ;"]<X^
MHX#,L24RF6TCN B2DE.Q3KR4)#/,MJ5XP0$SQV2)&D)E[UE/T]JF5>;I+EO*
MGQY=MB17'@B0XAN8I;,5DN=Z % J*N2QYY)Q_L92;M-X>:ZMMGA1=.:@BOM1
MV'9EHC-M-O\ <%*5O(BI:#I&T$@JWX(YI"AG).RQQEXB\2]2ZAMNLW+1(-G9
M[B<W:[4[$%ON"7U(5'+CCSB9 +8"PML!(Z$D\@!LIBL#X]C^LAQ"_O>N/Y*[
M74X^<1KSPQT ]>K#!M]QN0DL,H8N<Q$5HI4H[SO6M *@D$A.X9/*M:=6]KN_
MZ[T#Q8MC6C'+O&9TQ)>CQ[6E;4YEM>6%.R6GB VG:YWX .0A)^4: E3T>/[#
M+A5]JC^/=K8JM=?1X?L,N%7VJ/X]VMBJ 4I2@%*4H!2E* 4I2@%*4H!2E6/6
MFMK)P\TU<=1:DN3%HLEO;[Z5-D9"&49 RK'O('TT!35NN=/Z$MR;AJ6]VZP6
M];@9$NZ2T1VBLY(3N60-QP<#W&HVN?%[@+>KK%NUQUIH"=<HNPQYDFYPW'6M
MB^\1L6593M7XACSYUB.H.VMV8=4PTP[WQ$TE=XJ5AU+$]OOT)6 1N"5H(!P2
M,^\U&.G.T+V2V.(6L94J^\/Q;7T0/5%+MS102EIP.;!W7+!(SRH#=2R7:#?K
M7%N5MEQY]OE-I>8E17 XT\@C*5H4.2DD8((KO5KS:.W/V<H#$2VVWB=IJ/';
M"(\>+&*D(0.B4)2$X Z  <JV$2<@_/0'U2E* 5"?:K@64:&C7F_Z+TUK&V6N
M2EQQ&HWG4)CEPAE!92W'>4M:EK2C:$CY76ILJ%.UVR\SP9NMR9N+D0PG8JC'
M,CN6I(5+824*(COG>02&R&U8<*3@^0&7<"Y]MN7"/2LJT6B)8;8[ ;5'ML!+
MB6(Z>?@0'&VUX']LA)]U<'$/6ECO&D>(%B@W6'+O%MLTI4V"R^E;T<*CN%)6
M@'*<UQ]GAR%(X':,5;4!$ VMH,([X/;48( WAIH*^<-H_BBH8XB=DV,Y:.+U
MQNNH)R[)>VIEW1!MTAZ*\F1DO@N.)7@I24; E"4A25G?N(% 7OT</["WA;]K
MW?RI^ME*UK]'#S[%W"S[7._E3U;*4 I2E *4I0"E*4 JA^2:K5#\DT!^>GTC
M8QVTN*GVQ:_)F:UNK9'TC?[-/BG]L&OR9FM;J =*4I0"E*4![G>B _8>0OMW
M/_RD5NU6DOH?_P!AY"^W<_\ RD5NU0"E*4 J(NTV[-GZ#@:6MFH#INY:MN;5
MA8EMP7I3A+C;JUI1W3K9;\#2U*<*L)0E?(DBI=J+^T@K1\;A9/G:WM=VNEE@
MO-2!\!1Y#L^.[NVH>8+!#B%)*CXTD8!.>1.0,7[/EE@63A?J^P--%URVW6?#
MFPK?!E1'$.=V@E"$R)#ZR5(4A2%API4'$$ '-1OZ/Q+2(6K!N;?D(CVIE+L4
ML%IB,EI_N(;W=,-#UQD%:7RK<25-^+EBKK>K_H?3'95U;(TA8]0VBQQ[@W%<
M<N@N-MF/R'9,="YKKQ_5:TA3J5+<&5*2TM(SBNIV#M;C6+6LE-*E.LI$"0E3
M]VN<[N"X)*3')G'(6CN@HJ; 2H.HR,IH#;)UAN2PMIUM+C:TE*D+&0H'J"/,
M&NG&L5NA.LNQX,=AUEH1VUM-)24-9!V)(').0/".7NKO_M:P:5QCTG U]]1L
MFZH8O@:[Y3;B%);2.[4[M+A&T*[M"UX)^2DGW4! 7HSP!P2U7C]^][_')K;>
MM&O1Z<8-!Z.X0ZI@W[6VG++,5K.\NICW&[QX[BD*>3M6$K6#@X.#T-;0_HC>
M%&<?7-T=GV?5!$_I* D2E1V.T=PG/3B;HX_]H(G])0=HSA0>G$W1W^,$3^DH
M"0STKR_F2]36/MN\=;MP>M\/5'&M,]AA&GKXK;;O@4Q(JGY).YOXU,@1D#XP
M>%Q7(]1OX>T;PH*#CB;HX_\ :")_25YO7[46FN+':QXUZ1@\2+9PL;F7-B^Q
M>*<&YLI6XVW#CL&W(<[QL*;<4YWIVN_*CCPG&4@=BVQK%%X6ZKL=AGR979MN
M$U3W$35TA.+Q:+J5H+D>&-HRV'4QD@]TYR=4<GK7>O!<G_6V&K +<U9%M'@6
M81S]5#P+9C)NGRL!1$4'[#R=76-P^+6E+SH^\<5&I=ALL+1[RK:_P:;N#"8N
MM"E24&>ZC*=RE%WO<]RYGN!XCU'+*UUIC3(TPMS55EU..*;B&HR'KDP?K4%W
M: Y&\:MG==[D9[C^QT\QSP!MSZ.&3J*9P^XF/ZM@QK7JAW7UT7=(4+[#'DD-
M=XA'B5X0<@<S\]?/I%DNS-+\(K8)3[$6Y<0(4.6AF;)B!YE427N;6Y&^-"3@
M?(R>0P*PWT>O$30G"SAYQ!L%^XJV"XR8^MKD&[M=;S':=N;>&@)7B=)4%X)W
M D'R)KL]NCC)HC4\3@PC3VN;%<Y,7B%!DO"TZDC,NLM"++!<+P60RD%0'>*Y
M D9ZT!BH[/\ I$=8*#_VQU;^97RUV>=&LI4&[:TV"HK(3K#5H!4HY43X.I.2
M:RU/%.TX&-=O?_&*WU7ZZ=J_?V]_\8K?0&"Z)T=#X>=K3@E'L;CL*/<W[JF8
MPS?[U-0^E$,E 6B> D 'F-N3GKY5Z+I&4IKSHF\4-/,]J3@3<+CK.*NVPY-V
M+TRY:\B7=F/NA$))*" SN/+*CXN0'.MTT=HSA3@#ZYNCL_WP1/Z2@-'NR>!^
MASX7GS^&])__ #254B\3DCX2U;@?_875 '^'TU"_9AXDZ1L_ +AM"G:JL<*6
MQ>=+N.QY%S8;<;0W<I*G%*25Y 2D@G/0$$\C6?<1N+6AY%QU06=9:>=#NB]2
M1VRB[1U;W5WP.(0,+YJ4C*@!S(YCE0&0:V'Q_%/V_">M?_DD:MC>Q_\ L7>%
M'][,#\2FM2=9<5]$/R.)7=:QT^YZQ<=7J9*+K'/>!VS1T-%/CY[U@I3CJ00.
M=;%=CGBWHB3P"X4:<8UCI]_4'U/08_P4U=6%2^\2P"I'=!>_< #D8R,'V4!L
M74:=HB\R;1PJNR(-U=LUPN;D>T19<>$Y+>2[*>3'3W3;;C:M^7.2MXVGQ'(!
M!DH'-8+QN:TVOAC?W-6VN9=[ PR)$F-;8[KTKP*"TK92U\8'$J 4E2/$DC(Q
MB@(Y[*FF(N@U:WTH)<=V[6FX1VIK3,&9&.2P-CV9$E_O$N)&X+04@X4"D$5%
MG8:BL1=?ZK:[EP%B &H;(4R7K7%]=>Q#N'=1VLS-P+F5J<5M4<D')5E=@U)H
M"P]GOBE<M$Z9U8U!A6]V9<)%W:N$*X7-Y;!45"4]^J'%)2$IWI)VC 16+=AS
MB"G4_$#5UO;>DSFFH84'S>;O.:;[N6XR!B<=OQH0'D% !#:PE62": W)G6Z+
M=8KL69':EQG!M6R^@+0L9Z%)!!Z5@?'2VQ(W!KB5):C--R9&GI_?/(; 6[MB
M.A.X@95@$XSTS4AJ5@5!W$_C)I+6'"[BY9[;=D.3;/8KBU)#R%-(SW4AG*5*
M "AWK3C?+]L@^XD"T>CQ_89<*OM4?Q[M;%5J]Z/S5]BM_8ZX6L2KS;X[Z+60
MIIV6VA23W[O(@JR*V$^KS37[X+7]_-?G4!?:58OJ\TU^^"U_?S7YU/J\TWR_
MW06OGT_5K7YU 7VE6 ZYTX>E_M?WZU^=6J>H?2C\)87KMOM$;4EUOV'VX$,6
M-[NYKS94G:E:=Q*2M."I(./9RQ0&Y=*\Q&/3!:F?<G,M<'D./6])5-;3.F*,
M0#.2Z/5,I ((YXZ5(_#'TLNAKMHE=^UWIR]:9[R:J/'7:[?(GPW$ )P?6%(0
M-Y5O!0 <;1S]@&^E*COACQ[T1Q3T+:-66:^1V[9=&N^81/=0P^$[BGQMJ5E)
MR#]&*AOCGVHM:Z?XTV#A]PRM^C+\]/L;UY>FZ@O"HS+7=O=WW86V2,D$$ \^
MOLH#9UZZPXSBFWI3#2QU2MU(/W":,W:$^ZEMJ6PXXKHE#J23]&:\[M=\,-;\
M3=3SM1ZIX,\ ;W?)H2)$^7J5]3KFU 0DDX'1(2/F%<.@.%&M>&.H+9?]-\&N
M -KOMN!]7N4?4KZ7D$H*%*!P>92I0/ST!Z15KKZ0L#]!KQ6^U/\ YS=6#@KV
MG=<7CCA=.'?$ZWZ*L2V-/-WZ/-T[>526W N260VI:\ *\"R1U P>AKM=OW5=
MDN/8\XIL1KS;Y#RK3A+;4MM2C\<WR "LGI0$5_ -L^IJVJ^#(6XZ+U4LGU5O
MY2;W#"3TZ@$@>S-9LO3=H%UUNV+5 "$:ZNK:1ZHWA*1IHJ 'AY#//'MK!SJ&
MTC3-N!ND($:*U4@YDHY%5\AE(Z]2 2/;6;KU+9E776Z_A>"4KUU=5I/K*,*2
M=-;<CGS&>6?;RH#7CCE:($?L=//M08K3_P!37#Y?>MQT)5N4^YN5D#.3YGJ:
M]0T=#\]>77'&^6V5V.'F6;A$<>.FN'R.[0^@JW)?<W#&<Y'F.H\Z]-+=J2TW
M1Y3$*YPYCP!46X\A#B@,]< DT!<Z50'(Y56@%0YVL[<_<."]T[J<[$88D17Y
M;*)$)A,J,B0VI]I:YB%,A/=A:O%C.S!."09CJ">UM$T<K2-IFZXTC<=0V2',
M!^$[6^VT]9W7-K29&Y;B-H^,(WY.WZ<T!F?9[5;W."VCEVI4I=M5;FC&5-6P
MMTM\]N5,)2T>70MI"<8QRJ\\50/K9:O]OP/,_$.5U>#:[>[PLTN;3(ER[8+<
MRB(_/6VM];*4!*"M39*%':!S23G&<DUK_P 2KSQY"^-#S.FX)LBK,RU96+G<
MFQ"0PE4Q,E84WEPR%LEMPA0VIPA.?.@,@]'#^PMX6_:]W\J?K92M:_1P_L+N
M%O+_ )N=_*GZV4H!2N&2I;;+JVVRZM*24MI."H@' Y],U WU^.+J>7Z'.^G'
MG]4EL_I* G^E:\CM#<5C.5#'9VOWK(:#Q3]4EM^224YSWGM!KNP>.'%B7-C,
M/]GN^1&774(<D+U';5):25 *60',D 9.!S.* GFE?*.8)KZH!5#\DU6J'Y)H
M#\]/I&_V:?%/[8-?DS-:W5LCZ1O]FGQ3^V#7Y,S6MU *4I0"E*4![G>A_P#V
M'D+[=S_\I%;M5I+Z'_\ 8>0OMW/_ ,I%;M4 I2E *C3M*(A.<"-<)N#4]^&J
MVN!QNV)2I\CEC 40G&<;MQV[=V[PYJ2ZCSM"N/L\%-9N1Y5RA/(MSBDR+.DJ
ME-XZE"005<LY2DA1&0GF10$8=C_6%GF\ +E?;*8#,1J7)>[Y5OA6J'W@9;4?
M[%/=% )"5.9SE*@?D5<>RCQCUMQ8AZ@.M;?;;?)MZV UZ@ZT0\'%/G>D-ONY
M:*$-;%JVE1#G+E7:X$-VK5_";4TRX7>+J6VWJ;+D3&E6J5;8,<*:0EQEN/,W
M.(;\)<.[(W.N8  Q6)=C#3?U*R]71(XC1K6_%M4N%#;DQY+@96W(*'BZU#C;
MFW$!&W<'""A?,9Q0&T?45%.K>S/HK7&NI>IK[&D7+UR'ZE+M3SN84D=TXSO6
MC&2KNG5HZXP0<9&:E7=@=#7PEW=@8(Z>1H#R2T;V?>&]P[ _&[6,G1MI>U/:
M+K?&8%U6Q\?&0TZ@-)0<\@D$@>S\-CA\&N'KL:,\=*Z0=3W33AD-19GJ1WH"
M=Y"E=\8ZCE#0^RB2%EW]3%%2[H$?^C2[0W/_ )YU%^/;K%H-PWLQ)*9;_<!E
MI\..:G2^\$K;#6[X0&$A:BGNU3<;9: +<!N:- 8?]8GA^U(+1T=;F@V L^OM
M)*T]WC<72T=I2WG]7! W*)'J. #6'<6N$NB+'HA3T+3-CM\@38<?<]'=[\!<
MI&4+*#L[]:2HME/Q7J^X.?'E-35M]4E;2TAAAM(6&41#;R@QP-Q2T?['+6?B
MW2,6,$AS.^L XVNEKA^MMQY25)N$)D(;G"&@%4MIQ*!&/-M!2"M4/K(7B:,)
M010'HDGL&=GXI_XIM,]!_P E/\]5'8*[/W/^M-IGW?J4_G5/:.GT"OJ@("_0
M%=G[^";3/WH?SJ?H">S[_!-IK[U/YU3[2@(#'8*[/O\ !-IG[T/YU4/8*[/O
M+^M-IG[T/YU3[2@(#'8+[/OGPFTS]Z'^>GZ OL^_P3::^]#_ #U/E* @,=@O
ML_>?";3/WH?SJH>P5V?<<N$VF?O0_P ]3[2@("_0%=G['_%-IG[U/YU/T!79
M]Y_UIM,_>I_.J?:4! 7Z KL_?P3:9^]#^=5ZT7V/N#7#S4\#46F^'5BLU[@+
M+D6?$CE+K*BDI)2<^Q1'TU,=* ^4)VC'X*Q7BJF(KAIJT3VY[L(VF4'F[6E2
MI2D=RO<&0D@ES&=N".>.=996+\34O.</=4HCO3X\A5KDAMZUX]:0KNEX+.<#
MO!U3GSQ0&O78+U/I^[:!U%(M :8BQI#")#[=G@0&04LX(+D,]VZM.T[RHY3D
M>2A5][,W&_77$S5FHK;JR%9F845LR(<NUR&%MR$ET)!8+;[A=:'B!=4E&2$\
MO$0GG[)\B%JW3>H[H[?_ *HA<G8K<JWJLTVW1HVR.EK'<3,J*W$I!<(.U1 .
M,Y)Q#LAZ/AZ0X@WINSB#"T_,M"9%NCLS8\LO,^N.)2ZTXU!CGNQA22E2W"#L
M\N:@-MB-P^8UK;QB[,>A[7PJXQW"1$?O";S:YD]4.Y.]ZQ&<;$B6CN4@#;B0
MZX[DDG*L9P *V2)VU@7'AP*X(\0>1'^YZX^7_57: \L=0=FSAG#[ '"'7S6D
MHB-6WFZV^/<+IWSH7(0X^\E:595M&X)2.0'3'+.:Z_Z'7AHWN,K2T%IW(WB9
M(=MR@O/ZJ"F]R]BD)YOLY/P:GXT*?^34IZH_^BZX#=?^'+7TP3_9,CH#R_U9
M\ZZ,!E2TI+#SZ06XBA\%);=;V+60UM,G"RTVKG"4KXQYSPW (:)- 1O^ASX=
MJ0GNM)L+E@$*;80Z^\'<_$)5&WC:ZIO<IF/N/KK69.YK9W9^])]GCA?=NT1P
MDL+NE[6_9+U>9++D5N[.O-RX8ANN(+"Q@SH_>@[9X[O>I*FN[ :W*D!P#U1#
MJRTXT&)!$>4I:8:D)= < 6V._P"X4H@R5'XYM\)1$"HQ4:[FAVW4]J[@RIQV
MXE0U3,0^B2S&2>^^#G2I4O8<(F8("FXN8@0&RE7>J<% ;:I]''V<%)!^M7:\
M_P!U2OZ6J_I<?9QYCZU=JQ_=,K^EK9!K[&/FK[H#6W]+B[-_\%=K^^I7]+5/
MTN+LX?P5VO[YE?TM;)TH#6S]+B[.'GPKM?WU*_I:K^EQ=G#^"NU_?4K^EK9*
ME :V_I<79O\ X*[7]]2OZ6J'T<79P_@KM?WU*_I:V3I0&MGZ7%V<.?\ 6KM?
MWU*_I:J/1Q]G#^"NU_?,K^EK9*E :VCT<?9P'_W5VO[ZE?TM4_2X^SC_  5V
MO[YE?TM;)TH#6P>CC[.'\%=K^^97]+68\*^R#PAX*:F5J'0^B(6GKTJ.N*9D
M=YY:BTH@J3A:U#!*4^7E4Q4H"@&!BJTI0"H]X]N6B/PPNK]\B7>7;&7(KKOP
M E2IS!3*:4A]H)YY:6$NG&>39Y'I4A5!_;$OMJ@<%[G:[G%ER1=G6(S18BR'
M6F5!]M9=>+*%E+: G>0<;PDH'-0H#/\ A W9FN&VGQIYJ<S9C%2N*FYMK;DE
M!).YU*P%!9)).0.M<W%4?ULM7_:>9^(<K&NS-ZNWP"T.F(P['CHM;24(=4M:
ML#(R2L)5SZ^( \^?.HYXN=I>/IVV<5[-JFS&TV2T6TQV;Q ?7<2Z])2XVPT\
MRTUEEQ>-^W<K:@@K*-PR!]>CB..Q;PMS_P"KW?RI^MDDK"LXSR]U:V^CB/\
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M5+M0MVK+'K'4W#Q-HT=IE.J)4Q\-R8TB3%;C-M=>\=:D(4E_:0"EL;<J )4
M* R#LXR&97 _1BV4M(;^#FTA# 0$)P2"!L;;3R(/R4)'NKXUUPZTMIO27$2_
M6G3UMMMZNMIFJGW")%0V_+)9627%@96>0YG/05>N#MFFZ=X8::MESC/0IT2
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MC;B!H5XDMG/,W-DUZ?US][3L;1>QO\J(I2E5RR*4I0"E*4 I2E *4I0"E*4
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ME*O?Y_17R=D'#A%_!;AK6E]SAM]J(1N62<\L5E-KA-NI"B@[AT2*1(&6@HC
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MT7IQ$>.B0X@#PX2G'/YZZFM-,VHEEQ3"4J6L(44G;E7D<>?G62?"7JS*$A(
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M7YDUV@, U'_U[M. ?V!JS_$V\?Z+5?KX:<__ "&K/\3;Q_HM>3LX04%I&?\
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MF *K2@* 8ICE5:4!0#%,56E 4Q3%5I0%,56E* IBJTI0%,8IBJTH"F*8JM*
A^0D YKZI2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-3_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &% 7L# 2(  A$! Q$!_\0
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MF%_Z*]D\X]>2?R'D>7V ]ZK&>$_3=VL>Y7B D7.VR8+-PU@J1%<?:*$2&_*
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M"Y41IT*<8"OJ]:>Z<^F:H-;-M-:VSP=V74?F:OE[BW*ZPD36Y,F0X\VPF<>
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M&S7]B"[Y[#4IEP(2OXE*7 %#CLK(IUQO$WK&%';CL-6MEEI 0VVW$Z4I X
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M->+\3!"D_6%4X-5@Q^Q-CGC<W*PKI-HR">/8_P#:I(>\>&Z++I3^T_3\H/\
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M:T.@*KMXZV0[LB$=_P!M(O\ ,Y5B/2J^^. $[+\=_I2-_,Y0M#D^=JK>$#D
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MYJ=/A]U0N%J.79T^2E:BIUI+X/<#D9'(X]?E45'<.4;DV_(D..NNI3YI>'O
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M+AM %&>.5?"H?AZ3A(0?. >![<Y(^^IF\6:$(W<+RB<B$UG/IRKM4'W35<>
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M@DX?2ZWTJ&>M)]T9^=3)HJ[>>$-J<0EWI[D\+SGD5?K6W@-TIK):757B9!?
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M8T98A8RHV80(X@]6<^S^4GRLYYST=/>E^DK2RDJT[;2GV4@QFCF!_N<^X/\
M!?Y'[WY8I5H2%8]#6:QZ&@*@:2_QFVM?\QVOZUBK?CM50-)?XS;6O^8[7]:Q
M5OQVJ60@(S6"DX[UM14$D0>(S9Q.Z.D%KA@-7^W?EX+Z3TJZAST9^>./GBD[
MPR[U*W)T[(L][)8U?8R(\]EP86^D$A+P'SQA7P4#\14V.#J!%50\1^AKMM7K
M:!N]HQHA]A8%TBHX0^D\*"@/W*P #\%!)^-<>1>5+S8\=SW>DDNMP_@LC]2M
MP?SWC]GV^2V(/%9]*:FVVX5JW,T?;M169SS(<M&2A7UVECA3:AZ*2<@TZAQF
MNM;JT>&TXMQ:IHVK!.**\7WTLMJ4LA*$CJ4I1P !W)J>"#+LA#+:EK4$H2,E
M2C@#[35?M6ZOO&_.H7](Z.D.0=,,*\N[W]&1UCL6F3ZD\@FO/4NJKMX@[])T
MKI*2Y T?%<\J[7UK(]H/JTT?4?$CY5-.D]*6O0^GX]JL\1,:%&3@(;'O*/J2
M?51QWKB;>=Z5]*Y?O\'O0A'PV*R9$GE?"?\ U^7\^R_-E?W-C-*S=U;KHU$%
M,:W-:;CJ9<;X<;=\Q0\WJ_??/_13GVSW NVA-2IV^UV]F6.+3=U\-SFQV23^
M_P 5XV[6#PWWFWTZ7U(FVR+8S;4/*M:P ZEU1)/P1@CFI+W+VSM>Y^FUVZX(
M+;HPY&EMC#D=P=E)/VXK''CI.6/E-_FCOZCJG+1AZYZH2C'?EQ=<K^4/(*&/
M4^F:WS4';4[EW33VH/[GFO'/+OS(Q;[DLX1<FAV(/[_ [>N#ZU-R59 QR*[L
M>19%:/G>JZ6?23TSW7*:X:]T;CFLU@#%9K4Y$8)K4N 5E5-C<#7MJV[TQ)O-
MV?#;#0PA"3[SJSP$)'J2:JVHJWP7QXYY9J&-6WP<.ZFZ%NVRTZNX2P7Y;I\N
M)";Y<D.'LD"H]VVVQN+QN6O=; /ZKGQW/(C'ZEO9*5=*$_ _'UK&UN@KKKS4
MW]T77#)1*4/VGM#G*(37HHI_?$5*^LM,R]3VE4*%?)=A<4H=4F$E!<*><I]X
M$8/V5R)/+ZVMNR_D]V>2'0K\+BDM3^N7/_BJ[>[[_89WAL(_N.V(#OAS^L54
MHCO3!VPVL?VUB&&C4MQN]O2@)9B2T-A+/))(Z4@Y/SI^I2 ?UUT84XP2DCS.
MMG#)U,YXW:;;LVZ:YI$!F4DI?9;>3\'$A0_3776,5HTFCC3:W17GQ1[262XZ
M!FWMIE%O>M:"\EN&PV@.J) ]\@9. :DK9W04;0&B(%MC2793)0'0M]*0H=7/
M3D#D#YUR[QZ)U%KZQ/66U7&!!M\ILHE&4RM;A/4"DI((QV]:<&A;??K594QK
M_*A3)36$-K@M*;0$ 8&0HGGBN...,<SDH]CW,G69<GAT>GGENI-U\=ARA&!B
M@)Q616:[#PC&*,4'L:@[=WQ//;2:L@V63MWJ.\-W&0B';Y\ L>5+>4GJZ$=2
MP<X^(J03B!BLTDZ6O,F_V*%<)=JDV61(;"UP)G3YK)_>JZ21G[#2M0!1110!
M1110!1110!1110"7J:V"]:=NMO+PCB7%=C^:1D(ZT%/5]V<U42'X*M?-6E^#
M$W.L7D/:77I)2D:<RI4%:BHY4'N5G/UJN'=K<Q=[9+@R4J5'E-*8<"5%)*5
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M'W<YX^--/<#=72>UEF<NFK=0P+%"2"H+EO!*E_\ \4]U?<#0#L/ -4L\97B
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MOZUBK?CM50-(D'\)MK3!S_YCL_UK%6_':I9",T445!(4444 4444 5@BLT4
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M2%VL6D^TI:/99;^L$_/&*5_QYG_X$MT?Y <_52A9:6BJM?CSO_P);H_R O\
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M3/!U?-3;>ZPU7LSJNU-VQ=L!O=E:BS/;&683RS^1\S ("5YZ0H ]) ["@+9
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/% %%%% %%%% %%%% ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-3_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O @<# 2(  A$! Q$!_\0
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MS" QB&(S" QB,PA (0A (0A (0A (0A (0A (0A (0A (0A (0A (0A (0A
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M0<HLWTJ/SV:0_09W[8BL@Y1M6Z>C5JV_<W0JU(=AA#L,>[>^A;?HG_E5K/\
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M<HVK=/1JU;?N;H5:D.PPAV&/=O?0MOT3_P JM9_I$A]A<;$C&NWHG_E5K/\
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MD(0@$(1B PKP3%(=2JYJ)L\[45[7X=+ZKJE;%T2$E+2,Y16NOF*6&4J"F"@
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M[T+Y+\L8RRA8?>&.8C&^GRCRQX\:>+$VZ_\ &&LGK*PFK]49O*$X1N]S 8_
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M+:02&%<>8W4D ]H2(L"-.EI?E'A<5;3W-,SDSNIFN#G7E1W% CBAO>^]C\7
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MRA <H1V9\W.BOWY%UOZ(Y[(V;;#Y V3-+,G_ )D9]IC63?GR+K?T1SV1>[9
MT<->T,V>[H^,53:^+U/?F^XB[O-S7= *>K7_ )J.:1V1S'B_KX6DNX_9[X7'
MUCV6Y!S&8PD$#CY(S&@.LD(0@$8[(S&(#RVINI=O:1V74;KNF=-/H=/2E4Q,
M!I3A0"H)'>I!)XGLBE>UG>6R7J'>DM_"#<=1H5X2DFPMNHT:7F&9DR[J XT%
M+0@@C=5D \1G$7QJU)DJU(.R=0E&)^4= "V)EL.-KXYXI.08I)K-J+J@_M$7
M'8VG&C5AWTU2I*5FG)RH(2'F$+1A*'EG"4J[T[J>>Z(D9KV>OV&*WL[2RJY;
MNBE1F*I5 VF>JLW/,O\ =+R2K=2I3CB1D9[!%N$\HUKT;:QUOTUJUY3,_H)9
MM+8M%MM^Y)>D/]S3K4H>^#J #]\1@$A6"GA&P^R[GE+TM.CU^0*C)5.3:G6=
M_P +<<0% 'S\<'SB,LXNQ[NZA"$12,'E^<>V,Q@\OSCVP&LWHVO' U[_ )Z8
M_7%10?:1\8;5#UEJ'OUQ?CHVO' U[_GIC]<5%!]I'QAM4/66H>_7%A)1U"$(
MR8N*_ 5Z(_H7V1_%BTJ]6Y#W"8_GH7X"O1']"^R/XL6E7JW(>X3&,LH2L_,M
M2K2G7W$,M)QE;B@E(]),=#<]Z2M$MZI3\F&ZQ-RS"W6J?+3#8=F5 $AM))QD
M\N,0;TCLPY*[&&I;S+BV74R\IA;:BE0_CS'(B(OL/HP]);CLFWJM-5B]DS4_
M3I>:>#5P*2G?6TE2L#<X#*C@1%?)5MH-QUFY9BH[)5<4W<'4_#*G9NGD3VYP
M;ZWCWQ&1C,2OI/M.7'=-V4JW:EHA7K(HZDJ:^%)Z?DS+2B4H[T;J#D#@ ,1X
M\]%3HZ>!K%\D>0W"H_\ \(S]RJT>_P LWS_^X5?L01;IJMTYU80W/RSBU' 2
MAY))/D S'V9R(UG:D[+UJ;,NU-L[(M"I7"^BL7$E,TFKU-4R"$*3C P,<^,;
M,$#"!Z!!6M+I4?GLTA^@SOVQ%9!RBS?2H_/9I#]!G?MB*R#E&U;IZ-6K;]S=
M"K4AV&$.PQ[M[Z%M^B?^56L_TB0^PN-B9_WQKLZ)_P"56L_TB0^PN-B1C0,?
MJU:N<X_5JUEK,V?OESK;ZY3'L5$SQ#&S]\N=;?7*8]BHF>.;;P\57J\[!Z9'
ME]5/FOO'ZFG?<+CU$>7U4^:^\?J:=]PN/"P_STZP_2<I3[L*>*/I=]3H^VJ)
MX\L0/L*>*/I=]3H^VJ)X\L=/AZ:<V80A%"$(0&.PQQ/(>D>V.788X'D/2/;
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MI44!2#P())SN\1YXMNG..,9RQAF$(1%(P>7YQ[8S&#R_./; :S>C:\<#7O\
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M,1(=X6[I/M^Z6B;MNO-34Y3']^FW!3LM3M)FQQ2<'"@#VI/ CB.(S%:?X,]
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M',M(<<)(0#G@, QZ/2;1*T-%9"K25G4I-'DZG.KJ#\NVXI2 XKF$ ^ GR)'
M1[Q(P,<XR^)C$"?!C,(1BR(0A (0A (0A >'UAU?MC1"QJC=MVU%-/I4H,#A
MEQ]P^"TVG\9:B, ?G/ 11S5K:%UE7:M*NS4S3RW5Z(W=/,TPVO,N!=3;EWL]
M4ZH]CA WQCE@<!D&+TZKZ2VQK/9=0M:[::W4Z3-IP4JX+:7^*XVKFE:3Q!$:
M\Z=IS/: [2-A6KKI4ZS>>FD@Z6;$J+F5R3$TI?WL32 ,EQ(X#).#@\N$8TQ>
M>9.3X[CTQ>V+=9;;N*\J-6M4M')=IU-K!2R^NA33I"T(4P>]*SX(4>84".*2
M(M!LE:,W(YJ!>6N=\R#5O7+>S+34M;4JD)33I).Z4=<?QGE!""KR=O$G%G9F
MGRU28ZJ9EVIEG>"^K=0%C(.0<'M!XQ]81@YC.)[,;7$IW>$9)Q G$>!UFNFY
M*'I_7UV')2-:OAF36]3J3-S ;ZU0[=W.3@9('#)&,C,8SR91Z.SK^J5H6S<$
ME0JM=%(I=:GL"6D)R<;;>=SRW4$@G/\ MC7S2+&UQL^\K[HLAHO2KDO6OUYV
M=&I-R+;?DVI4J!8* L'&X!D <CV$\(C"G2EM:YV$JUJ7;]4O?:;N6H];6*Q7
MFRPY;BF705N;PX-,I W4H3SR<\@(L;:E0O?6_4J\-F[6F?9G?@VGRU:E[@L2
M8<D5L[JDA+3I)5DG>![X9R./,$6(MS';:(WUK#IQM6RNE-]7W):F2U4HBZM-
MNRDN&U4=T$@). ,).. /,$<HNRED$A12G(Y''$1%>A&S'9&S])3PMN7G)NIU
M A4]6JQ,F:GYK'(+=(' ?R0 (EB"$<5*&Z?]\9WN!BN^TMM")T;N"C4J[K9G
M4Z8W#+N4^H7?(S!"J=,.90D+2D;R$D$]_G@2",X,/E"N_P!8-J^P-#;PI%!O
M2=F*4BJR#T_*U'J%.2ZBVO=+.4Y/6*YI';B*ZUG5BJ-[:%%:U?2JBV%4J5,2
MEI/R[KB:34A,%)'=:5\.M*%%)"@-TXX<C'B]<K3M6W:I:EEZG4A<[H8[*=SV
M7?U,GWGIBDS#J0"Y-N$X7O'!!(PG P",Q(=@Z0:N:AR,MI)JS1+?OG2F22IU
MB^#-$3DY+[H[FZ@H.4NIX$K/,<.S)1$9RDWRA[C3O9(JFD^IU6IEMSM/J6A%
MRL.O5.T:P"\).8/(2PY;BCQXXQCMX&+)VC9E$L2A2U%MVERM&I,L"&I.3:#;
M:,G)P!Y8^NAT>5H-*E*=(M]5)RC*)=ELJ*MU"4A*1D\3P XF/O!X0OV(9C@5
MC!X^:,E>,\(K9M)W%37-2;!HU(J=6>U+EDSM2H-$E)IQJG33J62!\(% .&\X
M )YE6#P.1)FRP^F0VS;-OA5RVS:DQ,*U$D$5)IB@3,HX'2[+))"B0,!"N!22
M1GB.<4MTRU0J54DI75:1U NWN^UI)54OU=1J:4,34R<[M*DY-?>YSPW\82,<
MU&/7V[;4OK;6JK?.FB'-,=J.W9M<S<%NSKZ^HJ9("7$;BS@M*P-W' ;Q!Y@Q
M/FB6S%3=1*C.:B:PZ16M;E[O5#NB7DJ8ZXXD(2$X<F$;W5K<*PI0.[RQY..4
M<N:3SY0LA8=P+O:QZ'79FFN4QRJ2#,VN0F.^6SUB KJU>4C.(]"@;HQR]$$(
M#:=T  #D!&0,$Q" # C,(04A"$ A"$ A"$ A"$ A"$ A"$ CCN>>.4(#RDYI
M7:<_?\E?$Q09)V[)*67*2]64U]_;:5S3GM\Q/$9..9CU0&(8C, A"$!^,S+-
MS;+C+S:767$E*VUIRE0/ @@\P?)%:=-]DJI:':_SUS:=W"BCZ<UU"WJS:+R"
MMH3(\!<OV(&3GS<N(X19R,;HSF$<IN"<[HSSQ&8P!@8C,!@\4F*2[?VE&LCD
MQ):EZ77O<4HW1I?JYZWJ5,%LAH$J6\TA. Z<#OD+SRX1=N.*D@B)\UAJQJFE
MNM^U=I?0KEMK4&UM2S37@]3ZP[*BF5ZE/IXJ9+B  D\MY*A@\#YXN9H)HY5*
MS*6IJ#J[;5*9UCIDFY(.56GN$J<9. E3H3WA<*1QYA.3CGP]3I]LT6CIEJS<
M]]VV)NE3%PLH1/4F6>*)!3H427@R.&^?+V<<<S$LI&Z" 8RNPMZ@0 ,#A&0,
M#$9A&+)#^J^U?I=HQ=<C;5YW7+42JSK/="&W$+4$-YP%+*0=T$YQGR&*G+UM
M:T+NZMOS=Z2^L>@%Y3#AG'N[DSD]077LA8<2#O\ 4*!QR &,C!SFS>U;LGVQ
MM.V@F4J+;4A<D@"NDUM+84Y+KY[B@1W[:CS0>':./.HVCFS+I=JQ<]<TLU1T
MR<LS5:ARX??J=MEV7DZI*Y"432-W+0R<=[@ \<<<B$<R]GL+<T!J5H5"5L"G
M4Y6KNS-?I+LDWUZ5O6XI0*@XTZ3D-CF"..?(K.;7Z [/%I;.EJ3-"M1$ZXW-
M/]TS4[4YDS$S,+QA)6L@#"4@   8'Z8_?0'0J@;/6GDK9UMO3TQ367G'^LJ$
MP77%+6<JQV)'^:D <SS),20!B+VM#&(]1(Q&8P!C,9@R(0A (0A (0A (0A
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& 0A" __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>forms-3_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $\ 8X# 2(  A$! Q$!_\0
M'@ !  (" P$! 0            <( 08"!0D$ PK_Q !:$  ! P,# @,$ PD-
M P8-!0 ! @,$  4&!Q$2""$3,4$)%")1%3)A%ADC.$)QE=+3%Q@D,U)65W5V
M@92RM"5BD34V0U-R="8G-SESA)*AHJ2SP=0H1E6"L?_$ !L! 0$  P$! 0
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M;<F4IOQ R76U(YE.XWVY;[;C>H$RWHHFY-TFX3HPG+&([V./P7E7E4!2DO\
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M^OX12AO\@*ERN*4\=_\ [5RJ[NY$K"E*4**4I0"E*4 I2E *4I0"E*4 I2E
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MD(N;)0J.X^8[;P5RVX*>!:"O(K'$=ZVI-C@)4E0A1PI*DJ20TD%)2.*2.WF
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MEJNJPE]ZV.J4HLJ_W%*"C\^WG6ZZ49G@=_L[5HP*Z6J;:[,PU%1&M3@4W%:
MXMH 'D-D[#\U5A]H1=]/$V!RWJ%M&HP=A.<C&/O9A\U?]+Q^IL%=N7S[5O\
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MIK?C&-KD/>X7?![[[K!F)2M2"ZB)(+K/%12?R-_3TKTHP=,Q&'V)-P=EO3Q
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M&2!Y]Q7IV1N/E7F-[4:W2M']=M(-;K8VL.V^6VB2IIM.Q+#H6 ?F5-E2>_H
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M-B?FI(]:B30?3S5+*NH&YZPZG8Q9,!D(Q_[G8-AM$T37WTJ?2\M^2^GX5$<
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M5'>H37_674'6K',IF1+399."W21,LEND,J\2*I11NV_OMS(\-/F!7M(6QO\
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M4E945@@#5/9]:N91>M"L#P2PL"'.AV"YK1/N>/R%0?$\0F$?'2\ M*5*7X@
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MGK3S%+_D\^->K198T.8PBRRG$MNH3LH!24$*[^H.U >AE*J']]:Z<?YW7']
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M]:N7[P7I[_HGQS_#J_6J?DUF@( _>"]/?]$^.?X=7ZU85T#=/@23^Y/CF_\
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M)(4.WF#W!%2\D ]Z @+]X+T]_P!$^.?X=7ZU/W@O3W_1/CG^'5^M4_UC>J"
M#T#=/823^Y/C?^'5^M5><.]F?9H75YEN37K"L7D:.2K<IFU6,.K4IF1Q8V66
M=AQ[I>[\C];[>UO=7]?\.T-7C'W9W)5HBY#<A:HLU;1,=IXH*@7G/)M)VVY'
MU/?L"1(C*T/MA:%!:" 0H'<$?.@($'0-T^$?^2?'/\.K]:NZPSHWT6T^R>WY
M'CFG-CL][M[A=BSHK*DN,J*2G<'E\E$?WU,H&PVK- <4IX=AY5RI2@%*4H!2
ME* 4I2@%*4H!2E8)"1N: PH@>9J.,NZ@,!Q*PY9='LFA7(8NP9%W@V=Y,Z9#
M2" >;#14M/<C?< #S.P!KKNJ+&]0<QT3R6TZ77EJQY@\P1'?7\*W$?EM-N?]
M"XM.X2X0>)^7UA3'HZP_%]3NH+'+Y@^GPTKAZ;VB1:<MAW!WE<[O<I+1;4P^
MG?DXVV05EYT J5L .W:)7N@<-;8F;:^6/376.9@D++<.R+''+3<;=8X:,@E8
MXAV6M9FPX[FR7)"V>+2E<5%M2#V/$ V_Z0[+DV/Z0LP,@LB\8@,S7F\?L,C8
MRK=:$[)B,R2%*Y/\$E2R5$\EG<^@^S1/IQM>@^1Y>]BUWGQL4OLA,UC$U!)@
MVN2=_&7&_*0ESX?P>_%.W;TVEY(X@BJGV#<SN*<A\ZZ+-LZL.G.+7/),END>
MSV.VM%Z5-E*XH;2.W]Y)V 2.Y) &Y-53SGKNM^?Z)ZIR-,(%^MFH&.6H7!BV
MW^T*CRC#6XE)N##2B0ZA*"I8!V.Z1R !J> -UZQ^I][0)G%[7!N-GL$_(C*<
M3?\ (6GGH,%F.E"E@,L_&^^LN(2VT" ?B)/;O7_2ZT3L]U#R7+.GF//TKU'8
M2P_E5CSVWOLVO(XTSQ7&KB& MQ3:^8<6A((^'X>P)W_73]VWW7673_&<&UMO
MVKF-9K:+A*O2;K.8N4W'G6V-VKDPX6R(;GB+\,(4G<$]@=NUSM'M%+%HY:9K
M%KDW.[W.Y/B5<[]?99EW&XNA(2E;SQ WXI 2E( 2D>0[DF[$WPC<K$Q/CVF$
MW<I+<RX(8;3)D,M>$AUT) 6M*-SQ!4"0G<[ @;FOOWI769'D=MQ2QW"\WB:Q
M;;5 87)E3)2PAIEM )4M2O0  T;Z@_2^7VW8W9I]VNLQFWVV"PN1*ER%A#;+
M2$E2EJ4?(  DFHLU2Z?M/NI5>,WO)6SD%IAV^8B#'0Z/=7VIK2$J=\M^02E*
MFU@@I)W'>H0O'4UD>OF07*W:1QK+DMNA0%-WO3C.(#]EN-WAO#M+B/N=O#6A
M0 YI  .ZOK)KM/9VZ@7/[C<DTFR6SW7'[[@,SW>);[Z@)EIM+Q4N'S(^%?!(
M4WR22"$)/K46=R[;$D=,^!:EZ3HON$Y;>&,JPVTJ:3BN0/O$W)R,=]XTI&VQ
M+6R4AS?X@1Z>4ZCRH!VK!.PJ^)$9WVK7[UDV/"]Q<4N%RAHNUWBONQ[8ZZ ]
M)80 'E)1YE*0L;G[:T77OJ4P_0*VQEY [.EW&:VZ[&MEI@.3I2F6QN](4TC8
MI9;!!6LD #L#OVJEFLFH&L;..8)J^JQV;4^WXK.%\LVH6 ++*7;8L%,V+.A+
MW6VE37+<H)"%MI"N_*HLEM@EOJ?Z?-.<6P'"[)%TYU RUZV6J58,99Q"3)<%
MK<4$N-NO.!U/'=:$ +<*D[ [C8"K%].UAS+&M%<-M6H-R3=LQB6UMJYRDJY\
MG1OV4K\I24\4E7Y123Z[G;L1R>VYMC%IR"SR1*M5TB-3(KR3V6TXD*2?^!%=
MRD;5<JZ9-P*XE8 \^]9*MJJIJOU=P;SEZ-.],LKMMFS<SS$C7C)[2^Y8+A*:
M_C;:B6D@>/W3N4\MOJCXR!4[BDD:OX%B?51IK>K#;;['-PM5Q*8-\MRPX[9;
MO&4%(<20>RVU<0I.XW2HCUJM&$Z!'%>HC3F)@.#Y39,@Q*8X,SU(NK!CP<GB
MN,*4^22ZHR7'9"]T[CX-M_)*:^CI_P _S#2WJ\OV-YW@4C3Z'J6W[ZTAF6F7
M:G[Y'1^&<B/)V&S[(2I2%;+"T['?TO@A(*=Q56,C?!R2" -ZY5C?:M5U*U*Q
M_2G$)V2Y-/\ H^U1>*2M+:G'''%J"6VFVT@J<<6HA*4)!))J; [+*\QLF#V=
M=UR"Z1;/;4.M,F5,<"$<W%A#:=SZJ6I*0/4FH4UIZ7+1>=(,KL^G5LA8SE<F
M[)RR!-8W07+TT\'VW75DDGDI/ []DA78 "H+U%U/S/JFPS/(V(6.V:B:=RV#
M;;KA$AI5GRS')*!NEWBZ2AUQ*T^(E)*=RD)3W"JGGHCUCN&L6A-K<R%I^+FF
M/NJQ_(8LMOPWVYL?9*E.(_)4M/!9'S4?E19(29H[F%VS[3;'\AOV/3,4O,Z*
MER99IZ>+L5X$I6G;^22"4D]RDI) K<AVK"4\=ZR3M5!A9V0HCY>M50C=;B,<
MZF\NTZS6T)LV(,72-9K)EZ.7NAGJBM/JB2EJ.R%J\0<%#8=MCZD39JOK99M(
M9N&-7R/+$3)KVU86Y[:!X$1YU"RTIY1/PI4I(0#\U>@!K[\\T@Q#4_$;_C61
MV*'<+1?1_M!DM)0IY8 2EPJ W#B>*>*]^2>(V/:IWE[B@%YZ*=6LLU/RQG&H
ML#3J-CUWN,FU91[V^PO)(<J4F6S;W/=RE89;472IP[J"E!*?+MZ5V]+R(; D
M\/> VD.^%OQY;=]M^^V^_GW^=:MH_IU^Y3IU8\3%\NF2)M3'NZ;G>G0Y*>0%
M'B%J  /%.R1]B1YUN57I8=;C?>HDZFM9I^B>G";Q:+?'N5\N%SA62VM3G%-Q
M$293H:;<D+3\26DD\E;=SML-M]ZEA:^(W W^P#>HZPO5^PZD9WG>&MPWXUXP
MZ='8EL3VT@NI<:#K,EH;D^&3R"5=CNA7V;S<%?\ $<<>ZE\ZO^G6OUIM-TR3
M3:0F3X5D+B+3>(MQB+0AQ32]UI6W\0!!!2I((J2.FG2[431"[WW!;G=VLGTO
MA-H=Q:ZS9!-SB(4H@P7D[?&AL#X7.W8@#Y)CS-.D#*=2>J;+[_<\@=MFDU^B
M6E^Y6VW/^'*N\B(%AN,M:?C;92=EJ((*MT@>6XN TV&T\1Y#MVHMB'-/E6:4
MJE%*4H!2E* 4I2@%*4H!2E8W - /0U!W6A=\WL'3QD]QP-<YJZQ?!=DNVE(,
M]N"'4F4J+N"/&#044DCMW/GM4C:F:I8OI#B4S)\ON[5EL40H2],=;6L(*E!*
M1Q0"H[D^@/;<GL#40Z2]0SN5Z^Y7ALN\6J]8[<[='R+"KM:7$.,2X0 :E,EQ
M)(6ZVZ H]R>+GH *F^PVR1#I+J[=](+Y@US@YW/U;Z?]0)C5LM=]O+P?NN/W
M)W<-L2'  5MK4"@A0"D*['8_7M*O0W$5:Q1M4&K<J)F+<!=M=F17E-)ELJVV
M\=">SJD ;)*M]M_L3MI5IZ*-);-J<C.K?CCD.XMSOI5%N8F.HMJ9VQ E"(#X
M8= )V5MV\P-ZG9*>(VJ]Y+&0-JZO(\FM6(VI^Z7NYP[/;6 "[,GOH89;W.PW
M6H@"NT*@/6JU];VG%]R_#<5R:PX[%SO[C+RF]S,+GM!UF]Q@TXVXV&R"%.H2
MOFV"#\0[ G8&%63L^J/0I'4_IG:W,9R1N'>;1-;OE@G(<3)MLB2V=VQ(;')#
MS9(VW(/'<D;C<&*>C.\3-3M<]1,MU36FW:XVR*WC\C$TQBPQ:;4E?-*V"2KQ
MT/.**R[R(')('8@G4>D_4#$L=Z@[-8]&+^NXZ9YU"GW&YX*^%>\89/CA)6HM
MGNPVZH^'P/8J^KN G:^T>RPF;F]<D0XZ+@\TAEV6EI(=<;224(4O;<I!4H@$
M[#D:JP3N.KQ73;$\(>G/8YC%GL#LY?.4Y:X#494A7S<*$CD?/SWK8]@!61VI
M4*09U8=1R^GS"[6_!M[4[(<@N#=GM*[DLL6V/(</9V9(\FFD@\B-^2MB!ZD0
M%K!*U:TGLL)G76\V?6'17)78]JR1=KMHM3]E6XZCPW06U NQRO9)).^Q'EOW
MN=GV V'4W$;GC&36MB\6.Y,EF3#D#=*T_P#^@@[$*'<$ BJFXUTA:EOSXVE^
M7YJB]Z 6*:S<K<VYWNUR0A86Q;92_P#J&5H"BH#=8X ; ;)(=#Y=.>E+-\FU
MS&5:AVZW6K[G[[/N\#+;!=5B??4O%M,2.0D;L1&8[:6RRI1Y<0 -BHJM/BND
MF/XKGV5YG$;DO9#D@CMS94J0IW@TRDI:9:2>S;8Y*5Q3YE1-;FV@(3L!L/D/
M*OTJW)WG$D(23Z54G)]:M1-=-=,LTOTHR6V:;MX6VE5XN]]MJ9D^<\OZB(L-
MPC^#C\I\^94GCV()MO4 ]2_34_J;(MN<X-<AB.KV. KLM_;&R'T]RJ)*'_2,
M+[C8[\>1([%0,\2E;[V=2=59^<X3?,9M$K7W&X-OC2WXLU<.#EN+&:'G665'
M=,<OJ2$+) \RGL"0)XT/Z2X6+Z49K9+\'[))SUZ3*O%CQZYN(M]J2^M9]WA;
M!(;V;6E"EI2.?$]MMJ[_ *=M%,DQ^^WO4S4R;&N6J.31V8TMNW#C!M,-LE34
M&..Y4$D\E+))4K\VYG=/85EW$.JQ7%K7A>-VNPV2&W;[3;(S<.)%:^JTTA(2
MA(_,!YUU.JNH<'2C3S(,PN46=.@6:(N6]'ML=3\AQ*?1"!_[R=@D;DD $UME
M?F\T'4*0I(4DC8@C?<5B[]"HI#;=0.IW-=-8VMF(Y#A]XM,E!N<?3.)#2^%P
MAONS](@\E2@D'D!LD+!2/Y)T:+H._P!2UKQ"1A.*VI>B.1V%CW*7<KFOWO%'
MU7!<JZ*:9(4IR4^Y\ =21Q\/S"1LJ5LEZ4]2M-LTND?0?*(.(8'FBUIOUKG-
M>*BQ/*^O.MR-]@M:04^']4*4D^0'&RVD^F5ET>T\L&%XZRMFS6:,F,P'5<G%
M^94M9]5*45*)^:C62MN2_0Z-6@V,RKU@5WGKN=UFX2PXU:%7&X./@.+;#9D.
MA7\:\$ @.*[CD?G4DH[)K.WV4VK$(K?U.]0E_P .S7"]*L&7"M>=YHM:8E^R
M!!3;;>RC?FL;["1(.VR& >Y(Y=B 8IRF7J?BFI&'Z?ZSS;-G]MO=Q,O!LZCV
M\P4V[(&67?=FID5H\5)W45)\P2/78A-H-<]"<8U_P*9BV4Q5.L.*#T2;'(1)
M@2$_4?87YH6D^OJ-P=P:A32+ITU6O.;8[<-;\MB9/;-/I"_N79MZ"A5S?XE*
M+G.).Y>2VKPTH]"%*)))*B*W8Z?I+Z6,FQG-(.H&>V>/B63VRV"SJ8LEX5)^
MGW2XZN3<;BL !U3JU\T(.Y3YGN$A-D]+M(\?TFBWMJQ-2"]>[H_>;C,FR%2)
M$J4Z1R6M:NYV 2E(\@$@5NK:>*=MMJ*^H?2J2Q^4N8S!CN/R'4,LMCDMQQ02
ME(^9)[ 5"O43U"S-*V<>M6,6R%>\IR%$N1"5=)?NMLB18K)>DRY3X"N+:$;;
M!(W42!VJ"^JB0W=>H[%L>UT1(BZ W!M+5E5!D+:MTJ[G\B[K!2I('Q>&G<(\
ME$G9>VO.:!1\6UCR/IQQW)[D=-,ZQ63>(\!#_O,G$GFWV]BVI9)]U>(2/#/9
M1&V_8J.*NT9+!H=KQ:X]5^F6=,8;J+=,.RF:T;AD^F6HCZYL>&\H)>:G0WW.
M+T=&X;<;=3ND=@H #8W@Z1-5;CK1T[8/E]W84S=9T'PYBC]5YYI:F5O)/JEQ
M396".VRJ^O1C0AC3:VW25?KLK.,SO1WO.3W&"RT_-2$)0ED(0-FV$H0D):W(
M\R=R2:DRVVV-:(+$*%&9APXZ$M,QXZ AMM"1LE*4C8  =@!67<C$^H5\J[E'
M;EMQ%2&A*=!4VP5I"U@>9"=]R!\Q7P9>[>F,8NR\<8AR;\F*X8#-Q6I$9;_$
M^&'5)!4$<MM]O2O/K1G1' ^I:PY@-1+ID-@ZF;/(6]?+O.GKC3[*\"2P["0A
M0;]Q2-N/$;;'NH;I-0IL?4SU9_3_ +_9I^/7N-I-],2[--R/&+N]&O[3L%0]
MZGLL-)/\#CNE*%E9^([';;8'J+-"S'1;J)T?U&1J3;]6L*SDIPUFYL,(;NTV
M,Z5.QW'_  SPDAA2>[P 4E)(6/EWVB6C^1=6^ 8CJ%D.>3K0^Y;9N'Y&U:8;
M2H^3VYJ>XHNH6H?@?'(W6M /-.X[>=79M^%6*ULVIF'9+=$9M(4FW(8BMH$,
M*'%09 'X,$=CQVW'G55D1Y.Y0@#OZ^5<MJ)&PVK-1%%*4J@4I2@%*4H!2E*
M4I2@.*E<0:@+/>N?1?3C4)S#+_F+<2ZQW$L3'VXKKT2"ZK?BV_(0DH;4=O(G
MM^5M4U919EY!CMSM:+A,M2YL9R,)]N<#<F.5I*?$:400E:=]P=CL0*HA@688
MSTEXM?\ 07J!M-M1B3\>5,M65)@%47*8Y)4ZA](!)G#<#S*E'CL=^)5 =!U"
MYUJ=8M39]_5J#&LU_B,3\AMN-2KLVK'I>--*#,:,I@#^%2ISA)Y;DH  &WPU
MO3_2XM_-]$M5].],']+,Y>O;<G)[<U-:3!@P%-J$M+S*%<2MQ("4%I())',
MCMN?1UT]VN7H=@LK4'#&95QLDR9+Q=K)8R'[C9[<X^5Q&5J4"4K2C@>/Y/;R
M([6S\)/RJK!-\AKLG;T]*Y$@#O6MZAZ@X_I7A]SRC*+I'LUBMS)>DS)*MDI
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>forms-3_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_014.jpg
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M8K*8EE*+0,?ORU:J[E74S,24G:64IIIH-((F+E"4LIL57))-XD$>&IV,&_\
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M'6<@:6=>D2;PU-JW)TJF J$QBZA561QUL[FUAJ6Q51,Q90X=S,TTH<Y*O?\
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M8[]">X0PZUCI%-0WXNXA)6 $J6K-QOZ1PUZH9=0VCL34S,2[LLII)<#10ZX
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M">S77CIOC:I&%ESCQ'-H<0?ZJ1NMO.F[M[8:>-L'S#[#[#*&\NHL$J( UUS
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M[Y2_UL'L?>1G^!MF?OE+_6Q-&PG!.RG!-#J,MLHE</RM*=F@Y-HP\^AYLOY
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MI#]$J<Q)3  =964*RJS#0D;_ $1H0001[&^!)^XACW\HT_JK4>B[KB6T$J(
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M)&73+,M*1[E=1)4$CJW$]9,2AM%VQ2DC+NI=G&F1J$E.ENN^H[!ZXK57MN[
MFUI:YJ81J"I*"H#@=^_=\,1U6]I,S4,X0AL%2<N=&9)W[^_MA 5B>=*@4N%
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M$$$$>QO@2?N(8]_*-/ZJU&/+)VNL;/N5J_(/.B5,UA65=:4DBZU)=F+W!W@
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M&ZNX6UM'0_0F$3H3S:0I1"M59E9QJ"=>K6PT^&.Q%!8K:T.NK<#)LM#CW0!
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MA/-$>ZEPJL H[P.))_;&W,R04A332$+*-5*43SBCJ#J8ZES$O($LK;#W$AL
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M7\I1XW)A+F0TA#B4I96LJS-I%\MQ8:GCK;2&I5*&'&RU:[3=@2E&^^_X_5"
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MA)-E'+FN+$=8)MU6TO#.:Q4^GQ=T2J)9EMM2 D(!*@>)&Y/'0>F\,NMXP?\
M&7D_S#:3<J*+E1MIQA@3NTY+3JTN3" X3E3<:'>+_!"IA?:5+Y0/&6M+)N4[
MB2=3_'&)BPMM-E9=;:!--/*L.@D6S'JU^*)BPOCMJ8*5J4E+E@E0$2'2JRS,
M %#B%"_]7^.N''3JH$= A-[9AT876Y]"T#.-%=D)58ERW<I0E:%"_;I#(Q$
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M&^/:-06Y83:I92ZC-+;)RI4<V1 MO)!&AW)M?C$@UW&#--IA3,A >+73*+I
MMO%['=_'&(6Q1M"%3=*6@I(N=2JUM>CT1O'48BRLXQ8E)L.HR%W7I*!R\<IT
MN-]Q<:PB26UB6E)A?22LK< NL^4.M/=O^>)/P5MPE9F8:0Q,*<F+E24K.O\
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,@@@@@@@@@@@@C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>forms-3_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I ;D# 2(  A$! Q$!_\0
M'@   00# 0$!            !P %!@@! P0""0K_Q !K$  ! P," P,&!0P(
M#@\&!P ! @,$  41!A('(3$305$(%")A<94R5X&1TQ46%R-"4E5VH;3!U DS
M.&)RL;+A&"0E-T-%9'1U@I3"T=(F)R@T-39$1U-68Y*6L\1&97.$HN)FA8:3
MHZ3P_\0 &P$  @,! 0$               ,! @0%!@?_Q  W$0 " 0,# @0$
M! 4$ P$      0(#$1($(3%!4043(F$R0G&1@:&QP0854G+1%",S8C3"\/'_
MV@ , P$  A$#$0 _ +V<6.+ETT)?[ZA$VT6NQV73R+W)DW"&[(<6I3[K0;2$
M.M@9[, =22K%1?@+QEXC<7K==6+LC3>D]4VEY+<^QNP)#ZFFW$A<=U*Q)3N2
MM"@>G(Y'=75Q-X3VGB]QT5:;^X^Y9(]BM\V3;6R U/V3910T]RR6PK"L#&2!
M4MLGD[Z2TCQ(AZTTQ%.F9;<-R!,A6Q"6XUP;404%Y..:D$$I4"",D=*2M\KM
MB(IMRNR0)A<0R.=[TSG_  /)_6ZSYCQ#_#>F?<\C];J8M A.#R]M>\CU9]E7
MQ?=C,?<A?F/$/\-Z9]SR/UNEYCQ#_#>F?<\C];J:<O52"D^JC%]V&/N0OS'B
M'^&],^YY'ZW2\QXA_AO3/N>1^MU-,CU4@1ZJ,?<,?<@SS/$".A;CM^TNVVD;
MBM=HD  >))ETW66^ZJU&'3:=8Z+NJ6SA9A0'G@D^!VS#BM_';0-RXC</IMGM
M#[#<Y3K3R692BEB4E"]Q8<*<D(6!@\C[*&6I>''$*_PI[NG=*:<X>S?-F(_;
MV^?B;+0EP*<92ZVT$-(*>044J5GPH4?=D8^["T(7$0Y_JUIKW-)_6Z\=AQ +
MRFA?M+EU*0HM_4B1N \<>=T&[7P:XFW/4=M^J-VN%IT<F=(=59F]1NO2663'
M"4)5( "E@NY5MSZ/B:A[_D[<6TQH;Z;A)>O\JW1(4Z\-ZA<:<;#<DEU'[[>R
M>2QS!'CSHQ?=D6]V665$XAI"BJ]Z92D<\FS21@?Y737)U!JF%;4W&3K+14>W
MK4$IENP74LJ/@%F9@GU9H57/@UQ1@WZ<S:;K)DQ%3DJM]TE7YTMQ+>$X5&<C
M*22ZL\_2)R<@DC&*(/"3A-*TYP+MVC]20($R;'CNH4RM*7V@LE6TC(QWCGCO
MHP]V&/NSOM.JM0WUP-VW76A;@X3@(B1''23X83,-/8A<1#_;K37N:3^MT'+5
MY,\M&C^%MJ7"BVMZQ+<7=G+2\(KB\MJ2-KC8"E<R.^HS>."7'AU5J3&UI*,6
M+%[!IENXA*V'@ZK[:XI0RZ"C;@G)ZY'?1C[LG%]V6)$'B(?[=::]S2?UNEYC
MQ$_#6FO<TG];H(W7@KQ0^H=UDM7J9<;_ #[OO<[2^OM-(@@?!:0DI2DYYX)'
M4\Z@MOX;<;(EWMUCNR[O>.SM\LLJCZE<C,1W%/9CK<="3VA0D_!))Y8YT8^X
M8ONRU @\0_PUIKW-)_6Z0A<0C_;O3/N>1^MT%=':<XE+XL1=.S=27&;IJ&U'
MN=WG+#K>Z6E.TQV7" %-*.%$#I\M6>3C'4&C%]V3C[LAGF/$/\-Z9]SR/UNE
MYCQ#_#>F?<\C];J:#!\*7+U5%O<,?<A?F/$/\-Z9]SR/UNEYCQ#_  WIGW/(
M_6ZFF1ZJ7R?DJ<?<,?<A?F/$/\-Z9]SR/UNEYCQ#_#>F?<\C];J:#Y*61X"H
MQ]PQ?=D+\QXA_AO3/N>1^MTO,>(?X;TS[GD?K=308]7S5GV#\E3C[AC[E6N-
M_'SB3PHUK8-.LS.'^;K'=D&??1+@,-=G]SD.N9)^2I-P+XMZ[XU:7EW=B5I>
M$(LM<-2X\)^5'>4GJMIT21N3[4BI;Q)X'HU[K*S:HC:DN&G;O:V'8S3D2-&?
M0M"_A;D/MK'S5V\)^#%NX3HO3D6Y3KQ/O,H3)TR>&DEQS&!M0TA"$ > 348^
M[*XONSO$'B'^&],^YY/ZW6?,>(?X;TS[GD?K=30$8[C\E+(QW5./N6Q]R%^8
M\0_PWIGW/(_6ZQYCQ#_#>F?<\G];J:;D^(^:ED>KYJ,7W88ON"HZWO*;N;2K
MB!H)-U"MA@F*X'MWAL\\SGU8I^<C\06FUN+ONF$-I&XJ59I(  ZDGSN@IJ'@
MEK&ZP=:Z>:TE8'&K]<C+CZCE3TAV&D[<+#09*]Z<9&%]_4=_*WP'XNQM6S2[
MJY^YV]Q:@W-=N10A48L[ PN-L(!SWCQSG-&/NR,7W8<8GU^7",W)BZATM)CN
M)"D/,VB0M"AX@B7@UO\ ,N(GX:TU[FD_K=5ED>3UQGA1M/Q;9<X\%%K9A-M.
M0;T^VA*6S]N2IL^B21G ">?>:<X'#SBUK9C6D*V:LNMI@VI3S&G)<Q;K#LI;
MBMSG:E0)*4#<A*L'X61THQ?<,7W98?S+B'^&M->YI/ZW3<JYZP;MCMQ7JO1R
M8#1(7*-M>#2<'!RKSO P>5!.)P4XNHM\5$FZ/S;.W-[5_3RM2.M.O([-2<B4
MA&4@+(5LR00/DJ26_P G^_N>2=/X:SFX2KO+2\E;:I:G6=JY!7M4Z4A2O1."
M<9)HQ]V&+[L(LJ\ZM@J;$G5VC(Y<;[9 =MSR2IO[X9E\QSZ]*[6%:\D-..,Z
M@TL\E"BE:FK3(4$D=0<2^1'A5=M0^2AQ"AZI[.P7R')TM#LKL&TB9(4B9!4X
MM)+._:=[8 .U74=.=.6CO)AU7;M6RFI<EZ!IOZK7&YK5;]0R4&:7FTA@+;&"
M E8.4YP<YY]*G'W88ONPX09VM[FE*H>I=)2DJ&X%FUOKRG)&>4OID8S6R>YK
MJTPW9<[4>E(D5I)4X\_:9"$('B29>!5=6?)CXG6J,Z]:[FW#O3]J8BOW%F\.
MI+A;D+6MD@C "T* W@<ORT=^!^B]3Z9TE-@:NDF=VLI:HT63+\]+#)Z(4X4C
M=SR<'..F34*/N1B^[."W\2Y]V=+4'B1P\F.C!*(["UG!.!R$SQ(^>I6(?$,_
MVZTU[FD_K=!:X^3%=97#GB)8FHMJCSK]J?ZJQ'8Z@T4QNW;61O2@%"MJ#@#H
M<<ZY-3\".*C,N:Q8-2S%Z71>%2F+.Y>70\N.IA*=O;K!4-KH*MF['/KW4*/N
MPQ?=AU\QXB?AK37N:3^MTO,N(GX:TU[ED_K= QC@-Q1<8NTZXZCD7&\MZ>8A
M6I*[_*:91+WN=JISL@@*.Q20'",DCY:@L[A'QFT]*L\62;I>K1,U#$=-LAZE
M?:(83&=#X=>&2VA2]AQN5DXYT8ON3B^[+6^9<0_PUIKW-)_6Z0@\0R/^&M->
MYI/ZW5<WN'W%NTW33.GXFH[GYS?%2(MY(DO2F;5;2Z7&E-R2 "^A +(40"K>
M">@-6YA,"+':825J0V@(!6HJ)P,<R>9/KHQ?<%%]V1/S'B'^&],^YY'ZW2\Q
MXA_AO3/N>1^MU-/D%9'L_)1C[DX^Y"O,>(?X;TS[GD?K=8\RXA_AO37N>1^M
MU->7@*7+/05&/N&/N-^GVKLU!Q>9,.5-W*RY!CK8;VYY#:M:SGQ.[YJ<ZPGI
M6:8MBZV!@V/]T-=>?_LK#_/)-541Q:UX;C);&K;IM#SB0"^   HX[JM8T1_1
M$70'_JK$/_\ <DU434FEY-ADIEOEI+4Q;KC327 5I3O."H=U,H;Y7,]^;=R:
M1>,.L(D9HO:AFJ:<4$./J<W%'7G[*T3>*VM8\C[7J2Y/(5R06WLI]N*9=,P4
M7N,["</)Q.WY>ZG"W6+LYC=N=;\U+9VH?)R":U."N:]/'S7:YT2>).OVD R-
M37*(>N>V!!_)3C!XD\1;<AF:[>)%QC8)5'[;TU#Q!QBMBD)TX^\Q>(@E1,'(
MSG'K!'=7(LNQ9*)>FE=K$3C?#<7N 'J\/8:%32Y.C'31>S-PXTZ@O7:+A:@N
M+"D\EQE.[76SZTX_+7!)XGZU8;/^RBY[C_VW3\E<%TL\'7DY3K+*K'>&Q\(>
M@I!\?8:C$Z1<=)RTV[42 K>=K$YL>@KU*\/;5G!+IL8JNF=+>)U2^-.OH\P#
MZ[KKLST[?E_%1=TYQ'U+=+*V^;].4YCF>TZU7_4D#L'<A04" KE1&X37$2+6
M['5S*.E$8Q9@E?N$1&O-2E*@;[.!'_:=:;IW$35+85MO\])'@[7/+0&U%70T
MTW/:ILJ!YGK4RA'L539R73BMK-H*V:GN2/8[_-0AXR<?>)-ET/>)-OUM>8LE
MIH%#K4@!2#O \/"I=?)'9;N>:#'%Y+4[1]W;>_:E(3N //X0K,XH9"3O8 B?
M*WX[("ER^+VI8T;IVGGV3\@VTUS?+4X[1UD(XM:F+*!R)E#*AXDXZT/[O%2I
M;C8<W!*L): ]$BH-<U/LRPT^A0;S@!/0BD6-%BQ&G/+-XYW&/)"N*FJ'7 @J
M;VS!D_\ TUBW>5OY0-UD]@QQ4U25DA)Q,'+_ .FA;PXM*I4UQQ"5(">21N[Z
M.-BTI'MY3(#0#A&3@5-.+DR9/%;!2TMY1G&"V0D^>\0[_/>4D<Y$O=@^/2IO
M9_*"XH25 KUS>5#P+_\ -0DMD42'QA/?CI4_L-H* C[7R)Y5T(P7%C#E)A:T
M_P :N(,A:$NZNNJ\D?">S^BB/]G^]:>9/:7N;>'$)'VIM.Y15X'N'ST#W)K-
M@B@)2'9KOHM,HYJSXTYWV.O3]O;F.A/;+0E2FQ]R?OB*T*BG'?8Z6DTTJSR?
M 0^'_EFZMU5JB?9Y-C>@^;96MQX9*$9Y<L8)]AHQR?*"D:8LRY][*&8Z&^U#
MCB.:T^H#G\E53LFI7+)#EWLJ=?DEK:AF("5%/=DC]-5\X@:^UGQGU:BW*N#;
M$-E8+:8[YVM@?=+5X@=U8)I4]N6/GI\ZK4=HH^F6G/*EM>K;8U(MK)+KAQV#
MB2'4^LI)Y"N?4?&JYK:)8>\V!']BY5\[8NIEMW-C3_#^_N_5,2&_JA<0,E\@
MC+;8^?)JVUQ0XF$T7G=SI0"H=^<<\TJG:9CK4W3=[[%C.!&J;CJFUW5ZX3%R
MU-2 E!7]R,44N?=02\EYLIT]>59SNDI[_P![1MSRI<U9V*)W!3Y3U\NNF.!V
MJ[I9;@_;+E'CA3,J,K:XV=PZ&OEQ?/*#XU#M7&.*&IF\#DEN9RS\U?4?RHH?
MGW K5C!4$A<<#)_A"OFIJ'AM.A(:,2,N<P]C:ZRG=D^&!5X1NK$.ZX(%I[CS
MY0-YFH95Q9U0R'74(2M4O( )QW)IQXU\>..W">\MVUSBKJI]+K:5M2C,"0L'
MO'H_DJ7V'2DW1<YIW4=DD-VJ3A)<6C]K/<<CI5IM-V71VI[7#\_A1[HTE&UI
MZ0VE[N]8Y594[[#X1R5RM'!KCUQ+X]Z$D6J+Q*U19=86_EYXS-.R1SY%0*3^
M2AKQ6XF^5/P;E)%ZXF:GD1%C*)4>;N;/M]'E\M%;B/98W ;CQ'O>G8#5NLUP
M0E+S$5.U"CWJ"1RS1UU#:;=Q@TDXU*0B2EYG 41U&.AIBHIJU]QN*/G</+0X
MZ/)WM<6=4''PD&8,C\E=EL\M?CC*5V+O%34B>7PA+&0?FJ*\8.#TKA?Q"\R=
M:6Y;'7TEI;0/I(W<T9\<=*D7'WR?W]%O0]2:7MD]S34V,A_TP2Y&5CFE?+O\
M:S8O?V%8,D5O\LSC7/B.-_9-U%VQR@D3 "E0Z8Y=]=L'RP>,T93!D<2]4.)4
MK:I*Y8YC[H XY>HU7-B?V#J)*$82X E>3T(J:A0G0_26"M3?;-]W3K5>"4HL
M/VHN//&YNR&_:;XOZDN]H6,*:5+ ?85]ZH8YT.K?Y8/'$%X/<5]3E8/,*FXV
M^KX-0#2VKKGI&09420&W,9,98!;=3X'P-26>G3_%1'GUJ:CZ=N;*09++R]J'
M5?O ,Y-,2S6PM[$^M'E9\:9$P)=XGZE4G: D":,*/_=K1Q=\JSC?IRT6F1$X
MI:FC*?=4A>R8.?+V5$=(:;?@3VT38B@K=A!7R!'C6SRCK2VO3E@0WM;'G#F5
M8_>U5Q:5QBLXV1'X_EJ<?WSA/%W5)_\ G?YJEFD/*MX_7:<VASBOJI:/N@9O
M\U!'2NGURYA9*,YZ&CUHS3+=E9!4D*<.,\JF$,F9Y/%!OLO'WBXRR@R>(VH'
M5%.<*E Y_)4MM7';B>\!OUW?%'J<R!_HJ%:%3IQV-<WI07<;A'PAJ&"H DCF
MI7[T4]6:(N7*2EME#16>2$= *VPA'L4>2:7<)MDXO\1I3S;?UXWAU:\8!?\
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M.*W--.G4M>+1K1>;C#EN-?5!^&=V Q.1N'SFM]VU'*^IZO.8,:YH\8[FU7M
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M-%2B4I^45VZ:;BRW5J4GIWBH]+205TZ:6!:2X=V#6>5R=B\?DUM--<,V4M?
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MTI7];]W6LGTY*5#/LHS5CX((-QH5LX97X_\ 8_IJI<%X+4.9]E6OXXKQPNU
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M=;*A*Q"5@=C7^LA_S8W/WM ^EI?9 UE\6-S][0/I:(E*I)!W]D#67Q8W/WM
M^EI?9 UE\6-S][0/I:(E*@ =_9 UE\6-S][0/I:P=?ZR/_-C<S_^;P/I:(M*
M@ <#76L.?^UA<N?_ +VM_P!+2^OK6'Q7W+WK;_I:(]*@+ Y^OO6'Q7W+WM ^
MEI?7WK#XL+E[V@?2T1J5&Y%D#@ZZU>>O#"Y>]H'TM+Z_-8CIPPN?O:W_ $M$
M>E4W860./K[UAW\+[G[VM_TM+Z^]8?%A<_>T#Z6B/2J-PL@<_7WK#XL+E[V@
M?2TOK[UA\6%R][0/I:(U*INPL@<_7YK ?\U]R][6_P"EK'U]ZP^*^Y>]K?\
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8WWVGE  \E;FU*3SZXSFG>O#??7N@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>forms-3_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( ;D# 2(  A$! Q$!_\0
M'0 !  (" P$!              8' P@! @4$"?_$ %@0  $# P$$ @T&"04-
M"0    $" P0 !1$&!Q(A,0@3%!<B05%487&1E:/1TA465I/3U!@C)C)&@862
MH20T0D2R)3,U-D524V)S=)3!\$-59')V@Z2T\?_$ !P! 0 " P$! 0
M       !! (#!08'"/_$ #T1  $"! (&!0H%! ,       $  @,$!1&1T086
M(3%24P<2%1=!%$-$46%Q@9*AHA,B5+'P(S,TP7+A\?_:  P# 0 "$0,1 #\
MW^VEZZN^F[XS&@.-H94R%G>;"CDDC_E45&US4PY2(_ZV!7V;:N&J6!_X9/\
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M6.:O0J;*/8'.@M!]RF/;>U*!DR8P_P#8%16[=*6?8;\NV7%:HB$.,LJN#L-
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M<%I25) 2 "..,FISI?3T72>G+9982EJBV^,W&;4X<J4$C&2?">=4*EI-.,A
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M.2G6>5X'+7_>\_HIGS^BM@>U1IOQ#VBO?7':GTUXA[17OIW3U?FLQ.2:SRO
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5B)2E*(E*4HB4I2B)2E*(E*4HB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>forms-3_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %= D8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_KE+_P"RUJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]/T%&U_^>GZ"GT4 ,VO_ ,]/T%&U_P#GI^@I]% #-K_\]/T%&U_^>GZ"GT4
M,VO_ ,]/T%&U_P#GI^@I]% #-K_\]/T%&U_^>GZ"GT4 ,VO_ ,]/T%&U_P#G
MI^@I]% #-K_\]/T%&U_^>GZ"GT4 ,VO_ ,]/T%&U_P#GI^@I]% #-K_\]/T%
M&U_^>GZ"GT4 ,VO_ ,]/T%&U_P#GI^@I]% #-K_\]/T%&U_^>GZ"GT4 ,VO_
M ,]/T%&U_P#GI^@I]% #-K_\]/T%&U_^>GZ"GT4 ,VO_ ,]/T%&U_P#GI^@I
M]% #-K_\]/T%&U_^>GZ"GT4 96HAAJ6E9;/[]NW_ $S:M6LS4_\ D):5_P!=
MV_\ 1;5IT %%%% !1110 4444 %%%% !1110 4444 9=U_R,=A_URE_]EK4K
M+NO^1CL/^N4O_LM:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ1O?_GF?S%/HH 9O?_GF?S%&]_\ GF?S%/HH 9O?_GF?S%&]_P#GF?S%/HH
M9O?_ )YG\Q1O?_GF?S%/HH 9O?\ YYG\Q1O?_GF?S%/HH 9O?_GF?S%&]_\
MGF?S%/HH 9O?_GF?S%&]_P#GF?S%/HH 9O?_ )YG\Q1O?_GF?S%/HH 9O?\
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MBBB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH **** "BDI: "BBB@ HHHH
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M/[8U3_H"2_\ ?P5N44[/N1[6'\B_'_,P_P"V-4_Z DO_ '\%']L:I_T!)?\
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ME4YIZR,G^VY?^@;=_P#?-']MR_\ 0-N_^^:UJ*=GW*Y)_P QD_VW+_T#;O\
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MG_A)HO\ GQOO^_-'_"31?\^-]_WYHY)=@YX]RM_PK_PY_P! X?\ ?Q_\:/\
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M93^_;H?^F;5JUB?V%8V&HV4UC91Q,)"'9%Z#:>OXUMT %%%% !1110 4444
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M1D(VPJ03QP4 /L?:KOAO3)-'T"TLIV5IHU)D*]-S$L0/;)- &I1110 4444
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M[ DB@#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>O\ >'YT .HIN]?[P_.C>O\ >'YT .HI <]*6@ HHHH **** "BBB@ HHHH
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M H3>20P3>7H]Q-%<7%H2Q9Y$!Z-G(!.PG_<]ZU-)\-Q:)K%W<6#^79W4:>9
M2S'S5R-X8D]5(!'^R*M;=6_YZ6WY&C;JW_/2V_(T :-%9VW5O^>EM^1HVZM_
MSTMOR- %V:%9TVOG&<\'%5)=.4*/*#$YYR_:F[=6_P">EM^1HVZM_P ]+;\C
M6-2A3J?$BE)K86/3P9#N1E3'9\\U9AM4@8E-V2,<G-5=NK?\]+;\C1MU;_GI
M;?D:5/#4X:I:@YME>#0%CN-8ED,4AU"3>N8^8_W:ICW^[G\:SE\-ZK9V%M:6
MMY97%NEI%;RV]];EXPR#&] #QGN#Z"MG;JW_ #TMOR-&W5O^>EM^1K<D=HFE
MKHNBVFGK*THMXPF]AC/X=AZ#L*OUG;=6_P">EM^1HVZM_P ]+;\C0!HUGW.C
M6UU<--(9=S==KD"DVZM_STMOR-&W5O\ GI;?D:&KDRBI:-%*;PM$[L8I61<<
M \Y/N:L#PY9A0,S#V$AJ7;JW_/2V_(T;=6_YZ6WY&ERHA4*:UL1ZQH[:CH,F
MEPS&&.4+'(YR28\C>![E<C/O6;)X*AMKW[1HEQ)IIDMGMIF1F=B.#&R[B<%6
M!X[AB*UMNK?\]+;\C1MU;_GI;?D:9KL9NG^'[[^WX=5U26Q\Z")XE-G 8S-N
MQDR$DYQC@>IKHZSMNK?\]+;\C1MU;_GI;?D: -&HKFW2ZMY(9-VQQM.TX-4]
MNK?\]+;\C1MU;_GI;?D: 3MJBE-X1LGA=8I)U<CY2TA(!]Q5:W\*"64-=!HH
MU_A29F+'UR>E:VW5O^>EM^1HVZM_STMOR-3R(Z%BJJ5N899^'K.QNDGA,Y=<
MXW2$C\JJWWA6VU;7)+[5/W\:P+!;Q!F3RQDER2",[CM_!15W;JW_ #TMOR-&
MW5O^>EM^1II);&,IRF[R=S,T/PM+H]Y9R&Z$L-G;S6L*[3GRVD5D!.?X57;[
M\5T$W^HD_P!T_P JI;=6_P">EM^1IK1ZJRE3);8(QT-,DET;_D%0?0_S-7JK
M:?;M:V4<+D%E!R1TZU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
.HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>forms-3_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-3_018.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  8X# 2(  A$! Q$!_\0
M&P !  ,! 0$!              0%!@," 0?_Q !6$  ! P,! P<&" <,"00#
M   !  (#! 41!A(A,1,4%19!4=$B559ADY0R5'&!D9+2TR,S-4)24Z$'%R0E
M<G1U@I6BL;,T-C=E@Z.RP?!#1$5&8J3A_\0 %0$! 0
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MOI'U?XX$-8P9()#?A8#B!V[)[E[K:*:X5CZJIT?5/D>S9=BX1!IW%H. _&T
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MI$])5U$E.^32M>3!"8!_&;/+C.,M?Y?E@XWYR@\,?9'QAXUI<<'<,UK0>!/
MM[FDKK3QVJKJ64U/J^Z2S/>Z-K&58)+FC)_-[._@H?049="^31-3+)"[:8^2
MXQN=G+3O)?OQL,&_L&.&5*MU'/:JHU%'HZICE)?@\_B. X@D %VX9:-W8@BT
M-7:JZ(R=9;Y3LY7D6&>K8.4?DC9  )SN.XX*]05=AJ(8Y6ZQNK6R;.R)*G9/
ME9QD%F[.#\V]&V>1K(X^J5P='%,)XF.NK"V.0$D.:-O<02<?*@LQ$#(>IM7L
MLE;,W^,8\AP! W[?#!(QPP@]<O9'.>V/6%TE>SBUE6W/$#]'UA=:1MLKJ,5-
M-JF\R-=$9@P5(#]D-#CY);G@X?2%R;:2S8QHNI\@@M_C"/=C&/S_ %!**VU5
M!5U$\>EJUW*TC*,,?70D,B;G<#M9.=KB>P =B"+2W.TU<-)(V_ZB9SJJ;2L:
MZ9IPYS6N!):" W#FC.=Q< =Z[T<U#60U4K;SJ:,4\#JC9?(-J2,%S2Y@#3G>
MTC''ANWKM4VSG<4$=1H>21E/#R,(-9#^";D'+?*W.RT>4-^[BOM)034453'%
MI"L+:EAC?MW*-Q#"2=EI+\M&7$X&-Y1'&DJ;156\5K]57BGC._$]8P'&2,[@
M01Y+MX/84FJK' Z /U?=L3 N#A5##&@.)+CL[O@.&_?E<&Z?<VHCD.DZUS61
M2L+'U\+B]TA!>]SB[:+O) X[M_>I$]H-1*Z271U62XN<X"Y1AI<2[+B-O&?+
M<,]Q17222R1-D=)K*YL$9 =M58&"03^AZCGNP<KX9;&&[1UI<0.3=)OK0/)!
M()^#W@[O4ODML?-/--)HZJ<^5SG'-QCPW:#MK9&WY(.VXD#B3E>)+,))Y9CH
MRI$DK',>X7",;6T223Y?'>=_K074.GA/"R:+4-Z=&]H<UPJAO!X?FKY8&U%-
M?;S025U55PP"!T9J7ASF[379W@#=N"\TE==:&CAI:?2M2R&%@8QO/83@#A^<
MNMB@N#KS=KA6T#J-M2(6QQNE8\G8:03Y)(&\HC0(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B#+:GI8Z^_Z>HJATO-I9IS(R.9\>UB%Q&2T@
M\5)ZEV+XO4^_3_;7C44=;'>+'<*6WU%;'22S&5D!8' .B+0?*<T<3WKIUBKO
M1:\_33_>H(5VTU8K7:JFM%%5S&%A>(VU\X+O5\(_X+-U$]@II1!/9JR"?8C)
M%1=)XV->YP!87EV!AI:[Y#P"V!U#7$8.E;S]-/\ >KXZ_P!8X8=I.\$'L/-_
MO4&:EBL,-3&'66Y&E-''523BNG_!;>=EI!?C.1CCVYX D?!/HKRAS>XC& ,U
M4V\GL_&<?EX]F0M.=05I!!TI>#D8.>;[_P#FKFV]5#-K8TA=F[3MMV!3[W=Y
M_"\4&7%5I(R-8+?<B1CE2*V8AAPTX&'Y<=YX#L4J!FDJELQBHKG^"@DF.U5S
M8.P,EH(D.3\F[UK0]/58.1I.[YX_^W^]7PWVJ+"PZ2NY:1LEO\'QCN_&HK-T
M<5@JKQ';C::N-[I71[72<SL8&X[G;_6.P8SQPOA.F*<$5UKN5._\+AHKIGYY
M,[+M_*8^$"!W\=V5?,U0]E=S%FEKNVH;%RP8!3[F9V<YY7O&%(-^K'<=)W<\
M>/-_O410T4.D:ZHIH64=R9SEKW1/DJI@UP8,N_\ 4_\ ,%0Q5:-?3231T-U<
MUH.,U4P!=GAGE,>O/#':M4+_ %@((TG>,C@?X/\ >KYT]5[.SU3N^.[^#_>H
M,Q5C3U).UAM56YIBCDP+G-M^4W:R&[62T 8+N_=A?*>HTC45'(-MUT,KGAL;
M6U<QVLN:T;^4P,EWS8WXX+4]/UFUM=5+QG&,_P 'X>U7SIVK'_U*[_\ Z_WJ
M+7"WZ7T_<;?!5LI:MK96!VR:Z?(_OJ3U+L7Q>I]^G^VOC+_611MCCTG>&L:,
M-:.;@ >U7KK%7>BMY^FG^]1'+3-+'072_P!% 9>;PU4?)LDE=)LYAC)P7$GB
M25I%0:=;5R5]YKJJ@GHFU52QT4<Y87EK8F-)\EQ'$'M5^@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(HESGDI;365$1 DB@>]I(S@AI(_P %F[9;
M-15UIHZM^KZQKIX(Y7 45/@%S03CR/6@UZ+-] Z@],:WW*F^PG0.H/3&M]RI
MOL(-(BS?0.H/3&M]RIOL)T#J#TQK?<J;["#2(LWT#J#TQK?<J;["= Z@],:W
MW*F^P@TB;EF^@=0>F-;[E3?83H'4'IC6^Y4WV$&DW*-<*V*VVVJKIPXQ4T3I
M7A@RXAH)./7N5)T#J#TQK?<J;["JM2V6^1:5N\DNK*R6-M'*YT9HZ<!X##D$
MAF1GU(+9NJ:IS0X:4ON",CR(/O4ZSU?HI??J0?>KO3ZITZ*:(&^VL'8;NYW'
MW?*H-RNFGKA*R1NK:2F+6EI$-=& [/?O0=^L]7Z*7WZD'WJ=9ZOT4OOU(/O5
M5T\MBIW.(UQ$YO)N8QKJZ/#2<^4-_'>G*V(.<YNN(FY=M;(KX\9^3*""'W0:
M_.HNA]2\U-"*?F6(-G;VL[7XWACL[]ZT?6>K]%+[]2#[U5G.;-L/:-=0ATDH
MD<_GL>T&@. :-^X9.?F7PU%FVLC7H#<\.?Q<,Y[_ )D%GUGJ_12^_4@^]7WK
M/5^BE]^I!]ZJ=QL3G@]>VAH=M;/2$?'OX[U9VV\6&@,ADU=256V /PU=&0W'
M=OW(/4FJJF*)\C]*WT,8TN<=B#<!_P 57M#5Q7"WTU;"'"*HB;*P.&#LN (S
MZ]ZIKCJC3SK95M;?+6XF%X %7'O\D^M5.G;)?7Z8M+X]65D3'44):P4=.0T;
M W9+,[D&WW)N6;Z!U!Z8UON5-]A.@=0>F-;[E3?80:1%F^@=0>F-;[E3?83H
M'4'IC6^Y4WV$&D19OH'4'IC6^Y4WV$Z!U!Z8UON5-]A!I$6;Z!U!Z8UON5-]
MA>M/27&.[7:WU]RDKQ3&$QR20LC< YI)'D  [P@T2(B B(@(B("(B B(@(B(
M"(B B(@(L]<;G=SJ-MJM;*$ 4G.7OJ=L_G[. &_(O6-6_I63ZLWB@OT6?/6T
M#)=9,?R9O%<6UFHWQB1M7I\L(!#MJ7&_AVH+6_R,BT[<GR/:Q@II,N<< >2>
MU<],R1RZ6M3XGM>PTD0VFG(W, 5'<X+U>+95VRMGT])3U,3HY6%TGP2"._\
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M3M;]_:<8'[/F3F,C9Y)FV6$.:[:R"<N .[&_CC_OWJ-<]":8@M-9+':8&/9
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MJIZE:6]';5[HSP3J5I;T=M7NC/!!;\ZI_P!?%]<+$1N;U5MSMH;/6#.<[O\
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M<6M)P?(X;E<-U!IIN]MWM(^2IC\56:IU%8YM(WB**\VY\CZ*5K6-JF$N)8<
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M3]9US'N' T-/N/=D,QE :TM:\:UK2QSBUKA0P$$C&?S/6KOI_3.R&]+VG &
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M=;U@X8/,8,.SW>0K\ZBTZ]H#[S:W;NVJC/\ W42X7ZRR4^*2\V<2D_"?41$
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7[+0W/<,+TB("(B B(@(B("(B B(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>logo_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !M 48# 2(  A$! Q$!_\0
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M61D."I"'!%?/'P^\2Z]>>/=$M[G6M0FADGPT<D[%6&P]1FOH?Q3_ ,BAK/\
MUXS?^@&OF3X:_P#)1M _Z^?_ &0UM12Y)"EN?65+117,6>!?&K6-6T[QA:Q6
M&H7MM$;,$I#,R@G<><"O./\ A)O$7_0<U7_P)D_QKZ]>WAE;,D,;GIEE!K+\
M16=J/#.K,+:$$6<W/EC^X:Z:==))6(<3Y5_X2CQ#_P!![4__  *D_P :7_A)
MO$?_ $&]5_\  F3_ !J_\.5#_$'0E8!@;@9!&>QKZM^Q6O\ SZP_]^Q6]6HJ
M;M8E*YYO\$;^^U'PM>RW]W<7,@O" T\A8@;5XYKT\U''#'"NV-%0=<*,5)7#
M)W=S5$%S<QVEK-<S';'"AD<^@ R:^2M0\9>(+_4[J[CUC4(DGF9TCCN6 0$\
M #->_?%[6O[)\ 7<:/B:^86J8/.&^]^@->2_!G0QJOCE;F6,/!I\1F.1QO/R
MK_,G\*Z:*48N;,Y;V.4_X2;Q'_T&]5_\"9/\:W?!/B#7KGQSH<%QK&HR0R7B
M!TDG<JP]",U]/_8K7_GVA_[X%*MI;*P98(@1T(4<5+KIJUA\I-2T45S%A111
M0 445GZKJ]CHNGRW^H7$=O;Q#YG<_H/4^U %ZN?\0>-/#_AE#_:FI112XR(5
M.Z4_\ '->+^,_C-J>KM)9^']^GV73S_^6T@_]E'TYKS"1GED>1W:21CDNQR3
M]3733PS>LB'(]MUCX^Q(S1Z+HS2>DMW)M'_?(_QKC[[XR^,[TMY5Y;6BDY M
M[<<?B^:X"D)QUKJ5&FNAGSLZ:;X@^+YY-[>(]0!_Z9R[1^0J+_A._%O_ $,F
MI_\ ?\U@QH\IPB-(?]@$U)]DN?\ GVG_ ._1J^2'8+L](\(ZMXBU*WDO[SQ'
MJDB!C&D0N" 2.I-=E'XAU>$ +?RG']XY_G7GG@.[>."?3IHI(V#>;'O0C(Z&
MNQKX_,:M6&):OZ'V&74:,\,G9/N;4?BS6HS_ ,?>[_>C!J9?&FLJV3)"P]#%
M7/T5PK$55]IG8\)AWO!'3_\ "=:G_P \K;\C_C2_\)UJ?_/*V_(_XUR]%5];
MK?S$?4,-_(='+XUU=SA?(C^B9_G5&;Q)K$[9:]<8.<)@"LJI;:UGO)A%;QM(
MY["I]O6EI=EK"X>FN;E1ZSI-\-0TR"Z(VF1 2/?O13=(L!IVEV]HQWF- "??
MO17T]._*N;<^+J<O,^78T.U<I\0O$@\+>#KV]1MMRX\FV_ZZ-T/X<G\*ZNOG
M+XU^)?[4\4QZ1 ^;;31A\'@RGK^0P/SK:E#GE8ENR.9^'WAL^*O&5G9R M;1
MMY]T?]@<_J<#\:^G]<T>VUO0;W2;@ 0W,1CZ?=]#^!P:\!^&GCGP_P""K*\>
M^M+R:_N7 ,D2 A8QT')]<FO3=!^+_A_Q!K5KI4,%[!+<G;&\R +NQP.#WK7$
M*;G=+8B-CP&RN+[P=XLCE(*WFF76)$]<'!'T(_G7UQIU_;ZGIMM?VS;H+F,2
MQM[$9KPCXY>&OL.MVVOVZ8AOAY4V.TJC@_B/Y5TGP,\2_;-&N?#\S9ELCYL&
M3UB8\C\#_.G5_>4U40+1V/1_%/\ R*.L_P#7C-_Z :^9/AK_ ,E&T#_KY_\
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M>NV=S'>6D5Q&?DD4,*SP<J=:'+)*Z-<QA5P]3FIR=F8C^"=(?[HE3_=>F?\
M"#Z5_?N/^^O_ *U=-^5'Y5V?5:/\IY_US$?SLP(O"&C1$'[.S8_O.3FM>VL[
M:SCV6T,<2^BC%6, =J:3[BM84H1^%&-2M4G\;;'XHI:*T,S$\5:Y%X;\-7^J
MRX_T>(E!_><\*/SQ7ROHFE7WB_Q1#8K)F[OIB\LIYQW9C7TMXW\&+XVT^VL9
M=2FLX(9?-98D#>8<8&<^G-9W@?X8V'@K4KB_BO9;R>6/RE,L87RQG)QCUXKH
MI5%3@^Y#5V<3_P ,_P!S_P!#!%_X#'_&GP? :^MKB*X@\21I+$X>-A;GA@<@
M]:]PHJ?;U.X^5'->+_#A\3>#;O2IMC731!HW' $R\@CTY_G7S5X/UZ;PIXOL
M]0D5E6&7RKF/OM/##\/Z5]=5Y;X@^"NF:[KUWJ:ZG/:"Y?>T,<:D!C]['UZT
MZ-1)-2$UV.W\2S)-X-U:6-@R/82LI'<&,U\J>&-8'A_Q'I^KM"9Q:2>88E."
MW!'7\:^IK#PV;/P8/#LM_+.OV9[47#* VT@@<>P/Z5YV/V?]/ Q_;UW_ -^5
M_P :JC4A%-,&FR'_ (:"A_Z%V7_P*'^%6=.^.T.H:G:60T"6,W$RQ;OM(.,G
M&>E,_P"&?]/_ .@]=_\ ?E?\:LZ?\"[#3]2M;U-;NG:WE64*T*<X.<4W]7#W
MCUNLSQ'_ ,BOJ_\ UYS?^@&M.JFHVBW^G75DS%!<1-$6'49&,_K7(MRSY6^&
MW_)0M _Z^1_(U]:=J\L\/_!:Q\/Z]8ZM'K-S,UK)O$;1* W%>IUO7FIRNB(J
MPM%%%8EGDOQQ\-R:GH5KK-K$7FT\D3*!SY3=_P "/U->;_#SXB2^"IIK>>W-
MSIUP0[QH<,C?WE[?A7T\Z!U*N 5(P0>]>5^(_@AI&I3R76D73Z;*W)AV[XL^
MPZBNBG5CR\DR&GNC$\7?&VUO](GL/#]G<QRW$91KBX 7RP>N "<FN/\ A/X:
MGU[QI:7'EG['IS">9R.,C[J_4G]!79Z9\ 2)\ZKKFZ$$?):Q8)_$]/RKUK0M
M TWPWIJV&EVJP0+R<<ECZD]S5.I3C'EIBLWN:M+117*:"5S'C_Q ?#/@R_U%
M&Q<;?*@_ZZ-P/RZ_A73UXK\?M298-'TI6X=VN'&>N.!Q^)K2E#FFD)['B!))
MR223R2>]=;\._!<GC/Q"(9-RZ=:XDNI!W'9![G^6:Y+!() ) ZX'2OJ?X:>&
MT\->"[.%DQ=7(%Q<-WW,.!^ P*[:U3ECH915SJ[:UAL[:*VMHEBAB4)'&@P%
M ["K%%%><;!1110 4444 ,K&\4PB?P[=#&2H#C\#6T/6LW76"Z%>L>GDFLJJ
MO3?H:T':K%KNCR:O0/ UV9M,EMF/,+\?0UY_76^ W(U*ZC_A,0;]:\+!3M67
MF?4YG!2PS\CT"BBBOHCY$**** "BBB@ HI*6@ I**R_$.E/KF@7NF1W;VCW,
M1C$T?5* --2",@Y%.KG?!GAZ7PKX9M]*FOI+UXB297Z#)S@#L!70TGN M%)1
M3 6BBB@ HHHH **2B@!:*2B@!:**2@!:*2B@!:*** &\8KP7XMV,VO\ Q'L[
M"/Y8X;)3))_=4N3FO>L<8KS;QM9QQ>(_M8'[R>!5)]D)X_6L:U=T*;J+<Z<)
M05>LJ<MCD;/PY:R6]OH]K JQS31*^>K#<"23]!7NV !@=*\BT>00:U9RMT69
M<_G7KHQBN/ 5'*#N^IW9M!1J1LM+#Z***](\@**** "BBB@!A&1S7.^,KM;;
M0FB!^:=@H'MU-=%G/%>9^*]5&HZJ4C?,$'RKZ$]S7'C*JITGYGH9=1=7$+LM
M3!KK/ :,=3NG_A$07]:Y.N_\"VACTZ:Z88,KX'T%>/@HWK(][,YJ.&?F==11
M17TA\B%%%% !1110!C>)/$5CX7T675+\MY285409>1ST4#U-<I#JWQ)U91<V
M>BZ1IEJXRD=],[2X[9V=*7XLP7 T32]4BMWN8=+U&*[N(E&3Y8SDX]JZO1/$
M>D^([);K2KZ&XC89(1OF7V(Z@U:TC>PCFK'Q#XVLM2MK37_#,,T%Q((_MFF3
M;UCR>KJ>0/>NLUJ\DT[0M0O80IEM[>250W0D*2,UH5D>*O\ D4=9_P"O*;_T
M TMV!!X/UB?7_".F:K=*BSW,(DD$8(4'/;-'BCQ7IOA/3A=Z@[%W.R&"(9DF
M;T450^&/_)-=!_Z]1_,UA>';8>*OB1K7B&\'FV^D2_8-/4\JK#_6,/?_ !I\
MJN^R E@UCXDZP!<66A:5IEJW*+?RLTI';(7I3SXO\4>&R)/%V@P_V?G]YJ&F
M2&1(O=T/('O7H6*9(B2(8W4,C#!!&012YEV Y"3Q=*_Q T?1K,V\VFZA827?
MGKDDXSC!SC%=#KEY+IF@ZA?0A#);V\DJANA(!/->5Z7H[:!\=;/3(W/]GQV<
MTME&?^64;Y)0>P?./K7IOBS_ )%#6?\ KSE_]!--I)JP',1?$6.V\*Z+=SV<
MEYK>J0B2'3[-<M(>Y]E]S4#:G\5;H":#0]$M(VZ0SSL\@^I!Q4'P=T8KX7M]
M=N\2WES$(86/_+.W3A5'ID@DUZ;3DU%V2!'G.D?$34+;6X="\8Z/_9-].<6]
MPC[H)CZ9[?F:WO%'C*WT"6"QM[2?4M7N03;V%L/F8?WF/\*^]4OBGH\6K> =
M18IFXLT^U0/T*,G.0?IFH/AK9RW6C#Q/J6V75=6 9Y0/NQ 85!Z#C/U-%HM<
MP:[%5M0^*T_[V+1-!MD/(AEG9G'U(.*?H/Q"O!KT7A_Q9I!TC4IN() ^Z&<^
MBGU_$UZ'7 _%W2H[[P%=WH&+O32MU!*."A##/Z4DU)V: [ZN)UOX@+;:M+H>
M@:9<:UK$?$L4/RQ0'_II(>!73Z-=G4-#L+TDDSVT<ISZE0:L1V\$3RO%$D;R
MMN<JH!8],GUJ59/49PIN/BG)$94L?#D)/2%I9&8>V>E3Z#XZO#KJ>'O%.E?V
M5JDHS;NK[H;G_<;U]J[K%><_&2)8_"EIJ<8Q=V-_#)!(.JDM@U2:D[6%L>C4
MM,1MR ^HS3Z@8TCBN-\>6I:WMKD#[C%#^-=G5'5;%-2TZ:U;^->#Z'M6%>'M
M*;B;X:K[&LJAY%G!R*]4T#5$U32TE)'FJNV4>AKRV6)X)7AD4JZ':P/8U:TO
M5+C2;L3P'V93T8>AKPL+7]A+78^GQV%^M4_<W6QZZ"?2G5A:7XGT_4PJB013
M'K&[8_(]ZW.".#7T,:D:BO%GRDZ<J;M)6'444AJR!O '2C.!TK+O]=T[3UQ<
M7*EO[B?,WZ5QVL^+[F_4PV@-O >"<_,WX]JY:V)ITMWJ=>'P5:N_=6G<TO%'
MB541["Q?+GB20'[GL/>N(HHKP:U:5:5V?58;#0P\.6)-;6TEW<Q6T0R\IVBO
M7;"U2QL8;:/[L2A17,^#]"-K'_:%RO[UQ^[4_P *^OU-==FO7P-#V<.9[L^?
MS/%*K4Y(;(=1117HGE!1110 4444 ,90RD$ @]0>]<-K'PH\.:E<->6D<^E7
MIY\ZP?R^?ITK0\4>+9_"UY:R76DW,^C.I^T7L'SF!L\97KCWJS9^.O"]_;B>
MWUZP9#_>F"D?@>:I<RU0M#B[J]\7?#<QW>IW_P#;_APR*DLKKMN;<'C/O_GI
M7=^(Y8Y_!>K2QL&CDL)64CN#&<5Q?COQ78>)-*F\)>')%U35-0Q$?L_S1PID
M$L[=!Q76ZO9C3_A]?68.X6^EO%GUVQ8_I5/HWN!5^&/_ "370?\ KU'\S61\
M-&6QU3Q9HLAQ<6^JR3<_Q))R#^E:WPQ_Y)MH/_7J/YFJ/BSPYJUOKT/BSPN(
MVU2)/*NK20X6\B],^H[4=6@.[HKS^'XM:%"HCUJ"_P!(NQP\%S;/P?8@<BFR
M_$.?7$^R>#=+N[ZZE&!=SPF.W@S_ !,QZ_05/)(+E&[U&*[_ &@]/MHB";/3
M9(Y"#_$06Q^1%=OXM_Y$_6?^O.7_ -!->=:7H T'XN>'K=YC=7DNFW%Q>73=
M9I68Y;Z=A[5Z+XM_Y$_6?^O*7_T$U4K75@1G?#8 ?#G0@!_RZK75=ZY;X;_\
MDYT'_KT2NI[U,_B8(P/''_(C:Y_UXR_^@FH?AZ,?#W0<?\^<?\JF\<?\B-KG
M_7C+_P"@FH?A[_R3W0?^O*/^5'V1=3I:Y7XE?\DWU_\ Z]'KJJY7XE?\DWU_
M_KT>E'XD-[%WPO(D/@G2)7.$2PB8GV$8KB=(M=9^)L<NL7NL7>F:#)(T=I8V
M+['E0'&Z1O?TKM?#42W'@72H7^[+I\2'\8P*XCP/XBMO!D)\&^)918W%I(PM
M+B?Y8KB(G((;IFK75K<#9C^$WAU$ ,^KL1W;4),G\C7(_$KP'HWA[P@U_8O?
M&9;B%1YUW)(N"_H3BO2;KQOX7LH#-/K^GJ@_NSAC^0YKROXCZSJ'BWP\=2MH
M)K3P[:3Q>0TRE7O7+8W =D SCUJZ;FY*Y+L>Y1_ZI?H*DJ.+_5+_ +HJ2L"P
MI*6B@#C?%GATW2_;[-,SJ/WD8_C'K]:X7&.#UKVD_=ZUSNM^%+74B9H6%O<'
MJP'RM]17EXO!\[YZ>Y[. S%4E[.KMW/-ZM0:G?VV!#>3H!V#G%6K_P /ZEIY
M/F6S,G]^/YA65T.#Q7D-3IO70^@3IU5I9HU?^$DUG&/[0D_2JL^I7UQD2WL[
MCT,AJK1FDZLWNQJC36T5]P45)%!-.VV&%W/HJDUO:?X.U&ZPT^RVC_VN6_*J
MITJE3X$35Q%*DKS=CGE4LX1023P .]=IX>\)E"EYJ*G(YCA/;W/^%;VE>'K'
M25#QJ'F[ROR?P]*UC]W[U>OAL HOGGN>!B\T=1<E+1=QXI:**],\8**** "B
MBB@ HHHH :5# @C(/4&N=N_ GA6_F,USX?T]Y3U;R0,_E7244)M; 9VFZ+IF
MC0>3IMA;VD>,;88PN?KZU:N+:&[MY;:>,20R*5=3T8'J*GHH JV-A:Z78Q65
ME D%M"NV.*,8"CT%0-K.FKK"Z2UY"-0:/S5MBWSE?7%:-<[XE\&:3XICC-[&
MT5W"<PWEN=DT1]F_I35KZ@;CPQ3 >;$KX_O &AVBMH2S%8XD&23P%%>,^)M;
M\8> 4$4?B0:G%N"K]LLU+CORP;FM33?#FL>.[>.7Q'XGN9=/=1(UA:0"W1L_
MPLP))%:>R:5V]!7+WA&8^+/B)J_BN($Z9;0C3K&0])<'+L/;/\Z]#N+:&[MY
M;:XC$D,BE'4]&!ZBHM/TZTTJPBLK&!(+6%=D<2#  JY6;>N@RK96-MIUE%9V
M<"0VT*[8XD& H]!5JBBD!7NK2WOK26UN8EE@F4I)&W1@>H-)96=MI]G%:6D*
MPV\*A8XT'"CT%6:* "JM]8VNI64UE>0)/;3+LDB<9##T-6J* *]M;06=M%;6
M\:QPQ*$1%Z*!T%5]1T;3M8MS;ZE907<7]R:,-CZ>E:%% '.6?@3PKI\PFM?#
M^GQRCHWD@X_.M34M)L-7LOL>H6D5S;Y#>5(,C(Z5?HIW8"  # Z4M%%( HHH
MH *2EHH 3%5)M.L[C/FVT+YXY05<HQ2:3W&FUL9'_".Z1_T#X/RI\6AZ9#DQ
MV$ SU^7-:/'I1GVJ/9070IUIO[3$CCCB7"(JCT Q3Z6BM"!*6BB@ HHHH **
-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
